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Abstract
Non-selective T cell depletion reduces the incidence of severe graft-versus-host 
disease after allogeneic haematopoietic stem cell transplantation but the cost is 
delayed and disordered antigen-specific immune reconstitution and increased 
infection. A method of selective depletion of alloreactive donor T cells 
expressing the activation marker CD69 after co-culture with recipient stimulator 
cells in a mixed lymphocyte reaction has previously been shown to reduce 
alloreactivity, whilst retaining third party responses in vitro and in a mismatched 
murine model led to donor T cell engraftment with a virtual absence of GvHD 
and significantly increased survival.
We have further developed this technique by comparing two methods of 
potentiating allostimulation in the HLA-matched setting. Cytokine pre-treated 
recipient stimulator cells led to successful allostimulation of a minority of HLA- 
matched responder cells whereas the strategy of pre-treatment of recipient 
stimulator cells with OKT3 led to effective allostimulation in all pairs tested and 
led to more efficient selective abrogation of alloresponses after depletion of 
responder alloreactive cells.
The retention of donor antiviral T cell frequencies were compared after selective 
HLA matched allodepletion using both techniques of potentiating 
allostimulation. Using both techniques the majority of CMV-specific T cells 
(quantified by by HLA Class I tetramer assay and IFN-y ELISpot) and EBV- 
specific T cells (quantified by IFN-y ELISpot) were retained in the selectively 
allodepleted T cell pool. Preservation of antiviral CTLs in selectively 
allodepleted stem cell grafts would lead to improved antiviral immunity post 
transplant.
The phenotypic characteristics of the alloreactive and non-alloreactive T cells 
within the donor pool were examined. CD69* alloreactive T cells were found to 
consist of both nalVe and memory T cells and to exhibit significant skewing of 
TCR Vp sub-family distribution in both the HLA-mismatched and HLA-matched 
setting. The technique of selective allodepletion based on CD69 expression 
was found to retain functional CD4+CD25+ T regulatory cells The retention of 
immunosuppressive CD4*CD25* T regulatory cells could lead to more ordered 
immune reconstitution and further suppress alloreactive responses post
3
transplant. Direct stimulation of donor T cells with CMV peptide led to up 
regulation of CD69 on CMV-specific T cells and these cells exhibited TCR Vp 
sub-family overuse consistent with previously published data. Homology of TCR 
Vp sub-family overuse in HLA A*0201+ donor T cells following CMV peptide 
stimulation and HLA-matched allostimulation was demonstrated in some 
individuals suggesting supporting the existence of donor T cells possessing 
TCRs with affinity for CMV and minor histocompatability antigens. Sequential 
selective allodepletion and CMV antigen stimulation of donor T cells might lead 
to production of CMV-specific non-alloreactive donor T cell pools suitable for 
use as adoptive immunotherapy post-allogeneic haematopoietic stem cell 
transplantation.
The techniques for allostimulation and selective allodepletion at a clinical scale 
and under sterile conditions have been developed in order to test the safety and 
the efficacy of this technique in a clinical pilot study of HLA-matched sibling 
donor allogeneic haematopoietic stem cell transplantation in adults with acute 
myeloid leukaemia.
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Chapter 1 Introduction
1.1 Haematopoiesis
In 1909 Alexander Maximov first postulated that among the lymphocytes in the 
peripheral blood, a population of common stem cells (gemeinsame 
stammzeilen) circulated that had the ability to differentiate into all lineages of 
haematopoietic cells.[Maximow A. 19090] Human blood cells are derived from 
such pluripotent stem cells that are capable of self-renewal and reside within 
the adult bone marrow.[Payne and Crooks 2002] Haematopoiesis, the division 
of haematopoietic stem cells and their subsequent maturation and 
differentiation into specialised cell lineages within the bone marrow, occurs 
under the influence of haematopoietic growth factors and adjacent bone marrow 
stromal cells.[Cantor and Orkin 2001] The production of functional blood cells 
by the bone marrow can be impaired or totally destroyed by pathological 
processes affecting the bone marrow stroma or stem cells. Such processes 
include leukaemic transformation of haematopoietic cells and infiltration of the 
bone marrow by malignant non-haematological tissues.
1.2 Allogeneic Haematopoietic Stem Cell Transplantation
The therapeutic benefit of administration of saline extracts of bone marrow to 
patients with anaemia was demonstrated as early as the 1920s. [Leake CD 
1929] Allogeneic (Greek, from alios, other, and gene, race) transplantation of 
haematopoietic stem cells (in the form of spleen cells) was first shown to lead to 
regeneration of peripheral blood counts in lethally irradiated mice in 
1951 .[Jacobson ef a/. 1951] In the same year Lorenz et al showed that lethally 
irradiated mice and guinea pigs could be protected by the intravenous injection 
of bone marrow from litter mates.[Lorenz E et al. 1951] Transplantation of 
cellular material (as opposed to humoral factors) in such mice led to the 
regeneration of donor-derived blood cells.[Ford et al. 1956] Subsequent 
experiments in lethally irradiated mice examined bone marrow repopulation by 
spleen cells and led to the concept of ‘multipotential colony-forming units’. 
Extension of this work with dosing studies showed that repopulation of mouse 
bone marrow could be achieved with the administration of a single cell, leading
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to the concept of the self-renewing pluripotent stem cell.[Till JE and McCulloch 
EA 1961]
The capacity for ‘self-renewal’ of haematopoietic stem cells was exploited in the 
first allogeneic bone marrow transplants in humans. There are many case 
reports of such procedures undertaken in the 1950s. Mathe reported good 
evidence of (albeit transient) allogeneic engraftment (as evidenced by red cell 
antigens) in a group of scientists who had been accidentally exposed to sub- 
lethal doses of ionising irradiation and subsequently given multiple allogeneic 
marrow infusions from family members, autologous marrow regeneration 
eventually occurring.[Mathe G et al. 1959] Allogeneic haematopoietic stem cell 
transplantation (AHSCT) was subsequently undertaken as a treatment for acute 
leukaemia and aplastic anaemia. The determination of radiation doses needed 
for recipient marrow ablation, the practical procedure of marrow harvesting and 
development of supportive treatment of bone marrow transplant recipients were 
undertaken by E. Donnell Thomas in the 1960s, (now widely recognised as the 
forefather of modem AHSCT), for which he received the Nobel Prize for 
Medicine.
AHSCT was first performed in patients with acute leukaemia and aplastic 
anaemia whose life expectancy would otherwise have been very 
limited.[Thomas et al. 1971] [Pillow et al. 1966]The use of AHSCT was 
subsequently extended to patients with chronic myeloid leukaemia, and 
malignant lymphomas.[Mackinnon and Goldman 1988;Thomas, et al. 1971] 
More recently the spectrum of diseases successfully cured by AHSCT has 
widened further, including chronic non-malignant haematological conditions 
(structural haemoglobinopathies, thalassaemias), congenital and inherited 
immune deficiencies and some severe metabolic disorders.[Bernaudin et al. 
1993;Hirschhom 1980;Lucarelli et al. 1984;Yamamura et al. 1972] With the 
establishment of international unrelated donor volunteer bone marrow 
transplant registries and the advent of molecular HLA typing techniques, 
allogeneic transplantation of haematopoietic stem cells from matched unrelated 
donors has become possible. [Davies et al. 2000;Petersdorf etal. 1998;Shaw et 
al. 2001]
Cord blood is rich in haematopoietic stem cells and many cord blood banks 
have been established in the past 20 years, providing an additional source of 
donor cells available for AHSCT, particularly for paediatric recipients.[Almici et
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al. 1995;Gluckman et al. 1992;Laughlin 2001] Recent advances in graft T cell 
depletion techniques (vide infra) have allowed AHSCT between haplotypically- 
matched individuals.[Aversa et al. 1998] Thus both the spectrum of diseases 
successfully treated with AHSCT and the availability of a donor to an individual 
requiring an AHSCT have greatly increased in recent years.
1.3 Alloreactivity
Alloreactivity is the term given to the immune system’s recognition of non-self in 
the setting of allogeneic transplantation and is the immunological process that 
underlies both graft rejection and in AHSCT, Graft-versus-Host Disease 
(GvHD).
The human immune system has evolved to recognise and destroy foreign (‘non­
self) antigens whilst acquiring tolerance to components of the body’s own cells 
-‘self ‘ molecules. Since the advent of allogeneic transplantation the 
understanding of this recognition of self and non-self has assumed much 
greater importance clinically. A complex of closely linked and highly 
polymorphic alleles was first recognized as the major histocompatability 
complex (MHC) in mice.[Counce S and Smith P 1956] These alleles coded for 
molecules involved in the recognition of self and non-self, and the human 
counterpart (residing on chromosome 6) was identified as the human leukocyte 
antigen (HLA) system in 1965.[Dausett J and Rapaport FT 1965] It was soon 
realised that HLA discrepancy between donor and recipient was the major 
determinant of both graft rejection and also the already recognised secondary 
syndrome of GvHD. Shortly after HLA typing techniques became available the 
first HLA-matched sibling AHSCT was performed in 1968.[De Koning et al. 
1969] Globally, fewer than 25% of patients requiring AHSCT have a fully HLA- 
matched sibling donor but many can be found a fully HLA-matched unrelated 
donor via international bone marrow donor registries.[Cleaver 1993] High 
resolution molecular HLA typing at allelic level has revealed a much higher level 
of polymorphism in HLA molecules than had previously been identified using 
serological HLA typing techniques and molecular HLA typing has become a pre­
requisite for selection of HLA-matched unrelated donors. [Little and Madrigal 
1999]
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In HLA-mismatched unrelated donor AHSCT the incidence of both graft 
rejection and GvHD are inversely correlated to the degree of closeness of HLA 
matching between donor and recipient and this translates into an increased 
survival benefit for those transplanted with more-closely matched grafts. 
Conflicting evidence has been published regarding which mismatched HLA 
locus is most likely to result in GvHD.[Petersdorf et al 1998;Sasazuki et al. 
1998] Although AHSCT from related donors with one full haplotypical mismatch 
(typically a parent) can now undertaken with relative safety, the incidence and 
severity of GvHD is unacceptably high unless the graft is profoundly T cell 
depleted and contains a very high dose of CD34+ cells to ensure engraftment. 
Such graft manipulation results in reduced quantitative and qualitative immune 
reconstitution in the host post-transplant and an increase in post transplant 
mortality and morbidity from infections.[Aversa et al 1998;Keever et al. 1989] 
The use of unmanipulated grafts in AHSCT from HLA genotypically identical 
siblings still leads to clinically significant GvHD in 20-30% of recipients. [Chao 
and Schlegel 1995]
The first of a novel system of human antigens subsequently implicated in the 
development of GvHD in recipients of HLA-matched AHSCTs was first 
described over 2 decades ago, the H-Y antigen.[Goulmy et al. 1976] This 
antigen has been joined by many others, the genes for which are located on sex 
chromosomes or autosomes, and are now collectively termed the minor 
histocompatability antigens (mHags). These mHags are naturally processed 
peptide fragments originating from intracellular proteins that associate with HLA 
molecules.[Goulmy 1997]
Donor T cells recognise mHags in an HLA-restricted manner. Some mHags 
have been shown to have heterogeneous tissue distribution.[Warren et al. 1998] 
After AHSCT, those HLA molecules and mHags that are disparate between 
donor and recipient collectively form the alloantigen repertoire. There is 
frequently disparity between donor and recipient mHags in the HLA-matched 
sibling setting. mHag-specific cytotoxic T lymphocytes can be detected in 
AHSCT recipients with GvHD by the use of tetrameric HLA class l-mHag 
peptide complexes, and disparity for some mHags has been shown 
retrospectively to be associated with an increased risk of acute GvHD after HLA 
identical sibling AHSCT.[Gallardo et al. 2001;Mutis et al. 1999a] Conversely in
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the syngeneic setting where there is complete genetic identity of donor and 
recipient at all HLA and most mHag loci, GvHD is rarely seen.
Allogeneic proteins are processed into antigenic peptides by antigen presenting 
cells (APCells). Peptide loading of MHC Class I molecules occurs in the 
endoplasmic reticulum and in cytosolic vesicles in the case of MHC Class II 
molecules, which are the transported to the cell surface. Specialised 
(‘professional’) APCells include dendritic cells and are distributed in high density 
in the areas of the body that interface with the external environment (skin, 
mucosa) and frequently encounter antigen. They take up antigen in these sites 
by endocytosis and migrate to the lymph nodes where they present antigen to T 
cells. Immature dendritic cells express high levels of surface molecules, which 
aid the endocytosis of antigen, whereas mature dendritic cells express very high 
levels of MHC Class II molecules and co-stimulatory molecules to facilitate 
efficient antigen presentation. Macrophages, activated B cells and human T 
cells (under some circumstances) are also able to present antigens. [Arnold et 
al. 1997;Mannie et al. 1998;Mannie and Walker 2001;Pichler and Wyss-Coray 
1994;Tsang etal. 2003]
Classical human MHC Class I molecules (HLA A, B and C) are membrane 
bound proteins expressed almost universally on nucleated cells. The three 
extracellular domains of the MHC Class I molecule are associated with p2- 
microglobulin. Antigen in the form of peptide is bound between two of the 
extracellular domains. Antigens that bind to MHC Class I molecules are 
principally endogenous or derived from virus after intracellular processing. 
Human MHC Class II molecules (HLA-DP, HLA-DQ and HLA-DR) consist of two 
extracellular polypeptides, each of which has two domains, and antigen binds 
between the two extracellular polypeptides and is usually exogenous in 
nature.[Bryant et al. 2002;Moron et al. 2004]
T cells bear surface membrane receptors belonging to the immunoglobulin 
superfamily. 90% of mature T cells express T cell receptors (TCRs) consisting 
of two a chains and two p chains. Each a and each p chain consists of a 
constant region and a highly polymorphic variable region. It is the latter that 
binds to processed antigenic peptide when presented to the TCR whilst in 
association with an MHC molecule. The TCR also consists of five associated 
polypeptides: CD3-e, CD3-8, CD3-y and usually a homodimer. These
31
associated chains are involved with signal transduction and activation of the T 
cell, and are identical on all T cells.
Peptide antigens sited in their MHC molecules make contact with T cells; every 
antigen/MHC molecule will only interact with high affinity with T cells bearing the 
corresponding specific T cell receptor.[Davis and Bjorkman 1988] CD4+ T cells 
interact predominantly with peptide antigen presented in context of an MHC 
Class II molecule whereas CD8+ T cells interact predominantly with peptide 
antigen presented in context of an MHC Class I molecule. However, dual HLA 
class I and class II restricted recognition of alloreactive T lymphocytes mediated 
by a single T cell receptor complex has recently been described. The 
alloreactive human CD8+ T cell clone MBM15 was found to exhibit dual 
specificity recognizing both an antigen in the context of the HLA Class I A*0201 
molecule and an antigen in the context of the HLA Class II DR1.[Heemskerk et 
al. 2001]
Other molecules are involved in strengthening the interaction between the 
APCell and the T cell (the ‘immunological synapse’). Both the CD4 and the CD8 
receptor increase the affinity of this association. Adhesion molecules stabilise 
the peptide antigen/MHC molecule interaction with the TCR. T cell activation 
stimulated by the contact between peptide antigen/MHC molecules and the 
corresponding TCR can be augmented by interaction between complementary 
receptor pairs on the APCell and T cell. The most important of these are the 
CD28 receptor, expressed on many T Cells, which interacts with the B7.1 
(CD80) and B7.2 (CD86) molecules on the APCs. Lack of additional CD28 co­
stimulation during antigen presentation to a T cell can lead to specific 
hyporesponsiveness of that T cell, a state called T cell anergy. Inhibitory co­
stimulatory molecules also exist on APCells, the best-described being CTLA-4 
(CD152) which is structurally related to CD28, binds CD80 and CD86 but 
delivers an inhibitory signal to the T cell.[Allison 1994;Mescher 1995]
The high affinity stabilised interaction between antigen (presented in the context 
of MHC molecule) and the TCR triggers a cascade of intracellular events that 
lead to T cell activation. The intracellular portion of the TCR complex contains 
an invariant region, the immunoreceptor tyrosine-based activation motif (ITAM). 
The TCR complex and CD4 (or CD8) co-receptors are associated via ITAMs 
with the Src-family protein kinases Fyn and Lck respectively. Upon formation of 
the immunological synapse Fyn and Lck become activated and activate the
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tyrosine kinase ZAP-70, which in turn activates phospholipase C-y. Three 
important intracellular pathways are then initiated. Firstly, the transcription factor 
NF-kB is activated, secondly calcineurin activates the transcription factor NFAT 
and thirdly Ras activates a MAP kinase cascade that in turn activates Fos, a 
component of the AP-1 transcription factor. These three transcription factors act 
to induce specific gene transcription. Two important genes that demonstrate 
marked upregulation of transcription upon activation of T cells are the 
Interleukin 2 (IL-2) and the IL-2 receptor genes. Increased production of IL-2 
leads to increased T cell proliferation via the autocrine positive feedback loop 
mediated by increased cell surface expression of the IL-2 receptor.[Carpino et 
al. 2004;Denny etal. 2000;Judd and Koretzky 2000]
The physiological process of T cell development and maturation occurs in the 
human thymus. Here the TCR genes are randomly rearranged in every T cell to 
generate a highly diverse repertoire of T cells.[Zuniga-Pflucker 2004] After this 
has occurred dendritic cells within the thymic microenvironment present self­
antigens as MHC bound peptides and all T cells whose receptors recognise self 
antigens are deleted, which results in immunological tolerance to self.[Nossal
1994] Negative selection of B cells also occurs. These processes are not 
completely effective and both T and B cells with affinity for self-antigens may 
escape the thymus. These cells are normally inhibited by clonal anergy or by T 
regulatory cells and lose their abilities as effectors of an immune response. It 
has been proposed that the loss of function of T regulatory cells leads to 
increased activity of autoreactive T and B cells and that this may lead to 
autoimmune disease.[Saoudi et al. 1996]
The molecular basis of alloreactivity remains to be fully defined. Between 0.1% 
and 10% of an individual's T cell repertoire react with alloantigens,[Ashwell et al. 
1986a;Lindahl and Wilson 1977a;Lindahl and Wilson 1977b;Matesic et al. 
1998;Suchin et al. 2001] compared with a frequency of <1/100000 for nominal 
peptide antigens.[Karulin et al. 2000]
Initial hypotheses of the mechanisms underlying alloreactivity relied on the 
principle of cross-reactivity of host TCRs for allogeneic MHC/peptide complexes 
in a peptide-dominant fashion.[Lechler and Batchelor 1982] Alternatively there 
is some evidence that the allogeneic MHC molecule itself may be the 
conformational structure to which alloreactive T cells respond, independent of 
the bound peptide (MHC dominance).[Uu et al. 1993] As understanding of the
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molecular interaction between MHC molecules, the peptides they bind and the 
TCR with which they interact has deepened, several mechanisms have been 
suggested to explain recognition of foreign MHC molecules. Fortuitous contacts 
between the TCR and polymorphic helical residues on the allogeneic MHC not 
present on self-MHC may augment TCR contacts. Since such allogeneic MHC 
specificities were not deleted by negative selection in the thymus due to their 
absence, the TCR-allogeneic MHC affinity may be high and T cell activation 
robust.[Sykulev et al. 1994] Furthermore, these additional TCR-MHC contacts 
may relax specificity requirements for peptide residues, thereby allowing more T 
cells to respond to allogeneic stimulator cells expressing a range of bound 
peptides.[Daniel et al. 1998] Second, as many polymorphic residues of the 
MHC antigen-presenting platform are not exposed to the TCR but do contribute 
to peptide binding specificity, different pools of peptides are bound by different 
MHC alleles. These variations in peptides may affect thymic selection 
processes differentially as well.[Kranz 2000] Third, differences in conformation 
of the same bound peptide in the groove of two different MHC alleles may result 
in differences of TCR recognition.[Hennecke and Wiley 2002] Thus the 
alloantigen should be viewed as a combination of foreign MHC and the peptides 
bound therein.
Two pathways have been described by which the alloantigen complex may be 
presented, first defined by Lechler and Bachelor.[Lechler and Batchelor 1982] 
Presentation by donor APCells is termed direct alloantigen presentation. 
Indirect alloantigen presentation can also occur when foreign MHC molecules 
are processed and the derived peptides presented by host APCells. Although 
the relative importance of direct and indirect alloantigen presentation in the 
clinical AHSCT setting has yet to be determined, it has been shown in vitro that 
the frequency of human T cells engaged in the indirect pathway of 
allorecognition is about 100-fold lower than that of T cells participating in the 
direct recognition of native HLA-DR antigen.[Liu et al 1993] A cartoon of these 
two pathways of alloantigen presentation is shown in Figure 1.1.
Allogenicity still occurs between genotypically HLA identical siblings and this is 
due to differences in mHags. Recipient mismatching for the mHag HA-1 has 
been associated with acute GVHD after HLA identical sibling bone marrow 
transplantation.[Tseng etal. 1999]
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Figure 1.1 Direct and indirect pathways of allorecognition (as defined by Lechler and Bachelor).[Lechler and Batchelor 1982]
1.4. Graft-versus-Host Disease
The major barrier to solid organ allogeneic transplantation in humans is host 
rejection of the transplanted tissue and long-term host immunosuppression is 
required to overcome this obstacle. Transplantation of allogeneic 
haematopoietic stem cells differs from solid organ transplantation in that the 
transplanted tissue itself constitutes a functionally immunocompetent organ. As 
a result alloreactivity in AHSCT is bi-directional. Allogeneic haematopoietic stem 
cell grafts are not only capable of being rejected by the host (graft rejection) but 
are able to recognise the host as foreign and attempt to reject the host tissues. 
This phenomenon is Graft-versus-Host Disease, and is a major cause of 
morbidity and mortality post AHSCT. The phenomenon of GvHD was first noted 
when irradiated mice were infused with allogeneic spleen cells. These mice 
recovered from their radiation-induced marrow aplasia but subsequently died 
from a ‘secondary syndrome’ consisting of diarrhoea, weight loss, skin changes 
and liver disease.JVan Bekkum etal. 1967]
Initial experimental observations of van Bekkum and De Vries led to the 
theoretical formulation of the requirements for the development of GvHD by 
Billingham, [Billingham 1966] namely that;
(a) the allogeneic graft must contain immunologically competent cells,
(b) the recipient must be incapable of destroying the graft cells
(c) the recipient must express tissue antigens (now known to be HLA 
molecules and/or mHags) that are not present in the donor.
Billingham’s requirements are fulfilled in all clinical situations where GvHD may 
be observed, namely AHSCT and/or the subsequent infusion of donor 
lymphocytes to control disease relapse, transplantation of small bowel 
containing functional lymphoid tissue, and transfusion of unirradiated blood to 
immunocompromised patients.
Acute GvHD can occur within days after AHSCT (and by definition occurs within 
the first 100 days). Host organs affected are those rich in APCells- commonly 
the skin, gut and the liver. The classical three-step model of the
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immunopathogenesis of GvHD was first described by Ferrara.[Ferrara et al. 
1985] In step one, the recipient conditioning regimen simultaneously damages 
and activates host tissues, leading to secretion of pro-inflammatory cytokines 
such as tumour necrosis factor-alpha (TNF-a) and IL-1, and upregulation of 
adhesion molecules and MHC/antigen complexes on host 
tissues.[Leeuwenberg etal. 1988;Norton and Sloane 1991;Xun et al. 1994] This 
amplifies antigen presentation to allogeneic donor T cells. In step two, donor T 
cells, activated by host alloantigens proliferate and secrete a variety of 
cytokines. Donor CD4*T cells secrete T helper 1 (Thl)-type cytokines such as 
IL-2 and interferon-gamma (IFN-y) critical for the development of acute 
GVHD.[Via and Finkelman 1993] Th2-type cytokines (e.g. IL-4) are also 
released but the donor CD4+ T cell cytokine profile is deviated towards Th1-type 
cytokine release. The third step represents the effector arm of the process. 
Damage to host tissues occurs in the third step and may be the result of the 
direct effects of cytokines or cytolytic cell pathways.
Mononuclear phagocytes, primed during step two by Th1-type cytokines receive 
a second trigger signal from lipopolysaccharide (LPS) released from the gut 
mucosa during step one. LPS may also stimulate keratinocytes and 
macrophages in the skin to produce inflammatory cytokines.[McKenzie and 
Sauder 1990] Release of TNF-a and nitrous oxide can also cause direct host 
tissue damage in the gut. Cytolytic pathways are at least as important as 
cytokines in mediating host tissue damage in the third step of the pathogenesis 
of GvHD. Donor CD8+ cytotoxic lymphocytes cause host cell death by both the 
direct cytolytic damage that results from perforin and granzyme release and by 
the Fas-Fas Ligand triggering of target cell apoptosis.[Graubert et al. 1997;Via 
et al. 1996] The latter mechanism is probably the most important in the 
pathogenesis of hepatic GvHD.[Baker et al. 1996;Hattori et al. 1998] It is of 
critical importance that both donor CD4* and CD8* T cells play a crucial role in 
the pathogenesis of acute GvHD, which is represented in cartoon form in Figure 
1.2.
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Figure 1.2 The three-step pathogenesis of GvHD.[Ferrara et al 1985]
Chronic GvHD is defined as GvHD occurring more that 100 days after AHSCT. 
It may supersede acute GvHD directly, develop after resolved acute GvHD or it 
may develop in the absence of any preceding GvHD. The clinical syndrome of 
chronic GvHD affects primarily the skin with the development of skin atrophy 
and changes resembling scleroderma. The liver and gut may be affected and 
the pulmonary syndrome of bronchiolitis obliterans is seen with a progressive 
restrictive lung defect. The multisystem changes seen in chronic GvHD have 
often been likened to those seen in autoimmune connective tissue disorders. 
There is some experimental evidence that alloreactive T cells in mice with 
chronic GvHD show specificity not restricted to host alloantigens but to a 
common MHC class II antigen epitope. Such T cells secrete a mixed cytokine 
profile (IL-4 and IFN^y but not IL-2). The persistence of autoreactive IL-4 
secreting T cells that promote collagen formation in patients with chronic GvHD 
has been linked to absent or impaired thymic function (and thus impaired 
deletion of autoreactive T cells). [Parkman 1986]
The risk of developing acute GvHD (and its severity) is difficult to predict, 
especially in the HLA-matched setting. The mixed lymphocyte reaction (MLR) is 
an in vitro test quantifying cellular proliferative responses to stimulation by 
allogeneic PBMCs.[DuPont and Hansen 1976] The MLR utilises y-irradiated 
PBMCs as stimulatory cells and live allogeneic PBMCs as responder cells. The 
assay measures the proliferation of responder cells after 120 hours of co-culture 
by measuring their incorporation of tritiated thymidine. The MLR is useful in the 
HLA-mismatched setting to predict graft rejection or GvHD.[Odum et al. 1987] 
However the MLR does not detect responses evoked by HLA DP and mHag 
mismatches between donor and recipient, and has neither high positive nor high 
negative predictive value for the occurrence of GvHD in HLA-matched sibling or 
unrelated donor transplants.[al Daccak et al. 1990;Bishara et al. 1994;Bishara 
etal. 1999]
In an attempt to improve the predictive value for GvHD of the MLR in the HLA- 
matched sibling setting the MLR assay has been modified by both the pre­
treatment of the stimulator cells with cytokines (TNF-a and IFN-y) and the 
addition of stimulatory cytokines (IL-2 and/or IL-4) to the MLR co-culture itself. 
HLA-matched responder proliferation above and below 5% of that seen with 
mismatched stimulator cells was found to have fair positive and excellent
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negative predictive value for acute GvHD after T replete full intensity 
conditioning sibling allogeneic transplantation (66% and 90% 
respectively).[Bishara eta! 1994]
Using only IL-4 addition to the MLR co-culture, responder ceil proliferation 
(RRI>5%) has been shown to be predictive of clinically significant GvHD in HLA 
A, B and DR-matched unrelated bone marrow transplants and to correlate with 
molecular HLA-C disparity between donor and recipient.[Bishara et al 1999] 
Limiting dilution assays include the Cytotoxic T Lymphocyte Precursor (cTLP) 
and Helper T Lymphocyte Precursor (hTLP) assays. These assays quantify the 
frequency of CDS'" and CD4* cells with activity in the GvHD direction. High 
cTLP frequency has been shown to correlate with HLA Class I mismatch and 
hTLP frequency with Class II mismatch although cTLP frequency cannot 
distinguish between Class I mismatches that cause GvHD and those that do 
not, and is thus not a reliable tool to predict clinical risk of GvHD.[EI Kassar et 
al. 2001;Madrigal etal. 1997]
Another in vitro assay in use to predict GvHD is the skin explant assay. First 
described by Vogelsang in1985 this technique uses recipient skin as the target 
and donor PBMCs (which have been pre-stimulated with irradiated recipient 
PBMCs) as effector cells.[Vogelsang et al. 1985] Histopathological changes 
(akin to GvHD) in the skin biopsies are assessed after 72 hours of co-culture 
with donor PBMCs. The skin explant model has been shown to be a clear 
predictor of GvHD in adult HLA Class I and II matched non-T cell depleted 
sibling AHSCTs. In this setting the technique is better than limiting dilution 
assays (CTLp and/or HTLp frequency) in predicting GvHD, and has a positive 
predictive value as high as 91% in paediatric patients undergoing matched 
sibling transplants.[Dickinson et al. 1998;Hromadnikova et al. 2001;Sviland and 
Dickinson 1999]
More recently, polymorphisms genes encoding cytokines and cytokine 
receptors have been shown to be associated with increased risk of occurrence 
of both acute and chronic GvHD after sibling AHSCT. These include 
polymorphisms of the IFN-y, IL-6, oestrogen receptor alpha and IL-1 alpha 
genes. [Cavet et al. 2001;Cullup et al. 2003;Dickinson et al. 2001;Middleton et 
al. 2003] The relative importance of such polymorphisms in the HLA- 
mismatched or matched unrelated setting is yet to be determined.
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Clinically severe GvHD occurs in 20-30% of non-T cell depleted HLA-matched 
sibling transplants and at least 40% of non-T cell depleted unrelated HLA- 
matched transplants[Chao and Schlegel 1995]. Treatment of established acute 
GvHD is ineffective and mortality is high.[Jacobsohn and Vogelsang 2004] 
Conventional treatment for established GvHD is highly immunosuppressive and 
delays Immune reconstitution post AHSCT and the subsequent susceptibility to 
infection contributes significantly to the high mortality seen in recipients with 
severe GvHD. Various strategies have therefore evolved to prevent GvHD after 
AHSC transplantation.
Much work has focussed on the critical role of damage to the gut mucosa and 
LPS release. Gut decontamination with non-absorbable antibiotics has long 
been administered to recipients prior to AHSCT to reduce GvHD and there is 
evidence in both murine models and human trials of the efficacy of this 
strategy.[Lampert et al. 1988;Yabee ta l. 1988]
The pharmacological blockade of LPS has also been shown to reduce GvHD in 
a mouse model.[Cooke et al. 2001] Murine work also supports the efficacy of IL- 
11 administration to polarise host T cells to Th2-type cytokine release and thus 
reduce GvHD.[Hill et al. 1998] A Phase I/ll clinical study did not however 
support the use of IL-11 in adult AHSCT.[Antin et al. 2002] Keratinocyte growth 
factor has also been shown to reduce GvHD in murine experiments and is 
currently being used in a Phase I/ll clinical trial in patients undergoing 
mismatched related or unrelated transplants.[Panoskaltsis-Mortari et al. 
1998;Ratanatharathm V et al. 2003] Both of these strategies have been shown 
not to adversely affect the graft-versus-leukaemia effect (vide infra) in murine 
models.
Reduction in intensity of recipient conditioning (especially the use of regimes 
that do not contain total body irradiation) theoretically should result in less 
GvHD by minimising host tissue damage, the initiating step in the pathogenesis 
of GvHD, and this has been reported in many published series of transplants 
utilising such reduced intensity conditioning regimes.[Bacigalupo 2002]
Anti TNF-D antibody treatment administered during conditioning delayed the 
onset but did not prevent acute GvHD in a Phase I/ll clinical study.[Holler et al.
1995] IL-2 also has a fundamental role in the pathogenesis of acute GvHD and 
when administered to recipients of autologous HSCT induces a GvHD-like 
syndrome.[Massumoto et al. 1996] However prophylactic anti-IL-2 antibody
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treatment does not reduce the development of GvHD in the AHSCT and indeed 
when given as a treatment for acute GvHD worsened survival.[Blaise et al. 
1991 ;Blaise et al. 1995]
The earliest pharmacological manoeuvres to prevent GvHD acted to suppress 
responsiveness of donor T cells either by ex vivo non-selective donor T cell 
depletion or by in vivo (post-transplant) donor T cell depletion/suppression by 
pharmacological treatments or antibodies administered to the transplant 
recipient.
The most commonly used pharmacological agents used to suppress donor T 
cells post transplant are drugs that share the common final pathway of action of 
inhibition of T cell activation. The longest established are the fungal derivatives 
cidosporin and tacrolimus, which inhibit the calcineurin serine/threonine 
phosphatase that mediates transcription factor activation (e.g. NFAT) thus 
reducing the upregulation of pro-inflammatory cytokine production such as IL-2 
by activated lymphocytes. Either of these two drugs is administered to the 
recipient post-transplant, often in conjunction with the dihydrofolate reductase 
inhibitor methotrexate. Initial use of these drugs developed historically after 
evidence of activity in animal studies and no randomised studies exist 
comparing the use of no GvHD prophylaxis with these pharmacological agents 
in human AHSCT. Several non-randomised trials have suggested benefit of 
pharmacological GvHD prophylaxis in non-T cell-depleted AHSCT. A landmark 
trial from Stanford, USA demonstrated that use of both cidosporin and 
methotrexate (in conjunction with corticosteroids) halved the frequency of GvHD 
seen in matched sibling transplants given cidosporin and steroids alone. A 
subsequent study in Spain demonstrated that corticosteroids as part of GvHD 
prophylaxis with cidosporin and methotrexate were of no additional benefit and 
were possibly detrimental.[Ancin etal. 2001;Chao etal. 1993]
Animal studies have shown that tacrolimus treatment of CD34* haematopoietic 
stem cells promotes the development of dendritic cells that drive CD4* cells 
towards a Th2-type cytokine profile.[Shimizu et al. 2000] Indeed there is animal 
evidence that the myeloid growth factor granulocyte colony-stimulating factor 
(G-CSF) mobilizes Th2-inducing dendritic cells, which may help to protect 
against GvHD. It has been suggested that this effect underlies the relatively low 
incidence of acute GvHD seen allogeneic transplantation of G-CSF-mobilised
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peripheral stem cell grafts, despite the presence of 10-20 fold more T cells than 
conventional bone marrow grafts.[Arpinati etal. 2000;Franzke et al. 2003]
Newer immunosuppressive agents include the TOR protein-binding P7056 
kinase inhibitor rapamycin, which causes cell cycle arrest in G1, and the inosine 
monophosphate dehydrogenase inhibitor mycophenolate mofetil (MMF) that 
preferentially inhibits T cell activation as a result of selective purine metabolism 
in lymphocytes. Although the use of these two agents in both prophylaxis and 
treatment of GvHD is increasing, they are still mainly employed prophylactically 
when there is intolerance to cidosporin and tacrolimus.
Anti-T cell antibodies have been employed as part of host conditioning regimes 
when there is a higher chance of graft rejection (aplastic anaemia, unrelated 
and mismatched transplants, reduced intensity conditioning regimes). 
Lympholytic concentrations of the humanised pan-lymphocyte anti-CD52 
antibody Campath 1H can be detected for several days after transplantation 
when administration to the host as part of conditioning. There is no doubt that 
persistence of this antibody will cause a degree of depletion of donor T cells, 
and may serve to deplete recipient circulating (but not tissue) dendritic cells, 
which may abrogate GvHD by reducing indirect alloantigen 
presentation.[Buggins et al. 2002;Klangsinsirikul et al. 2002;Morris et al. 
2003;Ratzinger et al. 2003]
1.5 Non-selecttve T Cell Depletion
Undoubtedly the single most effective method of preventing GvHD after AHSCT 
is donor T cell depletion prior to infusion of the graft into the recipient. This can 
be achieved either by the destruction of T cells within the graft or their removal 
by cell sorting techniques. Indeed the critical role of donor T cells in the 
pathogenesis of GvHD is underlined by the observation that the development of 
GvHD Is related to the number of residual donor T cells left in the graft after T 
cell depletion, and that reduction of the infused T cell dose to 1x105/kg recipient 
body weight effectively removes the incidence of severe GvHD in HLA-matched 
sibling AHSCT.[Atkinson et al. 1987] No additional pharmacological 
immunosuppression is required to prevent severe acute GvHD in this setting. T 
cell depletion has also been shown to be effective in GvHD prophylaxis in HLA-
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matched or mismatched unrelated donor transplantation although some severe 
GvHD may still seen in this setting.[Ash et al. 1990]
The earliest methods used to deplete donor grafts of T cells included soybean 
lectin agglutination and sheep E rosette formation, which in combination leads 
to a 100-fold reduction in numbers of T cells within the graft.[Reisner et al. 
1981]
The use of monoclonal antibodies in non-selective T cell depletion was 
pioneered in the early 1980s by Prentice et al. and Filipovich et al, with 
incubation of murine anti-CD3 (OKT3) antibody with (predominantly matched 
sibling) bone marrow grafts prior to reinfusion.[Filipovich et al. 1982;Prentice et 
al. 1982]
Other monoclonal anti-T cell antibodies have been used to T deplete grafts 
either alone or in combination and include anti-CD6 and the combination of anti- 
CD6, anti-CD7 and anti-CD8. [Prentice et al. 1984;Soiffer et al. 1997]
More recently dual selection procedures using immunomagnetic cell sorting 
systems (such as the CliniMACs system and the Isolex 300i device) using 
positive selection of CD34* cells followed by T cell depletion (by various 
methods) have been developed. These techniques lead to profound T cell 
depletion of grafts with a 3-5 log-reduction in T cell dose, often to below 104/kg 
recipient body weight, which is sufficient to prevent severe GvHD even in adult 
recipients of haplotype-mismatched related donor grafts.[Aversa et al. 2001] 
Reduced rates of engraftment were seen in early reports of the use of T cell 
depleted HLA-matched sibling AHSC. Rates of engraftment comparable with 
non-T depleted HLA-matched sibling transplants were subsequently achieved 
by increasing either the dose rate (if given as a single fraction) or the total dose 
of irradiation (if administered in a fractionated regime) in the recipient 
conditioning regime, or the addition to recipient conditioning of 
immunosuppressive agents such as fludarabine and/or anti-T cell antibodies to 
reduce the number of host CTLps that mediate graft rejection. Depletion of the 
CD8* cell subset alone has been undertaken (in an attempt to improve post 
transplant immune reconstitution), and does reduce the incidence of GvHD in 
HLA-matched sibling donor transplants.[Nimer et al. 1994] However there is 
evidence that CD4* cells play a critical role in the pathogenesis of GvHD and 
when CD4+ cells alone are given as Donor Lymphocyte Infusions (DLI), post
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transplant at time of relapse, fatal GvHD has been reported suggesting that 
CD4+ cells alone are capable of mediating severe GvHD.[Alyea et al. 1998]
An early series published by Horowitz et al demonstrated a significant increase 
in disease relapse in patients who received non-selective T cell depleted sibling 
allogeneic bone marrow transplants for leukaemia (when compared to those 
who received non-T cell depleted transplants).[Horowitz et al. 1990] This raised 
concerns about the concomitant loss of the anti-tumour effect that might also be 
mediated by donor T cells (the Graft-versus-Leukaemia effect, GvL) in non- 
selectively T cell depleted grafts. Horowitz also reported a lower relapse rate in 
recipients of non-T cell depleted grafts that developed GvHD suggesting that 
the allogeneic GvL and GvHD T cell responses were linked. However when only 
the transplant recipients with acute myeloid leukaemia are considered in this 
series, the increase in relapse in recipients who receive non-selectively T cell 
depleted grafts is greater than the number of recipients of non-T cell depleted 
grafts who developed GvHD, and so it could be postulated that allogeneic T 
cells exert a GvL effect in some recipients who do not develop GvHD. The latter 
observation suggests that the GvL effect and GvHD are to some degree 
separate processes, albeit with some common ground (underscored by shared 
alloantigens on recipient leukaemic cells and non-leukaemic tissues vulnerable 
to GvHD).
Further compelling evidence for the existence of the allogeneic GvL effect has 
been provided by the therapeutic efficacy of post-transplant DLI in treating 
relapse.[Kolb et al. 1995;Mackinnon et al. 1995] The GvL effect (as measured 
by overall response to DLI) is more marked in some diseases (e.g. Chronic 
Myeloid Leukaemia, (CML)) than others (e.g. Acute Lymphoblastic Leukaemia, 
Myeloma) and this probably reflects a combination of over-expression of 
tumour-restricted or tumour specific antigens in diseases susceptible to DLI, 
and the kinetics of disease progression.[Clark et al. 2001;Peggs et al. 
2003a;Rezvani et al. 2003] Further evidence that the GvL effect and GvHD may 
be separable came from the ability of DLI, especially at low doses to induce 
disease remission without causing GvHD.[Mackinnon eta l 1995]
Profound non-selective T cell depletion also leads to quantitative and qualitative 
delays in post-transplant immune reconstitution and to an increase in infections 
during this period.[Chakrabarti etal. 2002a;Chakraverty etal. 2001]
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It is clear, therefore, that whilst non-selective T cell depletion is an effective way 
of abrogating GvHD in AHSCT, the loss of the GvL effect and increases in post­
transplant infections are major disadvantages of this manoeuvre.
1.6 Selective Allodepletion
Some groups have reported the use of pharmacological agents or antibodies 
(such as butyric acid derivatives, T cell co-stimulatory blockade +/- anti-CD40 
antibody, use of the proteasome modulator bortezomib) administered to the 
whole T cell population within the graft to reduce allogeneic responses. 
Although published reports describe successful abrogation of GvHD in MHC 
mismatched murine models there is little evidence presented for preservation of 
the GvL effect or cellular responses to infection and indeed no putative 
mechanism why these responses should be selectively retained using these 
techniques.[Blazar et al. 1997;Gilbert etal. 2003;Sun etal. 2004]
Genetic modification of T cells within the allogeneic haematopoietic stem cell 
graft has also been undertaken to permit pharmacologically triggered inhibition 
(or destruction) of donor CD8+ cells, to be employed when GvHD develops. The 
reinfusion of donor CD8* cells transduced with the herpes simplex thymidine 
kinase enzyme (which allows them to be selectively destroyed by administration 
of ganciclovir to the recipient) is the most elegant of these systems but has 
proved a difficult one to develop to clinical grade and is also limited by cell cycle 
dependence and increased immunogenicity of transfected T cells.[Helene et al. 
1997;Riddell etal. 1996]
The triggering of apoptosis via the intracellular FAS/FKBP-mediated pathways 
in CD8* cells causing GvHD is an alternative approach which has been shown 
to eliminate >80% of human transduced CD8+ cells regardless of their 
proliferation status.[Thomis et al. 2001] However, these methods lack 
specificity, and when employed are not restricted to alloreactive T cell inhibition 
and/or destruction.
An alternative approach to reducing GvHD, whilst potentially retaining cellular 
responses to infection (and possibly tumour cells) is the identification and 
subsequent removal/disablement of T cells within the graft able to recognise 
and respond to host alloantigen stimulation. This process is called selective T 
cell depletion or allodepletion.
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All published techniques of selective allodepletion of haematopoietic cells utilise 
a common fundamental mechanism. Stimulator (usually irradiated) cells 
capable of presenting alloantigens are incubated with live HLA-mismatched (or 
matched) responder cells in a mixed lymphocyte reaction. T cells within the 
responder cell population that are specific to stimulator alloantigens are 
subsequently identified and either rendered anergic, destroyed or removed, 
depending upon the individual technique. The resulting allodepleted responder 
cell fraction is available for re-infusion to the transplant recipient.
Many individual techniques have been described for achieving selective 
allodepletion of allogeneic haematopoietic stem cell grafts and can broadly be 
divided into three categories:
1. Induction of anergy in alloreactive T cells (e.g. by CTLA-4 antibody
administration to the MLR).
2. Identification of alloreactive T cells by their increased metabolic activity
or proliferative rate and their subsequent destruction or depletion using 
the techniques of photodynamic purging or carboxyfluorescein diacetate 
succinimidyl ester (CFSE) dye dilution.
3. Identification of alloreactive T cells by their cell surface expression of
antigens associated with T cell activation and their subsequent 
destruction or depletion, (e.g. CD25-linked immunotoxin techniques, 
CD69 immunomagnetic depletion, CD95 ligation).
Different mechanisms utilise different MLR conditions and different APCells and 
some individual techniques have been investigated using several APCells. The 
optimal choice of APCell and individual co-culture conditions in the MLR may be 
different for each technique and may also differ when allodepletion techniques 
are applied clinically, depending on the degree of HLA mismatch between donor 
and recipient and the disease groups of recipients. A cartoon illustrating the 
various techniques that have been published for selective alloreactive T cell 
depletion is shown in Figure 1.3. It also shows the range of APCells that may be 
used to present recipient alloantigens to donor (responder) cells in the MLR.
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The published evidence for the use of each individual technique is described in 
detail in subsequent sections.
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Figure 1.3 Techniques available for selective allodepletion of haematopoietic stem cell grafts and the range of antigen presenting cells
used in such techniques.
1.7 The Induction of Anergy In Alloreactive T Cells
An alternative to depletion or destruction of alloreactive cells is the induction of 
anergy in such cells. The presentation of antigens in a one way (host to graft) 
mixed lymphocyte reaction leads to the activation of alloreactive cells within the 
graft unless co-stimulatory blockade is employed: in this situation the result is the 
induction of hyporesponsiveness or anergy on host reactive donor cells. Such 
anergy can be induced by blocking the interaction of the B7 molecule on the 
surface of antigen-presenting cells with the CD28 molecule on the surface of T 
cells, thus preventing key signalling events essential for the activation of T cells. 
The blockade of this and numerous other co-stimulatory pathways have been 
shown to reduce GvHD in murine models, including CD40/CD154 and 
CD134/CD134 ligand interactions.[Blazar et al. 1994;Durie et al. 1994;Tsukada 
etal. 2000]
Blockade of B7/CD28 interaction was the technique used in a clinical trial in 12 
HLA non-identical haematopoietic stem cell transplants for the induction of 
anergy in donor T cells to recipient alloantigens prior to infusion into the recipient. 
Recipient PBMCs were collected before myeloablation and served as 
alloantigen-presenting cells. To induce alloantigen-specific anergy, bone marrow 
from a donor mismatched with the recipient for one full HLA haplotype was co 
cultured with irradiated recipient PBMCs for 36 hours in the presence of anti- 
CTLA-4 antibody, an agent that inhibits B7/CD28-mediated co-stimulation of T 
cells. After conventional myeloablation and immunoprophylaxis, the treated 
donor cells were transfused into the recipient. After the induction of anergy, the 
frequency of T cells capable of recognizing alloantigens of the recipient in donor 
marrow was reduced whereas the responsiveness to alloantigens from persons 
unrelated to the recipient or the donor was unaffected. In all 11 evaluable 
patients, the haploidentical bone marrow cells engrafted. Of these 11 patients, 3 
had acute GVHD confined to the gastrointestinal tract. No deaths were 
attributable to GVHD. Five of the 12 patients were alive and in remission 5 to 29 
months after transplantation. This trial seems to support the technique of 
induction of anergy in alloreactive cells by co-stimulatory blockade, although it 
must be noted that several of the recipients were in frank haematological relapse 
pre-transplant and thus the majority of the cells used to present alloantigens in 
the donor co-culture were leukaemia cells. If leukaemia-restricted (or-specific)
antigens were presented to donor T cells and subsequently rendered anergic 
then the anti-leukaemic activity (GvL) of the AHSC graft would be reduced with 
the possibility of increased disease relapse. It is therefore of note that no long­
term follow-up of patients on this trial has been published.[Guinan et al. 1999]
1.8 Antigen-independent Selective Allodepletion Techniques
1.8.1 Photodynamic Purging
Photodynamic purging (PDP) of alloreactive cells is a technique that utilises the 
increased metabolic activity seen in alloreactive donor T cells when stimulated by 
recipient alloantigens, and has been demonstrated in a non-identical murine 
model. Donor cells were stimulated with irradiated BALB/c (H-2 (d)) host spleen 
cells in a 5-day mixed lymphocyte culture. Following this activation, a photoactive 
rhodamine derivative called 4,5-dibromorhodamine 123 (TH9402), was added. 
This compound is selectively retained in the mitochondria of activated host- 
reactive cells (but not tumour- or third-party-specific resting cells). Treated cells 
were subsequently exposed to visible light (514 nm) to deplete the TH9402- 
enriched activated alloreactive cells. Selectively allodepleted T cells were 
subsequently infused into C57BL/6 (H-2 (b)) mice. Treatment with photodynamic 
cell purging process inhibited antihost responses (measured by cTLP by 93%, 
and IFN-y production by 66%). By contrast, anti-BCL1 (BALB/c-origin 
leukaemia/lymphoma) and anti-third-party C3H/HeJ (H-2 (k)) responses were 
preserved. PDP-treated primed C57BL/6 cells were also further tested in vivo. All 
lethally irradiated BALB/c mice inoculated with BCL1 leukaemia/lymphoma cells 
and T cell-depleted bone marrow cells developed leukaemia with a 50% mortality 
by 100 days. All mice died of GvHD after addition of 5 x 106 untreated primed 
C57BL/6 bone marrow cells. However, addition of same numbers of PDP-treated 
C57BL/6 bone marrow cells allowed 90% of the recipients to survive more than 
100 days without detectable BCL1 tumour cells and free of GvHD. Moreover, 
PDP-treated primed C57BL/6 cells retained the ability to induce GvHD in third- 
party (C3H/HeJ) mice.[Chen et al. 2002]
1.8.2 CFSE Dye Dilution Techniques
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Donor cells may be labelled prior to allostimulation in the MLR with 5-(and 6-) 
CFSE, which is diluted out when cells divide. The CFSE*'9*1 (non-dividing) cells 
after allostimulation in the MLR may be sorted flow cytometrically, a positive 
selection system of non-alloreactive cells. This technique has been used in an in 
vitro human model using HLA-mismatched PBMC stimulators. After flow 
cytometric sorting of CD4+ CFSE responders, proliferative responses to 
original allostimulator PBMCs were reduced, much more markedly so (90-95% 
reduction) if responder cells were depleted of cells expressing the activation 
marker CD25 {vide infra)\Godfrey et al. 2004] The reduction in proliferative 
responses after alloreactive cell depletion using this technique was improved 
when purified matured monocyte-derived dendritic cells (DCs) were used as 
stimulators (a 100-fold (99%) reduction in alloreactivity was attained). 
Significantly, the CFSE13"9^  CD25' cells recovered from these cultures retained 
responses to Candida and cytomegalovirus (CMV) antigens. In addition, the 
CFSE-based approach prevented GvHD in a MHC Class II disparate murine 
model. An obvious criticism of this technique is that when allodepletion is based 
on CFSE alone, only proliferating CD4+ cells are removed and any alloreactive 
response in non-proliferative cytokine secreting CD4+ and CD8+ cells will remain. 
This presumably explains the further reduction in the alloresponse when CFSE 
technique was combined with selection of cells negative for the activation marker 
CD25. Cell sorting by flow cytometry is a difficult technique to perform under 
sterile conditions and thus would be potentially difficult to develop to a clinical 
scale.
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1.9 Antigen-dependent Selective Allodepletion
1.9.1 CD95
Huber’s group recently described a technique of selective allodepletion that 
utilizes the upregulation of the FAS receptor (CD95) upon alloreactive T cells and 
activation-induced cell death (AICD) (by apoptosis) caused by antibody-mediated 
ligation of the FAS receptor on such cells in a MHC mismatched murine model. 
Activation of resting or pre-activated T lymphocytes from C3H/HeJ (H-2 (k)) mice 
was induced in an MLR with irradiated BALB/cJ (H-2 (d)) mouse-derived 
stimulators. A substantial decrease (80%) of proliferative and lytic responses by 
activated alloreactive T cells was subsequently achieved by incubating the MLR 
with an agonistic monoclonal antibody to CD95, and residual T cells recovered 
did not elicit alloreactivity upon challenge to H-2 (d). Depletion of alloreactive T 
cells by AICD was shown to be specific to host alloantigens because reactivity to 
an l-A (d)-restricted ovalbumin (OVA) peptide by OVA-specific CD4+ T cells 
mixed into the allogeneic T cell pool and subjected to induction of AICD in the 
absence of OVA peptide could be preserved. Adoptive transfer of donor-derived 
allogeneic T lymphocytes, depleted from alloreactive T cells by AICD in vitro, in 
the parent (C3H/He) to F (1) (C3H/He x BALB/c) GvHD model prevented lethal 
GvHD.[Hartwig etal. 2002]
1.9.2 CD25
CD25 is a 55KD glycoprotein and forms the D-chain low affinity component of the 
IL-2 receptor. Surface expression of CD25 is increased on T and B cells upon 
activation when the high affinity trimolecular IL-2 receptor complex is 
formed. [Smith 1984]
The earliest report of selective alloreactive cell depletion in a human in vitro 
model utilised the upregulation of the CD25 antigen on alloreactive cells, 
published in 1990. After a two-day MLR with HLA-mismatched human PBMCs as 
stimulators, activated host alloreactive (blood or bone marrow) T cells were 
incubated with a ricin A-chain toxin conjugated with the antibody 33B3.1 directed 
against the CD25 receptor. Complete inhibition of proliferation in the MLR to 
original HLA-mismatched stimulators was seen, and reduction of cytotoxic
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responses was also observed. This method only modestly reduced the 
alloreactivity of blood or marrow T cells toward third party HLA-mismatched 
stimulators. Limiting-dilution analysis of residual alloantigen-reactive T 
lymphocytes showed that this technique resulted in a twenty fold to fifty-fold 
reduction of antihost reactivity.[Cavazzana-Calvo et al. 1990]
This technique was used by the group in an H-2 haplotype disparate murine 
transplantation model and was found to reduce pathological changes of gut 
GvHD. It was also shown to increase survival in such mice, one third being alive 
at 100 days (by which time all the mice give unselected grafts had died). 
[Cavazzana-Calvo et al. 1994] Preservation of anti-leukaemia and antiviral 
activity after selective allodepletion using this technique was subsequently 
evaluated by limiting dilution assays measuring the frequency of CTLp directed 
against autologous leukaemia blasts (LB) and CMV- and Epstein-Barr virus 
(EBV)-infected target cells. Anti-leukaemia activity was evaluated in PBMC of 3 
patients treated for acute myeloid leukaemia, who had developed a high 
frequency of LB-reactive CTLp after either autologous or allogeneic BMT. 
Depletion with CD25 immunotoxin efficiently inhibited proliferation to original 
HLA-mismatched stimulators in the MLR and effector cells obtained after 
allodepletion fully retained the capacity to lyse LBs. In contrast, the frequency of 
CTLp directed against patient’s pre-transplant bone marrow remission cells was 
always undetectable. Data from 4 healthy donors showed that specifically 
allodepleted T cells recognized and killed autologous CMV-infected fibroblasts 
and autologous EBV-B-lymphoblastoid cell (LBC) lines [Montagna etal. 1999] 
This technique has subsequently been developed to a clinical scale in a phase 
1/2 study, in which 1-8 x 105 allodepleted T cells/kg were infused between days 
15 and 47 into 15 paediatric patients who had acquired or congenital 
haemopoietic disorders and who received CD34-selected AHSCT on day 0 (with 
no additional GvHD prophylaxis). Most transplants were HLA non-identical family 
members and some were full haplotypical mismatches. Less than 1% residual 
anti-host alloreactivity was recorded in 12 of 16 procedures. No cases of severe 
GvHD arose, although it must be note that the doses of allodepleted T cells the 
patients received were relatively small, (although a dose of unselected T cells of 
>104/kg is sufficient to induce GvHD in a haplotypic transplant). The cases where 
GvHD was seen were recipients of grafts that retained some anti-host reactivity 
in the MLR after selective allodepletion.[Andre-Schmutz et al. 2002]
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The efficacy of this technique in vitro has been confirmed by other groups.[Datta 
et al. 1994;Harris et al. 1999] The Pseudomonas exotoxin-based immunotoxins, 
anti-Tac (Fv)-PE38 and anti-Tac (Fv)-PE38KDEL, (both targeting the IL-2 
receptor on activated T cells), has been used to specifically deplete alloreactive 
lymphocytes against haploidentical stimulators. Mean residual reactivity 
(proliferative responses) after depletion was 8% of that seen pre-depletion 
against the haploidentical stimulator and 65% against third party stimulators. The 
immunotoxin did not affect growth of normal BM cells.[Mavroudis et al. 1996] 
This technique has been extended to fully HLA-matched pairs (in patients with 
chronic myeloid leukaemia and their HLA-matched sibling donors). Donor hTLP 
frequencies were measured against recipient PBMCs, recipient LBs and third- 
party PBMCs, before and after depletion. There was a 4.3-fold reduction of 
donor-versus-host hTLP frequency without a significant change in the donor 
frequencies against third party PBMCs. There was a smaller non-significant 1.8- 
fold reduction in donor-versus-leukaemia hTLP frequency.[Mavroudis et al. 1998] 
This technique has been developed to a clinical scale, in which stimulator cells 
were generated from immunomagnetically selected and OKT3-expanded 
recipient T lymphocytes. Stimulator cell selection/expansion yielded high 
numbers of enriched CD3+ cells. After selective allodepletion, cell recovery and 
viability was high, permitting a selectively allodepleted T cell dose >1x10® CD3+ 
cells/kg to transplant recipients. Depletion efficiency and reduction in proliferative 
responses to original stimulators were akin to the smaller scale in vitro work this 
group have published. Furthermore cellular responses to staphylococcus 
enterotoxin B and CMV Ag (measured by IFN y secretion) were largely 
retained.[Solomon et al. 2002] A phase I study utilising this technique of selective 
allodepletion is underway in HLA-matched sibling adult donor-recipient pairs, with 
reduced intensity recipient conditioning. Preliminary results have now been 
reported in abstract form.[Solomon et al. 2003] Eight patients with advanced 
haematological malignancies with a median age of 66 years have received 
selectively allodepleted grafts from sibling donors after reduced intensity 
conditioning. The median CD3+ cell dose was 1.1 x 108/kg recipient body weight. 
Ciclosporin was used as additional GvHD prophylaxis. Acute GvHD requiring 
treatment occurred in 6 of the 8 patients, although severe acute GvHD was seen 
in only one recipient. T cell recovery post-transplant was equivalent to T replete
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historical controls, and 5 were free of disease with a median follow up of 5 
months.
This technique has recently been modified using an alternate system of recipient 
antigen presentation, using recipient EBV-transformed LCLs as stimulators to 
activate donor alloreactive T cells. Allodepletion with an anti-CD25 immunotoxin 
following stimulation with HLA-mismatched host LCLs more consistently depleted 
in vitro alloreactivity than stimulation with host PBMCs, (as assessed by 
proliferation in MLR pre- and post-depletion) Allodepletion using this approach 
specifically abrogated cytotoxic T cell responses against host LCLs in IFN-y 
enzyme-linked immunospot (ELISPOT) assays, whereas antiviral responses to 
adenovirus and CMV were largely preserved in similar assays following 
allodepletion. Donor anti-EBV responses were partially retained by recognition of 
EBV antigens through the non-shared haplotype. The frequency of T cells 
recognizing the PR1 epitope of proteinase 3 (an antigen over-expressed on CML 
cells) assayed by specific tetramer binding, was not significantly reduced in 
allodepleted cells from patients with CML.[Amrolia etal. 2003a]
A phase 1 clinical trial of infusion of selectively allodepleted donor T cells after 
haploidentical stem cell transplantation is underway in paediatric patients and 
preliminary results have been presented only in abstract form.[Amrolia et al. 
2003b] 9 patients with relapsed/refractory haematological malignancies have 
received allodepleted T cells after disease-specific conditioning (reduced 
intensity in 2 recipients) from haploidentical donors. 6 recipients received 104 and 
3 patients 105 allodepleted T cells/kg body weight at day 50, 80 and 110 post 
transplant. At a median follow up of 9 months 8 recipients were alive and 5 were 
disease-free. 2 recipients (one at each dose level) developed severe GvHD. 
Immune reconstitution was improved (compared to historical controls) in the 
recipients of the higher dose of allodepleted T cells.[Amrolia et al 2003b]
It is important to note that selective allodepletion based on CD25 expression will 
remove all cell expressing CD25 (not just those expressing CD25 upon 
allostimulation). Cells that constitutively express CD25 include CD4+CD25+ T 
regulatory cells, now recognized as playing an important role in the pathogenesis 
of GvHD. CD4+CD25+ T regulatory cells are required for the ex vivo induction of 
tolerance to alloantigen via co-stimulatory blockade and to inhibit allogeneic skin 
graft rejection. Depletion of CD4+CD25+ cells from the donor T cell inoculum 
resulted in increased GVHD mediated by CD4+ or whole T cells fractions in mice.
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The infusion of high numbers of purified CD4+CD25+cells donor cells significantly 
inhibited rapidly lethal GvHD.[Taylor et al. 2002] Thus there are concerns that 
removal of alloreactive cells based on induced expression of CD25 will also 
remove CD4+CD25+ T regulatory cells and that the absence of the T regulatory 
cell component in such manipulated AHSC grafts may disrupt immune 
reconstitution, (and could actually favour the development of GvHD).
1.9.3 CD69
CD69, (previously known as activation inducer molecule, very early activation 
antigen, MLR-3 and Leu-23) is a Type II transmembrane glycoprotein and a 
member of the natural killer (NK) cell gene complex family of signal transducing 
receptors.[Ziegler et al. 1993] CD69 has a C-type lectin-binding domain in the 
extracellular portion of the molecule, the crystal structure of which has been 
described. CD69 is constitutively expressed on human monocytes, platelets and 
epidermal Langerhans cells, whilst expression of CD69 is induced in vitro on 
activated cells of most haematopoietic lineages, including T and B lymphocytes, 
NK cells, murine macrophages, neutrophils and eosinophils, Although the gene 
for CD69 has been identified and cloned, the specific ligand for CD69 has not 
been identified.[Santis et al. 1994] The wide cellular distribution of CD69 and the 
induction of intracellular signals upon CD69 cross-linking suggest a role for the 
receptor in the biology of haematopoietic cells.[Marzio et al. 1999]
The function of CD69 on T lymphocytes is well established, acting as a signal 
transmitting receptor and co-stimulatory molecule resulting in proliferation and 
cytokine secretion. More recently data supporting a role in T cell development, 
particularly thymic emigration have been published, although CD69 knock-out 
mouse models did not show any functional impairment of T cells.[Borrego et al. 
1999;Feng et al. 2002;Lauzurica etal. 2000;Nakayama etal. 2002]
Data are also emerging regarding the role of CD69 expression on NK cells. It has 
been shown that CD69 triggers NK-cell-mediated cytolytic activity, and the 
interaction of CD69 ligation with other C-lectin type NK inhibitory receptors (e.g. 
CD94) is under investigation.[Borrego etal. 1999]
CD69 also functions as a transmembrane signal transduction molecule in both 
neutrophils and platelets.[Testi et al. 1994] CD69 expression is inducible on T 
cells and the magnitude and kinetics of the CD69 response to polyclonal
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mitogens and other antigenic stimuli are well described. CD69 expression on T 
cells is rapid, typically occurring within 4hrs in response to Staphylococcal 
Enterotoxin B, Tetanus toxoid and OKT3, peaking after stimulation with the latter 
at 48 hours.[Simms and Ellis 1996]
CD69 is expressed earlier on normal T cells stimulated with mitogens or antigens 
than other inducible activation antigens (such as CD25, CD71 and HLA 
DR).[Caruso et al. 1997] Although most (but not all) data published supports a 
relationship between the magnitude of the CD69 response on T cells and 
subsequent T cell proliferation (in tritiated thymidine assays), this relationship has 
not been found to be a direct linear correlation, and may vary between specific 
antigenic stimuli. Some reports have noted that the CD69 response to low dose 
antigenic stimulus is more sensitive than proliferative responses.[Caruso et al. 
1997;Prince and Lape-Nixon 1997;Simms and Ellis 1996]
CD69 expression on T cells induced by HLA-mismatched allogeneic stimuli has 
been described. In the first of such reports, HLA-mismatched allogeneic PBMC 
induced CD69 expression on 6-13% of CD3+cells between days 3-6.[Simms and 
Ellis 1996] Leiva described equivalent T cell CD69 responses to allogeneic 
PBMC sonicates and irradiated allogeneic PBMCs, (with mean CD69 expression 
in 7% of CD3+ HLA-mismatched responders, and a significant correlation 
between CD69 expression and proliferation (thymidine uptake at day 6), but ‘with 
significant individual variations’.[Leiva etal. 1997]
CD69 expression on responding T cells after HLA-mismatched allostimulation by 
PBMCs occurs later than CD69 expression in response to mitogens, (peaking at 
72 hours but showing a second increase in expression at 120 hours). Expression 
of CD69 in response to HLA-mismatched PBMC allostimulation occurs earlier 
than CD25 expression.[Craston et al. 1997]
Although some data have been published describing phenotypic characteristics 
of T cells expressing CD69 in response to mitogen, no reports describe such 
data in cells expressing CD69 in response to allogeneic stimuli.[Rutella et al. 
1999]
Alloreactive cells have been identified by their expression of CD69 after 
allogeneic stimuli and specifically depleted by immunomagnetic sorting. Koh et al 
described an in vitro model in which HLA-matched donor PBMCs were co­
cultured with irradiated recipient cells, which had been pre-stimulated with 
cytokines (IFN-y and TNF-a) in a modified MLR. In 5 pairs, mean proliferative
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responses post-depletion were 11.5% of the pre-depletion response to the 
original matched stimulators, (while the post depletion third-party responses were 
largely preserved at 80% of the pre-depletion value.[Koh et al. 1999]
The CD69 allodepletion strategy has been tested in a non-obese diabetic/severe 
combined immunodeficient (NOD/SCID) murine model of aggressive GvHD. 
Recipients of infusions of non-manipulated MHC class I and class ll-mismatched 
donor T cells suffered rapid onset of acute, and generally fatal, GvHD. (The 
model was akin to aggressive clinical transfusion-related GvHD). Donor 
splenocytes were stimulated with irradiated recipient mononuclear cells in an 
MLR and subsequently depleted of CD69" alloreactive donor cells ex vivo by 
immunomagnetic sorting. The depleted donor cells were infused into sub-lethally 
irradiated recipient mice, monitored for 10 weeks post infusion. Mice receiving 
selectively allodepleted donor cells demonstrated significantly improved survival 
(71.4% compared with 12.5% in recipients of unmanipulated donor T cells, 
Figure 1.4) and absence of clinical GvHD, despite the presence of circulating 
donor lymphocytes demonstrated by flow cytometry. [Koh et al. 2002] The 
efficacy of selective allodepletion based on CD69 expression has been confirmed 
in vitro models by other groups. Fehse et al used a fibroblast enriched stromal 
layer of recipient cells as an antigen presentation system for allogeneic 
stimulation of donor cells. Alloreactivity of donor T cells (assayed as MLR 
proliferative responses and hTLP frequencies) was significantly decreased after 
depletion using magnetic cell sorting of cells expressing either CD25 or CD69. 
Interestingly the lowest level of post depletion alloreactivity was found when both 
CD25* and CD69* cells were depleted. No data have been published describing 
whether CD69 and CD25 are co-expressed on alloreactive T cells or whether 
these antigens are expressed on different subsets of alloreactive cells.[Fehse et 
al. 2000a;Fehse etal. 2000b]
Selective depletion of donor alloreactive cells by immunomagnetic sorting of 
CD69+ cells stimulated by recipient keratinocyte cells has also been reported in 
an attempt to differentially remove cells with alloreactivity (resulting from tissue- 
specific mHag disparity) directed against skin.[van Dijk et al. 1999] No data have 
been published confirming the preservation of anti-leukaemic responses after 
allodepletion based on CD69 expression.
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Figure 1.4 Selective depletion of CD69+ cells and effect on survival of 
NOD/SCID recipient mice. Recipient mice received either phosphate buffered 
saline (controls, n = 18), 5-10x106 non-manipulated fully MHC-mismatched T 
cells (n = 27) or 5-10x106 allodepleted fully MHC-mismatched T cells (n = 14). 
Survival curves were compared using the log-rank test. Comparison of the 
survival curve of the control cohort with that of the mice receiving allodepleted T 
cells was not statistically significant. In contrast the survival of controls and of 
recipients of allodepleted T cells were both significantly better than that of 
recipients of non-manipulated T cells (P<0 0001 and P< 0-001 respectively). 
Figure adapted from Koh et al.[Koh, Prentice, Corbo, Morgan, Cotter, and 
Lowdell 2002]
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1.10 Clinical Application
The ultimate test for the safety and efficacy of the CD69 allodepletion technique
(in terms of abrogating severe GvHD and improving immune reconstitution) is
the development of the technique to a clinical scale and its subsequent
application in a Phase I clinical trial in adult AHSCT.
1.11 Aims of this Thesis
1. To evaluate an alternative antigen presentation system (the use of OKT3 
pre-treated PBMCs) as stimulator cells in the MLR prior to CD69- 
mediated allostimulation.
2. To study residual antiviral responses in CD69 selectively allodepleted 
cells using a variety of alloantigen presentation systems.
3. To study in depth the phenotype of alloreactive and non-alloreactive cells 
based on CD69 expression.
4. To study the co-expression (and kinetics of expression) of CD69 and 
CD25 on alloreactive T cells and the effect of CD69-mediated 
allodepletion on the number and function of CD4+CD25+ T regulatory 
cells.
5. To investigate the possibility of T cell cross reactivity for alloantigens and 
CMV antigens.
6. To develop the CD69 mediated allodepletion technique to a clinical scale 
and instigate a Phase I clinical study of the use of CD69-selectively 
allodepleted T cell re-infusion in HLA-matched sibling haematopoietic 
stem cell transplantation for adult patients with acute myeloid leukaemia.
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Chapter 2 General Materials and Methods
General materials and methods are described herein. Specific materials and 
methods only relevant to individual results chapters are described at the 
beginning of the relevant chapter.
2.1 Cell Culture
2.1.1 Reagents for Cell Culture
All cell culture was undertaken in “complete medium”, which consisted of 
Roswell Park Memorial Institute hydrogen-carbonate-buffered medium 
(RPMI1640, Gibco/Life Technologies Ltd,) with 10% Foetal Calf Serum (FCS, 
Gibco) or 10% human AB serum (North London Blood Transfusion Centre) 
where stated, and 50units/ml Penicillin + 50pg/ml Streptomycin (Gibco/Life 
Technologies Ltd). Human cells for incubation and hybridoma cell lines were 
suspended in complete medium at 0.5-1 x106 cells/ml in 24 or 96 well plates, 80 
ml or 200ml tissue culture flasks (Nunc), and Lifecell 160cm3 or OptiCyte 
390cm2 gas permeable bags (Baxter). All incubations were at 37°C, 5% CO2 
and 60% humidity unless otherwise stated.
2.1.2 Centrifugation
All centrifugation of tubes was undertaken on a Beckman GP machine 
(Beckman-Coulter) with a rotor arm length of 22.5cm, upon which a spin rate of 
1500rpm equates to 400g and 1000rpm to 200g. Centrifugation of cell culture 
bags was performed at 200g in a Rotina temperature controlled centrifuge 
(Hettich), which was programmable directly for g force.
2.1.3 Isolation of Fresh Human Peripheral Blood Mononuclear Cells
Fresh peripheral blood samples were collected into 50ml plastic tubes (Nunc) 
with 100pl preservative free heparin/10 mis blood. Samples were diluted 1:1 in 
Hanks’ Balanced Salt Solution (HBSS, Gibco/Life Technologies). PBMCs were 
isolated by discontinuous density gradient centrifugation. Diluted blood was
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layered onto an equal volume of Ficoll (Nycomed Pharma AS) into 50 ml Falcon 
tubes (Nunc) at room temperature and spun at 400g for 25 minutes with no 
brake. The isolated mononuclear cell fraction was recovered at the interface 
with a sterile Pasteur pipette, diluted in complete medium and centrifuged for a 
further 10 minutes at 400g. The supernatant was discarded and the cell pellet 
was then gently disrupted manually with a sterile Pasteur pipette and 
resuspended in 1-4mls of fresh complete medium depending on the size of the 
cell pellet.
2.1.4 Cell Counting and Viability Assessment
10jxl of PBMC suspension was pipetted into a 0.5ml microcentrifuge tube 
(Nunc). 90pl of 0.4% Trypan Blue (Sigma) stain (which is extruded by viable 
cells but taken up by non-viable cells) was added, making a 1:10 dilution (the 
final concentration of Trypan Blue was 0.36%) and thoroughly mixed. A bright- 
line haemocytometer (Sigma-Aldrich) was loaded with 10pl cell mixture (Trypan 
Blue and PBMCs) under a glass cover slip. The cell suspension was allowed to 
settle for 30 seconds in the haemocytometer and cells were counted with any 
part within the central 25 large squares (excluding cells that touched the bottom 
or right vertical perimeter line) using a phase contrast microscope (Nikon). The 
number of PBMCs/ml was then calculated as:
PBMC (106/mL) = PBMCs in all 25 squares x 104
25
To calculate cell viability:
% Viability = Number of clear (viable) cells counted x100
Number of Clear (viable) and blue (non-viable) cells 
counted
Unless otherwise specified, cells were resuspended and used at concentrations 
of 106 viable cells/ml complete medium.
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2.1.5 Cryopreservation of Cells
For cryopreservation of cells ‘cryomecT freezing medium was made up with 80% 
FCS (or human AB plasma) and 20% dimethylsulphoxide (DMSO, Sigma- 
Aldrich) and stored in aliquots at -20°C for up to one year. Cells for 
cryopreservation were brought to a minimum concentration of 10x106/ml and 
mixed drop by drop with an equal volume of cryomed freezing medium on ice. 
The mixture was transferred immediately to cryopreservation vials (Nunc) in 
0.5ml aliquots and the vials placed in isopropyl alcohol freezing containers 
(Nalgene) for controlled rate freezing and placed in a -70°C freezer overnight. 
The vials were then transferred to storage in liquid nitrogen at-196°C.
For resuscitation of cryopreserved cells, cryopreservation vials were transferred 
from liquid nitrogen on ice to a 37°C water bath. Cryopreservation vials were 
partially immersed and gently agitated until only a small frozen part remained. 
Cryopreservation vials were then wiped with alcohol and the contents pipetted 
immediately into a 30-fold volume of complete medium, pre-warmed to 37°C 
and then centrifuged at 200g for 10 minutes. The resulting cell pellet was gently 
disrupted manually with a pipette and resuspended in fresh complete medium 
for counting and viability assessment.
2.2 Flow Cytometry
2.2.1 Antibody Staining Protocols for Flow Cytometric Analysis
Unless otherwise stated antibodies used were supplied from Becton Dickinson 
(BD) and used at a volume of 10p.l/105 viable cells. Polystyrene falcon tubes 
(BD) were used for staining of cells. For staining of PBMCs 10Ojxl of PBMC cell 
suspension at 106/ml was incubated with 10pl of each of up to 4 fluorochrome- 
conjugated primary antibodies for 15 minutes at room temperature (unless 
otherwise stated) in the dark. (Simple titration experiments confirmed adequate 
cell labelling with 10pL of BD antibodies per 105 cells except BD PerCP 
fluorochrome conjugated antibodies, where 5|iL of antibody adequately labelled 
105 cells). Cells were then diluted in 500pl HBSS and centrifuged at 400g for 10 
minutes and the cell pellet resuspended in 300pl of HBSS. Samples were kept
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at 4°C and acquired within 12 hours of antibody staining. Antibodies used were 
conjugated to the following fluorochromes; Fluorescein isothiocyanate (FITC), 
Phycoerythrin (PE), Peridinin Chlorophyll Protein (PerCP) and Allophycocyanin 
(APC). If an unconjugated murine primary antibody was used to label cells, the 
initial staining procedure was identical to that described above. After staining 
with primary antibody a repeat washing step was added. 10pL of secondary 
fluorochrome conjugated goat (or rat) anti-mouse Fc-y antibody was added for a 
period of 30 minutes and then washed twice as described. Cells were labelled 
with any additional fluorochrome-conjugated primary antibodies at this stage if 
required. The cells were then resuspended in HBSS (300|jJ), stored at 4°C and 
analysed by flow cytometry within 12 hours.
Samples of fresh whole blood in ethylene diamine tetra-acetic acid (EDTA) 
anticoagulant were also used for direct antibody labelling in some instances. 
10pL of fluorochrome-conjugated primary antibodies were added to 200jxl of 
whole blood and incubated at room temperature in the dark for 15 minutes. 2mls 
of FACSLyse solution (BD) was subsequently added for 10 minutes at room 
temperature to lyse red blood cells. The cells were then centrifuged at 400g and 
resuspended in 500pl HBSS and this was repeated. The cells were then 
resuspended in HBSS (300pJ) stored at 4°C and acquired within 12 hours.
All samples were acquired as list mode data using CellQuest software (Becton 
Dickinson Immunocytometry Systems) on a BD FACSCalibur flow cytometer in 
4-colour mode. The number of events acquired was determined by the 
frequency of the events of interest within the cell pool. For experiments requiring 
quantification of rare events (defined as occurring with a frequency <5%) a 
minimum of 100 positive events were acquired wherever possible to give an 
intra assay co-efficient of variation (CV) of 10%. Data were subsequently 
analysed using CellQuest and CellQuest Pro software (BD). Data files for 
analysis were exported directly into Excel spreadsheets (Microsoft). Dot plot and 
histogram images for illustrative purposes were created using Windows Multiple 
Document Interface for Flow Cytometry software (WinMDI).
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2.2.2 Basic Regions and Gates for Flow Cytometric Analysis
A forward scatter (FSC) versus (vs) side scatter (SSC) dot plot was always 
created for each list mode data file to be analysed on CellQuest/CellQuest Pro 
Software and an initial region (Region 1) drawn around the area of live 
lymphocytes.
To identify CD3+ T cells a new dot plot (FSC vs CD3) was created gated on 
Region 1 (Gate 1) and a second region drawn around the CD3+ cells (Region 2). 
For assessment of expression of a single antigen (e.g. CD69) on viable CD3+ T 
cells a new dot plot (FSC vs CD69) was created gated on ‘Region 1 and Region 
2’ (Gate 2). For assessment of expression of a single antigen (e.g. CD69) on 
subsets of CD3+ cells (e.g. CD3+CD8+ cells) a new dot plot (FSC vs CD8) was 
created gated on Gate 2 and a region around the CD8+ cells was drawn (Region 
3). A new dot plot (FSC vs CD69) was created gated on ‘Gate 2 and Region 3‘ 
(Gate 3).
For the assessment of antigen expression on live responder cells in co-culture 
with irradiated stimulator cells an initial FSC vs SSC dot plot was drawn and by 
72 hours of co-culture a discrete region could be drawn around live responders 
with apoptotic (smaller) stimulator cells appearing to the left of the live 
responders.
When live cells responded to mitogenic stimuli (e.g. stimulatory anti-CD3 
antibody OKT3, allostimulation) responder cells became activated lymphoblasts 
and enlarged, thus appearing to the right of the live lymphocyte region on a FSC 
vs SSC dot plot. Region 1 was expanded to include such responder cells in 
these instances. More complex and specific regions/gating procedures 
(including backgating) are described in individual chapters. The process of high­
speed cell sorting on the FACSVantage device is described in Chapter 5.
2.2.3 MHC Class l-Peptide Tetramer Staining of CD8* T Cells
MHC Class I Peptide tetramers consist of 4 biotinylated HLA Class I molecules 
loaded with specific peptides (presented in conjunction with the HLA Class I 
molecule) coupled to a streptavidin molecule that has been conjugated to a 
fluorochrome (Figure 2.1). HLA A*0201 peptide tetramers conjugated with the 
PE fluorochrome (a gift from the Anthony Nolan Research Institute, and
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Proimmune) were used to assess numbers of CMV-specific cytotoxic T 
lymphocytes.
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Figure 2.1 The molecular structure of an HLA Class I -peptide tetramer with 
the peptide-MHC specific TCR binding site indicated.
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Tetramers were stored at 4° C in the dark. The optimal amount of tetramer 
added per million cells was titrated down to minimise non-specific binding. 
Generally 0.5-1 ug of tetramer was added to 106 PBMCs along with 10pL of anti- 
CD3-APC antibody and 10pL of anti-CD8-FITC (or -PerCP) in complete 
medium in polystyrene tubes (BD) and incubated on ice for 30 minutes. The cell 
suspension was centrifuged at 400g for 10 minutes and resuspended in 300pL 
of HBSS. Events were then acquired on a FACSCalibur flow cytometer and data 
was analysed on CellQuest/CellQuest Pro Software.
No fixed minimum number of total events was acquired as tetramer binding cells 
usually occur in relatively low frequencies (<5% of CD3+CD8+ cells) and thus 
qualify as rare events. The intra-assay co-efficient of variation (CV) of such rare 
events acquired flow cytometrically is described by the following equation
CV = 100
Vn
where n is the number of positive rare events acquired. Thus to obtain a CV of 
<10% more than 100 positive events need to be acquired. To obtain a CV of 
<5% more than 400 positive events need to be acquired. The minimum number 
of positive events acquired, whenever possible was 100 to give a CV of 10% or 
less.
The calculation of tetramer frequency (as percentage of CD3+CD8+ cells) was 
done as follows: an initial FSC vs SSC dot plot was created and Region 1 
created around the live lymphocytes. A new FSC-CD3 dot plot was created 
gated on Region 1. A new region (Region 2) was drawn around CD3+ cells, and 
a new tetramer vs CD8 dot plot created gated on ‘Region 1 and Region 2’. The 
percentage of tetramer+ cells was then calculated using quadrant analysis. This 
strategy is illustrated in Figure 2.2.
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Figure 2.2 Regions and gates used to calculate the frequency of CD3+CD8+ 
Tetramer + cells. (From the CD8 vs FSC dot plot, percentage CD3+ CD8+ 
Tetramer+ cells is the number of cells in the upper right quadrant/number of cells 
in upper right and upper left quadrants x 100%).
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2.3 Allostimulation Techniques and Proliferation Assays
Allostimulation was achieved by the co-culture of y-irradiated stimulator PBMCs 
with live responder PBMCs in the MLR. For HLA-mismatched stimulator- 
responder pairs (corresponding to recipient-donor pairs) allostimulation was 
achieved via co-culture in the standard MLR. For HLA-matched pairs 
allostimulation was achieved in the cytokine-modified and OKT3 pre-treated 
MLRs. MLRs were used as proliferation assays to quantify the alloreactive 
response by responder incorporation of thymidine after 120 hours of incubation, 
and also to generate CD69* alloreactive cells within a responder cell fraction 
prior to cell sorting procedures.
2.3.1 ^Irradiation of Stimulator Cells
All stimulator cells were exposed to a y-irradiation dose of approx 30Gy by 
irradiation for 6.5 minutes in a Gammacel 3000 ELAN irradiator (Nordion 
International Inc) which emits approx 500 rads per minute (5Gy per minute).
2.3.2 Mixed Lymphocyte Reaction
For the standard MLR proliferation assay, PBMC suspensions were used in 
complete media (with human AB serum) at 106 cells/ml. 105 irradiated 
stimulators/well and 105 live responders/well were added to round bottom 96 
well plates (Nunc) in triplicate and incubated under standard conditions. Control 
wells were live responders with irradiated autologous stimulator cells. After 108 
hours of incubation 1pCi tritiated thymidine (Amersham) was added to each well 
and after 120 hours of incubation plates were harvested on a plate harvester 
and counted on (5-scintillation counter (Wallac) Proliferation of responders in 
response to allogeneic stimulus was expressed as mean counts per minute 
(cpm) above autologous control.
In order to generate CD69+ alloreactive cells within a responder cell fraction 
prior to cell sorting procedures the mixed lymphocyte culture was set up on 
various larger scales in 24 well plates, 80cm2 cell culture flasks and Lifecell and 
Opticyte cell culture bags (‘bulk MLRs’). Both irradiated stimulator and
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responder PBMC cell concentrations were fixed at 106/ml and the stimulator 
responder ratio was (unless otherwise stated) fixed at 1:1. Bulk MLRs were 
depleted of CD69* responder cells after 72 hours of incubation.
2.3.3 The Cytokine-Modified MLR
In HLA-matched stimulator-responder samples the MLR was modified by the 
pre-treatment of stimulator cells with cytokines. Stimulator PBMCs were 
incubated at 106 cells/ml in complete medium (with human AB serum) for 24 
hours under standard conditions with 1000iu/106 cells of recombinant human 
IFN^y and recombinant human TNF-pt (R &D systems). Cells were then 
centrifuged at 400g for 10 minutes and resuspended in complete medium and 
the wash step repeated prior to y irradiation. Irradiated stimulator cells were then 
added to live responder cells under the conditions described in Chapter 2.3.2 
with the addition of 1000iu/106 responder ceils of recombinant human IL-4 (R 
&D) to the MLR. Negative control wells were cytokine pre-treated autologous 
irradiated stimulators and live responders, and positive controls were irradiated 
HLA-mismatched cytokine pre-treated third party stimulator cells and live 
responders (Third Party Controls).
The cytokine modified MLR was used both as a proliferation assay for HLA- 
matched stimulators/responders and as a bulk MLR technique prior to depletion 
of CD69* alloreactive cells. For the proliferation assay the results were 
expressed as mean counts per minute (cpm) (above autologous control) as an 
absolute value and also as a percentage of the equivalent result with the third 
party control (the Relative Response Index (RRI). A RRI of >/=5% was 
considered positive in the cytokine modified MLR.
2.3.4 The OKT3 Pre-Treated MLR
In HLA-matched stimulator-responder samples the MLR was also modified by 
the pre-treatment of the stimulator cells with the mitogenic stimulatory anti-CD3 
antibody OKT3. OKT3 was obtained from a fermentation system using a murine 
hybridoma secreting human mitogenic OKT3 (American Type Culture Collection 
Cell Line CRL-8001, ATCC) The hybridoma was produced by the fusion of
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P3x63Ag8UI mouse myeloma cells with splenocytes from CAF1 mice 
immunized with human peripheral blood lymphocytes and secretes murine 
lgG2a reactive to the human T cell CD3 molecule. The concentration of OKT3 in 
hybridoma supernatant was quantified by murine IgG Enzyme Linked 
Immunosorbent Assay (ELISA) (Bethyl laboratories Inc) After optimisation 
experiments 1ml of filtered hybridoma supernatant containing 500ng/ml of OKT3 
was immobilised on a 24 well plate by overnight incubation at 4°C or 4 hours of 
incubation at 37°C. Wells were then washed twice with sterile HBSS and 106 
stimulator PBMCs in 1ml of complete medium (with human AB serum) was 
added. The plates were incubated for 48 hours under standard conditions and 
the cells were then removed by pipette, diluted to a volume of 10mls in HBSS 
and centrifuged at 400g for 10 minutes. This washing step was repeated twice. 
The cells were resuspended at 106/ml and irradiated prior to use as stimulators 
in the MLR. No additional cytokines were added to the MLR. Negative control 
wells were autologous irradiated OKT3 pre-treated stimulators and positive 
controls were live responders with irradiated HLA-mismatched OKT3 pre-treated 
third party stimulators cells.
The OKT3 pre-treated MLR was used both as a proliferation assay for HLA- 
matched stimulators/responders and as a bulk MLR technique prior to depletion 
of CD69* alloreactive cells. For the proliferation assay the results were 
expressed as mean cpm (above autologous control) as an absolute value and 
also as a percentage of the equivalent result with the third party control (RRI).
2.4 The CD69 Selective Allodepletion Schema
Alloreactivity was determined before (primary MLR) and after (secondary MLR) 
selective depletion of CD69+ alloreactive cells. Alloreactivity was quantified as 
responder ceil proliferation in these MLRs with co-culture with the original 
irradiated stimulator cells (first party alloreactivity) or HLA-mismatched third 
party irradiated stimulator cells (third party alloreactivity)
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2.4.1 HLA-Mismatched Stimulator-Responder Pairs
In the HLA-mismatched setting the MLR was used to assess first party 
alloreactivity using first party irradiated stimulators and unmanipulated 
responder cells (primary first party MLR) and CD69 depleted responder cells 
(secondary first party MLR)
Residual first party alloreactivity (%) was expressed as:
Secondary first party MLR (cpmVautolOQOUs control x100%
Primary first party MLR (cpm)-autologous control
The MLR was used to assess third party alloreactivity using third party irradiated 
stimulators and unmanipulated responder cells (primary third party MLR) and 
CD69 depleted responder cells (secondary third party MLR)
Residual third party alloreactivity (%) was expressed as:
Secondary third party MLR (cpm)-autologous control x100%
Primary third party MLR (cpm)-autologous control
2.4.2 HLA-Matched Stimulator-Responder Pairs
In the HLA-matched stimulator-responder pairs the cytokine and OKT3 modified 
MLRs were used to potentiate allostimulation. Proliferative responses to first 
party stimulators in the primary and secondary MLRs were expressed as 
percentage of the response seen to third party stimulators (RRI). The CD69 
allostimulation and selective allodepletion schema with assessment of 
alloresponses by MLR responder cell tritiated thymidine uptake at 120hrs is 
illustrated in Figure 2.3.
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MLRs were used to potentiate allostimulation. Proliferative responses to first 
party stimulators in the primary and secondary MLRs were expressed as 
percentage of the response seen to third party stimulators (RRI). The CD69 
allostimulation and selective allodepletion schema with assessment of 
alloresponses by MLR responder cell tritiated thymidine uptake at 120hrs is 
illustrated in Figure 2.3.
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Figure 2.3 Schema for allostimulation and selective allodepletion of CD69* cells and assessment of alloreactivity (pre- and post­
depletion) to first and third party stimulators. Note that in the HLA-matched setting both the first and third party stimulators were
pre-treated with either cytokines or stimulatory OKT3.
2.5 Cell Sorting Techniques
2.5.1 MACs Immunomagnetlc Depletion
This is a sterile cell sorting technology (Miltenyi Biotech) that utilises colloidal 
super-paramagnetic 50nm diameter microbeads conjugated with monoclonal 
mouse anti-FITC lsomer-1 antibodies (anti-FITC microbeads). Cells expressing 
antigens (e.g. CD69) were labelled with anti-CD69 antibody conjugated to FITC 
fluorochrome. Anti-FITC microbeads were then added, binding to the FITC 
fluorochrome attached to the antibody identifying the cells to be isolated. Cells 
were then passed through a column within a magnetic field. Cells with anti-FITC 
microbeads attached were retained on the column magnetically and the 
depleted cells (negative fraction) passed through the column and were 
collected. Washing the column through after it was removed from the magnetic 
field subsequently allowed collection of the positive cell fraction.
For depletion of CD69+ cells, PBMCs were labelled with 10pL/106 total cells of 
CD69-FITC primary antibody for 15 minutes at room temperature. Cells were 
diluted in 500-1 OOOpL of sterile HBSS and centrifuged at 400g for 10 minutes 
and resuspended in 90pL/106 cells of Dulbecco’s Phosphate buffered saline 
(Gibco/Life Technologies) supplemented with 2mM EDTA (Sigma-Aldrich) and 
0.5% bovine serum albumin (BSA, Sigma-Aldrich) (‘MACS Buffer’) at 4°C. If a 
primary non-fluorochrome-conjugated CD69 antibody was used, cells were 
subsequently labelled with secondary goat anti-mouse FITC antibody (BD) at 
this stage. 10pl of anti-FITC microbeads were added per 107 total cells and 
incubated on ice for 20 minutes. The cells were then ready for immediate 
magnetic sorting.
AS columns were used, suitable for removal and retention of up to 3x107 
positive cells. The column was place in the magnetic field of the VarioMACS, 
prefilled with 2mls of cold MACS buffer and a 25G flow resistor attached to the 
outflow. The cold-labelled cell suspension was applied to the column in situ and 
flowed through the column with a flow rate of 0.3ml/minute. The negative cell 
fraction was collected from the outflow. The column was washed in situ with 
3mls of MACS buffer.
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The column was removed from the VarioMACS magnetic field and the positive 
cell fraction collected by back flushing through of the column under pressure 
with 3mls cold MACS buffer.
2.5.2 Dynabead Immunomagnetic Depletion
Dynabeads (Dynal Biotech) are paramagnetic polystyrene beads with affinity 
purified sheep anti-mouse IgG antibody covalently bound to the surface.
The labelling of cells with a primary murine antibody and subsequent labelling 
with the Dynabead enables cell sorting by application of a magnetic field which 
retains cells bound to Dynabeads. The system may be used as part of a sterile 
cell selection technology at both a small laboratory scale using a hand-held 
magnet or at a larger clinical scale using the Isolex 300i automated cell sorting 
device.
Dynabeads were supplied in a sterile, non-pyrogenic suspension of 10mls
containing 4x108 beads/ml in PBS with 0.1% human serum albumin.
Dynabeads were prepared by washing in 10mls of sterile PBS and application 
to a hand-held magnetic particle concentrator (MPC) for 1 minute. The wash 
solution was drained off and the beads resuspended at a concentration of 4x108 
beads/ml in PBS. For small-scale CD69* cell depletions, PBMC cell 
suspensions were incubated with non-fluorochrome-conjugated murine anti- 
CD69 antibody at optimal concentration (individually determined for each 
antibody used) for 15 minutes at room temperature. Cells were diluted in 500pL 
of sterile HBSS, centrifuged at 400g for 10 minutes and resuspended in sterile 
HBSS to a concentration of 106/ml in HBSS. Washed and thoroughly mixed 
Dynabeads were added to 106 labelled cells at various bead:cell ratios and 
incubated at room temperature in 2ml polystyrene tubes (Sarstedt) for 30 
minutes with continuous vertical rotation. The tubes were then placed on to the 
MPC for 1 minute and the supernatant (containing the negative cell fraction) 
removed carefully by Pasteur pipette.
For clinical scale up procedures the Isolex 300i automated device (with 2.5i
software) (Nexell) was used to immunomagnetically deplete large numbers of
CD69 labelled cells with Dynabeads. The procedure is described in detail in 
Chapter 7.
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2.5.3 Eligix Particle Immunomagnetic Depletion
Goat anti-mouse (GAM) High Density Microbeads (HDM) (Eligix) are Inco 123 
Nickel particles about 10pm in diameter coated with GAM IgG antibody. Mouse 
IgG can be rapidly coupled to these HDMs. The GAM is specific to Fc-y and 
therefore must always be used with whole mouse IgG (not Fab or F(ab’ )2  
fragments. For small-scale laboratory depletion of CD69* cells GAM-HDM 
particles were reconstituted by washing with in 10mls of HBSS twice using the 
MPC to retain the particles. Particles were then reconstituted with 10 mis 2% 
dextran (Sigma). 100pL of reconstituted particle suspension contained 25 x 10® 
GAM-HDM particles. 100pl of reconstituted GAM-HDM particle suspension 
were added to 2ml microcentrifuge tubes (Sarstedt) containing 1.5mls 
Phosphate-Buffered Saline (PBS, Gibco-Life/Technologies). The tube was 
placed onto the MPC to retain the particles, the supernatant decanted and 
discarded, and 1.5mls of PBS added to the tube. This was repeated twice to 
leave a wet GAM-HDM pellet. An optimum concentration of primary murine 
CD69 antibody was added in 100pL volume in PBS with 0.5% BSA, thoroughly 
mixed and incubated at room temperature for 15 minutes, mixing occasionally. 
The GAM-HDM particles were retained on the magnet and washed with 1.5mls 
HBSS three times and the particle degaussed using a hand-held degaussing 
device (Eligix). 1ml of PBMCs (106 cells) were then added to the labelled GAM- 
HDM particles and mixed with continuous vertical rotation for 15 minutes at 
room temperature. The HDM-GAM particles were then allowed to settle with 
gravity upright for 10 minutes and the tube applied to the MPC. The depleted 
cell fraction was collected in the supernatant by Pasteur pipette.
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2.5.4 Cell Sorting Parameters
The frequency of CD69+ cells was determined by labelling with fluorochrome- 
conjugated monoclonal antibodies and flow cytometric analysis.
Depletion efficiency of CD69* cells was defined as:
(%CD69* cells prior to sorting) - (% CP69+ cells after sorting) x100% 
(%CD69+ cells prior to sorting)
Depletion efficiency of CD69+ positive cells was calculated in this way for CD3+, 
CD3+CD4+ and CD3+CD8+ cell subsets, identified flow cytometrically.
Cell yield of CD69* cells was defined as:
Number of CD69' cells after sort x100%
Number of CD69* cells before sort
2.6 IFN-yELISpot Assay
The IFN-y Enzyme Linked Im mu nospot (ELISpot) assay (MabTech) was used to 
assess cellular responses specific to a range of immunogenic CMV-peptides 
and to an EBV-peptide. The MabTech kit using polyvinylidene difluoride-lined 
(PVDF) plates was chosen as it has low intra- and interassay variance. 
PVDF-lined 96 well plates (Millipore) were pre-wet with 100pl/weil 70% ethanol 
for 10 minutes at room temperature and then washed 3 times with 200pl of 
sterile filtered PBS by pipette.
Coating antibody (Murine lgG1 anti-human IFN-y antibody 1-DIK) was diluted to 
15jxg/ml in sterile filtered PBS and 10OpI of working dilution added to each well 
of a prepared PVDF 96 well plate, which was then incubated overnight at 4°C. 
The plate was then washed by hand six times with 200^1 sterile PBS/well to 
remove non-bound coating antibody. 150pJ of complete media was added to 
each well for 1 hour at 37°C 5% CO2 60% humidity (to block further non-specific 
antibody binding) and decanted prior to addition of cells.
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Fresh or recently resuscitated PBMCs at 106/ml in complete media were added 
to the wells prior to the addition of stimulatory peptide. Cells were added to 
wells at 5 x 104, 1 x 105 and 2 x 105 cells/well. Immunogenic CMV- or EBV- 
peptides (Prolmmune) with known HLA restriction were stored dissolved in 
DMSO at high concentration at -70°C (2mg peptide in 200pl DMSO) in 5pl 
aliquots. The working concentration of peptide was 10 pmolar i.e. 1:1000 
dilution of frozen stock. This diluted out the DMSO so minimal toxicity to cells 
would result. Peptides were reconstituted in complete medium (with human AB 
serum) to 1pg/100pL for use in the ELISpot assay. 1pg of CMV- or EBV-peptide 
of appropriate HLA Class I restriction (in 100pl complete medium) per 105 cells 
was added to each well and incubated for 20 hours. Negative control wells were 
cells without CMV- or EBV-peptide and cells with CMV-peptide restricted to an 
HLA Class I type not possessed by the cells ('dummy peptide’). Positive 
controls were 105 cells plus 10uL phytohaemagglutin (PHA, Sigma-Aldrich). 
Plates were incubated under standard conditions for 20 hours. Cells were then 
removed by washing six times with 200pl sterile PBS. A second biotinylated 
murine lgG1 anti-human IFN^y antibody (7-B61), (which recognises a different 
epitope of human IFN-y to the 1-DIK antibody), was then diluted 1:1000 in 
filtered sterile PBS with 0.5% FCS and 100pl was added to each well and 
incubated for 90 minutes at room temperature. Wells were then washed six 
times with sterile, filtered PBS. Streptavidin-Alkaline Phosphatase was diluted 1 
in 1000 in filtered PBS with 0.5% FCS and 100pl was added to each well and 
incubated for 1 hour at room temperature. Wells were washed 6 times with 
sterile filtered PBS and 100 pi of reconstituted alkaline phosphatase colour 
change substrate (Biorad) added per well. Plates were agitated gently at room 
temperature for 10-20 minutes until spots appeared just visible to the naked 
eye. Colour development was then stopped by washing three times with 
200pl/well of tap water. Plates were left to air dry at room temperature overnight 
(during which time the spots became more prominent) and wells were 
subsequently photographed using an digital camera (Olympus) and dissection 
microscope. The ELISpot assay is depicted in Figure 2.4
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When a substrate for the enzyme 
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production by a single cell
Figure 2.4 The principle of the IFN-y ELISpot Assay.
81
Frequency of responding cells was defined as:
Mean number of dots/well in test wells -number of dots/well (negative controls)
Number of cells/well
Frequency of CMV- or EBV-specific cells (percentage of CD3+CD8+ cells) was 
defined as (percentage CD3+CD8+ PBMCs x frequency of responding cells). 
Note that the percentage of CD3+CD8+ within PBMC cells was determined by 
flow cytometry.
2.7 IFN-y Secretion Assay
The APC-conjugated flow cytometric intracellular IFN-y cytokine secretion assay 
detection kit was used (Miltenyi).
PBMCs were stimulated with 5ug CMV-peptide/106 cells in polystyrene tubes 
(Kendall-Elkay) for 12 hours at 37°C. Up to 106 PBMCs were suspended in 1 ml 
of cold MACS buffer, centrifuged at 400g for 10 minutes at room temperature 
and resuspended in 90pL of cold medium. 10pl of IFN-y. catch reagent was 
added and the cells were incubated on ice for 5 minutes. Warm complete 
medium was added to the cells (1ml per 106) which were then incubated for 45 
minutes at 37° C with intermittent agitation to resuspend settled cells. The cells 
were then put on ice and centrifuged at 400g for 10 minutes at room 
temperature after adding 3mls of cold buffer. The cell pellet was resuspended in 
90pl of cold buffer and 10pl of IFN-y detection antibody (APC-conjugated) was 
added along with 5pl of CD3-FITC, CD4-PE, and CD8 -PerCP (all BD). The cells 
were incubated on ice for 1 0  minutes and then 2 mls of cold buffer added and 
centrifuged at 400g for 10 minutes at room temperature. The cell pellet was 
resuspended in FACSFlow and samples acquired on a flow cytometer. Negative 
controls were cells stimulated with no peptide or with a dummy peptide. Note 
that this protocol is optimised for <5% cytokine secreting cells.
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2.8 Murine Anti-human IgG ELISA
Murine anti-human IgG was quantified by ELISA in hybridoma supernatants 
using an ELISA kit (Bethyl).
Affinity purified capture antibody (supplied at 10pg/ml) was diluted 1/100 with 
coating buffer (0.05M Sodium Carbonate pH 9.6). 10Opil was added to each well 
of 96 well Immulon plates (Nunc). The plate was incubated overnight under 
standard conditions. Capture antibody was removed from wells by aspiration 
and each well carefully washed with 200pl of wash solution (50mM Tris, 0.14M 
NaCI, 0.05% Tween 20, pH 8.0) 3 times. 200pl of post-coat solution (50mM 
Tris, 0.14M NaCI, 1% BSA, pH 8.0) (all Sigma-Aldrich) was added to each well 
and incubated for 30 minutes. After incubation each well was washed as above 
3 times. Standards and test samples were diluted in sample diluents (dilutions 
were based on the expected concentration of the analyte to fall within the 
concentration range of the standards. Standard mouse reference serum was 
supplied with a concentration of murine IgG of 7.3mg/ml and was diluted to 
500ng/ml by the addition of 100pL of standard to 730pL of sample diluent 
(50mM Tris, 0.14 M NaCI, 1% BSA, 0.05% Tween 20, pH 8.0) to yield 
10,000ng/ml and then 100pL of this added to 1.9ml of sample diluent. Serial 2- 
fold dilutions were then made for standards between 250 and 7.8 ng/ml. 100pl 
of standard or test sample was added to duplicate wells and incubated for 30 
minutes at room temperature. After incubation the wells were washed 4 times. 
100pl of diluted goat anti-mouse IgG Fc-Horseradish peroxidase-conjugated 
antibody was added to each well and incubated for 60 minutes at room 
temperature. This was followed by 4 wash cycles. The prepared enzyme 
substrate colour change reagent (Amersham) was added at 100pl/well and 
incubated for 20 minutes at room temperature. 100pL of stop reaction reagent 
(Amersham) was then added to each well. A microtitre plate reader (Anthos 
Labtec) was then used to assess the light absorbance at 450nm (appropriate for 
the colour change substrate used.) A standard curve was created and the mean 
concentration (of two readings) of murine IgG from each test sample calculated.
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2.9 PKH-26 Dye Labelling of Cells
Target cells were cell surface membrane labelled with a fluorescent cell linker 
kit, which incorporates the fluorescent dye PKH-26 (Sigma-Aldrich). PKH-26 is 
a red fluorochrome with emission wavelength range homology with PE, which 
fluoresces very brightly with an emission peak of 580nm and can thus be 
detected in the FL2 channel on a FACSCalibur flow cytometer. This allows 
PKH-26 labelled cells to be identified by flow cytometric analysis. High-level 
fluorescence with PKH-26 staining, membrane dye stability and lack of dye 
transfer to effector cells has been documented.[Lowdell et al. 2002]
To label with PKH-26 dye, cells were centrifuged at 200g for 10 minutes, 
counted and viability assessed by trypan blue staining, and resuspended in 1 ml 
of labelling diluent at a concentration of 4x106 cells/ml. 4pL of PKH-26 
membrane dye was then added to 1 ml of labelling diluent in a separate 
microcentrifuge tube. 0.5ml of diluted dye was added to 0.5ml of target cells and 
incubated on ice for 2 minutes. After 2 minutes, 0.5mls of neat FCS was added 
to the cell suspension to stop the reaction. The labelled cells were then washed 
twice in a micro-centrifuge. Adequate cell labelling was confirmed by analysis of 
cells on a flow cytometer. Labelled cells were then used variously in the MLR or 
as targets in cell-mediated killing assays.
2.10 PKH-26 Dye Cytotoxicity Assay
Briefly, T2 target cells (a kind gift from the Anthony Nolan Research Institute) 
were split in culture 24 hours prior to the assay to ensure that they were in 
exponential log phase.
Target cells were untreated T2 cells suspended in complete medium at 106 
cells/ml or T2 cells to which excess CMV NLV peptide (10 pg/106 cells) had 
been added, incubated for 1 2  hours under standard conditions, centrifuged for 
1 0  minutes at 2 0 0 g and resuspended in complete medium.
Effectors were healthy CMV IgG positive HLA A*0201+ donor CTLs, either 
unselected or CMV-selected (after 3 rounds of stimulation with CMV whole 
antigen (Dade Behring) at day 1 (1 mg/ml) and 0.5mg/ml at days 7,and 14), 
(supplied by Dr Kwee Yong).
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Target cells were labelled with PKH-26 as described in Chapter 2.14. The PKH- 
26 killing assay was then set up (with each condition in duplicate) with an 
effector: target cell ratio of 10:1. A minimum of 2x105 PKH-26 labelled target 
cells were added to effector cells and gently centrifuged for 1 minute to pellet 
the cells. The assay was incubated for 4 hours under standard conditions. After 
incubation, 100pL of Propidium Iodide (1pL/ml) was added to each tube and 
cells analysed by flow cytometry. PKH-26-labelled target cells were identified by 
their intense fluorescence in the FL2 channel on the FACSCalibur flow 
cytometer and the percentage lysis of target cells was determined as the 
percentage of labelled target cells taking up the propidium iodide (PI), (which 
fluoresces in the FL3 channel on the FACSCalibur flow cytometer). Spectral 
overlap between PKH-26 and PI was eliminated electronically using appropriate 
controls. Background target cell death was determined in PKH-26 labelled 
target cells incubated under similar conditions in the absence of effector cells. 
Specific target cell killing was calculated as the (percentage target cell death -  
percentage background target cell death) for each condition. (Figure 2.5)
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2.11 T2 Cell Peptide Binding Assay
The ability of synthetic CMV-peptides to stabilize MHC Class I molecules on the 
surface of the T2 cell line was measured by flow cytometry. T2 cells only 
express HLA A*0201 Class I molecules on their surface and have weak 
expression due to their lack of the transporter-associated protein (TAP) and 
consequent inability to process antigenic peptide which is needed to stabilise 
the expression of HLA Class I molecules on the cell surface. Addition of 
exogenous HLA A*0201 binding peptide leads to stabilisation of HLA Class I 
molecules and consequently an increase in HLA Class I median channel 
fluorescence intensity assessed by flow cytometry.
T2 cells were split in culture 24 hours prior to the assay to ensure that they were 
in exponential log growth phase. CMV-peptide was added in excess (10 pg/106 
cells) and the cells incubated overnight under standard conditions. 1 0 5 cells 
were diluted in 500pL HBSS and centrifuged for 10 minutes at 400g to wash 
them free of unbound peptide. Cells were then labelled with 10pL of W162 anti- 
HLA Class I FITC-conjugated antibody (Pharmingen) and acquired on a 
FACSCalibur flow cytometer (BD). Controls were cells with no peptide and a 
dummy (non HLA A*0201 restricted) CMV-peptide. The median channel 
fluorescence of cells was determined. The MHC-stabilization efficiency (MSE) 
for each peptide was calculated as the percent increase of the median channel 
fluorescence above that of the negative controls. Peptides with MSE greater 
than 50% were considered as positive binders.
2.12 HLA Typing
HLA typing was undertaken at the Anthony Nolan Research Institute for all 
normal control individuals and donor-recipient transplant pairs. HLA typing was 
performed using the Sequence-Specific Oligo-Primer (SSOP) technique for 
allelic typing at both class I and Class II antigens. Individual details of HLA 
types of samples used are given in the relevant chapters.
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2.13 Consent
Written informed consent was given by all individuals concerned for the use of 
their blood samples for research purposes including cryopreservation and 
storage of cells for indefinite periods of time prior to experimental use. 
Unrelated donors gave written informed consent for use of their blood samples 
whilst at their local Transplant Centres before stem cell donation. Such samples 
were shipped to our laboratory in an anonymised form.
2.14 Statistical Analyses
The paired or unpaired two-tailed Student’s t-test was used when samples 
exhibited similar variance. If a significant difference in sample variance was 
seen then Welch’s correction was applied to the Student’s t-test. A p value of 
<0.05 was chosen as the level for rejection of the null hypothesis.
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Chapter 3 0KT3 Pre-treatment of Stimulatory Cells and Selective
Allodepletion
3.1 Introduction
All modalities of selective alloreactive cell depletion rely on the principle of 
stimulation of alloreactive cells in a live responder (donor) cell population by 
irradiated stimulator (recipient) cells in a unidirectional MLR. The optimum 
number and type of stimulator cells remains to be determined and may vary 
depending upon the individual technique used, the degree of major and minor 
histocompatability disparity between stimulator and responder cells and the 
lineage of the cells to which a retained GvL effect is desired. It is important that 
the stimulator cells be free of malignant cells to prevent presentation of 
leukaemia-specific antigens and subsequent activation and depletion of 
responder cells with specific anti-leukaemic activity. The remission status of 
potential recipients of selectively allodepleted grafts should be confirmed using 
the most sensitive techniques available (which include the use of the 
polymerase chain reaction (PCR) for TCR or Immunoglobulin Heavy Chain 
gene rearrangements for lymphoid malignancies, known specific chromosomal 
translocations in myeloid malignancies, and/or patient-specific multicolour flow 
cytometric profiling).
Unselected PBMCs have been used in the unmodified MLR prior to selective 
allodepletion based upon CD25 expression in the haploidentical 
setting,[Cavazzana-Calvo et al. 1990;Cavazzana-Calvo et al. 1994] and CD69 
expression in HLA-mismatched pairs in vitro.[Koh et al. 1999] Dendritic cell 
enriched stimulators (via a fibroblast monolayer) have been utilised for 
stimulator cells prior to allodepletion based on either CD25 or CD69 expression 
and on both.[Fehse et al. 2000a;Fehse et al. 2000b] Allostimulation prior to 
selective allodepletion based on CD25 expression in haplotypical mismatched 
stimulator-responder pairs has been found to be more reproducible in vitro with 
the use of EBV transformed LBCs derived from recipient stimulator 
cells,[Amrolia et al. 2003a] and this strategy has been utilized in a clinical pilot 
study of haploidentical paediatric stem cell transplants.[Amrolia et al. 2003b]
For selective depletion of alloreactive cells based on responder cell expression 
of activation antigens a measurable upregulation of activation antigen is
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required for the immunomagnetic sorting of alloreactive cells and the 
assessment of the efficiency of this process, whereas an additional readout 
(e.g. responder cell proliferation in the MLR) is required for assessment of the 
selective abrogation of T cell responses to first party stimulators with retention 
of responses to third party stimulators. In the HLA A, B and DR-matched setting 
hTLP frequencies are often low and proliferative responses may not be 
seen.[DeGast etal. 1992;Dickinson etal. 1998]
Bishara et al reported a modified MLR in a series of HLA A, B, DR and DQ- 
matched (by serological typing) sibling pairs with pre-treatment of stimulator 
cells with IFN-y and TNF-a prior to irradiation and the subsequent addition of IL- 
4 to the MLR.[Bishara et al. 1994] They defined a positive read-out as a 
proliferative response with HLA-matched stimulator PBMCs at 120 hours of co­
culture of >/= 5% of the proliferative response seen with HLA-mismatched third 
party PBMC stimulator cells (the Relative Response Index, RRI). RRI was 
positive in 15 of 40 (38%) HLA-matched sibling pairs they tested. They found 
that the modified MLR had a positive predictive value of 6 6 % for acute GvHD 
(all grades) in recipients of T cell depleted transplants and 70% for recipients of 
non T cell depleted transplants. The negative predictive value for development 
of acute GvHD was 93% and 90% respectively. The authors did not attempt to 
correlate the RRI in the modified MLR with the severity of acute GvHD. Use of 
an attenuated cytokine modified MLR (with no pre-treatment of stimulators, IL-4 
added to the MLR culture only) has subsequently been reported in HLA A, B, 
and DR locus matched unrelated pairs. The RRI was >/=5% in 19 of 35 (54%) 
pairs tested and correlated with HLA C-mismatch.[Bishara etal. 1999]
The full cytokine-modified MLR has been utilized for CD69 allostimulation and 
depletion in vitro by Koh et al. He reported 5 of 9 HLA A, B and DR-matched (A 
and B serologically typed, DR antigens typed at allelic level) sibling and 
unrelated donor-recipient pairs tested had a positive cytokine mMLR 
(RRI>5%).[Koh et al. 1999] Another group has recently used this strategy with 
data published in abstract form and the proportion of pairs RRI>/=5% was not 
stated.[Schumm et al. 2003] Thus the use of the cytokine-modified MLR as part 
of a CD69 selective allodepletion strategy is limited to the 40% of HLA A, B and 
DR-matched pairs that exhibit a RRI>/=5%.
The use of dendritic cell-enriched stimulator cells has the advantage of 
enriching the stimulator cell population with professional APCells that might be
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more effective at presenting alloantigen, however myeloid-restricted antigen 
responses might be lost which might reduce the GvL effect if these antigens are 
not shared (or are differentially expressed) between normal host haematopoietic 
cells and myeloid leukaemia cells.
The use of EBV-LBC lines is not ideal for use in the HLA-matched setting due to 
the theoretical risk of loss of responder cell activity to EBV antigens presented 
by such stimulator cells and also has the disadvantage of possible direct 
transfer of the EBV genome during the graft engineering process, both of which 
could increase the risk of EBV-related post-transplant lymphoproliferative 
disorder (PTLD) (although PTLD was not evident in the single report of a clinical 
trial using this strategy).[Amrolia et al 2003b]
The demonstration of limited tissue distribution of mHags, specifically the 
limitation of expression of the HA-1 and HA-2 antigens to haematopoietic cells 
has led to the successful development of the strategy of harnessing allogeneic 
CTLs specific for these mHags to exert a specific GvL effect in the setting of 
haematopoietic malignancies.[de Bueger et al. 1992;Kloosterboer et al. 
2004;Marijt et al. 2003;Mutis et al. 1999b] Although mHags with different levels 
of expression on myeloid and lymphoid lineage cells have yet to be identified, 
the antigen-presenting cell used for allostimulation prior to selective 
allodepletion in the HLA-matched setting would be of crucial importance if such 
lineage-restricted mHags exist.
The cytokine pre-treatment of stimulator cells with TNF-a, IFN-y and /or IL-4 
leads to selective upregulation of adhesion molecules (CD11a, CD54), HLA 
Class I and II molecules and co-stimulatory molecules (CD80, CD8 6 ) on CD14+ 
monocytes with less effect on CD3+ T cells.[Davies et al. 2003] This strategy 
may therefore preferentially increase presentation of myeloid/monocytes- 
restricted mHags in the HLA-matched setting and might also lead to loss of 
myeloid-restricted tumour antigen responses if used in a setting of myeloid- 
lineage malignancy.
The use of predominantly lymphoid stimulators could lead to the preferential 
presentation of lymphoid-restricted or lymphoid-specific antigens. This would 
have the theoretical advantage of preservation of responses to myeloid 
restricted antigens which might result in better anti leukaemic activity in the graft 
in the case of myeloid malignancy, but has the disadvantage of the use of non­
professional APCells which might be less effective at presenting a broad
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spectrum of alloantigens (particularly those presented in the context of HLA 
Class II molecules) required for effective stimulation (and subsequent removal) 
of alloreactive cells and abrogation of alloreactive responses.
When activated, human T cells express MHC class II antigens and adhesion 
molecules characteristic of APCells. Recent in vitro and in vivo evidence 
supports an antigen-presenting function for T cells. Human T cell clones have 
been shown to be capable of presenting influenza peptide antigens directly but 
not an appropriate strain of inactivated whole influenza virus, indicating an 
inability to process antigen conventionally.[Hewitt and Feldmann 1989] Antigen 
presentation by T cells (T-T presentation) induces an initial T cell activation 
phase as measured by proliferation and IL-2 production. These activated T cells 
became anergic only upon antigenic restimulation by professional APCells, as 
shown by a failure to proliferate or produce IL-2 or IFN-y.[Taams et al. 1999] In 
this guise, T cells may provide down-regulatory signals for the immune 
response by inducing anergy in T cells that have already been activated. It has 
been suggested that this may represent an important negative mechanism for T 
cell homeostasis. [Pichler and Wyss-Coray 1994]
The ability of HLA-DR-expressing human T cell clones to function as APCells 
has been investigated using highly purified T cells. These T cell clones were 
unable to act as autonomous APCells, and recognition of nominal or 
alloantigens on the surface of T cells led to a state of non-responsiveness. One 
reason for this may be the relatively low expression of co-stimulatory molecules 
on T cells as MHC/TCR interaction without the second signal provided by 
ligation of co-stimulatory receptors is known to induce a state of anergy in 
responding T cells. In the presence of soluble peptide and PBMCs T cells were 
capable of displaying antigen to each other, and PBMC derived APCells 
provided co-stimulatory signals. [Sidhu etal. 1992]
A potential technique to potentiate antigen presentation by a PBMC pool is to 
pre-treat T cells within the stimulator PBMC pool with a stimulatory anti-CD3 
antibody to activate T cells and potentially to increase their capacity to present 
alloantigens either directly or indirectly via non-T cells in the stimulator cell pool. 
This technique has recently been described to quantitatively expand the 
stimulatory cell pool prior to CD25-mediated selective allodepletion.[Solomon et 
al. 2 0 0 2 ]
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We chose to investigate the strategy of pre-treatment of stimulator cells within a 
PBMC pool with stimulatory OKT3 and/or stimulatory anti-CD28 on alloantigen 
presentation and subsequent selective allodepletion based on responder CD69 
expression.
OKT3 was chosen as a stimulatory anti-CD3 antibody. By mimicking antigen, 
anti-CD3 antibody can produce T cell activation but also anergy and death. 
Activation of resting T cells in vivo by anti-CD3 antibodies results in cytokine 
release both from T cells by cross-linking of T cell receptors and also from Fey 
receptor bearing cells (monocytes). Although anti-CD3 antibodies have been 
engineered with low Fey receptor binding affinities to minimise cytokine-induced 
toxicity when used as immunosuppressive treatment after solid organ 
transplantation, OKT3 has high Fey receptor binding affinity and was selected 
for use as any Fey receptor mediated cytokine release from non-T cells within 
the OKT3 treated PBMC pool might additionally increase the efficiency of 
alloantigen presentation. [Carpenter et al. 2000]
Immobilised OKT3 has been shown to be more effective than soluble OKT3 in 
stimulating mitogenesis and direct cytokine release from T cells, [van Lier et al. 
1989]
The CD28 molecule is present on 95% of resting CD4+ cells and 50% of resting 
CD8 + cells.[June et al. 1990] Activation of T cells via antibody mediated ligation 
of CD28 has provided evidence for a CD28 signalling pathway which involves 
stabilization of cytokine mRNA levels and is separate from that used by the 
TCR-CD3 complex.[Siefken et al. 1997] Thus antibody mediated CD28 ligation 
of T cells may increase autocrine production of cytokines which might increase 
their expression of molecules important in presentation of alloantigens via an 
additional and separate pathway to CD3-mediated activation via OKT3. 
Treatment of T cells with stimulatory anti-CD28 antibody alone has been shown 
to cause activation and IL-2 secretion.
Proliferative responses and T cell survival after anti-CD3 antibody stimulation 
may be increased by additional co-stimulation with anti-CD28. [Boise et al. 
1995;Meijer et al. 2001;Siefken et al 1997]
The initial hypothesis tested was that immobilised OKT3 +/-stimulatory anti- 
CD28 antibody stimulation might lead to activation of T cells and upregulation of 
expression on T cells of molecules involved in antigen presentation (Figure
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3.1(A) and 3.1(B)), and an increase in the capacity of such T cells to present 
alloantigens in a one-way MLR.
T cells can stimulate apoptotic cell death via interaction between CD178 (FAS 
ligand) and CD95 (FAS) on target cells Expression of CD178 on T cells within a 
PBMC pool was measured, as this could provide an increased FAS-mediated 
signal to target cells in the one-way MLR and result in increased selective cell 
death of alloresponder cells. This pathway has been exploited (via the 
administration of exogenous anti-CD95 to responder cells) and has been found 
to effectively deplete alloreactive cells in an MHC-mismatched murine model 
and in human in vitro pairs.[Hartwig e ta/2002;Nonn etal. 2003a]
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Figure 3.1 OKT3 pre-treatment of T cells and T-T antigen presentation.
(A) Molecules involved in presentation of alloantigens to alloreactive T Cells
(B) Possible mechanism of OKT3 in potentiating the capacity of T cells for 
presenting alloantigens.
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3.2 Aims of Experiments Described in this Chapter
1. To examine the effect of OKT3 pre-treatment of T cells within the PBMC 
stimulator cell pool on their expression of various molecules important for 
the presentation of alloantigens;
2. To examine whether responder cell hyporesponsiveness and anergy was 
a frequent occurrence in the HLA-mismatched and HLA-matched setting;
3. To examine the effect of OKT3 pre-treatment of stimulators on the 
temporal kinetics of responder cell CD69 expression;
4. To compare the allostimulatory capacity of PBMCs in the cytokine 
modified MLR and OKT3 pre-treated PBMCs in HLA-matched pairs;
5. To compare the efficacy of CD69 based selective depletion in HLA- 
matched setting following the cytokine modified MLR and the OKT3 pre­
treated MLR.
3.3 Methods
Human monoclonal mitogenic OKT3 was obtained from culture supernatant and 
quantified by ELISA (Chapter 2.8).
OKT3 was bound on to the surface of individual wells of multiple 24 well plates. 
After initial experiments to optimise the amount of OKT3 added to each well to 
result in stimulation of cells a standardised protocol was established in which 
1ml of OKT3 supernatant (500ng) plus 2-4mg of anti-CD28 (stimulatory azide- 
free murine lgG2a anti-human CD28, Diaclone) was added to each well and 
plates incubated for 24 hours at 4°C (or 4 hours at 37°C). The OKT3 
supernatant was then removed and each well washed with 1 ml of HBSS. 
OKT3-layered plates were kept at 4°C wrapped in foil and used within 7 
days.[Duarte et al. 2002] 1 ml of fresh PBMCs from healthy donors at 106 
cells/ml in complete medium was added to each well. The following wells were 
set up in triplicate:
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Well OKT3 Anti-CD28
1 None None
2 500ng/well None
3 None 2 pg/well
4 None 4pg/well
5 500ng/well 2 pg/well
6 500ng/well 4|xg/well
Table 3.1 0KT3 +/- anti-CD28 stimulation of PBMCs.
After 24 and 48 hour culture periods, cells were incubated with the following 
panels of monoclonal antibodies and analysed by flow cytometry:
Panel/Fluorochrome FITC PE PerCP
1 CD11a CD54 CD3
2 HLA Class I CD69 CD3
3 CD178 CD69 CD3
4 CD80* CD8 6 CD3
5 HLA DR CD54 CD3
‘ some subjects only
Table 3.2 Antibody panels used to measure expression of molecules 
important in presentation of alloantigens on OKT3-stimulated T cells.
PBMCs from 5-8 healthy donors were used. Antibodies for flow cytometric 
analysis other than CD178 (Bender Med Systems) and HLA Class I (Serotec) 
were supplied by BD. The staining procedure was as described in Chapter 
2.2.1. CD178 was used at 1jiL/ 2 x 105 cells and incubated on ice for 30 
minutes prior to the addition of 500ja.L of HBSS, centrifugation at 200g for 10 
minutes and resuspension in 300pL HBSS. The relative proportions of cell 
subsets within PBMCs were subsequently assessed at 0, 24 and 48 hours after
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pre-treatment with 0KT3 alone utilising the following cell panels (all BD 
antibodies)
Panel/Fluorochrome FITC PE PerCP APC
1 CD56 CD69 CD8 CD3
2 CD19 CD14 - CD3
Table 3.3 Antibodies used to phenotype cells within PBMC pool before/after 
OKT3 stimulation.
The OKT3 stimulated proliferation of PBMCs (and the effect of ^irradiation 
upon this) was assessed to ensure that OKT3 pre-treated stimulator cells did 
not proliferate after irradiation and were therefore suitable for use in the MLR. 
105 fresh PBMCs/well (untreated or pre-treated with OKT3 for 48 hours) were 
incubated under standard conditions for 1 2 0  hours in 96 well plates and tritiated 
thymidine was added (1pCi/105 cells) at 108 hours. Proliferation was measured 
at 120 hours (Chapter 2.3.2). This was repeated with cells exposed to 30Gy y- 
irradiation prior to incubation. To confirm that OKT3 pre-treated stimulator cells 
underwent sufficient apoptotic shrinkage after 30Gy of y-irradiation to enable 
reliable differentiation from live responder cells in a FSC vs SSC plot, stimulator 
cells (either untreated or pre-treated with OKT3) were labelled with PKH-26 dye 
(see Chapter 2.9) prior to y-irradiation and HLA-mismatched MLRs were set up. 
At 72 hours cells were labelled using the standard protocol with CD3-FITC, 
CD4-PerCP and CD69-APC. No PE fluorochrome was used to avoid 
interference with the PKH-26 dye, which fluoresces brightly in FL2.
The effect of OKT3 pre-treatment of stimulator cells in 16 HLA-mismatched 
(Table 3.4) and 16 HLA-matched (Table 3.5) stimulator-responder pairs was 
assessed. Responder cell CD69 expression and proliferation was measured 
and compared to that seen in the standard MLR and cytokine-modified MLR 
allostimulation strategies. Finally the efficiency of selective depletion of CD69+ 
responders using the Miltenyi anti-FITC microbead system was compared after 
pre-treatment of stimulators with OKT3 and after the cytokine-modified MLR 
strategy in 14 of the HLA-matched stimulator-responder pairs using the schema 
set out in Figure 3.2
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Figure 3.2 Experiments to investigate the effect of OKT3 on PBMC stimulators in the MLR.
Pair Stimulator HLA type Responder HLA type
1 A*0201 ,*24; B*5101 ,*4405; 
0*0202 ,*1502; DRB1*04, *11
A *0201, *01 ;B*0801 ,*40;C*01 ,*12 
DRB1* 0403, *0404
2 A*0201 ,*3001 ;B *0702, *4402; 
C*07,*05; DRB1* 1401,*0810
A*0201 ,*302; B*52,*40  
C*1502,*1202;DRB1*1502,*16
3 A*0201 ,*29;B*08,*15;C*07,*03; 
DRB1*0301 ,*13
A*0201 ,*0101 ;B*1402,*4101; C*17,*08; 
DRB1 *0302,*0701
4 A*0201; B*08,*04; C*03,*07; 
DRB1*0101,*0301
A*0201 ,*6801 ;B*51 ,*0702; C *1502,*07; 
DRB1* 1501/13021
5 A*0201; B*57,*40; C*02,*06; 
D R B1*1101,*1104
A*0201,*33;B*58,*3508C*0302,*04; 
DRB1*1601,*0301
6 A*0201,*33; B *58,*3508 C*03,*04; 
DRB1*1601 ,*0301
A*0201 ,*3001 ;B*0702,*4402; C*07,*05; 
DRB1* 1401,*0810
7 A*0201,*24; B*5101 ,*4405; 
C*0202,*1502; DRB1*04, *11
A*0101; B*0801; C*0701; 
DRB1* 0301
8 A*0201,*24; B*5101 ,*4405; 
C *0202,*1502; DRB1*04, *11
A*0201 ,*24; B *0702,*1401; 0*07,*08; 
DRB1 *0401,*0701
9 A*0201,*24; B*5101 ,*1502; 
C *0202,*1502; DRB1*04,*11
A*0201 ,*1101 ;B*44,*27;C*02,*05; 
DRB1 *1501,*0401
10 A*0201 ,*0101 ;B*1402,*4101; 
C*17,*08; DRB1 *0302,*0701
A*02,*0101; B*08,*04; C *03,*07; 
DRB1*0101,*0301
11 A *0201,*6801 ;B*51,*0702; 
C*15,*07; DRB1*1501/13021
A *02,*01; B*57,*40; C *02,*06; 
DRB1*1101,*1104
12 A*0201,*302; B*52,*40  
C *1502,*1202;D R B 1*1502,*16
A*0201 ,*29; B*08,*15; C *07,*03; 
DRB1*0301,*13
13 A*0201,*24; B*5101 ,*4405; 
C*0202,*1502; DRB1*04, *11
A*0201 ,*0301 ;B*35,*37;C*04,*06, 
DRB1 *0404,*1303
14 A*0201,*24; B*5101 ,*4405; 
C*0202,*1502; DRB1*04, *11
A*0101 ;B*0702,*3701 ;C*06,*07; 
DRB1 *0404,*0701
15 A*0201,*24; B*5101 ,*4405; 
C*0202,*1502; DRB1*04, *11
A*0201 ,*31; B*44,*35; C *05,*12; 
DRB1*1501,*1401
16 A*0201,*24; B*5101 ,*4405; 
C*0202,*1502; DRB1*04, *11
A*0201 ,*0101 ;B*08,*18;C*03,*07; 
DRB1* 0301
Table 3.4 HLA typing of HLA-mismatched Stimulator-Responder pairs.
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Pair Stim ulator HLA type Responder HLA type
1 A, B, C, DR-matched SD A*201, *01 ;B*0801 ,*40;C*01 ,*12 
DRB1* 0403, *0404
2 A, B, C, DR-matched SD A*0201,*302; B*52,*40 
C*1502,*1202;DRB1*1502,*16
3 A, B, C, DR-matched SD A*0201 ,*0101 ;B*1402,*4101; C*17,*08; 
DRB1 *0302,*0701
4 A, B, C, DR-matched SD A*0201 ,*6801 ;B*51 ,*0702; C*1502,*07; 
DRB1* 1501/13021
5 A, B, C, DR-matched SD A*0201,*33;B*58,*35080*0302,*04; 
DRB1 *1601,*0301
6 A, B, C, DR-matched SD A*0201 ,*3001 ;B*0702,*4402; C*07,*05; 
DRB1* 1401,*0810
7 A, B, C, DR-matched UD A*0101;B*0801; C*0701; 
DRB1* 0301
8 A, B, C, DR-matched UD A*0201 ,*24;B*0702,*1401 ;C*07,*08; 
DRB1 *0401,*0701
9 A, B, C, DR-matched UD A*0201 ,*1101 ;B*44,*27;C*02,*05; 
DRB1 *1501,*0401
10 A, B, C, DR-matched UD A*02,*0101; B*08,*04; 0*03,*07; 
DRB1*0101,*0301
11 A, B, C, DR-matched UD A*02,*01; B*57,*40; C*02,*06; 
DRB1*1101,*1104
12 A, B, C, DR-matched UD A*0201,*29; B*08,*15; C*07,*03; 
DRB1*0301,*13
13 Single DRB1* mismatched UD A*0201 ,*0301 ;B*35,*37;C*04,*06, 
DRB1 *0404,*1303
14 Single A locus mismatched UD A*0101 ;B*0702,*3701 ;C*06,*07; 
DRB1 *0404,*0701
15 A and C locus mismatched UD A*0201,*31; B*44,*35; C*05,*12; 
DRB1*1501,*1401
16 Single C locus mismatched UD A*0201,*0101;B*08,*18;C*03,*07; 
DRB1* 0301
Table 3.5 HLA typing of fully or partially HLA-matched Stimulator-Responder 
pairs. SD=Sibling Donor, UD=Unrelated Donor.
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3.4 Results
In experiments to ascertain the optimal dose of immobilised OKT3 for 
stimulation of the T cell pool within unselected PBMCs, activation of T cells was 
measured by the upregulation of CD69 and HLA DR. Expression of both CD69 
and HLA DR were maximally up regulated with 500ng of immobilised OKT3 and 
1 0 6 cells/well (data not shown).
For antigens not constitutively expressed on CD3+ cells (CD69, CD54, HLA DR, 
CD8 6 , CD178,), antigen expression was quantified as the percentage of CD3+ 
cells positive for the antigen (MCF) >101. For antigens constitutively expressed 
on CD3+ cells (HLA Class I, CD11a) density of antigen expression was 
quantified as MCF. Changes in antigen expression on CD3+ cells are presented 
as mean fold increase in percentage positive or MCF (above baseline levels 
seen in complete medium only wells).
3.4.1 Expression of Molecules involved in Antigen Presentation on T 
cells after Stimulation with OKT3+/-anti-CD28 Antibody
3.4.1.1 Expression of CD69
Only 1.2% +/-0.7% of baseline CD3+ cells expressed CD69.
The percentage of CD3+ cells expressing CD69 increased in all subjects (mean 
30-fold increase) with OKT3 stimulation at 24 hours (p=0.007) and a 40-fold 
increase at 48 hours (p=0.002).ln 2 of 6  subjects tested CD28 alone increased 
the percentage of CD3+ cells expressing CD69 at both 24 and 48 hours at both 
CD28 doses but no increase was seen in the other individuals. The combination
of OKT3 and CD28 did not result in an increase in the percentage of CD3+ cells
expressing CD69 above that seen with OKT3 alone.
3.4.1.2 Expression of CD11 a
CD11a was expressed on all CD3+ cells at rest. CD11a density on CD3+cells 
was not significantly altered by OKT3 after 24 hours but was significantly 
increased after 48 hours. (1.6-fold increase, p=0.04). CD28 alone had no effect
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on CD11a expression on CD3+ cells and no additional effect when used in 
conjunction with OKT3.
3.4.1.3 Expression of CD54
Only 5.3% +/-3.6% of baseline CD3+ cells expressed CD54. The percentage of 
CD3+ expressing CD54 increased after co-incubation with OKT3 at 24 hours 
(4.9 fold increase, p=0.03) and at 48 hours ( 8  fold increase, p=0.002); the 
increase at 48 hours was significantly larger than the increase at 24 hours 
(p=0.04). CD28 alone had no effect and no additional effect when used in 
conjunction with OKT3.
3.4.1.4 Expression of HLA Class I
HLA Class I was expressed constitutively on baseline CD3+ cells. HLA Class I 
density on CD3+ cells was not significantly increased by OKT3 alone at 24 
hours, however the combination of OKT3 and CD28 (at the higher dose used) 
significantly increased HLA Class I MCF of CD3+ cells at 24 hours (1.8-fold 
increase, p=0.02). HLA Class I MCF of CD3+ cells was increased by OKT3 
stimulation (3.9 fold increase, p=0.02) at 48 hours. CD28 alone had no effect 
and CD28 in conjunction with OKT3 conferred no additional increase above that 
seen with OKT3 alone after 48 hours.
3.4.1.5 Expression of HLA DR
9% +/-4% of baseline CD3+ cells expressed HLA DR. The percentage of CD3+ 
cells expressing HLA DR was significantly increased with OKT3 (2.2 fold 
increase, p=0.006) at 24 hours and at 48 hours (5.4 fold increase, p=0.007). 
CD28 alone had no significant effect and conferred no addition increase when 
used in conjunction with OKT3.
3.4.1.6 Expression of CD86
2.5% +/-1.3% of baseline CD3+ cells expressed CD8 6 . The percentage of CD3+ 
cells expressing CD8 6  was significantly increased by OKT3 stimulation alone at
103
48 hours (3.8 fold increase, p=0.002). CD28 alone had no effect. The 
combination of OKT3 and CD28 (at either dose) significantly increased the 
percentage CD3+ CD8 6 + at 24 hours (3.5 and 3.4 fold increase p=0.02) but 
conferred no additional increase above that seen with OKT3 alone after 48 
hours.
3.4.1.7 Expression of CD178 (FAS ligand)
2.4%+/-2.3% of baseline CD3+ cells expressed CD178. The percentage of 
CD3+ cells expressing CD 178 was not significantly increased after OKT3 for 24 
hours but was significantly increased (6.5 fold increase, p=0.01) after 48 hours. 
CD28 alone had no significant effect and conferred no addition increase when 
used in conjunction with OKT3. The positive results are summarised in Figure
3.3
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Figure 3.3 Expression of molecules important in antigen presentation on T cells after OKT3 pre-treatment for 24 and 48 hours. Error 
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3.4.1.8 Interpretation of Results
Following analysis of the results of the effects of OKT3 and/or anti-CD28 
antibody on the expression on CD3+ cells of molecules important in antigen 
presentation, a protocol of PBMC stimulation with 500ng immobilised OKT3/106 
cells for 48 hours without additional CD28 stimulation was adopted for further 
experiments.
3.4.2 OKT3 Stimulation and Cell Subset Distribution
Healthy donor PBMCs were phenotyped with the antibody panel in Table 3.3, 
fresh and following incubation for 48 hours in OKT3 coated wells or in media 
only under standard conditions. Vigorous efforts were made to dislodge 
adherent monocytes from the wells after incubation for 48 hours and this was 
confirmed by light microscopy. Following acquisition of a minimum of 20,000 
events on a FACSCalibur flow cytometer, a region was drawn on a FSC vs SSC 
dot-plot around live PBMCs (including monocytes) and the relative proportions 
of CD3\ CD19\ CD14+ and CD3'CD56+cells were calculated. CD3+CD56+ NK 
cells constitute a very small fraction of CD3+ cells and were not included in the 
analysis, which was intended to demonstrate major changes in the proportions 
of T and B cells and monocytes. The results are presented are the mean cell 
frequencies from three different healthy donors. Compared to values in fresh 
PBMCs, the proportion of CD3+ cells doubled after 48 hours of OKT3 
stimulation (73% vs. 34%), the proportion of CD19+ cells reduced by 25%, the 
proportion of CD3'CD56+ NK cells halved (2.1% vs. 4.3%) and the proportion of 
CD14+ monocytes was greatly reduced (36.2% vs. 4.1%). However similar 
changes in proportions of all cell subsets with OKT3 stimulation were also seen 
after 48 hours of incubation in complete media alone, suggesting that the 
increase in proportion of CD3+ T cells seen over this period was related to a 
growth advantage in cell culture and not directly related to the OKT3 
stimulation. The reduction of CD14+ monocytes might be due in part to retention 
of adherent cells in wells despite vigorous efforts to dislodge adherent cells prior 
to phenotyping. It is of note that OKT3 stimulation led to persistence of some 
CD14+ monocytes, which still made up 4.1% of cells in the viable stimulator cell 
population. These results are illustrated Figure 3.4.
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Figure 3.4 The effect of OKT3 stimulation on the relative proportions of cells 
within the PBMC pool.
4 % C D 1 4 +a  r  2% CD3' CD56+\  /
CD19+
73% CD3+CD56-
6% CD14+ 3% CD3- CD56+
107
3.4.3 Sensitivity to y-irradiation of OKT3 Pre-treated T cells
Before the effects of the OKT3 stimulator cell pre-treatment strategy on 
responder cells could be further investigated it was crucial to ascertain whether 
assumptions true for the standard MLR also held true for the OKT3 strategy. 
OKT3 pre-treatment is highly mitogenic and might render T cells more resistant 
to y-irradiation and it was therefore important to determine the y-irradiation dose 
required to abrogate proliferation of OKT3 pre-treated cells prior to use as 
stimulators in an MLR. Tritiated thymidine incorporation by untreated PBMCs 
from two healthy donors was measured at 72 hours before and after exposure 
to 30Gy of y-irradiation and the experiment was repeated on PBMCs pre-treated 
for 48 hours with immobilised OKT3. 3-9 proliferation assays were performed 
per experiment.
Proliferation, Tritiated Thymidine 
Uptake at 72 hours, cpm (mean+/-sd)
Irradiation None +30Gy None +30Gy
OKT3 Pre- 
Treatment No No Yes Yes
Pair 1 2264+/-441 574.3+/-261 16620+/-2345 325+/-129
Pair 2 1219+/-1224 340.6+/-138 53481+/-5036 1564+/-645
Table 3.6 The effect of OKT3 stimulation on proliferation of unirradiated and 
irradiated PBMCs
Minimal proliferation was seen with untreated PBMCs. OKT3 pre-treatment of 
PBMCs stimulated proliferation, with tritiated thymidine uptake significantly 
higher than that seen with untreated PBMCs (p<0.001). 30Gy of irradiation 
significantly reduced proliferation of OKT3 pre-treated cells (p<0.01) to levels 
not significantly different from that seen in untreated PBMCs after 30Gy of 
irradiation. A dose of 30Gy of y-irradiation was chosen to irradiate OKT3 pre­
treated stimulators prior to their use in the MLR
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3.4.4 Discrimination of Stimulator and Responder Cells
OKT3 pre-treatment of stimulator cells led to activation in a large proportion of 
cells (47%+/-14% of CD3+ cells expressing CD69) and many of these cells 
enlarged as they underwent blastoid transformation (as determined by FSC and 
SSC signals by flow cytometry). OKT3 treated PBMC were seen to shift to the 
right of a FSC vs SSC dot plot on flow cytometric analysis. To confirm that 
irradiated OKT3 pre-treated stimulator cells underwent sufficient apoptosis by 
72 hours to allow differentiation from live responders on a FSC vs SSC dot-plot, 
stimulator cells were labelled with PKH-26 dye prior to irradiation. The results 
after 72 hours of MLR co-culture with OKT3 pre-treated stimulators are shown 
in Figure 3.5. Figure 3.5 (A) shows a FSC vs SSC plot with apoptotic irradiated 
stimulator cells within region R1 and live responder cells within region R2. 
Figure 3.5 (B) is gated on the region R1 and shows 70% of cells within R1 were 
PKH+ stimulator cells and 30% were apoptotic PKH' responder cells. Figure 3.5
(C) is gated on R2 and shows that 98% of cells within this region were PKH' 
and only 2% were PKH+ stimulator cells. The low level of stimulator cells that 
contaminated the responder cell region is demonstrated in Figure 3.5 (E) which 
shows a FSC vs SSC dot plot back-gated on PKH+ stimulator cells (pink) or 
PKH' responder cells (lilac) from the dot plot in Figure 3.5 (D) after 72 hours of 
co-culture.
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Figure 3.5 Discrimination of Stimulator and Responder Cells after OKT3 pre­
treatment of stimulators. Stimulator cells were labelled with PKH-26 dye.
(A). FSC vs. SSC dot plot with stimulator (R1) and responder (R2) regions
(B). 70% of cells within R1 are PKH+ stimulator cells
(C). 2% of cells within R2 are PKH+ stimulator cells
(D). Regions of PKH+ and PKH' cells
(E). Back gated FSC vs. SSC dot plot demonstrating where PKH+ and PKH' 
cells lie
* above background level seen in unlabelled cells
FSC
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3.4.5 0KT3 Pre-treated Stimulators in the MLR
The strategy of OKT3 pre-treatment of stimulator cells was assessed in the 
CD69 selective allodepletion protocol and compared with the use of cytokine- 
modified stimulators. Pre-treatment with 500ng immobilised OKT3/106 cells for 
48 hours was chosen. Responder cell CD69 expression at 72 hours and 
proliferation (tritiated thymidine incorporation) at 1 2 0  hours was measured in 16 
HLA-mismatched and 16 fully or partially HLA-matched stimulator-responder 
pairs.
OKT3 pre-treatment of stimulator cells led to significantly higher expression of 
CD69 on CD3+CD4+ and CD3+CD8+ responders in HLA-mismatched MLRs 
compared to untreated stimulators (p<0.0001 and 0.0003 respectively) or 
cytokine pre-treated stimulators (p=0.0001 and p=0.002 respectively). Cytokine 
pre-treatment led to a smaller, non-significant increase in CD69 expression on 
both cell subsets of HLA-mismatched responders when compared to 
unmodified stimulators.(Table 3.7)
Responder Cells
% CD69+ (above autologous control) (Mean +/-sd)
Standard MLR Cytokine MLR OKT3 MLR
CD3+ 4.6%+/-3.7% 4.8%+/-3.7% 23%+/-14%
CD3+CD4+ 4.4%+/-3.1% 5.2%+/-3.9% 27%+/-15%
CD3+CD8+ 4.5%+/-3.4% 5.3%+/-5.3% 16%+/-10%
Table 3.7 CD69 expression on HLA-mismatched responder cells (above 
autologous control) with untreated (standard), cytokine pre-treated and OKT3 
pre-treated stimulator cells. Figures are mean +/- standard deviation.
Responder CD69 expression was greater following OKT3 pre-treatment of 
stimulator cells than with untreated stimulator cells in all pairs tested in 
CD3+CD4+ cells and in all but one pair in CD3+CD8+ cells. In contrast responder 
CD69 expression following cytokine pre-treatment of stimulator cells was 
unchanged in most pairs tested, with a marked increase (>33%) seen in both 
cell subsets in one pair (Pair 7), and a fall in expression in three pairs (Pair 2, 
Pair 3 and Pair 12). (Figure 3.6).
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3.4.5.1 Proliferation in HLA-Mismatched Pairs
Proliferation of HLA-mismatched responder cells with OKT3 pre-treated 
stimulators at 1 2 0  hrs was equivalent or greater than that seen with untreated 
stimulators in 14 of 16 pairs tested. The mean responder proliferation with 
OKT3 pre-treated stimulators was 157% +/- 54% of that seen with untreated 
stimulators. This difference did not reach statistical significance in a two-tailed 
paired t-test. Responder cell proliferation with cytokine pre-treated stimulators 
was also equivalent or greater than that seen with untreated stimulators in 14 of 
16 pairs tested. The mean proliferation of responders with cytokine pre-treated 
stimulators was 111 % +/- 24% of that seen with untreated stimulators. This 
difference was not statistically significant in a paired two-tailed t-test. Only Pair 
5 demonstrated markedly lower responder proliferation with OKT3 pre-treated 
stimulators (32% of that seen with untreated stimulators) despite greater 
responder cell CD69 expression with OKT3 pre-treated stimulators than with 
unmodified stimulators in this pair. Only Pair 12 demonstrated markedly lower 
responder proliferation with cytokine pre-treated stimulators (46% of that seen 
with untreated stimulators); this pair exhibited lower responder CD69 
expression with cytokine pre-treated stimulators than with unmodified 
stimulators (Figure 3.7).
113
Cp
m
, 
x1
03
1000
100
10
I
d
j
i I
Pair 1 2 3 4 5 6
^ 3  Unmodified MLR
7 8 9 10 11 12 13 14 15 16
Cytokine MLR OKT3 MLR
Figure 3.7 Responder cell proliferation in 16 HLA-mismatched MLRs after 120 hours of stimulation with unmodified, cytokine
pre-treated and OKT3 pre-treated stimulators. Error bars represent standard deviation of triplicate proliferation assays.
3.4.5.2 CD69 Expression in HLA-Matched Pairs
Mean responder CD69 expression was significantly higher with OKT3 pre­
treated than with unmodified or cytokine pre-treated HLA-matched stimulators in 
CD3+CD4+ cells in both matched sibling (p= 0.02) and matched unrelated donor 
pairs (p= 0.004 and 0.002). Only OKT3 pre-treated HLA-matched unrelated 
(and not sibling) stimulators resulted in significantly higher mean CD3+CD8+ 
responder CD69 expression than with unmodified or cytokine pre-treated 
stimulators, (p=0.0004 and 0.001 respectively). Mean responder CD69 
expression was higher with cytokine pre-treated HLA-matched unrelated 
stimulators than with untreated stimulators, but this increase did not reach 
statistical significance in both cell subsets. These data are shown in Table 3.8.
Responder Cells
% CD69* (above autologous control) (mean +/-
sd)
Standard MLR Cytokine MLR OKT3 MLR
All
Matched
Pairs
CD3*CD4* 1.5%+/-2.5% 4.6%+/-7.1% 25.8%+/-12.4%
CD3*CD8* 1.4%+/-2.4% 2.5%+/-3.9% 8.8%+/~6.4%
Matched
Sibling
Pairs
CD3*CD4* 0.97%+/-1.4% 0.79%+A0.95% 23.7%+/-10%
CD3*CD8* 0.95%+/-1.8% 0.61%+/-1.1% 10.9%+/-6.4%
Matched
Unrelated
Pairs
CD3+CD4* 1.9%+/-2.9% 6.9%+/-8.2% 22.1%+/-11%
CD3+CD8* 1.6%+/-2.7% 3.5%+/-4.5% 12.6%+/-6.1%
Table 3.8 CD69 expression (above autologous control) in 16 HLA A, B, C 
DR-matched (or 1-2 antigen mismatched) responders after allostimulation in the 
OKT3 pre-treated, cytokine pre-treated and standard MLR.
Figures are mean +/- standard deviation.
The CD69 responder expression with OKT3 pre-treated stimulators was greater 
than that seen with autologous stimulators in all pairs tested in both cell 
subsets, whereas in 3  sibling pairs the use of cytokine pre-treated stimulators 
failed to elicit a CD69 response above that seen with autologous stimulators in 
both cell subsets (pairs 3,4 and 5) (Figure 3.8).
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No significant difference was seen in mean CD69 responder expression with 
OKT3 pre-treated stimulator cells between sibling pairs (n=6 ) or unrelated pairs 
(n=10) in both cell subsets. However the cytokine pre-treatment of stimulators 
resulted in significantly greater mean CD69 responder expression in unrelated 
pairs than sibling pairs in CD3*CD4* cells (p= 0.04). Subdividing the matched 
unrelated donor group into full A, B, C and DR matches and those with 1 (or 
more) antigen mismatch did not yield any significant differences in CD69 
expression on responder cells between these groups for either strategy.
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Figure 3.8 Responder CD69 expression in 16 HLA-matched (6 sibling and 10 unrelated) MLRs with unmodified, cytokine pre-treated
and OKT3 pre-treated stimulators.
3.4.5.3 Proliferation in HLA-Matched Pairs
Responder cell proliferation with OKT3 pre-treated stimulators at 120 hrs was 
equivalent to or greater than that seen with untreated stimulators in all HLA- 
matched pairs. Mean responder proliferation with OKT3 pre-treated stimulators 
was significantly greater than with untreated stimulators for both sibling and 
unrelated donor matched pairs, (59631 +/-48244 vs.4084+/-5852 cpm and 
53439 +/- 54359 cpm vs 4084+/-5852 cpm respectively, both p=0.02 in two- 
tailed paired Student’s t-tests).
Responder cell proliferation with cytokine pre-treated stimulators at 120 hrs was 
equivalent to or greater than that seen with untreated stimulators in 14 of 15 
HLA-matched pairs tested and lower in one pair (Pair 1, which had also 
exhibited lower responder CD69 expression with cytokine pre-treated 
stimulators than with untreated stimulators). Mean responder proliferation with 
cytokine pre-treated stimulators was greater than with untreated stimulators for 
both sibling and unrelated donor pairs, (21896+/-14304 vs.4084+/-5852 cpm 
and 28803 +/- 42963 cpm vs. 4084+/-5852 cpm respectively) but in neither case 
was the increase statistically significant.
When first party responder proliferation was expressed relative to that seen with 
HLA-mismatched stimulators (Relative Response Index, RRI), the RRI was less 
than 5% in 11 of 15 HLA-matched pairs with unmodified stimulators. RRI was 
greater than 5 % in 9  of these 1 1  pairs with cytokine pre-treated stimulators and 
greater than 5% in all pairs after OKT3 pre-treatment of stimulators, and greater 
than 50% in 9 pairs (Figure 3.9).
Mean responder proliferation was not significantly different between HLA- 
matched sibling pairs (n=6 ) and HLA-matched unrelated donor pairs (n=9) 
under any of the conditions studied.
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Figure 3.9 Responder proliferation at 120 hours in 16 HLA-matched pairs with unmodified, cytokine pre-treated and OKT3 pre-treated 
stimulators: cpm (top) and percentage RRI (bottom) Error bars represent standard deviation. Proliferation assays failed in pair 11.
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3.4.5.4 Correlation of CD69 Expression and Proliferation
CD69 expression at 72 hours in HLA-matched CD3+CD4+ responders 
stimulated with OKT3 pre-treated cells correlated with the log of responder cell 
proliferation (assayed by tritiated thymidine uptake) at 120 hours. (Figure 3.10) 
This is in keeping with published data that CD4+ cell responses correlate most 
closely with proliferation in the MLR.[Nikaein etal. 1984]
No such correlation was seen with cytokine pre-treated stimulators. This was 
primarily because a substantial proliferative response was seen in several pairs 
after cytokine pre-treated stimulation despite only a very small CD69 response 
at 72 hours. Possible explanations for this observation include:
1. Cytokine pre-treated stimulators might cause maximum responder CD69 
expression later than 72 hours.
2. The use of cytokine pre-treated stimulators might lead to preferential 
expression of alternate activation antigens on alloreactive cells (eg CD25)
(Both of these hypotheses are examined in Chapter 5).
3.4.5.5 Correlation of both pre-treatment strategies
No significant correlation was seen between the responder cell proliferation 
(cpm) with OKT3 and with cytokine-pre-treated stimulators. When expressed as 
RRI, an association was seen with OKT3 and cytokine pre-treated stimulators, 
although this was not statistically significant by linear regression analysis. 
(Figure 3.11).
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Figure 3.10 Correlation of CD4+ responder CD69 expression (above 
autologous control) at 72 hours of co-culture and responder proliferation (logio 
cpm) at 120 hours with OKT3 pre-treated stimulators.
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Figure 3.11 Correlation of OKT3 and cytokine MLR RRIs.
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3.4.5.6 Reducing the Stimulator: Responder Ratio
The feasibility of reducing the Stimulator: Responder (S: R) ratio on responder 
CD69 expression and proliferation was investigated in 4 HLA-matched pairs 
(Pairs 1,8,15 and 16).
Reducing the S: R ratio to below 1:1 reduced both the responder CD69 
expression on CD3+CD4+ and CD3+CD8+ cells and responder proliferation in all 
4 pairs tested, although different patterns were seen in different pairs.
Pair 1 (an HLA-matched sibling pair) had a RRI<5% at all S: R ratios using 
cytokine pre-treated stimulators. However with OKT3 pre-treated stimulators the 
RRI was 30% at an S: R ratio of 1:5 and 100% at a S:R ratio of 1:1.
Pair 15 (a single A antigen mismatched unrelated pair) gave an RRI<5% at a S: 
R ratios of 1:10 and 1:5, and 80% at an S: R ratio of 1:1 using cytokine pre- 
treated stimulators, whereas the RRI was <5% at an S: R ratio of 1:10, 30% at 
an S: R of 1:5 and 90% at S: R ratio of 1:1 using OKT3 pre-treated stimulators. 
Pair 16 (a single C locus mismatched unrelated pair) gave an RRI>5% at S: R 
ratios of 1 : 2  and 1 :1  but not at lower ratios using cytokine pre-treated 
stimulators, whereas an RRI of >10% was seen at all S: R ratios tested with 
OKT3 pre-treated stimulators.
Finally pair 8  (a matched unrelated donor pair) gave an RRI >5% at an S: R of 
1:1 (but not at lower S: R ratios), whereas an RRI of >10% at all S: R ratios 
tested was seen with OKT3 pre-treated stimulators.
Thus the cytokine modified MLR was only seen to give positive readouts 
(RRI>5%) in pairs 15,16 and 8  at higher S: R ratios (1:2 or 1:1). Although the 
significance of levels of proliferative responses (and RRI) in the OKT3 modified 
MLR remains to be determined, proliferative responses and RRIs >10% were 
seen at lower S: R ratios in all pairs tested and in some pairs at S: R ratios of 
10:1. The OKT3 modified MLR might therefore prove useful in amplifying 
alloreactive responses in HLA-matched pairs when only small numbers of 
stimulator cells are available for use for clinical scale allostimulation and 
allodepletion of donor T cells (Figure 3.12).
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Figure 3.12 The effect of different S: R ratios on responder proliferation (expressed as RRI to HLA-mismatched third party stimulators) 
in 4 HLA-matched pairs. The pink dotted line represents a RRI of 5%, the level found to have a high negative predictive value for clinical 
GvHD in HLA-matched sibling pairs using the cytokine pre-treatment technique of allostimulation with an S: R ratio of 1:1.
3.4.6 Depletion of CD69* Cells in HLA-Matched Pairs
In 13 of the HLA-matched pairs, OKT3 and cytokine modified MLRs (Chapter 
2.3.4 and 2.3.3) were depleted of CD69+ alloreactive cells at 72 hours by MACS 
immunomagnetic sorting (Chapter 2.5.1) and responder proliferation to first and 
third party stimulators assessed pre- and post-depletion (Chapter 2.4.2). 
Depletion efficiency in the OKT3 modified MLR was 93%+/-10% for 
CD3+CD4+CD69+ cells and 92%+/-13% for CD3+CD8+CD69+ cells. Depletion 
efficiency was similar in the cytokine modified MLR, (91 %+/-10% for 
CD3+CD4+CD69+ cells and 90%+/-11 % for CD3+CD8+CD69+cells)(Figure 3.13). 
Reduction in first party proliferative responses was excellent utilising the OKT3 
modified MLR, with proliferative responses to first party stimulators using 
depleted responders reduced to 0.8%+/-2.1% of the pre-depletion value and 
RRI falling from a mean for all pairs of 69%+/-49% pre-depletion to 0.9%+/- 
2.4% post depletion. Third party proliferative responses were well maintained 
with a mean for all pairs tested of 87%+/-51% of the predepletion values. In one 
in pair tested the third party response was lost (post depletion value only 8.2% 
of the pre-depletion value) indicating failure of selective alloreactive depletion in 
this pair. If this pair is excluded the mean third party proliferative response post 
depletion was 93%+/-36% of that seen with unmanipulated cells.
Reduction in first party proliferative responses was good utilising the cytokine 
modified MLR, with proliferative responses to first party stimulators using 
depleted responders reduced to 2.1%+/-5.2% of the pre-depletion value and 
RRI falling from a mean for all pairs of 38%+/-35% pre-depletion to 0.7%+/-2% 
post-depletion. All pairs with a pre-depletion RRI >5% had a post-depletion 
RRI<5% using the cytokine allodepletion study. Third party proliferative 
responses were well maintained with a mean for all pairs tested of 99%+/-86% 
of the pre-depletion values (Figure 3.14).
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Figure 3.13 Efficiency of immunomagnetic depletion of CD69+ cells after 
cytokine or OKT3 pre-treated allostimulation. Error bars represent standard 
deviation. Results are presented for 12 HLA-matched pairs.
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3.4.7 Correlation of MLR and GvHD in HLA-Matched Pairs
The results of proliferation in cytokine and OKT3-modified MLRs (expressed as 
RRI,%) are shown for the 14 HLA-matched pairs tested from donor-recipients 
who went on to have AHSCTs are shown in Table 3.9, along with details of the 
stem cell source, transplant conditioning and acute GvHD.
Pair Donor Cytokine 
MLR RRI
OKT3 
MLR RRI
Stem cell 
source
Conditio­
ning
Acute
GvHD
1 HLA-matched
SD
1.8 147 TD*
PBSC Cy/TBI
1
(skin)
2 HLA-matched
SD 33 179
NTD
BM Bu/Cy
4
(skin)
3 HLA-matched
SD 15 90
NTD
PBSC Cy/TBI
4
(Liver)
4 HLA-matched
SD 44 74
NTD
PBSC
Flu/mel/
Campath 0
5 HLA-matched
SD 36 115
NTD
PBSC Cy/TBI
1
(skin)
6 HLA-matched
SD 39 24
NTD
PBSC
Flu/Mel/
Campath 0
7 HLA-matched
UD 11 9.5
NTD
BM Cy/TBI 0
8 HLA-matched
UD 15 31
NTD
PBSC
Flu/BEAM/
Campath 0
9 HLA-matched
UD 62 34
NTD
PBSC
Flu/Mel/
Campath 0
10 HLA-matched
UD 59 69
NTD
PBSC
Flu/Bu/
Campath
1
(skin)
13 HLA DRB1*04 
m/m UD 4.6 6.25
NTD
PBSC
Flu/BEAM/
Campath
2
(skin)
14 HLA A m/m 
UD
31 52 TD*
PBSC Cy/TBI
2
(skin)
15 HLA A and C 
m/m UD 83/80 89/89*
NTD
BM
Flu/Treo/
Campath
2
(skin)
16 HLA C m/m 
UD 29 246
TD*
PBSC Cy/TBI
2
(skin)
Table 3.9 Details of HLA-matched pairs tested that underwent AHSCT. 
* measured on two occasions
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Key to Table 3.15
SD Sibling Donor
UD Unrelated donor
Matched Matched at allelic level at HLA A*y B*,C*DR*
M/m mismatched
NTD Non T depleted
TD T depleted ( ex vivo with 10-20 mg of Campath IH)
PBSC Peripheral blood stem cells
BM Bone Marrow
TBI Total Body Irradiation (750cGy in a single fraction)
Cy Cyclophosphamide 120mg/kg
Bu Busulphan 8mg/kg
Flu Fludarabine 150mg/m2
Mel Melphalan 140mg/m2
Treo Treosulphan 10mg/m2/day for 3 days
BEAM BCNU 300mg/m2, Cytarabine 200mg/m2/day for 4 days, 
Etoposide 200mg/m2/day for 4 days, Melphalan 
140mg/m2
Campath Campath 1H 50mg in 5 doses
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3.5 Chapter Discussion
Anti-CD28 antibody pre-treatment alone led to activation (increased CD69 
expression) in PBMCs from 2 of 6  healthy donor samples. This heterogeneity of 
response may reflect an underlying polymorphism in these individuals 
increasing their sensitivity to anti-CD28-stimulated T cell activation. Such 
polymorphisms have been recently identified in the CTLA-4 gene leading to 
increased sensitivity to CD28-mediated T ceil activation.[Djilali-Saiah et al. 
2001;Huang et al. 2000;lhara et al. 2001] The combination of OKT3 and anti- 
CD28 pre-treatment led to greater upregulation of several molecules important 
for ailoantigen presentation than that seen with OKT3 alone but this additional 
benefit was not statistically significant.
OKT3 alone led to statistically significant increases in the expression of 
adhesion molecules (with the density of expression of CD11a increased by a 
factor of 1.6 and the percentage of T cells expressing CD54 increased by a 
factor of 8 ), which would potentiate the first stage of T-T antigen presentation. 
The density of HLA Class I molecules on T cells was increased by a factor of 4 
by OKT3 treatment and the proportion of T cells expressing HLA Class II 
molecules (HLA DR) was increased by a factor of 5 from 8 % to 40%. The 
increased expression of HLA molecules on T cells would facilitate autonomous 
antigen presentation. OKT3 pre-treatment also increased the proportion of T 
cells expressing CD8 6  by a factor of 4 (from 5% to 20% - above the threshold 
level of expression of co-stimulatory molecules need for effective tumour 
antigen presentation to T cells by AML blasts).[Whiteway et al. 2003]
Thus evidence has been presented for a molecular basis for the strategy of 
OKT3 pre-treatment of T cells to potentiation of their ability to present antigen. 
OKT3 pre-treatment of PBMCs led to enrichment of the percentage of T cells 
within the PBMC pool with a concomitant decrease in the percentage of B cells 
and monocytes. A small proportion of monocytes persisted after 48 hours of 
OKT3 pre-treatment of PBMCs, which may have been able to augment T-T 
antigen presentation. The need for accessory APCells for maximum OKT3 
mediated T cell activation has been demonstrated previously [van Lier et al 
1989] and this raises the possibility of a dual antigen presentation pathways by 
an OKT3 pre-treated PBMC pool with T cells presenting antigen directly and 
antigen presentation via persistent monocytes/dendritic cells.
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T-T antigen presentation has the theoretical advantage of non-presentation of 
myeloid-restricted antigens which when used in an MLR-based selective 
ailodepletion protocol would not lead to the activation (or subsequent removal) 
of myeloid antigen-specific T cells within the donor T cell pool, potentially 
preserving T cell anti-myeloid responses within the donor cell pool that could 
exert a GvL effect in the treatment of myeloid malignancies.
The increase in the percentage of T cells expressing CD178 (from 5% to 20%) 
after OKT3 pre-treatment provides evidence for an additional molecular 
pathway that could potentiate the reduction in alloreactivity after CD69 based 
ailodepletion. Alloreactive T cells in the donor T ceil pool would receive an 
increased FAS ligand-mediated FAS signal that could result in alloreactive cell 
specific activation-induced cell death.
A concern regarding any strategy that exploits T-T antigen presentation is that 
responder cells are rendered anergic. The data presented in this chapter show 
that OKT3 pre-treatment of stimulator cells leads to increased responder cell 
activation (CD69 expression) and subsequent proliferation in the MLR in both 
the HLA-mismatched and matched setting. The strategy of OKT3 pre-treatment 
of stimulator cells lead to a much greater and consistent responder CD69 
response that the cytokine pre-treatment strategy in HLA-matched pairs. The 
OKT3 pre-treatment strategy, in contrast to the cytokine strategy, represents a 
pathway to potentiate antigen presentation that is unlikely to be affected by 
stimulator (or responder) cytokine receptor polymorphisms.
The greatly increased responder CD69 expression after allostimulation in the 
MLR with OKT3 pre-treated stimulator cells suggests that a greater number of 
responder cells are activated than the expected frequency of alloreactive cells 
(1-5% in published data). It is unlikely that this vigorous responder cell response 
is due to a carry-over (and non-specific) effect of the OKT3 used to pre-treat the 
stimulator cells as;
1 The CD3 receptor needs to be cross-linked by OKT3 for effective T cell 
activation and this would not occur with OKT3 attached to stimulator cells 
of in solution carried over to responder cells.
2. The stimulator cells were vigorously washed following OKT3 pre­
treatment to remove any excess OKT3 that could be carried over to 
responder cells.
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3 0KT3-stimulated T cell activation leads to profound down-regulation of 
surface CD3 receptor expression which could be demonstrated after 
OKT3 pre-treatment of stimulator cells. Activated responder cells did not 
exhibit any significant reduction in CD3 expression (data not shown).
A more likely explanation for the increased frequency of activated responder 
cells in both HLA-mismatched and matched MLRs following OKT3 pre­
treatment of stimulator cells is that OKT3 pre-treatment potentiates antigen 
presentation that results in the activation of T cells with low affinity for 
alloantigens as well as those with TCRs with high affinity for such antigens. This 
would not affect the selective ailodepletion strategy (and might even lead to 
more effective ailodepletion) but would not be desirable if the OKT3 pre­
treatment strategy led to the activation (and subsequent removal) of donor T 
cells with cross-reactive TCRs, which share affinity for alloantigens and infective 
pathogen (e.g. viral) antigens.
Immunomagnetic selective ailodepletion of HLA-matched CD69* responder 
cells was as efficient following OKT3 pre-treated allostimulation as that seen 
after the cytokine technique of potentiation of allostimulation. The strategy of 
OKT3 pre-treatment of stimulator cells led to responder CD69 upregulation (and 
proliferation) allowing selective removal of alloreactive cells in HLA-matched 
pairs that did not exhibit significant CD69 responses (or proliferation) with 
cytokine pre-treated stimulator cells. The use of the OKT3 pre-treatment 
strategy did not lead to a significant loss of proliferative responses to third party 
stimulators after selective ailodepletion of first party responding cells. Thus the 
OKT3 pre-treatment strategy could permit alloantigen presentation and 
subsequent selective alloreactive cell depletion in HLA-matched pairs that do 
not exhibit a positive read-out in the cytokine-modified MLR. The S:R ratio data 
suggest that OKT3 pre-treatment of stimulator cells might lead to effective 
presentation of alloantigens (and subsequent responder cell CD69 expression) 
with S:R ratios less than 1:1 which might enable selective ailodepletion when 
stimulator cells are in short supply.
No data have yet been published regarding the positive or negative predictive 
value of proliferative responses in the OKT3 pre-treated HLA-matched MLR. 
Responder proliferation in the MLR correlates most closely with responder
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CD4* responses but other measures of responder cell activation (e.g. CD8 + 
IFN-y secretion by flow cytometric methods or in ELI Spot assays) could also be 
studied to define cellular responses to alloantigens before and after selective 
ailodepletion following the use of OKT3 pre-treated stimulators. Abrogation of 
alloresponses following selective ailodepletion could also be confirmed with the 
skin explant assay although obtaining skin biopsies from recipients in donor- 
recipient pairs has proved very difficult in practice.
A small and heterogeneous group of HLA-matched pairs were studied, and 
interpretation of the data regarding proliferation in the OKT3-modified MLR and 
acute GvHD must therefore be extremely cautious.
3 haematopoietic grafts were T cell depleted with Campath antibody ex vivo. 7 
transplants utilised full intensity conditioning ( 6  with total body irradiation) and 7 
reduced intensity conditioning. Additionally the source of haematopoietic stem 
cells varied, (11 PBSCs and 4 bone marrow). All of these factors have profound 
bearing on the risk of developing acute GvHD. Thus it is difficult to draw 
meaningful conclusions from data from the group regarding any association 
between proliferation in the MLR with OKT3 pre-treated stimulators and the 
occurrence and/or severity of GvHD.
In the data presented here, of 7 pairs with full intensity conditioning, 6  had an 
OKT3 RRI>/= 50% and of these 6 , 4 developed >/= acute grade 2 GvHD (PPV 
6 6 %) and the single pair with an OKT3 MLR RRI<50% did not.
Of the 6  pairs in which reduced intensity conditioning was used, if a similar cut 
off level of 50% for OKT3 MLR RRI is used then one of the 3 pairs with 
RRI>50% developed for >/= acute grade 2 GvHD (PPV 33%) whereas the 2 of 
the 3 pairs with RRI<50% did not (NPV 6 6 %).
To reliably establish the positive predictive and negative predictive value of the 
OKT3 modified MLR, a larger series of non T cell depleted transplant pairs 
should be studied, homogeneous for recipient conditioning, donor matching and 
stem cell source.
The original data published by Bishara describing the cytokine modified MLR 
detailed 16 non-T cell depleted, HLA-matched, full intensity conditioning sibling 
transplants, in which a cut off level of RRI of 5% gave a PPV of 6 6 % (4 of 6  with 
RRI>5% developed acute GvHD) and NPV of 90% (1 of 10 with RRI<5% 
developed >/= grade 2 acute GvHD). Koh reported cytokine modified MLRs in 8  
HLA-matched pairs ( 6  sibling and two unrelated, one of which was T depleted.)
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All patients received a TBI based conditioning regimen. 4 of these had a 
cytokine MLR RRI>5% and were evaluable for > grade 2 aGvHD. In this series 
the cytokine MLR RRI >5% had both a PPV of 50% and NPV of 75%.
In the data presented here, of the seven pairs with full intensity conditioning, 6  
had RRI>/= 5% (there was a higher proportion of unrelated donor pairs in these 
data than in Koh’s series) and of these 6 , 4 patients developed > grade 2 
aGvHD (PPV 6 6 %) and the single pair with a cytokine RRI<5% did not. This is 
in keeping with the published data.
All of the 6  pairs in which reduced intensity conditioning was used had cytokine 
MLR RRIs>5%, but only one recipient developed for > grade 2 aGvHD. It is 
likely that a higher cut off level for cytokine MLR RRI is a better predictor of 
acute GvHD following reduced intensity conditioning e.g. if a cut off of 80% for 
cytokine MLR RRI is used then none of the 5 pairs with RRI<80% developed for 
> grade 2 aGvHD (NPV 100%) whereas the single pair with RRI>80% did.
Data from pair 13 (DRB1*04 mismatch, in which failure of proliferation in cellular 
assays is well described despite frequent severe GvHD) were excluded from 
the above discussion.[Mickelson et al. 1993;Mickelson et al. 1996]
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Chapter 4 Retention of Antiviral Responses After Ailodepletion
4.1 Introduction
CMV infection post AHSC transplant is an important cause of morbidity and 
mortality and has considerable economic impact.[Squifflet and Legendre 2002] 
A significant number of adults who undergo AHSCT have had serologically 
detectable past exposure to CMV. In Meyer’s series from 1986 as many as 70% 
of CMV seropositive transplant recipients developed clinically significant CMV 
infection and CMV disease was the commonest cause of death in such 
patients.[Meyers et al. 1986] Prophylactic treatment with ganciclovir or aciclovir 
has only partially reduced CMV infection post-AHSCT and has the theoretical 
disadvantage of encouraging drug-resistant viral strains.[Prentice et al. 1994] 
The strategy of monitoring patients for viral shedding by the detection of viral 
genome by (real-time) PCR reduces CMV infection and death in the first 100 
days post AHSCT but may have the effect of postponing infection to a later 
stage post transplant.[Ljungman 1998] Such pre-emptive treatment is 
associated with adverse effects especially (reversible) neutropenia that often 
requires cessation of treatment. The crucial importance of T cell mediated 
immunity in controlling CMV disease after allogeneic transplant is underlined by 
the increased rate of CMV pneumonitis reported after non-selectively T cell 
depleted AHSCT.[Nguyen et al. 1999] A lower incidence of CMV pneumonitis 
was reported in CMV seropositive recipients of non-T cell depleted AHSCT from 
CMV seropositive donors as long ago as 1987.[Grob etal. 1987] Moreover there 
is evidence that grafts containing T cells from CMV positive donors may confer a 
survival advantage under certain circumstances to recipients at high risk of CMV 
disease. The recent European Bone Marrow Transplant metafile analysis 
demonstrated that CMV seropositive patients receiving grafts from CMV- 
seropositive HLA-matched sibling donors had the same survival as patients 
transplanted with seronegative donors. However, CMV-seropositive stem cell 
transplant recipients receiving grafts from CMV-seropositive unrelated donors 
had significantly better 5-year overall survival and reduced transplant-related 
mortality. Although this benefit was not found to be directly linked to CMV 
disease post transplant it was independent of all other variables. Furthermore in 
such patients with CML, T cell depletion abrogated the beneficial effect of donor
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CMV status, suggesting that the effect is mediated through transfer of donor T 
cell immunity.[Ljungman et al. 2003a]
The CD8 + CTL response is of critical importance for control of CMV infection 
and it has been estimated that between 1 and 5% of CTLs in healthy CMV 
seropositive individuals have specificity for CMV.[Gillespie etal. 2000]
In controlling CMV disease CD8 * responses are believed to be the main effector 
arms of the adaptive immune system although they are critically dependent on 
CD4* T cell help.[Gamadia et al. 2003] In the absence of CD4+ help there may 
be persistence of virus despite the presence of CD8 * CMV-specific CTLs as the 
latter become anergic.[Zajac et al. 1998]
EBV-related PTLD is another cause of significant morbidity and mortality after 
allogeneic haematopoietic stem cell transplantation, usually a monoclonal 
expansion of B cells with predominantly latent type infection with the EBV 
virus.[Tanner and Alfieri 2001] EBV-specific CTL responses are of paramount 
importance in the control of EBV-PTLD, and infusion of very small numbers of 
donor-derived EBV-specific CTLs are very effective at suppressing EBV-related 
PTLD.fHeslop etal. 1994]
Non-selective ex vivo T cell depletion techniques using anti-T cell antibodies 
with broad specificities such as the anti-CD52 antibody Campath removes both 
CD8 + and CD4+ CMV-specific cells and slows the recovery of CMV-specific 
CTLs (identified by tetramer and ELISpot assays) post-AHSCT.[Aubert et al. 
2001 ;Chakrabarti et al. 2002b]
A major advantage of selective alloreactive cell depletion would be to leave the 
donor CD8 +and CD4+ T cell pool largely intact, which would (in the case of a 
CMV and EBV seropositive donor) contain CMV and EBV-specific CD8 + and 
CD4+ cells; able to confer active immunity against CMV infection and EBV- 
PTLD.
However it has been previously reported that among the population of T cells 
specific for allogeneic MHC, there is a mix of naive and memory cells. [Ashwell 
et al. 1986b] It has also been shown that TCRs are broadly cross-reactive; and 
many T cells specific for environmental antigens also cross-react with foreign 
MHC. [Matzinger 1994]
On the basis of these data, it could be hypothesized that T cell ailodepletion 
might result in a reduction of the number of T cells specific for viral antigens. 
The degree of reduction (if any) seen would depend on the number of T cells
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possessing TCRs cross-reactive for alloantigens and for viral antigens and also 
on the relative strengths of TCR/MHC-Antigen interactions of such T cells.
The preservation of proliferative responses to CMV and Candida antigens in cell 
fractions depleted of cells alloreactive to haploidentical stimulators has been 
reported after ailodepletion based on expression of CD25. Preservation of CTLp 
frequencies against CMV and EBV infected cells has also been demonstrated in 
an HLA-mismatched in vitro model utilising CD25-mediated immunotoxin based 
ailodepletion. [Montagna et al. 1999]
Very recently this approach was refined by the use of haploidentical recipient 
EBV-transformed LCLs as stimulators to activate donor alloreactive T cells. In 
IFN^y ELISpot assays, CD8 + T cell responses to adenovirus and CMV were 
preserved following ailodepletion and the latter was confirmed with the use of 
HLA-A*0201-NLV-tetramers. Donor anti-EBV responses were also partially 
retained. [Amrolia et al 2003a]
Thus there is good evidence to support the conclusion that with TCRs cross­
reactive with antigens on such pathogens and stimulator non-self HLA 
molecules are not present at significant frequencies, or that they are not 
identified and removed by the CD25-mediated ailodepletion technique.
No data have been published regarding preservation of antiviral responses 
following CD25-mediated ailodepletion in the HLA-matched setting.
A very limited amount of data concerning the preservation of anti-CMV 
responses after selective ailodepletion based on CD69 expression has been 
published and only in abstract form. Nonn et al have reported enrichment of 
CMV reactive cell frequencies (assayed by pp65-stimulated IFN^y ELISpot) in 
the CD69dim responder cell fraction in HLA-mismatched MLRs. This observation 
would be consistent with T cells sharing TCR affinity for both alloantigens 
(perhaps with weak affinity) and CMV antigens.[Nonn et al 2003a] Schumm et al 
have reported preservation of CMV- and adenoviral-specific CD8 + cells 
(assayed by IFN-y ELISpot) following CD69 ailodepletion in some, (but not all) 
HLA-matched donor-recipient pairs using the cytokine modified MLR to 
potentiate PBMC mediated allostimulation. This observation would be consistent 
with the existence of T cells bearing TCRs cross-reactive for stimulator mHags 
and CMV antigens.[Schumm et al 2003]
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The work detailed in this chapter seeks to investigate whether antiviral activity is 
preserved after CD69-mediated ailodepletion in a short series of pilot 
experiments in the HLA-mismatched setting, and in a more detailed examination 
in the HLA-matched setting.
CD69-based selective ailodepletion (by immunomagnetic sorting) was used to 
remove alloreactive cells from responder cells in totally HLA-mismatched 
donor/recipient pairs and in HLA A, B, C and DR-matched (sibling and 
unrelated) donor/recipient pairs. Pairs were selected where the donor was 
known to be CMV and EBV (EBNA) lgG+. HLA-matched pairs were selected 
with a positive cytokine-modified MLR (RRI>5%). Both the cytokine-modified 
MLR and the OKT3 pre-treatment techniques were used to potentiate 
allostimulation in the HLA-matched pairs.
CMV-reactive CTLs were enumerated before and after selective ailodepletion by 
CMV-peptide-specific IFN-y ELISpot assay and by CMV-peptide HLA A*0201 
tetramer analysis. EBV-reactive T cells were enumerated by IFN-y ELISpot 
before and after selective alloreactive cell depletion in the HLA-matched setting.
4.2 Aims of Experiments Described in this Chapter
1. To investigate the retention of CMV- and EBV- specific CTLs after 
selective ailodepletion (based upon CD69 expression) in HLA- 
mismatched and HLA-matched pairs.
2. To compare retention of CMV- and EBV- specific CTLs after selective 
ailodepletion (based on CD69 expression) in HLA-matched pairs using 
both the cytokine and the OKT3 techniques for potentiating 
allostimulation.
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4.3 Materials and Methods
4.3.1 CMV and EBV serology
CMV IgG and EBV EBNA IgG serological status was measured by ELISA in the 
Department of Virology, Royal Free Hospital or at accredited haematopoietic 
stem cell donor centres. Ail cells used were from peripheral blood samples 
given with written informed consent.
4.3.2 CMV- and EBV-peptides used in IFN-y ELISpot Assays
Peptide epitopes within the CMV matrix protein pp65 have been identified as 
important targets for CMV-specific CD8 + cells, and CD8 + CTLs specific to pp65 
derived peptides persist at high frequencies in individuals exposed to CMV 
virus.[Longmate et al. 2001 ;Wills et al. 1996a] A number of different pp65 
derived peptides were thus selected with different HLA Class I restrictions which 
permitted the measurement of CMV-specific CTL responses in individuals of 
several different HLA Class I types.
To assess the frequency of cellular responses to EBV, the HLA-A*0201- 
restricted epitope GLCTLVAML derived from the EBV lytic protein BMLF1 was 
chosen. This lytic EBV antigen is recognized by a relatively large fraction of 
EBV-specific CD8 + T cells in HLA-A*0201 donors in various patho-physiological 
situations,[Lim et al. 2000a;Steven et al. 1997] and is restricted to a common 
HLA-A type (and would facilitate concurrent experiments measuring CMV- and 
EBV-CTL responses in individual samples).
The ELISpot assay was performed in an identical fashion for CMV- and EBV- 
peptide-stimulated responses (Chapter 2.6). The negative control for the EBV- 
peptide-stimulated ELISpot assay was ‘no peptide’. Two negative controls for 
CMV-peptide-stimulated ELISpot assays were performed; ‘no peptide’ and a 
‘dummy peptide’ (a CMV pp65-derived peptide restricted to an HLA Class I type 
not possessed by the individual). The purpose of the dummy peptide control in 
this setting was to ensure that the CMV-peptides only elicited responses in the 
expected HLA- restricted fashion and did not cause non-specific stimulation of 
CD8 + cells.
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Virus Amino Acid 
Sequence
HLA Class 1 
Restriction
Abbreviation Structural site
CMV NLVPMVATV A*0201 NLV CMV pp65 (495-503)
CMV TPRVTGGGAM B*0702 TPR CMV pp65 (417-426)
CMV DANDIYRIF B*0801 DAN CMV pp65 (516-524)
CMV IPSINVHHY B*35 IPS CMV pp65
CMV YSEHPTFTSQY A*0101 YSE CMV pp65
EBV GLCTLVAML A*0201 GLC EBV Lytic protein BMLF1
Table 4.1 Human CMV- and EBV-peptides used for IFN-y ELISpot assays.
4.3.3 CMV NLVPMVATV-HLA A*0201 Tetramer Assay
Details of the staining protocol and the flow cytometric analysis (including gating 
strategy) are given in Chapter 2.2.3.
4.3.4 Validation of CMV-Peptides and CMV IFN-y ELISpot Assay
Individual HLA Class I typing CMV
stimulatory
peptide
CMV dummy 
Peptide
1 A*0301,2601 ;B*0702,0801 TPR NLV
2 A*2,25; B*14,58 NLV TPR
3 A*0101,24;B*27,62 YSE NLV
4 A*1,2; B*63,68 NLV TPR
5 A*0201;B*15,39 NLV TPR
Table 4.2 Healthy controls used for validation of CMV stimulatory peptides.
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4.3.5 Experimental Design
Allostimulation of HLA-mismatched pairs was performed in a one-way standard 
MLR with cells from the CMV* donor acting as responders. Allostimulation was 
confirmed by measuring expression of CD69 on live responder cells and by a 
incorporation of tritiated thymidine in a standard 5 day one way MLR (Chapter 
2.3.2). Selective ailodepletion was performed using anti-CD69-FITC antibody 
(BD), anti-FITC microbeads and AS single-use columns and the VarioMACS 
magnet (all Miltenyi). Efficiency of ailodepletion was confirmed by using 
allodepleted cells in a secondary MLR with original (first party) stimulators and 
with HLA-mismatched third party stimulators, (Chapter 2.4). The frequency of 
CMV-responding cells (by both IFN-y ELISpot and by PE conjugated NLV-HLA 
A*0201 tetramer) and EBV responding cells (by IFN-y ELISpot) was determined 
both in unmanipuiated live responder cells and selectively allodepleted live 
responder cells.
The schema was followed for the HLA-matched pairs with the MLR modified by 
the pre-treatment of stimulators with either OKT3 or cytokines (as described in 
Chapter 2.3.3 and 2.3.4).
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4.3.6 HLA Typing and CMV/EBV-Peptides used
Pair
Stimulator 
HLA typing
Responder 
HLA Typing
CMV-
peptide
Dummy
peptide
1
A*0201, *24; 
B*5101, *4405; 
C*0202, *1502; 
DRB1*04. *11
A*0301,2601; 
B*0702,0801 
HLA C not done 
DRB1 *1501, *0301
TPR NLV
2
A*0201, *24; 
B*0702, *1401; 
C*07, *08; 
DRB1*0401. *0701
A*0101;
B*0702,*3701; 
C*06, *07;
DRB1*0404, *0701
TPR NLV
3
A*0101;
B*0702, *3701; 
C*06, *07; 
DRB1*0404, *0701
A*0201, *24; 
B*0702, *1401; 
C*07, *08; 
DRB1*0401, *0701
NLV YSE
4
A*0101,*2401; 
B*0702,*0801; 
C*07, *07; 
DRB1*15, *03
A*0201
HLA B and Class II not 
assessed
Not done Not done
5
A*2402,*3301; 
B*4405,*3508 
C*02, *04; 
DRB1*16, *13
A*0201
HLA B and Class II not 
assessed
Not done Not done
Table 4.3 Stimulator and Responder HLA types and CMV-peptides used in
ELISpot assays in HLA-mismatched pairs.
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Pair Stimulator 
HLA typing
Responder 
HLA Typing
ELISpot Peptide
CMV EBV
Stimulatory
Peptide
Dummy
Peptide
1 A*0201,*302;
B*52, *40;C*15, *12; 
DRB1*1502, *16
HLA-matched SD NLV TPR GLC
2 A*0201, *68;
B*51, *0702; C*15, *07; 
DRB1 *1501/13021
HLA-matched SD NLV YSE GLC
3 A*0201, *33;B*58, *35 
C*03, *04;
DRB1*1601, *0301
HLA-matched SD NLV TPR GLC
4 A*0201, *30;B*0702, 
*44; C*07, *05; 
DRB1* 1401, *0810
HLA-matched SD NLV YSE GLC
5 A*0101; B*0801; 
C*0701;
DRB1* 0301
HLA 
-matched UD
DAN NLV Nd
6 A*0201, *24;
B*0702, *14;C*07, *08; 
DRB1*0401. *0701
HLA 
-matched UD
NLV YSE Nd
7 A*0201,*0101;
B*08, *04; C*03, *07; 
DRB1*0101, *0301
HLA 
-matched UD
NLV TPR GLC
8 A*0201, *29;
B*08, *15; C*07, *03; 
DRB1*0301, *13
HLA 
-matched UD
NLV TPR GLC
9 A*0101;
B*0702, *37; C*06, *07; 
DRB1*0404, *0701
Single HLA A 
-mismatched UD
TPR NLV Nd
10 A*0201:
B*44,35;C*04,05 
DRB1 *1501 ,*1401
HLA A and C 
-mismatched UD
NLV TPR Nd
11 A*0201,*0301;
B*35, *37; C*04, *06, 
DRB1*0404, *1303
Single DRB1 
-mismatched UD
NLV TPR Nd
Table 4.4 Stimulator and Responder HLA types, CMV-and EBV-peptides 
used in ELISpot assays in HLA-matched pairs. SD =sibling donor, UD= 
Unrelated donor, nd= not done.
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4.4 Results
4.4.1 Validation of HLA Class I restriction of CMV-Peptides
The specific binding of the HLA A*0201-restricted peptide NLV to HLA A*0201 
was confirmed in a T2 binding assay (Chapter 2.11). The MHC stabilisation 
efficiency (MSE) of NLV was 84% whereas the B*0702-restriced CMV pp65 
derived peptide TPR gave an MSE of 2% (Figure 4.1).
Cytotoxicity assays using PKH-26 dye labelled T2 target cells and healthy donor 
CTLs were performed in duplicate, (described in detail in Chapter 2.10).
Specific killing of PKH-26 dye labelled T2 target cells was significantly greater 
with NLV peptide pulsed T2 target ceils than with untreated T2 ceils with both 
unselected and CMV whole antigen-pulsed healthy HLA A*0201+ CMV lgG+ 
donor CTLs. Specific killing of untreated PKH-26 dye labelled T2 target cells 
was significantly greater with CMV whole antigen -pulsed healthy HLA A*0201+ 
CMV lgG+ donor CTLs than with unselected healthy HLA A*0201+ CMV lgG+ 
donor CTLs. Although greater NLV peptide pulsed T2 target cell killing was 
seen with CMV whole antigen-pulsed healthy HLA A*0201+ CMV lgG+ donor 
CTLs than with unselected donor CTLs this was not statistically significant. 
(Figure 4.2)
4.4.2 Validation of the NLV-HLA A*0201 Tetramer Assay
106 PBMCs from an HLA A*0201+ B*0702‘ CMV lgG+ healthy subject were 
incubated for 30 minutes with 10pg NLV or TPR CMV-peptide. PBMCs were 
then centrifuged for 1 0  minutes at 2 0 0 g and resuspended at 1 0 6 ceils/ml in 
complete medium, and stained with NLV-HLA A*0201 tetramer (Chapter 2.2.3). 
The prior addition of NLV peptide to PBMCs from an HLA A*0201+ B*0702' 
CMV lgG+ healthy subject prevented the binding of NLV-HLA A*0201 tetramer 
to CD3+CD8+ CMV-specific CTLs whereas the addition of the non-HLA A*0201- 
restricted CMV-peptide TPR did not (Figure 4.3).
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Figure 4.1 12 binding assays and MHC Stabilisation Efficiency (MSE).
(A). NLV CMV-peptide
(B). TPR CMV-peptide
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Figure 4.2 Addition of the HLA A*0201-restricted CMV-peptide NLV to T2 
target cells significantly increased cell killing by HLA A*0201+ CMV lgG+ effector 
cells (either unselected or pulsed with whole CMV antigen) in a PKH-26 dye 
release cytotoxicity assay. Error bars represent standard deviation of duplicate 
experiments.
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Figure 4.3 NLV-HLA A*0201 tetramer binding to CMV-specific CTLs in an 
HLA A*0201+ CMV lgG+ subject. The figures shown are percentage CD3+CD8+ 
Tetramer+ cells
(A). Tetramer binding is seen with untreated PBMCs
(B). Tetramer binding is inhibited by the addition of exogenous NLV peptide 
prior to tetramer staining.
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4.4.3 CMV-CTL Responses in Normal Individuals
The baseline frequencies of CMV-specific CTLs were determined in 5 healthy 
CMV lgG+ individuals using NLV-HLA A*0201 tetramer staining (Chapter 2.2.3), 
(for 3 HLA A*0201+ individuals) and CMV-peptide-stimulated IFN-y ELISpot 
assay (Chapter 2.6). (Details of stimulatory and dummy (control) peptides used 
for ELISpot assays are given for each individual in Table 4.2)
Control
Subject HLA Class I Typing
NLV-HLA
A*0201-
Tetramer*
frequency
CMV-Peptide 
IFN-y ELISpot 
reactive cells 
(mean+/-sd)
1 A*0301,2601 ;B*0702,0801 nd 0.37 +/- 0.02
2 A*2,25; B*14,58 5.0 3.47 +/- 0.50
3 A*0101,24;B*27,62 nd 0.05 +/- 0.02
4 A*1,2; B*63,68 0.3 0.13+/-0.03
5 A*0201;B*15,39 1.3 0.77 +/- 0.24
Table 4.5 Frequency of CMV-specific CTLs in normal individuals. Figures 
given are percentage CD3+CD8+ Tetramer+/ELISpot reactive cells. nd= not 
done
4.4.4 Allodepletlon in HLA-Mismatched Pairs
Pre-Depletion 
Responder 
CD3*CD69 
expression, %
Depletion 
efficiency of 
CD3+CD69+ 
cells, %
Post-
Depletion
First Party 
Proliferation*
Third Party 
Proliferation*
CD3* 6.0+/-4.0 91+/-7.0
CD3*CD4* 4.3+Z-2.5 94+Z-6.2 1.9+Z-3.8 69+Z-31
CD3*CD8* 4.8+/-3A Q6+Z-11
Table 4.6 Allostimulation, depletion efficiency and residual first party and 
third party proliferation after depletion of alloreactive CD69+ cells in HLA- 
mismatched stimulator-responder pairs. All values are given as mean 
percentage +/-sd (above autologous controls). *= percentage of pre-depletion 
value.
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4.4.5 Allodepletion in HLA-Matched Pairs
OKT3
MLR
Pre-Depletion Depletion 
efficiency of 
CD3*CD69* 
cells, %
Post-Depletion
Responder
CD3*CD69
expression RRI RRI,%
Third Party
Proliferation*
CD3* 25+/-72
72+Z-49
96+Z-3
7+/-2 94+Z-47CD3*CD4+ 29+/-73 94+Z-9
CD3*CD8+ 15+/-9 92+Z-15
Table 4.7 OKT3 pre-treated allostimulation, depletion efficiency and residual 
first party and third party proliferation after depletion of alloreactive CD69* cells 
in HLA-matched stimulator-responder pairs. All values are given as mean 
percentage +/-sd (above autologous controls). *= percentage of pre-depletion 
value.
Cytokine
MLR
Pre-Depletion Depletion 
efficiency of 
CD3+CD69+ 
cells, %
Post-Depletion
Responder
CD3*CD69
expression RRI RRI,%
Third Party
Proliferation*
CD3* 5+/-7
44+Z-35
82+Z-16
1+Z-2 101+Z-90CD3*CD4+ 6+Z-8 90+Z-10
CD3*CD8+ 3+Z-4 90+Z-11
Table 4.8 Cytokine pre-treated allostimulation, depletion efficiency and 
residual first party and third party proliferation after depletion of alloreactive 
CD69+ cells in HLA-matched stimulator-responder pairs. All values are given as 
mean % +/-sd (above autologous controls). *= percentage of pre-depletion 
value.
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4.4.6 Retention of CMV responses in HLA-Mismatched Pairs
The frequency of CD3+CD8+ NLV-HLA A*0201 tetramer+ cells after selective 
allodepletion of HLA-mismatched pairs 4 and 5 was not significantly reduced 
when compared to baseline pre-depletion values (p=0 . 1 0  in a paired two-tailed 
Student’s t-test). The post-allodepletion frequency of CD3+CD8+ NLV-HLA 
A*0201 tetramer+cells was 8 8 %+/-6 .6 % of the pre-depleted frequency. 
Functional CMV-specific cell frequencies (measured by CMV-peptide-stimulated 
IFN^y ELISpot assay) were also not significantly reduced after selective 
allodepletion of HLA-mismatched pairs 1,2 and 3 (p=0.88 in a paired two-tailed 
Student’s t-test). Following allodepletion of these pairs the frequency of CMV 
reactive cells by IFN-y ELISpot was 114%+/-35% of the frequency in the pre­
depleted cells (Figure 4.4).
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Figure 4.4 Retention of NLV-HLA A*0201 tetramer+ cells (n=2) and CMV- 
peptide IFN-y ELISpot-reactive cells (n=3) after selective allodepletion in 5 HLA- 
mismatched pairs. Error bars represent standard deviation. Percentage 
retention is frequency of CD3+CD8+ Tetramer+/ELISpot reactive cells post­
depletion x100/frequency of CD3+CD8+ Tetramer+/ELISpot reactive cells pre­
depletion.
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4.4.7 Retention of NLV-HLA A*0201 tetramer+ Cells in HLA-Matched Pairs
All matched pairs studied for retention of NLV-HLA A*0201 tetramer+ cells were 
HLA A*0201+ The frequency of NLV-HLA A*0201 tetramer+ cells (expressed as 
percentage of CD3+CD8+ cells) in responder cells after 72 hours of 
allostimulation was not significantly different to that of baseline, unmanipulated 
responder cells using either OKT3 pre-treated stimulators or cytokine pre­
treated stimulators (data not shown).
After effective selective allodepletion of 7 HLA-matched pairs CD3+CD8+ NLV- 
tetramer+ cell frequency post-depletion was 77%+/-20% of the pre-depletion 
frequency utilising the OKT3 pre-treated MLR and 98%+/-26% utilising the 
cytokine-modified MLR, (Figure 4.5). Post-depletion frequencies were not 
significantly different to pre-depletion frequencies in a paired, two-tailed 
Student’s t-test (p=0.06 and p=0.7) although a trend was seen for lower 
CD3+CD8+ NLV-tetramer+ frequency post-depletion following the OKT3 
allostimulation technique. Representative dot-plots for an HLA-matched sibling 
pair and an HLA-matched unrelated donor-recipient pair are shown in Figure 
4.6. In 6  of the 7 HLA-matched individual pairs tested the CD3+CD8+ NLV- 
tetramer+ frequency post-depletion was lower than the pre-depletion value using 
the OKT3 allostimulation technique whereas this was the case in only 3 of the 7 
pairs tested using the cytokine allostimulation technique (Figure 4.7). No 
significant difference was seen in the percentage retention of CD3+CD8+ NLV- 
tetramer+ cells following allodepletion using the OKT3 or cytokine allostimulation 
techniques (p=0.12 in an unpaired two-tailed Student’s t-test).
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Figure 4.5 Percentage retention of NLV-HLA A*0201 tetramer+ cells after 
selective allodepletion in 7 HLA-matched pairs utilising the cytokine and the 
OKT3 allostimulation techniques. Error bars represent standard deviation. 
Percentage retention is frequency of CD3+CD8+ tetramer+ cells post-depletion 
x100/ frequency of CD3+CD8+ tetramer+ cells pre-depletion.
152
A Cytokine Modified MLR OKT3 Modified MLR
Pre-Depletion Post-Depletion Pre-Depletion Post-Depletion
m
1.5%
'.V  •'
2.1%
&
1.5%
B$r n
0.9%
1 .........V....
NLV-HLA A*0201 Tetramer-PE
B Cytokine Modified MLR OKT3 Modified MLR
Pre-Depletion Post-Depletion Pre-Depletion Post-Depletion
1.6%
'vf
1
1.7%
i ........- . r f .........■*'W-------------
5. 2.0% 1.6%
f i f ' .
....W....'«l.... s.
NLV-HLA A*0201 Tetramer-PE 
Figure 4.6 See Over for Figure Legend
Figure 4.6 CMV NLV-HLA A*0201 tetramer+ cells are retained after 
depletion of alloreactive cells in the MLR. Example dot plots for;
(A). An HLA A, B, C and DR matched sibling pair (matched pair 2)
(B). An HLA A, B, C and DR matched unrelated pair (matched pair 7)
The figures shown were generated in WinMDI following the gating strategy 
described in Chapter 2.2.3 Figures shown are for tetramer binding cells, 
expressed as percentage of CD3+CD8+ cells in the responder cell region.
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Figure 4.7 Retention of NLV-HLA A*0201 tetramer+ cells after selective 
allodepletion in individual HLA-matched pairs. (Pairs are shown in descending 
order of frequency of NLV-HLA A*0201 tetramer+ cells in unmanipulated cells);
(A). Cytokine allostimulation.
(B). OKT3 allostimulation.
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4.4.8 Retention of CMV-peptide-stimulated IFN-y ELISpot Reactive Cells
in HLA-Matched Pairs
11 HLA-matched pairs (9 HLA A*0201+) were studied for retention of CD3+CD8+ 
CMV-peptide-stimulated IFN-y ELISpot-reactive cells The frequency of 
CD3+CD8+ CMV-peptide-stimulated IFN-y ELISpot-reactive cells in responder 
cells after 72 hours of allostimulation was not significantly different to that of 
baseline, unmanipulated responder cells using either OKT3 pre-treated 
stimulators or cytokine pre-treated stimulators (data not shown).
After effective selective allodepletion of 11 HLA-matched pairs the frequency of 
CD3+CD8+ CMV-peptide-stimulated IFN-y ELISpot reactive cells post-depletion 
was 76%+/-26% of the pre-depletion frequency utilising the OKT3 
allostimulation technique and 89%+/-26% utilising the cytokine allostimulation 
technique (Figure 4.8). Post-depletion frequencies were not significantly 
different to pre-depletion frequencies in a paired, two-tailed Student’s t-test 
(p=0.28) following the OKT3 allostimulation technique. The frequency of 
CD3+CD8+ CMV-peptide-stimulated IFN-y ELISpot reactive cells post-depletion 
was higher after OKT3 allostimulation in the two pairs tested with the highest 
pre-depletion frequencies (Pairs 5 and 9) and lower in all the other pairs (Figure 
4.9(A)). The retention of CD3+CD8+ CMV-peptide-stimulated IFN-y ELISpot 
reactive cells post-depletion following the OKT3 allostimulation technique was 
not related to responder HLA type.
In a paired two-tailed Student’s t-test the frequency of CMV ELISpot reactive 
cells in HLA-matched responders post-depletion was significantly lower than the 
value pre-depletion utilising the cytokine modified MLR (p=0.05), although this 
difference was not seen if HLA A*0201+ responders alone were analysed (n=9, 
p=0.21). The frequency of CD3+CD8+ CMV-peptide-stimulated IFN-y ELISpot 
reactive cells post-depletion was lower after cytokine allostimulation in 4 pairs 
tested (Pairs 5,9,10 and 1) and unchanged in all the other pairs (Figure 4.9(B)). 
The retention of CD3+CD8+ CMV-peptide-stimulated IFN-y ELISpot reactive 
cells after allodepletion following OKT3 allostimulation was not significantly 
different to that following cytokine allostimulation when all responders were 
analysed together (n=11, p=0 . 2  in an unpaired two-tailed Student’s t-test), 
although there was a trend towards lower percentage retention after OKT3
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allostimulation compared to cytokine allostimulation if HLA A*0201+ responders 
were analysed alone (n=9, p=0.07 in an unpaired two-tailed Student’s t-test).
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Figure 4.8 Retention of CMV-peptide-stimulated IFN-y ELISpot-reactive cells 
after selective allodepletion in 11 HLA-matched pairs utilising the cytokine and 
the OKT3 allostimulation techniques. Error bars represent standard deviation. 
Percentage retention is frequency of CD3+CD8+ CMV-peptide-stimulated IFN-y 
ELISpot reactive cells post-depletion x100/ frequency of CD3+CD8+ CMV- 
peptide-stimulated IFN-y ELISpot reactive pre-depletion.
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Figure 4. 9 Retention of CMV-peptide-stimulated IFN-y ELISpot reactive cells 
after selective allodepletion in individual HLA-matched pairs. (Pairs are shown 
in descending order of frequency of CD3+CD8+CMV-peptide-stimulated IFN-y 
ELISpot reactive cells in unmanipulated cells).
(A). Cytokine allostimulation. (B) OKT3 allostimulation
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4.4.9 Retention of EBV-peptide-stimulated IFN-y ELISpot Reactive
Cells in HLA-Matched Pairs
All matched pairs studied for retention of EBV-peptide-stimulated IFN-y ELISpot 
reactive cells were HLA A*0201+. The frequency of CD3+CD8+ EBV-peptide- 
stimulated IFN-y ELISpot reactive cells in responder cells after 72 hours of 
allostimulation was not significantly different to that of baseline, unmanipulated 
responder cells using either OKT3 pre-treated stimulators or cytokine pre­
treated stimulators (data not shown).
After effective selective allodepletion of 6  HLA-matched pairs the frequency of 
CD3+CD8+ EBV-peptide-stimulated IFN-y ELISpot reactive cells post-depletion 
was 82%+/-16% of the pre-depletion frequency utilising the OKT3 
allostimulation technique and 113%+/-23% utilising the cytokine allostimulation 
technique (Figure 4.10). Post-depletion frequencies were not significantly 
different to pre-depletion frequencies following the both the OKT3 and the 
cytokine allostimulation technique (p=0.12 and 0.75 respectively in a paired, 
two-tailed Student’s t-test).
The frequency of CD3+CD8+ EBV-peptide-stimulated IFN-y ELISpot reactive 
cells post-depletion was markedly lower than the pre-depletion frequency in 
only one of the 6  pairs tested (Pair 1) after OKT3 allostimulation and relatively 
unchanged in all other pairs (Figure 4.11A), whereas the frequency of 
CD3+CD8+ EBV-peptide-stimulated IFN-y ELISpot reactive cells post-depletion 
was higher than the pre-depletion frequency in Pair 1 after cytokine 
allostimulation, lower in pair 2 and relatively unchanged in all other pairs (Figure 
4.11(B)).
The retention of CD3+CD8+ EBV-peptide-stimulated IFN-y ELISpot reactive 
cells after allodepletion following OKT3 allostimulation was significantly lower 
than that seen following cytokine allostimulation (n=6 , p=0 . 0 2  in an unpaired 
two-tailed Student’s t-test).
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Figure 4.10 Retention of EBV-peptide-stimulated IFN-y ELISpot reactive cells 
after selective allodepletion in 6 HLA-matched pairs utilising the cytokine and 
the OKT3 allostimulation techniques. Error bars represent standard deviation. 
Percentage retention is frequency of CD3+CD8+ EBV-peptide-stimulated IFN-y 
ELISpot reactive cells post-depletion x100/ frequency of CD3+CD8+ EBV- 
peptide-stimulated IFN-y ELISpot reactive pre-depletion.
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Figure 4.11 Retention of EBV-peptide-stimulated IFN-y ELISpot-reactive cells 
after selective allodepletion in individual HLA-matched pairs. (Pairs are shown 
in descending order of frequency of ELISpot-reactive cells in unmanipulated 
cells);
(A). Cytokine allostimulation. (B). OKT3 allostimulation.
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4.4.10 The Effect of HLA Matching and Donor Type on Retention of 
Antiviral Responses in HLA-Matched Pairs
Although numbers were small, no difference was seen in the retention of CMV 
tetramer, CMV ELISpot or EBV ELISpot-reactive cells following allodepletion 
using either technique of allostimulation between matched sibling pairs and 
matched unrelated donor pairs in unpaired two-tailed t-tests, and the retention 
of CMV and EBV responses were not significantly correlated with the degree of 
HLA matching in unrelated donor pairs.
There was a trend towards a negative correlation between the strength of the 
alloresponse (as measured by the RRI) after OKT3 modified allostimulation and 
the retention of both CMV and EBV responses by ELISpot in HLA-matched 
pairs (Pearson r=-0.53 p=0.09 n= 1 1 and Pearson r=-0.78 p=0.06 n= 6  
respectively). No correlation was seen between cytokine RRI or retention of 
third party proliferation post depletion and CMV or EBV responses with either 
method of potentiating allostimulation.
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4.5 Chapter Discussion
The preliminary experiments in fully HLA-mismatched pairs gave proof of 
principle that selective allodepletion based on the removal of CD69+ responder 
cells after allostimulation retains the majority of CMV-specific cells in the 
allodepleted donor cell pool. The retention of CMV-specific CTLs identified by 
tetramer binding was demonstrated in HLA A*0201" responders and the 
retention of functional HLA A*0201-restricted CMV-specific CTLs after 
allodepletion was confirmed by IFN-y ELISpot assay. In addition, retention of 
functional HLA B*0702-restricted CMV-specific CTLs after allodepletion was 
demonstrated by IFN-y ELISpot assay.
Subsequent work in HLA A, B, C and DR matched sibling pairs and fully or 
partially matched unrelated donor pairs (using two different techniques to 
potentiate allostimulation) has confirmed retention of CMV-specific cells by 
tetramer (in HLA A*0201" individuals) and IFN-y ELISpot (in HLA A*0201", 
A*0101" and B*0702" responders and retention of EBV-specific cells by IFN^y 
ELISpot in HLA A*0201+ responders. No prior data demonstrating preservation 
of specific cellular CMV and EBV responses following selective allodepletion 
based on CD69 expression in HLA-matched pairs and in non-HLA A*0201+ 
individuals has been published.
Considerable variation between individuals was apparent in CD3"CD8" NLV- 
HLA A*0201 tetramer" frequency. Baseline CD3"CD8" NLV-HLA A*0201 
tetramer" frequencies were 3-5-fold greater than baseline CD3+CD8+ NLV 
peptide-stimulated IFN-y ELISpot reactive cells, which is in keeping with 
published literature. [Lechner et al. 2001] This difference may represent an 
excess of tetramer" cells that do not secrete IFN-y, or simply differences in the 
sensitivity of the two assays.
In HLA-matched pairs no obvious pattern was seen in the degree of retention of 
any cellular response tested in relation to donor type or closeness of HLA 
matching but a small series such as this would only be able to detect such 
differences if they were very marked and independent of other variables.
In HLA-matched pairs both quantitative and qualitative differences in the 
retention of cellular antiviral responses after allodepletion were seen with the 
use of the two different techniques for allostimulation.
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There was a trend for less retention of functional CMV-reactive cells (identified 
by ELISpot assay) and significantly less EBV retention in HLA A*0201+ 
responders with the OKT3 technique than with the cytokine technique of 
allostimulation, despite very similar retention of third party proliferation post­
depletion with the two techniques.
The negative correlation between the strength of the primary alloresponse (RRI, 
%) after OKT3 allostimulation and retention of CMV/EBV responses supports 
the concept of the existence of donor T cells with TCR affinity for both 
alloantigens and viral (e.g. EBV and/or CMV) antigens. OKT3 pre-treatment of 
stimulator cells may lead to sufficient upregulation of molecules involved in 
antigen presentation on the surface of stimulator T cells to enable weaker 
affinity interactions between MHC/antigen complexes and responder cell TCRs, 
which would favour the activation of responder TCRs with shared affinity for 
alloantigens and viral antigens.
Differences in the retention of viral responses within and between individuals in 
HLA-matched pairs seen with the two different allostimulation techniques may 
be a result of presentation of different lineage-specific allogeneic mHags 
(myeloid for the cytokine technique and lymphoid for the OKT3 technique) to 
responder T cells, with different degrees of TCR shared affinity for viral antigen. 
Nevertheless the demonstration of retention of the majority of functional CD8 + 
cellular CMV- and EBV-specific responses after efficient allodepletion of HLA- 
matched pairs has great significance for the development of the CD69 
allodepletion strategy to a clinical scale.
Further studies need to focus on retention of CD4+ antiviral responses as well 
as CD8 + responses. It must be stressed that the viral peptide-stimulated IFN-y 
ELISpot assay measures only CD8 + CTL responses, and gives no information 
about HLA Class ll-restricted CD4+ effector and memory cells that are known to 
be required for the persistence of cellular immunity to CMV.[Gamadia et al 
2003;Zajac et al 1998] Experiments using professional antigen presentation 
with dendritic cells and whole CMV protein would be needed to examine the 
preservation of CD4+ cellular anti-CMV and -EBV activity after CD69-based 
selective allodepletion.
The benefit of preservation of CMV CD8 + responses in selectively allodepleted 
cell pools would clearly be to confer adoptive anti-CMV immunity to the recipient 
of a selectively allodepleted AHSCT, as CMV infection is still a common
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occurrence post-transplant although prophylactic antiviral therapy and 
monitoring with real-time PCR for CMV DNA and pre-emptive treatment has 
reduced the incidence of clinically severe CMV disease and mortality directly 
attributable to the disease.
The importance of retaining EBV-specific cellular responses after selective 
allodepletion based on CD69 expression is in the potential for adoptive transfer 
of such cells within selectively allodepleted grafts to recipients and the 
subsequent protection against EBV-related PTLD.
Whilst the majority of the EBV-related PTLD lymphoid expansions have been 
associated with latent type EBV infection, the EBV lytic cycle also appears to 
play an important role in PTLD. PTLD tumours have been examined with 
specific antibodies for detection of early and late lytic-cycle antigens, or with 
oligoprobes to measure the presence of latent- and lytic-cycle viral DNA. Under 
immunosuppressive therapy up to 80% of tumours examined showed evidence 
of EBV early lytic cycle reactivation and 30-40% of the tumours contained EBV 
late lytic antigens or replicative DNA. Strong evidence has also been gathered 
from animal models showing that the lytic cycle may be important in the 
development of PTLD. SCID mice injected with EBV-immortalized B-cell 
populations in the latent or lytic state revealed that mice injected with the lytic- 
positive population developed tumours more readily.[Tanner and Alfieri 2001] 
Thus the demonstration of retention of EBV lytic peptide GLC-specific CTL 
responses can be taken as evidence that CD69 allodepleted donor cell fractions 
could confer protection against EBV-related PTLD, (although EBV-specific 
responses to other latent-cycle peptides clearly also need to be studied). 
NLV-CMV and GLC-EBV-specific T cell are frequent in most HLA A*0201+ 
individuals although T cells responding to both peptides are often less frequent 
than T cells responding to B*0702- restricted peptides in A*0201+ B*0702+ 
individuals.[Hollsberg 2002;Kern et al. 1999] In such individuals it would be 
prudent to measure CMV and EBV responses to both HLA A*0201+ and 
B*0702+-restricted CMV and EBV-peptides.
Viruses other than CMV and EBV are controlled primarily by a T cell mediated 
immune response and are important pathogens post AHSCT. These include 
respiratory syncytial virus, and adenovirus.[Alwan et al. 1992;Walls etal. 2003] 
Life-threatening complications arising from infection from these viruses post- 
AHSCT have been treated successfully with donor lymphocyte infusions, with
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presumed transfer of antiviral CTLs.[Hromas et al. 1994;Kishi et al. 2000] 
Specific cellular antiviral immunity to such viruses might also be preserved by 
selective alloreactive T cell depletion of the donor T cell pool.
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Chapters Phenotypic and Functional Characteristics of Alloreactive
and Non-alloreactive Cells
5.1 Introduction
In order to provide effective quantitative and qualitative broad spectrum T cell 
reconstitution post-AHSCT, the graft T cell pool should contain antigen specific 
CD4+ and CD8 + T cells of both memory and effector phenotype.
Memory T cells can be differentiated from nalVe T cells by their relative 
expression of isoforms of the TCR stabilising molecule CD45, a transmembrane 
tyrosine phosphatase. The CD45 isoform expressed on the T cell surface 
changes after prolonged antigenic stimulation. Alternate splicing of exons that 
encode the extracellular domain of CD45, leads to increased production of 
CD45RO, (the isoform that binds and stabilises the TCR and facilitates antigen 
recognition) and decreased production of the high molecular weight CD45RA 
isoform that does not associate with the TCR or with the CD4 or CD8  
molecules. Memory and naYve T cells can thus be broadly identified by 
expression of CD45 isoform.[Janeway etal. 1999]
Lanzavecchia and Sallusto have further classified both CD4+ and CD8 * 
CD45RO+CD45RA' memory T cells based on functional characteristics and 
expression of the chemokine receptor CCR7.[Lanzavecchia and Sallusto 
2000;Sallusto et al. 1999] Central Memory and Effector Memory T cells (Tcm 
and TEm) were initially defined in the human system based on two distinct 
criteria;
(a), the expression of homing receptors such as CCR7 that allow cells to 
migrate to secondary lymphoid organs versus non-lymphoid tissues;
(b). the absence or presence of immediate effector function.
CCR7 is a transmembrane G-protein-coupled receptor important in 
lymphocyte trafficking and required for diapadesis through high endothelial 
venules (HEV) and migration to T cell areas of secondary lymphoid organs. 
[Campbell et al. 1998;Forster et al. 1999] Human Tcm are CD45RO" memory 
cells that constitutively express CCR7. When compared with naive T cells, TCm 
have higher sensitivity to antigenic stimulation, and are less dependent on co­
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stimulation. They also upregulate CD40 ligand effectively and are therefore able 
to provide effective stimulatory feedback to dendritic cells and B cells. Following 
TCR triggering, Tcm produce mainly IL-2, but after proliferation they efficiently 
differentiate to effector cells and produce large amounts of IFN-y or IL-4. Human 
Tem are memory cells that have lost their constitutive expression of CCR7 and 
display characteristic sets of chemokine receptors and adhesion molecules that 
are required for homing to inflamed tissues. When compared with TCm. Tem are 
characterized by rapid effector function. CD8 + TEm carry large amounts of 
perforin, and both CD4+ and CD8 + cells produce IFN-y, IL-4, and IL-5 rapidly 
following antigenic stimulation. The Tem pool contains CD4+ cells able to 
mediate both Th1 and TH2 type responses, and CD8 +CTLs.[Sallusto eta l 1999] 
[Campbell et al. 2001]Other work has tried to classify memory T cell subsets 
based on expression of co-stimulatory molecules such as CD27 and CD28. 
These molecules, which are expressed on naTve T cells, are also expressed on 
some memory T cells, however they are absent in a subset of CD8 + memory T 
cells characterized by high effector function and expression of CD45RA.[Appay 
et al. 2002;Hamann et al. 1997] The combination of CCR7 and CD45RA 
expression can thus divide CD4+ T cells into 3 functional subsets and CD8 + T 
cells into 4 functional subsets, although considerable heterogeneity of 
expression of other chemokine receptors, adhesion molecules and co­
stimulatory molecules exists within these subsets (Figure 5.1).[Sallusto et al. 
2004a]. Expression of CD62L (L selectin), which also guides lymphocytes into 
lymphoid tissue, is closely linked to CCR7 expression on memory CD4+ T cells 
and thus Tcm and Tem cells may also be differentiated based on their expression 
of CD62L.[Sallusto et al 1999]
Proliferative responses in HLA-mismatched MLRs have been reported with 
purified (CD4+ and CD8 +) CD45RA+ and CD45RO+ responder cells indicating 
functional alloreactive cells are contained in both naive and memory cell 
subsets. [O'Brien and Kemeny 1998]
Recently an increase in the Tem phenotype (CCR7" CD62Ll0W) of circulating T 
cells has been reported in AHSCT recipients with chronic GVHD, although the 
distribution between central and effector memory cell subsets in alloreactive 
cells has not been yet been described.[Yamashita et al. 2004]
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CD4+ T cells
1.Naive
2.Central Memory
3.Effector Memory
CD45RA
CD8+ T cells
1.NaTve
2.Central Memory
3.Effector Memory
4.Terminally differentiated Cells
CD45RA
Figure 5.1 The Classification of CD4+ and CD8 + T cells into NaTve, Central 
and Effector Memory Cells based on expression of the chemokine receptor 
CCR7 and CD45RA. Figure taken from Lanzavecchia and 
Sallusto.[Lanzavecchia and Sallusto 2000;Sallusto et al 1999}
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The TCR is a molecular complex comprising two units; a variable ‘recognising 
unit’ (either the <xp heterodimer or in 1-10% of T cells the 7 8  heterodimer) and a 
transducing unit that allows a signal to be delivered to the T cell. The 
‘recognising unit’ requires great variability in order to bind different antigen/MHC 
molecules and this is achieved by the somatic genomic recombination process 
in the thymus. Each of 4 TCR gene loci (a, p, 7  and 8 ) is composed of several 
highly polymorphic V, D and J segments and one or two constant genes. During 
T cell gene rearrangement in any given T cell, random V, D, J and C genes are 
joined together to form a single and unique combination. There are 65 Vp 
segments in the p locus that can be grouped into 25 sub-families (22 functional 
sub-families).[Neisig et al. 1993;Peggs et al. 2003b] The measurement of the 
relative frequencies of CD4+ and CD8 + cells within each of these Vp sub­
families is able to give a measure of the diversity of T cells within a given cell 
pool. Oligoclonal or clonal restriction of T cells within a given TCR Vp sub-family 
can be determined by the use of a set of PCR primers specific to each TCR Vp 
sub-family, to amplify the 3rd complimentarity determining region (CDR3) length 
of DNA. A distribution histogram (the spectratype) can be produced for each 
TCR vp sub-family.[Gorski et al. 1994] Polyclonal responses are characterised 
by the conservation of baseline CDR3 length distributions within each TCR Vp 
sub-family with multiple peaks in the spectratype, and normal spectratypes for 
all TCR vp sub-families. Restricted clonal responses demonstrate a single 
sharp peak with absence of the other peaks within a given TCR Vp sub-family. 
Although CDR3 PCR is only semi-quantitative, in highly restricted clonal T cell 
responses all T cells may belong to the same TCR Vp sub-family and the 
normal pattern within other TCR v p  sub-families is absent, and flat spectratypes 
are seen. Antibodies are now available to epitopes for most common TCR Vp 
sub-families that permit the direct assessment of TCR Vp sub-family distribution 
of individual cell subsets. Although this technique is quantitative, it has a lower 
resolution when compared to CDR3 PCR and no information about distribution 
of TCR Vp rearrangements within a given sub-family can be derived. 
Additionally there is no consensus about how the degree of diversity of TCR Vp 
sub-family distribution should be expressed following direct quantification by 
flow cytometric techniques, whereas several mathematical models have been 
constructed to describe diversity in CDR3 length frequencies both within and
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between TCR Vp sub-families.[Bomberger et al. 1998;Dumont-Girard et al. 
1998;Godthelp etal. 1999;Gorochov et al. 1998]
Human T cell responses to certain pathogens (e.g. Influenza A) are 
characterised by the presence of cells with a highly restricted TCR Vp sub­
family usage, which may be constant between different individuals.[Lehner et al. 
1995] Other pathogens (e.g. EBV, CMV) are characterised by less focussed T 
cell responses, with pathogen-specific T cells demonstrating restriction to 
several Vp sub-families within individuals, even in cell populations specific to an 
identified peptide antigen and selected cell sorting based on expression of MHC 
Class l-peptide tetrameric complexes.[Lim et al. 2000b;Peggs et al. 2002] 
Alloreactive cells were first shown to have restricted TCR Vp sub-family use 
when DNA was analysed by PCR for CDR3 length in alloreactive cell clones 
specific for identified MHC Class I and II molecules.[Li et al. 1996;Lobashevsky 
et al. 1996] TCR Vp sub-family usage has also been shown to be restricted in T 
cell lines derived from cells infiltrating renal allografts.[Hall and Finn 1992] 
Recently anergic T cells capable of suppressing both the cytokine and 
proliferative responses of other T cells have been identified and these T 
regulatory cells are present in healthy individuals. [Ng etal. 2001]
Although not identified by a highly specific cell surface antigen and not 
exclusive to a readily identifiable cell subset, they are enriched within the subset 
of resting T cells that co-express the CD4 receptor and the low affinity IL2 
receptor CD25.
These CD4+CD25+T regulatory cells form less than 10% of resting human CD4+ 
lymphocytes, but are increasingly recognised as playing an important role in 
suppression of immune responses both in healthy human subjects and in 
animal models of allotransplantation.[Papiernik 2001] CD4+CD25+ T regulatory 
cells are required for the ex vivo induction of tolerance to alloantigen via co­
stimulatory blockade and to inhibit allogeneic skin graft rejection.[Field and Gao 
1998;Gao et al. 1999;Jarvinen et al. 2003] There is also evidence that these 
cells can suppress the alloreactive response and limit the development of 
allograft rejection. [Kingsley et al. 2002;van Maurik et al. 2002;Zhang et al. 
2001] Such T regulatory cells have been shown to suppress GvHD responses 
in mice. Depletion of CD4+CD25+ T regulatory cells from donor T cell inoculum 
or in vivo CD25-depletion of the recipient before transplantation resulted in
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increased GvHD mediated by CD4+ cells or unselected T cells in mice. The 
infusion of freshly purified donor CD4+CD25+ T regulatory cells modestly 
inhibited GvHD when administered in equal numbers with CD4+ cells but at 
higher levels significantly inhibited rapidly lethal GvHD.fTaylor et al 2002]
CD25 is an important T cell activation antigen and as such has been used to 
identify and selectively remove alloreactive cells by several groups. Such a 
strategy is likely to remove CD4+CD25+T regulatory cells although the impact of 
this is not known. No data have been published on the co-expression of CD69 
and CD25 on alloreactive cells following allostimulation. A potential difference 
between the CD69-mediated allodepletion strategy and those based on CD25 
expression would be the retention of CD4+CD25+T regulatory cells.
5.2 Aims of the Experiments Described in this Chapter
1. To determine the memory/effector phenotype of both alloreactive and
non-alloreactive cells;
2. To determine the TCR Vp sub-family distribution in both alloreactive and
non-alloreactive cell subsets in both the HLA-mismatched and matched 
setting;
3. To determine the co-expression (if any) of the activation antigens CD69
and CD25 on cells after allostimulation and timescale of expression of 
these antigens in HLA-mismatched and HLA-matched settings;
4. To determine whether functional CD4+CD25+ T regulatory cells are
retained in the non-alloreactive cell fraction following selective 
alloreactive cell depletion by immunomagnetic sorting of CD69+ cells.
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5.3 Methods and Experimental Design
5.3.1 Memory and Effector Phenotype of Alloreactive cells
20 healthy subjects, (11 male and 9 female) were studied to generate normal 
values for CD4+ Tcm, Tem, and na'iVe cells and CD8+ Tcm, TEm, naive and 
terminally differentiated cells. Four-colour flow cytometry was performed on 
whole blood using the following antibody panels:
Fluorochrome Panel 1 Panel 2
FITC CCR7/GAM CD56
PE CD4 CD20
PerCP CD8 CD8
APC CD45RA CD3
Table 5.1 Antibody panels used for determination of naTve and memory T 
cell subsets in healthy controls.
Antibodies used were all from Becton Dickinson and the antibody staining 
procedure was as described in Chapter 2.2.1. Panel 1 was used to determine 
the percentage of CD4+ and CD8+ cells within the live lymphocyte region on a 
FSC vs. SSC dot plot within each quadrant of a CD45RA vs. CCR7-GAM dot 
plot. Panel 2 was used to determine the percentage of CD3'CD56+ NK cells, 
CD3+ T cells, CD3+ CD56+ NK-T cells, CD20+ B cells, CD3+ CD8+ T cells and 
CD3+ CD56" CD8' T cells (CD4+ cells) within the live lymphocyte gate. The total 
lymphocyte count was quantified on the same whole blood sample on an Advia 
automated cell counter. The analysis of the data from panels 1 and 2 and the 
total lymphocyte count allowed the calculation of absolute values for naive and 
memory cell subsets for each individual.
6 different HLA-mismatched MLRs were set up and cells were phenotyped after 
72 hours of co-culture with the panels described below using the phenotyping 
protocol described in Chapter 2.2.1
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Fluorochrome Panel 1 Panel 2
FITC CCR7/GAM CCR7/GAM
PE CD69 CD69
PerCP CD4 CD8
APC CD45RA CD45RA
Table 5.2 Antibody panels used for determination of naTve and memory T 
cell subsets in responder cells in HLA-mismatched MLRs.
5.3.2 TCR Vp Sub-family Phenotyping
TCR Vp sub-family distribution was assessed by flow cytometry using the 
lOTest Beta Mark kit (Beckman-Coulter, USA). Briefly this kit comprises 24 
murine and rat monoclonal and polyclonal antibodies directed against epitopes 
of 24 of the commonest human TCR Vp sub-families, covering 67% of TCR Vp 
sub-families expressed on human CD8+ T cells and 72% on CD4+ T cells. 8 
mixtures of 3 antibodies (murine IgM and IgG (22 antibodies) and rat IgM and 
IgG (one each) are supplied, each mixture containing a PE-conjugated antibody 
with specificity against one TCR Vp sub-family, a FITC-conjugated antibody 
with specificity against a second, and a third antibody with specificity against a 
third TCR Vp sub-family which is conjugated to both PE and FITC 
fluorochromes. 10pl of each antibody mixture was added to 0.5-1x106 PBMCs 
along with 5|iL of CD4/8 PerCP and 5|il CD69 APC (both BD) and incubated at 
room temperature in the dark for 15 minutes. (No CD3 antibody was used as 
preliminary experiments demonstrated that anti-CD3 antibody binding interfered 
with anti-TCR vp antibody binding). Cells were washed once in PBS for 10 
minutes and resuspended in 300|iL PBS. The cells were acquired within 4 
hours of staining on a FACSCalibur flow cytometer (Becton Dickinson) in four- 
colour mode.
Events were gated on a region (R1) drawn around the live lymphocyte region of 
normal controls or responder cells from MLRs on a FSC vs. SSC dot plot. For 
experiments where TCR Vp sub-family distribution was assessed in CD4+ and
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CD8+ subsets, further regions were drawn around CD8 bri9ht (or CD4+) cells (R2) 
or CD8‘ (or CD4‘) cells (R3) on a FSC vs. CD4/8 Per CP histogram gated on R1 
(G1). A further CD69-APC histogram was generated, gated on (R1+R2) (G2) or 
(R1+R3), (G3). Regions were drawn around the CD69'cells (R4) and the CD69+ 
cells (R5). Finally TCR Vp FITC vs. TCR Vp PE dot plots were generated gated 
on (G2+R4), (G3+R4), (G2+R5) and (G2+R6). The relative percentage of cells 
expressing each TCR Vp was determined from cluster analysis of these dot 
plots. This gating strategy is illustrated in Figure 5.1.
The normal ranges were derived in this way from 12 healthy adult individuals (7 
male, 5 female) using this staining protocol (with CD8 PerCP and without CD69 
antibody) to validate the TCR Vp antibody staining on PBMCs.
The flow cytometric measurement of TCR Vp sub-family distribution was 
chosen as it enabled discrimination of CTLs responding to stimuli (based on 
CD69expression) without more complex cell sorting procedures. The Beta Mark 
kit only allows the assessment of the percentage of CTLs in each TCR vp sub­
family (and does not therefore give the level of resolution of TCR spectratyping 
by PCR for CDR3 length). However DNA spectratyping cannot distinguish 
between DNA from different cell populations and would not be therefore be 
suitable for TCR assessment of responder cells in the allogeneic MLR as these 
cells are contaminated with irradiated stimulator cells. Moreover molecular 
techniques do not allow the assessment of TCR vp sub-family repertoire on T 
cell subsets and on cells expressing activation markers (e.g. CD69) without first 
using cumbersome cell sorting procedures.
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Figure 5.2 (See over for figure legend).
Figure 5.2 Gating strategy for flow cytometric determination of TCR Vp sub­
family distribution of responders in MLR. G1=R1, G2=(R1 and R2), G3=(G2 and 
R3), and G4=(G2 and R4). This example demonstrates the relative frequencies 
of 3 TCR Vp sub-families in HLA-matched responders after 72 hours in an MLR 
with OKT3 pre-treated irradiated stimulator cells. In this example cells 
expressing TCRVp-1 (identified the dual fluorochrome conjugated TCR Vp 
antibody) are over-represented in the CD69+ alloreactive responder cells (TCR 
vp -1 frequency 8% of CD8+ cells) compared to CD69' non-alloreactive cells 
(TCR Vp-1 frequency 3% of CD8+cells).
A similar gating strategy was used without CD69 antibody, generating a single 
TCR Vp-FITC vs. TCR Vp-PE dot plot gated on G2.for the determination of 
normal values using this method.
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5.3.3 CD69 and CD25 Co-expression on Alloreactive Cells
HLA-matched and HLA-mismatched MLRs were set up as described in Chapter 
2.3.2-4.
Responder cells were stained with the following antibody panel after 48, 72, 96 
and 120 hours of incubation in the MLR. All antibodies were supplied by BD and 
the staining protocol was as detailed in Chapter 2.2.1.
Fluorochrome Antibody
FITC CD3
PE CD25
PerCP CD8
APC CD69
Table 5.3 Antibodies used for flow cytometric assessment of the co­
expression of CD69 and CD25 on responder cells in MLRs.
5.3.4 CD4+CD25+T regulatory Cells in the MLR
The frequency of CD4+CD25+ T regulatory cells was assessed before and after 
allostimulation and after selective depletion of CD69+ alloreactive cells (by 
immunomagnetic sorting with Miltenyi system, Chapter 2.5.1) in HLA- 
mismatched and HLA-matched responders using the antibody panel shown in 
Table 5.3.
CD4+CD25+ T regulatory cells in selectively allodepleted HLA-mismatched 
responder cells were stained with CD25-PE and CD4-PerCP (both BD) and 
sorted on a FACSVantage SE high speed cell sorter (BD) to enrich the 
CD4+CD25+ T regulatory cell fraction to a purity of >80%. These sorted 
CD4+CD25+ T regulatory cells were added at a ratio of 1:1 to an HLA- 
mismatched third party MLR (with responders autologous to the CD4+CD25+ T 
regulatory cells) in order to assess the immunosuppressive capacity of the 
CD4+CD25+ T regulatory cells after selective allodepletion. The non-CD4+CD25+ 
T regulatory cell fraction from the sort was also added to the HLA-mismatched
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third party MLR (with responders autologous to the non-CD4+CD25+ T 
regulatory cell fraction) as a negative control. The experimental schema is 
illustrated in Figure 5.3 (overleaf).
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Figure 5.3 Experimental schema for functional assessment of CD4+CD25+ T regulatory cells after selective allodepletion in HLA-
mismatched MLRs.
5.4 Results
5.4.1 Naive and Memory T Cell Subsets in Normal Controls
The age, absolute lymphocyte count, and mean and standard deviation for 
CD4+ and CD8+ naive and memory cell subsets (expressed as percentage of 
total CD4+ or CD8+ cells) in twenty healthy volunteers are shown in Table 5.4. 
Also shown are the normal ranges for CD4+ and CD8+ naive and memory cell 
subsets (defined as mean % +/-1.96 x sd to encompass 95% of values from the 
whole population).
Cells Parameter Mean
/median
sd/range
Normal
RangeAge (years) Median 36yrs 25-65 years
ALC x10#/L 1.9 0.54 0.84-2.9
CD3*CD8+ Naive 21.3% 10.6% 0.52-42%
Tcm 9.60% 6.70% 0-23%
Tem 45.6% 11.5% 23-68%
TDC 23.5% 13.7% 0-50%
CD3*CD4+ Naive 24.6% 8.70% 7.2-42%
Tcm 37.3% 13.5% 10-64%
Tem 36.2% 13.9% 8.4-64%
Table 5.4 Normal ranges for CD4+ and CD8+ naive and memory cell subsets 
(expressed as % of total CD4+ or CD8+ cells) in twenty healthy volunteers.
ALC = absolute lymphocyte count.
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5.4.2 Naive and Memory Subsets in CD69* Alloreactive Cells
The percentage CD4+ and CD8+ naive and memory cell subsets in baseline and 
CD69+ alloreactive cells in 6 HLA-mismatched responder cells after 72 hours of 
allostimulation in a standard MLR are shown in Figure 5.4.
CD69+ alloreactive HLA-mismatched responders contain a mixture of naive, 
memory and terminally differentiated CD8+ cells. Although not reaching 
statistical significance there was a trend towards a higher frequency of CD8+ 
Tem in CD69* cells than in baseline responder cells (p=0.07 in a paired two- 
tailed t-test). In 4 of the 6 HLA-mismatched pairs studied the frequency of CD8+ 
naive cells in CD69' non-alloreactive cells after 72 hours of allostimulation was 
above the normal range seen in baseline healthy CD8+ cells.
CD69+ alloreactive HLA-mismatched responders contained a mixture of both 
nalVe and memory CD4+ cells, although a significantly lower frequency of CD4+ 
naiVe cells and a significantly higher frequency of CD4+ TEm cells was seen in 
CD4+CD69+ alloreactive cells compared to baseline responder cells (p=0.049 in 
a paired two-tailed Student’s t-test). An increase in the frequency of total CD4+ 
memory cells (Tcm +TEm) was seen in 5 of the 6 mismatched pairs.
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18%
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Alloreactive CD3+CD4+CD69+ Cells
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CD45RA+CCR7+ NaTve T Cells □  CD45RA CCR7- TEM Cells 
CD45RA CCR7+TCM Cells □  CD45RA CCR7+ TDCs
Alloreactive CD3+CD8+CD69+ Cells
Figure 5.4 Memory and effector phenotype of baseline and alloreactive CD3+CD8+ and CD3+CD4* cells.
Central Memory cells, TEm = Effector Memory cells, TDC = Terminally Differentiated cells based on expression of CD28 and CCR7,
as described by Lanzavecchia and Sallusto[Lanzavecchia and Sallusto 2000]
5.4.3 TCR Vp Sub-family Frequency Distribution in Cells after 
Allostimulation
Responder TCR Vp sub-family distribution was determined in 4 HLA- 
mismatched stimulator-responder pairs in baseline (unstimulated) responder 
cells and in CD69' and CD69+ responder cells following 72 hours of 
allostimulation in the MLR. Following allostimulation, TCR vp sub-family 
distribution in CD69‘ responder cells closely resembled the baseline distribution 
in both CD4+ and CD8+ cells, whereas CD69+ alloresponder cells showed 
skewing of TCR Vp sub-family distribution with increases in frequencies of 
some TCR Vp sub-families (consistent with an oligoclonal T cell response to 
allostimulation) and decreases in others. Changes in TCR vp sub-family 
distribution were quantified as the modular percentage change from baseline 
frequency in CD69" and CD69+ cells after allostimulation and are shown in 
Table 5.6. Skewing of TCR Vp sub-family distribution in CD69+ alloresponders 
was more marked in CD8+ than in CD4+ responders and the modular 
percentage change from baseline frequency was significantly greater in CD8+ 
CD69+ cells than in CD8+CD69\ TCR Vp sub-family distribution in CD4+ and 
CD8+ baseline responders and CD69' and CD69+ responders after HLA- 
mismatched allostimulation are shown in Figure 5.5.
Responder Cells
Modular TCR Vp frequency 
pertubation from baseline value. 
(Mean+/-standard deviation).
P value in 
paired two- 
tailed Student’s 
T-testCD69- CD69+
CD4+ 19.3 +/- 0.6 31.5 +Z-7.8 0.10
CD8+ 26.3 +/- 5.5 56.9 + /-12.9 0.03
Table 5.5 Pertubation from baseline frequencies of TCR Vp sub-families in 
CD69" and CD69+ responder cells after HLA-mismatched allostimulation.
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Figure 5.5 TCR Vp sub-family distributions in baseline, CD69‘ and CD69+ 
responder cells after 72 hours in the MLR with HLA-mismatched stimulator 
cells. Results are shown for CD4+ and CD8+ cells in 3 stimulator-responder 
pairs. TCR Vp sub-families are plotted in ascending frequency in baseline 
responder cells for each stimulator responder pair.
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Responder TCR Vp sub-family distribution was also determined in 4 HLA A, B, 
C and DR-matched stimulator-responder pairs utilising both the OKT3 and the 
cytokine allostimulation techniques. Again, TCR Vp sub-family distribution in 
CD4+ and CD8+ CD69" responder cells after 72 hours of allostimulation closely 
resembled that of baseline responder cells using both techniques of 
allostimulation, whereas skewing of TCR Vp sub-family distribution was seen in 
CD69+ responders following allostimulation. Skewing of CD69+ responder cell 
TCR Vp sub-family distribution was more marked in CD8+ than CD4+ 
alloresponders. Furthermore, different TCR Vp sub-families were over­
represented in CD69+ alloresponder cells after allostimulation utilising the OKT3 
and the cytokine allostimulation technique. The modular TCR Vp sub-family 
frequency pertubation from baseline values are shown in Table 5. 7. TCR Vp 
sub-family distribution in baseline cells and CD69' and CD69* responders after 
allostimulation (using both techniques) in a representative HLA-matched pair is 
shown in Figure 5 6.
Allostimula
-tion
technique
Responder
Cells
Modular TCRV  
perturbation, % 
value (Mean+ 
deviat
p frequency 
From baseline 
/-standard 
on)
P value in 
paired 
two-tailed 
Student’s 
t-test
CD 69* CD69*
OKT3
CD4+ 19.9+Z-8.6 35.6+/-16 Ns
CD8+ 24.6+Z-9.2 79.9+/-41 0.04
Cytokine
CD4+ 21.5+Z-5.5 64.4+Z-22 0.03
CD8+ 34.9+Z-18 79.9+Z-9.2 0.02
Table 5.6 Perturbation from baseline frequencies of TCR Vp sub-families in 
CD69' and CD69+ responder cells after HLA-matched allostimulation.
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Figure 5.6 TCR Vp sub-family distribution in baseline, CD69' and CD69+ responder cells after 72 hours allostimulation in the MLR with 
HLA-matched OKT3 or cytokine pre-treated stimulator cells. Results are shown for CD4+ and CD8+ cells in a representative stimulator- 
responder pair. TCR Vp sub-families are plotted in ascending frequency in baseline responder cells.
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5.4.4 Co-expression of CD69 and CD25 on Alloreactive T cells
Three subsets of alloreactive cells in both CD4+ cells and CD8+ cells could be 
identified by their expression of the two activation antigens CD69 and CD25 
following allostimulation by HLA-mismatched irradiated stimulator cells in the 
standard MLR. These are CD69+CD25', CD69+CD25+ (dual positive) cells and 
CD69'CD25+ cells. Considerable variation was seen in the percentage of 
responder cells expressing each activation antigen between HLA-mismatched 
pairs. CD69+CD25responder cells appeared earliest and exhibited the lowest 
maximal frequency in both CD4+ and CD8+ cells (with a larger response in CD4+ 
cells than CD8+ cells) Dual positive cells appeared later and were more frequent 
than CD69+CD25' cells in both CD4+ and CD8+ cell subsets with a greater 
frequency in CD4+ cells. Last to appear were CD69"CD25+ cells (in equivalent 
levels in CD4+ and CD8+ cells) and in much greater frequencies than 
CD69+CD25' and dual positive cells, not reaching a maximum level by the last 
time point tested (120 hours).
CD4* CD8+
CD69*
CD25-
CD69*
CD25+
CD69'
CD25+
CD69+
CD25~
CD69+
CD25+
CD69’
CD25+
Max
(Mean+/-sd)
3.8 
+/-2.7
6.2
+A3.6
22.2
+/-14
1.8
+/-1.6
2.5
+/-1.8
24.1
+/-17
Time
(hours)
72 120 120* 72 96 120*
* Maximal response not reached by final time point (120 hours)
Table 5.7 Mean maximal expression (Max) of CD69+CD25", CD69+CD25+ 
(dual positive) cells and CD69'CD25+ cells on HLA-mismatched responders 
(above autologous control) (and median time to maximal expression).
These three distinct subsets of both CD4+ and CD8+ responder cells 
(CD69+CD25', CD69+CD25+ (dual positive) cells and CD69'CD25+ cells) 
appeared with the same temporal relationship following stimulation with
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irradiated HLA A-, B-, C- and DR-matched (or single antigen mismatched) 
OKT3 pre-treated stimulator cells. Maximal CD69'CD25+ expression occurred 
earlier than after HLA-mismatched allostimulation. All three responder cell 
subsets were also identified following allostimulation with cytokine pre-treated 
HLA-matched stimulators, albeit at much lower frequencies than following 
allostimulation with OKT3 pre-treated stimulators, and responses above 
autologous controls were not seen in all matched pairs. In responders where 
CD69 and CD25 expression was seen (above that seen with autologous 
stimulators) the temporal relationship of the three cell subsets was similar to 
that seen after HLA-mismatched allostimulation, but maximal expression of 
CD4+CD69+CD25" cells occurred later (at 96 hours). (Table 5.8 and Figures 5.7 
and 5.8).
Allostimulation
technique
CD4+ CD8+
CD69+
CD25
CD69+
CD25+
CD69*
CD25+
CD69+
CD25
CD69+
CD25+
CD69*
CD25+
OKT3
Max
11.7
+Z-5.6
21.6
+/-7.0
39
+Z-15
2.8
+/-1.3
5.5
+Z-4.2
31
+Z-21
Time
(hours)
72 72 96 72 72 96
Cytokine
Max
1.8
+/-1.7
1.8
+/-1.7
8.5
+Z-6.6
0.9
+/-0.9
0.5
+Z-1.0
5.7
+Z-8.8
Time
(hours)
96 120 72 72 72 120
Table 5.8 Mean maximal expression (Max) (+/- standard deviation) of 
CD69+CD25', CD69+CD25+ (dual positive) and CD69'CD25+ cells on HLA- 
matched responders (above that seen on autologous control cells) following 
allostimulation with OKT3 or cytokine pre-treated stimulators (and median time 
to maximal expression).
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Figure 5.7 Expression of the activation markers CD69 and CD25 on HLA-mismatched responders (above that seen in autologous 
controls) in a standard MLR. The results of 7 mismatched pairs are presented. Error bars represent standard deviation of the total
percentage of responder cells positive for CD69 and/or CD25.
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Figure 5.8 Expression of the activation markers CD69 and CD25 on HLA- 
matched responders (above that seen in autologous controls) in the MLR. The 
results of 7 HLA-matched pairs (5 sibling pairs and two HLA A, B, C and DR 
matched unrelated donor pairs) are presented. Error bars represent standard 
deviation of the total percentage of responder cells positive for CD69 and/or 
CD25. Results are shown for the same 7 pairs using;
(A) OKT3 pre-treated stimulators. (B) Cytokine pre-treated stimulators.
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5.4.5 Retention of CD4+CD25+ T regulatory Cells after Selective
Allodepletion
With HLA-mismatched stimulator cells, using an unmodified MLR strategy for 
allostimulation the frequency of CD4+CD25+ cells in allodepleted cell fractions 
was 14.9% +/-3.6% of CD3+CD4+ cells, which was not significantly different to 
the frequency seen in the allostimulated fraction. CD4+CD25+CD69+ cells made 
up 24.6% of the total CD4+CD25+ cells in the allostimulated cell fraction and 
only 1.69 % in the allodepleted cell fraction.
In the HLA-matched stimulator setting using the cytokine pre-treatment strategy 
for allostimulation, the frequency of CD4+CD25+ cells in allodepleted cell 
fractions was 26.8% +/-13% of CD3+CD4+ cells, which was not significantly 
different to the frequency seen in the allostimulated fraction. CD4+CD25+CD69+ 
cells made up 21.3% of the total CD4+CD25+ cells in the allostimulated cell 
fraction and only 1.83 % in the allodepleted cell fraction.
With HLA-matched stimulator cells using the OKT3 pre-treatment strategy for 
allostimulation, the frequency of CD4+CD25+ cells in allodepleted cell fractions 
was 76.8% +/-19% of CD3+CD4+ cells, which was not significantly different to 
the frequency seen in the allostimulated fraction. CD4+CD25+CD69+ cells made 
up 33.9% of the total CD4+CD25+ cells in the allostimulated cell fraction and 
only 0.92 % in the allodepleted cell fraction. The figures are shown in Table 5.9 
and Figure 5.9.
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CD3+CD4+
cells
HLA-mismatched
stimulators
HLA-matched OKT3 
pre-treated stimulators
HLA-matched cytokine 
pre-treated stimulators
AC Pre­
depletion
Post­
depletion
AC Pre­
depletion
Post­
depletion
AC Pre­
depletion
Post­
depletion
CD25+CD69‘ 8.8+/- 12+/- 15+/- 15+/- 39+/- 76+/- 14+/- 20+/- 26+/-
3 5 4 6 18 18 2 3 13
CD25+CD69+ 0.90+/- 3.4+/- 0.20+/- 0.60+/- 18+/- 0.75+/- 1.3+/- 7.4+/- 0.40+/-
0.6 1.8 0.2 0.03 0.9 0.5 0.85 10 0.15
CD25'CD69+ 0.80+/- 3.6+/- 0.20 6.6 16.3+/- 0.6 1.2+/- 2.3 0.2
0.3 0.7 +/-0.3 +/-8A 7.2 +/-0.4 0.9 +Z-2.6 +/-0.2
Total CD25+ 9.7+/- 15+/- 15+/- 15+/- 57+/- 77+/- 15+/- 27+/- 27+/-
2.9 4.4 3.6 9 16 19 2.8 13 13
CD25*CD69+
% of total 11+/- 25+/- 1.7+/- 4.8+/- 34+/- 0.92+/- 8.2+/- 21+/- 1.8+/-
CD25* 8 15 2 3 11 0.5 4 25 1.5
Table 5.9 CD4+CD25+ CD69', CD4+CD25+ CD69+ and total CD4+CD25+ responder cells after allostimulation and selective
allodepletion Results of 12 fully HLA-mismatched pairs (of which 7 were selectively allodepleted) and two HLA-matched pairs are
presented as mean +/- sd. AC=Autologous Controls
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Figure 5. 9 CD3+CD4+CD25‘CD69+, CD3+CD4+CD25+CD69+ and 
CD3+CD4+CD25+CD69‘ cells before and after selective allodepletion of CD69+ 
cells;
(A). A representative dot plot of HLA-mismatched CD3+CD4+ responders after 
72 hours in a standard MLR.
(B). Mean frequency in 12 HLA-mismatched pairs. Error bars represent 
standard deviation of total CD3+CD4+CD25+ cell frequency.
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Two HLA-mismatched donor-recipient pairs were used to confirm the retention 
of functional CD4+CD25+ T regulatory cells after selective allodepletion following 
the experimental schema outlined in Figure 5.3.
Proliferative responses after 120 hours in a standard MLR with third party HLA- 
mismatched stimulator cells were reduced to 20%+/-12% of the value seen with 
unmanipulated responder cells when an equal number of sorted CD4+CD25+ 
cells (>80% pure) from selectively allodepleted responders were added to 
unmanipulated responder cells (p=0.005 in a paire two-tailed Student’s t test). 
The addition of non-CD4+CD25+ cells from selectively allodepleted responders 
did not significantly alter proliferative responses in this setting (Figure 5. 10).
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Figure 5.10 CD4+ CD25+ T regulatory cells present in selectively allodepleted 
cells retain the ability to suppress proliferative responses to third party HLA- 
mismatched stimulator cells. Results are the mean (+/- standard deviation) of 
triplicate proliferation assays in two HLA-mismatched pairs.
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5.5 Chapter Discussion
The normal ranges for naive and memory phenotypes of CD4+ and CD8+ T cells 
(based on their expression of CD45RA and CCR7) have been established in 
healthy individuals. Considerable heterogeneity was seen between individuals 
but the ranges described are in keeping with those published in the literature. 
[Sallusto et al. 2004b] The relative proportions of Tcm and TEm in blood vary in 
the CD4+ and CD8+ compartments; TCm is predominant in CD4+ and TEm in 
CD8+. Within the tissues, however, Tcm and TEm show characteristic patterns of 
distributions. Tcm are enriched in lymph nodes and tonsils, whereas lung, liver, 
and gut contain greater proportions of TEM.[Campbell et al 2001;Morimoto et al. 
1985]
The naTve and memory phenotypes of CD4+ and CD8+ T cells were examined in 
baseline and CD69+ alloreactive responder cells following 72 hours of HLA- 
mismatched stimulation in the MLR. All cell subsets were represented in both 
CD4+CD69+ and CD8+CD69+ responder cells in keeping with published data 
that both naive and memory T cells are able to proliferate in response to 
alloantigenic stimulation in the MLR.[Morimoto eta l 1985].
The presence of alloreactivity in both the CD45RA+ and CD45RO+ T cell 
populations is likely to be a manifestation of both intrathymic and post-thymic T 
cell selection and development. Alloreactive T cells can be detected in the 
circulation of individuals with no prior exposure to alloantigens (except possibly 
In utero).[Ryser and MacDonald 1979;van Oers et al. 1978] and initial 
publications indicated frequencies of responding T cells of between 1 and 5% to 
any given allogeneic haplotype,[Lindahl and Wilson 1977a;Lindahl and Wilson 
1977b] although recent reports investigating precursor frequency of alloreactive 
helper and cytotoxic T lymphocytes by limiting dilution assays have shown 
much lower frequencies.[Wang etal. 1996; Young etal. 1998]
The data presented demonstrates over-representation of TEm cells in the CD69+ 
alloresponding cell fraction, (with a significant increase compared to baseline 
frequency in the % of CD4+ CD69+ TEM cells after 72 hours of HLA-mismatched 
allostimulation (and a trend towards increased frequency of TEm in CD8+CD69+ 
cells). Although prolonged antigenic stimulation leads to an antigen-driven shift 
in the isoform of CD45 expressed on T cells (from RA to RO) this process takes 
several rounds of cell division (e.g 6-7 days of dendritic cell alloantigen
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stimulation for CD8+ cells).[Geginat et al. 2003] Thus the relative increase in 
Tem cells in CD69+ alloresponders is likely to represent a true over­
representation of this cell subset within the pool of T cells able to respond to 
allostimulation, (rather than a shift of phenotype of alloresponders from naive to 
memory cells). In order to prove this, experiments measuring the CD69 
expression, proliferation and cytokine secretion in response to allostimulation of 
sorted T cell memory and effector subsets could be performed.
There is conflicting data in the literature regarding the differential capacity for 
memory and effector T cell subsets to mount an alloreactive response and the 
responses may be different for CD4+ and CD8+ T cells.
Murine data have shown that alloreactive responses were mediated mainly by 
naive (CD62L+) T cells, and that the transfer of allogeneic memory (CD62L') T 
cells contributed to immune reconstitution without GvHD in irradiated recipient 
mice.[Chen et al. 2004a] Foster et al have recently demonstrated that human 
memory (CD62L-) T cells were less responsive to allogeneic stimuli than 
CD62L+ naive T cells.[Foster et al. 2004a] However, In vitro alloresponses do 
not appear to be limited exclusively to CD45RA+ naive T cells. O’ Brien et al 
reported responder proliferation after stimulation in the MLR with both purified 
CD45RA+ and CD45RO+ responders. Greater proliferation was observed with 
CD4+CD45RO+ cells than with CD4+CD45RA+ cells, whereas CD8+CD45RA+ 
responders proliferated significantly more in response to allostimulation than 
CD8+CD45RO+ responders.[O'Brien and Kemeny 1998]
Recipients of AHSCT who develop chronic GvHD have an increased frequency 
of circulating CD4+ Tem  cells.[Yamashita et al 2004] The pivotal role of memory 
T cells in the pathogenesis of GvHD has also recently been confirmed in a 
murine GvHD model where blockade of the CCR7 receptor led to reduced 
chronic GvHD. Further work needs to examine the naTve/memory phenotype of 
CD69 alloreactive and non-alloreactive T cells in HLA-matched allostimulation 
using different strategies of potentiating allostimulation, and with the 
assessment of expression of other molecules used to differentiate T cell 
subsets (CD62L, CD27.CD28).
TCR Vp sub-family distribution in CD69+ responder cells following HLA- 
mismatched allostimulation demonstrated significantly more perturbation from 
baseline frequencies in CD8+ responders. Increases in frequencies of 2-4 TCR 
Vp sub-families were seen with corresponding decreases in other sub-families.
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This may represent an oligoclonal response to alloantigens, (although 
expansions of discrete TCR Vp sub-families does not necessarily imply 
responses to different alloantigens). A single MHC-peptide combination can 
positively select thymocytes bearing many distinct TCRs (albeit based on 
interactions with relatively low avidity). [Chmielowski et al. 1999;lgnatowicz et 
al. 1996] Restricted (and conserved) T cell repertoires have been identified 
amongst PBMC pools from healthy blood donors responding to irradiated 
PBMCs disparate for a single HLA class II molecule in an MLR. [De Palma and 
Gorski 1995] Importantly, these data demonstrated that the TCR Vp sub-family 
restriction was conserved across different individuals to a given HLA class II 
antigen, whereas different responses were seen to different HLA Class II 
alloantigens. Subsequently much evidence has emerged for restricted TCR Vp 
distribution in cells mediating GvHD. Infiltrating T cells during liver graft-versus- 
host disease show a restricted T cell repertoire,[Margolis et al. 2000] as do T 
cells present in skin and mucosal GvHD lesions in patients post AHSCT.[Kubo 
et al. 1996] Separation of anti-host and anti-tumour responses based on 
infusion of CD4+T cells with selected TCR Vp sub-family restriction known to be 
associated with either a strong alloresponse or a strong anti-tumour response 
has been demonstrated in a murine model.[Patterson and Korngold 2001]
TCR Vp sub-family distribution in the CD69' non-alloresponding cell fraction 
closely resembled that of baseline responder cells, indicating that a broad 
spectrum of TCR Vp sub-families would be maintained in the non-alloreactive 
CD69‘ cell fraction following selective allodepletion and that the clinical use of 
such cell fractions might maintain potential for broad spectrum immune 
reconstitution.
Following HLA-matched allostimulation qualitatively similar results were 
observed. It is of note that the use of different techniques for potentiating 
allostimulation in the HLA-matched setting (cytokine or OKT3 pre-treatment of 
stimulators) within individual matched pairs led to different patterns of TCR vp 
sub-family distribution in CD69+ responder cells, with increases in some sub­
families common to both allostimulation techniques, but increases in other TCR 
Vp sub-families limited to one technique. This observation may represent 
differential expression of mHags on myeloid or lymphoid APCells.
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Alloreactive responses to mHags in the MHC-matched setting have only been 
recently defined. Much work has been published in murine H2-matched models. 
The immunodominant CD4+ TCR Vp sub-family repertoires involved in GvHD 
responses to mHags have been described in such murine models, and 
heterogeneity has been described of CD4+ T cell responses to mHags, and 
correlation with epithelial tissue infiltrates. Repertoire analysis of CD8+ T cell 
responses to mHags involved in GvHD has also been reported, with restriction 
in GvHD-mediating cells suggesting oligoclonal T cell responses to a limited 
number of murine mHags. [Berger and Korngold 1997;Friedman et al. 
1998;Friedman et al. 2001;Jones et al. 2004] Maccario et al have recently 
analysed TCR repertoire by CDR3 size spectratyping before and after selective 
allodepletion of HLA-mismatched responder cells based on CD69 expression 
and subsequent in vitro anti-CTLA-4 antibody.[Maccario et al. 2003] Only 
presented in abstract form, this work reported polyclonal TCR Vp repertoire in 
MLR cultures. However it is not clear how live responder DNA was 
differentiated from DNA from irradiated stimulator cells (or whether alloreactive 
cells were further identified by any means), a criticism common to the work 
published by De Palma et al demonstrating restricted responder cell TCR Vp 
sub-family usage in responder cells in the MLR.[De Palma and Gorski 1995]). 
Thus the degree of TCR Vp repertoire restriction in human alloreactive cells, 
particularly in the setting of either multiple HLA-mismatches or in the HLA- 
matched setting remains to be accurately described.
Characterisation of TCR vp sub-family distribution in responder alloreactive 
cells identified by CD69 expression might aid the development of strategies to 
raise non-alloreactive cells with specific anti-leukaemic activity or antiviral 
activity. This potential application is discussed in more detail in Chapter 6.
Three distinct populations of responder cells appear following both HLA- 
mismatched and HLA-matched allostimulation based on expression of CD69 
and CD25. The CD69+ CD25' response occurs first (maximum at 24-48 hours), 
followed by dual positive cell response (maximum at 48-72 hours) and lastly the 
CD69' CD25+ cell response (maximum at 96-120 hours). Only a proportion of 
alloreactive cells expressed both activation markers at any given time point. It 
remains to be determined whether the CD69" CD25+ cells upregulate CD25 as a 
response to cytokines secreted by CD69+ cells or as a response to direct
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alloantigen stimulation. Trans-well plate or PKH-26 cell labelling experiments 
would be needed to resolve this issue. It is also unknown whether CD69+ and 
CD25+ alloreponsive cells are predominantly two different cellular subsets or 
represent the expression of different antigens sequentially on the same 
alloreactive cells. To determine this alloresponders could be sorted by flow 
cytometry based on their expression of CD69, labelled with PKH-26 and 
returned to the MLR, and the expression of CD25 on PKH-26+ cells 
subsequently measured. Selective allodepletion of responder cells based on the 
expression of both activation markers at the same time point might improve the 
efficiency of allodepletion above that seen with depletion based on expression 
of either activation antigen alone. This approach was undertaken by Fehse et al 
who found selective immunomagnetic depletion of CD69+ and CD25+ HLA- 
mismatched responder cells was more effective that selective depletion based 
on either antigen alone.[Fehse et al 2000a] It has recently been shown that 
CD4+CD25+ T regulatory cells are hyporesponsive to allostimulation and 
therefore these cells are unlikely to upregulate CD69 expression upon 
allostimulation and become CD4+ CD25+CD69+ cells.[Browning M.B etal. 2003] 
Frequencies of CD4+CD25+ cells were retained in CD69-selectively allodepleted 
cell fractions. CD4+CD25+ cells from allodepleted cell fractions retained their 
immunosuppressive function in allogeneic MLRs when added in a 1:1 ratio to 
autologous responder cells. The role of CD4+CD25+ T regulatory cells in 
suppressing alloreactivity is increasingly being recognised and the loss of such 
cells from the donor pool might result in increased GvHD. Loss of T regulatory 
function is seen in individuals with autoimmune and atopic conditions.[Browning 
et al 2003;Papiernik 2001] Non-selective T cell depletion leads to disordered 
immune reconstitution and the loss of hierarchical control, which may be 
manifest as autoimmune disorders such as autoimmune haemolytic 
anaemia.[Drobyski etal. 1996]
MHC disparate murine models also support the ability of CD4+CD25+ T 
regulatory cells to suppress GvHD whilst retaining GvL responses against 
leukaemia and lymphoma.[Edinger et al. 2003;Hoffmann et al. 2002;Johnson et 
al. 2002;Jones et al. 2003] There is however a discrepancy between the murine 
data and emerging evidence from the human AHSCT setting. In a study by 
Clark et al, patients with chronic GVHD after AHSCT had markedly elevated 
numbers of CD4+CD25high T cells as compared to patients without GVHD.
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Although CD4+CD25high T cells derived from patients in both groups were of 
donor origin, these cells may be present in higher frequencies as a result of (or 
response to) the GvHD.[Clark et al. 2004] Importantly, Stanzani et al have 
reported an increase in CD4+CD25+ T regulatory cells in the graft inoculum of 
patients who subsequently developed GvHD.[Stanzani et al. 2004] Thus it 
seems the evidence of the role of CD4+CD25+ T regulatory cells in suppressing 
human alloresponses whist retaining GvL responses has yet to be 
demonstrated. Nevertheless attempts have been made to purify human donor 
CD4+CD25+ T regulatory cells that show antigen-specificity for recipient 
alloantigens with the therapeutic aim of suppressing alloreactive responses in 
vivo.[Trenado etal. 2004]
Selective allodepletion based upon the upregulation of CD25 will remove (or 
destroy) not only alloreactive cells that have upregulated CD25 upon 
allostimulation but any cells that express CD25 constitutively including 
CD4+CD25+ T regulatory cells: such techniques will therefore deplete the donor 
T cell pool of the T regulatory compartment with the potential of increased 
alloreactivity and disordered immune reconstitution.
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Chapter 6 Expression of CD69 on CMV-reactive Cells
6.1 Introduction
Evidence is emerging that any given TCR may interact with more than one 
MHC/peptide combination and in fact may be able to bind a variety of 
MHC/peptide combinations with different levels of affinity. The interaction 
between TCR and MHC-peptide shows degeneracy for both MHC class I-CD8 
and MHC class II-CD4 interactions and a single TCR is able to recognize 
structurally distinct MHC-peptide complexes.[Goldrath and Bevan 1999;Mason 
1998;Tallquist et al. 1996]
Although previously thought that rare microbial antigens with peptide sequences 
closely related to self-peptides could represent mimics (and thus be responsible 
for the induction of autoimmune diseases), it has now been shown that TCRs 
can share affinity for structurally diverse antigenic molecules.[Wucherpfennig 
2004] There are many animal data supporting a link between CMV infection and 
GvHD. Murine models have suggested that early virus-induced immune 
responses may promote the development of severe graft-versus-host 
responses, including the enhancement of donor antihost specific cytotoxic T 
cells.[Cray and Levy 1990] [Jones et al. 1996] The mechanism of exacerbation 
of murine GvHD caused by the induction of CMV disease remains to be 
elucidated and may not be limited to shared T cell affinity for CMV and 
alloantigens. The effect of CMV infection on worsening acute GvHD in mice was 
abrogated by depletion of host CD4+ cells (but not CD8+ cells) supporting the 
hypothesis that CMV-activated CD4+ T cells enhance the production of a donor 
anti-host MHC Class I CD8+ response.[Cray and Levy 1993]
An association between CMV infection and GvHD in humans was first 
suggested by a case series published in 1984 describing 68 consecutive 
allogeneic bone marrow transplant patients.[Lonnqvist et al. 1984] Chronic 
GVHD was significantly more common among patients who had previously 
experienced CMV infection with a median time of onset of 128 days prior to 
GvHD Other series later confirmed this finding.[Jacobsen et al. 1986;Ringden et 
al. 1985] Much evidence has been published demonstrating an association 
between CMV infection and acute GvHD, although in this setting clinically 
apparent CMV infection typically occurs 2-4 weeks after the onset of acute
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GvHD (and may be more closely related to immunosuppressive therapy used to 
control it).[Miller etal. 1986]
Recipients of non-T depleted marrow transplants for (both myeloid and 
lymphoid) acute leukaemia who developed CMV infection were at a significantly 
lower risk of leukaemic relapse (independent of the occurrence of either acute 
or chronic GvHD) indicating that donor T cells may share affinity for CMV 
antigens and leukaemia restricted or leukaemia-specific antigens.[Jacobsen et 
al. 1987;Jacobsen et al. 1990;Lonnqvist et al. 1986] In a series of 103 
consecutive patients who had leukaemia and who received non T-depleted 
bone marrow transplants from HLA-matched sibling donors, donor CMV 
seropositivity was shown to significantly improve overall survival due to lower 
relapse incidence in HLA-A*0201+ (but not HLA-A*0201') recipients. Donor 
CMV seropositivity was associated with chronic GvHD but, even in patients 
without chronic GvHD, donor CMV seropositivity significantly improved 
survival.[Nachbaur et al. 2001], supporting a hypothesis of HLA A*0201- 
restricted donor T cells with shared affinity for CMV antigens and mHags over­
expressed on leukaemia cells.
Recently large meta-analyses have been published from data derived from 
international registries and somewhat conflicting results have been reported. 
One series reporting over 6000 unrelated donor transplants found no effect of 
donor CMV seropositivity on acute or chronic GvHD, relapse or overall 
mortality,[Kollman et al. 2001] whereas another similar sized series found that 
donor CMV seropositivity decreased overall mortality (but did not independently 
affect rates of GvHD or relapse) in unrelated (but not sibling) 
transplants.[Ljungman et al. 2003b] It must be stressed that these series report 
the effects only of CMV donor serostatus (and not of subsequent CMV disease), 
and derive data from recent periods where molecular monitoring and pre­
emptive treatment have reduced the incidence of CMV disease considerably. 
Indeed reduced risk for extensive chronic graft-versus-host disease in patients 
receiving transplants with human leukocyte antigen-identical sibling donors 
given pre-emptive anti-CMV therapy (based on CMV DNA PCR monitoring) 
been reported.[Larsson etal. 2004]
The development of HLA Class I restricted CMV-peptide tetramers has allowed 
the measurement of CD8+ cellular CMV-specific immune responses to CMV 
after allogeneic transplantation.[Aubert et al 2001] However staining with CMV-
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peptide tetramers in this setting does not identify whether the CD8+ T cells 
originate from the donor or from recipient cells, and does not distinguish the 
individual T cell clones that comprise the tetramer positive population. The 
reconstitution of CMV-specific CD8+ T cells at the level of individual clones 
following AHSCT using clonotypic probing has been described.[Gandhi et al. 
2003] Following CMV IgG Donor+/Recipienf AHSCT, donor CMV-specific 
clones were not detectable in two of three CMV seronegative recipients 
whereas in a third (CMV IgG Donor+) CMV IgG' HLA-A*0201+ recipient and who 
experienced severe acute GvHD, a donor CMV-specific CD8+ T cell clone was 
repeatedly detectable after transplantation. A possible explanation for the 
persistence of this donor CMV-specific CD8+ T cell clone in the recipient is that 
its TCR may have been cross-reactive with another antigen in the recipient. In 
HLA-A*0201+ recipients, donor-derived CMV-specific T cells may cross-react 
with HLA-A*0201-restricted recipient minor histocompatability 
antigens,[Nachbaur, Bonatti, Oberaigner, Eibi, Kropshofer, Gastl, Nussbaumer, 
Einsele, and Larcher 2001] raising the possibility donor CMV clones might be 
alloreactive and directly participate in the GvHD. Cwynarski et al.reported that 
CMV-peptide tetramer-positive CD8+ T cells were detectable in only one of 
seven recipients following CMV IgG Donor+/Recipient' AHSCT, and that this 
recipient was the only one of the seven to experience acute GvHD.[Cwynarski 
etal. 2001]
Local tissue infection with CMV virus has been reported in acute intestinal 
GvHD (and in this setting antiviral treatment may lead to resolution of the 
histopathological changes of GvHD),[Einsele et al. 1994] but is not a universal 
finding.[Appleton et al. 1995]
T cell clones were generated from skin-infiltrating T lymphocytes in recipients of 
unrelated donor marrow (matched for HLA-A, -B, -DR, and -DQ but mismatched 
for -DP) with acute GVHD. Analysis of the clones showed that the majority of 
them lacked HLA specificity, including mismatched HLA-DP. However, mAb to 
HLA antigens blocked proliferation of the majority of the clones, indicating that 
the clones recognized HLA-associated molecules. A few of the clones revealed 
augmented proliferation in the presence of CMV antigens and a few revealed 
cytolytic activity, supporting the hypothesis that human CMV antigens stimulate 
skin-infiltrating T lymphocytes present in acute GvHD.[Nikaein et al. 1994]
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In donor-recipient pairs where donor T cells share affinity for CMV antigens and 
alloantigens, the selective removal of alloreactive cells might be expected to 
lead to a reduction in the frequency of cellular responses to CMV.
Following in vitro HLA-mismatched selective allodepletion of 4 HLA A*0201 + 
individuals (mediated by anti-CD25 immunotoxin,) no reduction in frequency of 
HLA A*0201-NLV-Tetramer+ cells was demonstrated, although 3 of 5 similar 
pairs tested showed a reduction in frequency (of 10-30%) of functional CMV- 
specific IFN^y ELISpot-reactive CTLs.[Amrolia et al 2003a]
In mismatched MLRs the majority of CMV pp65 IFN-y ELISPOT reactive cells 
are found within the responder CD69 du" (not the CD69‘) fraction of responder 
cells, suggesting that some CMV-specific responder cells become weakly 
activated by alloantigens in the MLR and could be removed by CD69-mediated 
depletion.[Nonn et al. 2003b] In a short series published in abstract form only, 
CMV IFN-y ELISpot reactive cells were retained in some but not all cases 
following HLA-matched selective allodepletion utilising the cytokine modified 
MLR and immunomagnetic depletion of cells expressing CD25, CD69 and HLA 
DR.[Schumm e ta l2003]
Results for selective allodepletion of HLA-mismatched and HLA-matched 
responders based on the expression of CD69 alone are presented in Chapter 4 
of this thesis. Use of this strategy led to the retention of the majority, but not all 
of CMV CTLs in both the HLA-mismatched and HLA-matched setting. In fully 
HLA-mismatched pairs 88% of HLA A*0201-NLV peptide tetramer+ cells were 
retained and 114% of functional cells by CMV-peptide-stimulated IFN-y ELISpot. 
In matched pairs utilising the cytokine pre-treatment strategy of allostimulation 
98% of HLA A*0201-NLV peptide tetramer+ cells were retained and 89% of 
functional CMV-specific cells by peptide-stimulated IFN-y ELISpot were 
retained.
However in HLA-matched pairs utilising OKT3 pre-treated stimulators only 77% 
of HLA A*0201-NLV peptide tetramer+ cells and 72% of functional cells by 
CMV-peptide-stimulated IFN-y ELISpot were retained following allodepletion. As 
the removal of only alloreactive cells (in the absence of cross-reactivity) would 
lead to relative concentration of CMV-specific CTLs in the allodepleted fraction, 
this loss of cellular CMV activity is perhaps under-estimated. The loss of 
functional CMV-specific cells is more marked than the loss of CMV tetramer+
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cells following HLA-matched allostimulation and selective allodepletion, and is 
in keeping with the data described by Amrolia et al following CD25 mediated 
allodepletion.[Amrolia et al 2003a] The greater degree of loss of functional 
CMV-specific cells in the HLA-matched setting suggests that there is greater 
cross-reactivity of alloreactive CTLs directed against mHags and CMV-specific 
antigens. Better preservation (albeit with greater variability) of third party activity 
post selective allodepletion was seen in HLA-matched pairs utilising OKT3 or 
cytokine pre-treated allostimulation (mean 94% and 101% respectively) than in 
HLA-mismatched allodepletion (mean 69%) which does not support the 
hypothesis that the loss of functional CMV-CTLs after HLA-matched selective 
allodepletion is a result of lower specificity of the allodepletion process.
The potential consequences of significant cross-reactivity between allogeneic 
antigens and CMV antigens would not be limited to the partial loss of CMV 
reactive CTLs after selective allodepletion. Considerable efforts have been 
made in recent years to raise CMV-specific donor CTLs for infusion post- 
AHSCT to aid recipient CMV recovery.[SiIi et al. 2003;Walter et al. 1995] Two 
studies have shown that repeated rounds of ex vivo stimulation with CMV 
antigen (or peptide) may reduce alloreactivity as demonstrated by in vitro 
proliferation assays.[Einsele et al. 2002;Rauser et al. 2003] However the post­
transplant infusion of small doses of donor derived CMV-specific CTLs (which 
underwent considerable in vivo expansion) caused Grade I skin GvHD in 3 of 
16 recipients.[Peggs et al. 2003c] The use of larger cell doses or repeated 
administration may increase the risk of severe GvHD. Indeed in work recently 
presented in abstract form up to 10% of donor-derived CMV-specific CD4+ cell 
clones intended for post-transplant infusion to aid recipient CMV immunity 
demonstrated significant proliferation in response to alloantigens.[Velardi 2003] 
Various methods have been recently used to isolate CMV-specific T cells in 
immune individuals, including secretion of IFN-y following simultaneous 
stimulation with CMV-specific MHC Class l-restricted peptides and CMV 
antigen,[Rauser et al 2003] and purification of CMV-specific CD8+ T cells from 
peripheral blood using HLA-peptide tetramers.[Keenan et al. 2001] CMV 
antigen has been shown to stimulate CD69 expression on responding T cells in 
CMV lgG+ healthy individuals.[Dunn et al. 2002] CD69 upregulation has also 
been used to identify Coxsackie virus B4-specific CTLs after incubation with 
infected cell lysate and TCR vp sub-family distribution of CD69+ responder cells
209
were assessed by flow cytometry with antibodies to multiple TCR Vp sub-family 
epitopes.[Varela-Calvino et al. 2001] Results presented in Chapter 4 of this 
thesis demonstrated restricted TCR Vp sub-family distribution of alloreactive 
responder cells based on their expression of CD69. Expression of CD69 on 
CMV-specific CTLs after CMV-peptide stimulation might allow their identification 
and flow cytometric assessment of their TCR Vp sub-family distribution, and any 
homology within individuals between CMV-specific and allospecific T cell TCR 
Vp sub-family distribution might support the hypothesis of the existence of T 
cells within individuals with TCRs with shared affinity for CMV antigens and 
alloantigens.
6.2 Aims of the Experiments Described in this Chapter
1. To assess if CMV-specific CTLs could be identified by CD69 expression 
after NLV peptide stimulation in HLA A*0201+CMV lgG+ individuals;
2. To determine whether the frequencies of NLV peptide-stimulated CD69+ 
CTLs correlated with the frequency of HLA A*0201-NLV-Tetramer+ cells 
and/or to alternative functional assays of CMV CTL frequency (including 
IFN-y ELISpot and intracellular IFN-y generation);
2. To investigate whether NLV peptide-stimulated CD69+ CTLs 
demonstrated any evidence of selective TCR Vp sub-family usage within 
and/or between HLA A*0201+CMV lgG+ individuals;
3. To examine any potential homology of TCR Vp sub-family usage 
between NLV peptide-stimulated CTLs and HLA-matched allostimulated 
CTLs within HLA A*0201+ individuals that might support the hypothesis 
that cross-reactivity of antigen-specificity exists in such CTLs.
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6.3 Materials and Methods
16 healthy volunteers who had past exposure to CMV were identified by the 
presence of CMV IgG by serological testing (either at the Department of 
Virology, Royal Free Hospital, London, or at registered transplant donor 
centres). Allelic typing of HLA Class I and Class II was performed on all 
individuals at the Anthony Nolan Research Institute.
Up to 106 PBMCs were suspended at a concentration of 106/ml in complete 
medium (with AB serum) in sterile plastic 12 x 75mm polystyrene tubes (Nunc) 
or polypropylene tubes (Kendall-Elkay) and stimulated with the HLA A*0201- 
restricted CMV pp65 derived nonamer NLVPMVATV (NLV) (Proimmune) or a 
CMV dummy peptide (restricted to an HLA Class I molecule not possessed by 
the individual). The optimal concentration of cells, amount of peptide and 
duration of stimulation was ascertained. CD69 expression on CD3+, CD3+CD4+ 
and CD3+CD8+ cells was assessed by flow cytometry. A variety of CD69 
antibodies was tested and assessed for sensitivity and specificity of CD3+CD8+ 
responses to NLV peptide.
All antibodies used were from BD and the staining protocol, event acquisition 
and analysis was as described in Chapter 2.2.1-2. The antibody panel used for 
flow cytometric assessment of basic cell phenotype before and after CMV- 
peptide stimulation/allostimulation is shown below:
Fluorochrome FITC PE PerCP APC
Antibody CD3 CD4 CD8 CD69
Table 6.1 Antibody panel used for assessing CD69 expression on cell 
subsets after stimulation with NLV peptide.
The frequency of HLA A*0201-NLV peptide-specific CTLs was assessed by 
tetramer analysis on baseline cells (Chapter 2.2.3) and the frequency of 
functional HLA A*0201-NLV peptide-specific CTLs was assessed by IFN-y 
ELISpot assay (Chapter 2.6). Intracellular generation of IFN-y was measured 
using the Miltenyi APC-conjugated flow cytometric IFN-y cytokine secretion 
assay detection kit (Chapter 2.7).
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TCR Vp sub-family distribution was assessed by flow cytometry using the 
lOTest BetaMark TCR Vp Repertoire kit (Beckman Coulter, Chapter 5.3).
PBMCs from 6 HLA A*0201+CMV lgG+ individuals were pulsed with NLV 
peptide for 12 hours and the frequencies of TCR Vp sub-families determined in 
CD8+CD69+ responders and CD8+CD69* non-responders were measured. TCR 
vp sub-family frequencies were also assessed on fresh baseline cells. 
Cytokine-modified and OKT3 pre-treated MLRs were set up with irradiated HLA 
fully- or partially-matched recipient PBMCs as stimulators, and live donor 
PBMCs as responders from 4 of the 6 individuals (Table 6.2). At 72 hours TCR 
Vp sub-family distribution was measured in both CD8+CD69+ and CD8+CD69' 
live responder cells.
Although criteria for defining size class peaks within TCR Vp sub-families are 
well described after spectratyping based on measurement of CDR3 length by 
DNA PCR,[Peggs, Verfuerth, D'Sa, Yong, and Mackinnon 2003b] there is no 
published consensus on how overused or over-represented TCR Vp sub­
families measured by antibody/flow cytometric methods should be defined. A 
frequency above or below 3 standard deviations from the mean has been used 
to define over- and under-represented sub-families for resting values in 
individuals with immune defects.[Pierdominici et al. 2003] However, any 
definition of TCR Vp overuse in cells responding to antigenic stimulation should 
take into account both relative change and absolute value of TCR vp frequency. 
Thus for the purposes of this analysis significantly over-expressed TCR Vp sub­
families in responder cells were defined as those with pre-stimulation 
frequencies within the normal range and post-stimulation frequencies which had 
increased relative to the pre-stimulation value by >/= 100% and to a level above 
the normal range (calculated from mean normal control values + (1.96 x 
standard deviation)). A diagram of the experimental schema is shown in Figure 
6.1.
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Pair Responder 
HLA Type
Stimulator 
HLA type
CMV
Peptide
CMV
Dummy
Peptide
1 A*0201
Class II not typed
n/a NLV None
2
A*0201;B*1501,3901; 
C*0303,1203; 
DRB1*0401,1101
n/a NLV TPR
3
A*0201,03001 ;B*39,27; 
C*01,02;
DRB1*0301,0301
A B C  DR 
matched NLV TPR
4
A*0201,*0101; B*08,*18; 
C*03,*07;
DRB1* 0301
C locus 
mismatch NLV TPR
5
A*0201 ,*24;B*0702,*1401; 
C*07,*08;
DRB1*0401 ,*0701
A, B, C, DR 
matched NLV DAN
6
A*0201,*31; B*44,*35;
C*05,*12;
DRB1*1501,*1401
A and C
locus
mismatch
NLV DAN
NLV= NLVPMVATV TPR= TPRVTGGGAM DAN= DANDIYRIF
Table 6.2 HLA typing and CMV peptides used to assess TCR Vp sub-family 
distribution after CMV peptide stimulation and HLA A, B, C and DR partially/fully 
matched allostimulation. n/a=not applicable.
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Figure 6.1 Schema for the experiments described in this chapter
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6.4 Results
6.4.1 Optimisation of CMV peptide Stimulation Technique
CMV-specific CTLs were identified by the expression of CD69 after stimulation 
with NLV peptide.
Only CD69 antibodies conjugated to APC and PerCP were investigated, 
suitable for subsequent use in conjunction with the dual fluorochrome (PE/FITC) 
TCR Vp antibody kit. APC-conjugated BD murine anti-CD69 antibody 
demonstrated the highest signal to noise ratio of those tested in preliminary 
experiments and was selected for use in further work (data not shown).
The dose of NLVPMVATV peptide required for optimal CD69 responses varied 
between individual HLA A*0201+ CMV lgG+ subjects. In 6 different peptide 
dose-titrations in 4 different healthy HLA A*0201+ CMV lgG+ individuals, the 
greatest mean CD3+CD8+CD69 response (1.5%+/-0.4%) was seen at a NLV 
peptide dose of 5pg/106 PBMCs with 12 hours stimulation. The CD69 response 
to NLV peptide stimulation was CD3+CD8+-specific with a CD3+CD4+ CD69 
response of only 0.2%+/-0.1 % (Figure 6.2).
A stimulatory peptide dose of 5pg/ 106 PBMCs was used for all subsequent 
experiments.
As CTL IFN-y responses to peptide stimuli are well known to occur within 4-6 
hours the CD69 response was assessed at 4 and 12 hours. No upregulation of 
expression of CD69 was seen after 4 hours of stimulation (data not shown) 
whereas CD69 expression was reliably seen by seen by 12 hours.
No additional benefit was seen when PBMCs were stimulated with peptide at a 
cell concentration of 5x106/ml when compared to stimulation at 106/ml.
For the sake of uniformity the latter concentration was used.
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Figure 6.2 CD69 response to NLV peptide stimulation in HLA A*0201+ CMV 
lgG+ individuals: effect of peptide dose (results of 6 different peptide dose- 
titrations in 4 different healthy HLA A*0201+ CMV+ individuals). Error bars 
represent standard deviation.
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6.4.2 CD69 Responses Specific to CMV peptide Stimulation
CD69 response specific to NLV peptide stimulation was defined as the 
percentage of cells positive for CD69 after NLV peptide stimulation - percentage 
of cells positive for CD69 after stimulation with dummy CMV peptide (i.e. CMV 
peptide restricted to an HLA Class I molecule not possessed by the cells being 
tested).
In the study of 16 HLA A*0201+ CMV lgG+ individuals the CD69 response 
specific to NLV peptide stimulation was 0.8% (+/-0.9%) of CD3+ cells, 0.9%(+/- 
0.7%) of CD3+CD8+cells and 0.3% (+/-0.4%) of CD3+CD4+cells.
Thus the response to NLV peptide stimulation was relatively specific to 
CD3+CD8+cells as was expected using a direct peptide stimulation protocol.
4 of the 16 HLA A*0201+ individuals tested were also B*0702+. Three of these 
individuals demonstrated CD3+CD8+ CD69 responses specific to NLV peptide 
stimulation below and one above the median response (not significant in a sign 
rank test). One of these individuals had a much larger CD3+CD8+ CD69 
response specific to the HLA B*0702-restricted CMV-peptide TPR than to NLV 
(5.3% and 0.79% respectively). This pattern of immunodominant response is 
well reported but not universal in HLA*0201+B*0702+ individuals.[Lacey et al. 
2003]
6.4.3 NLV-HLA A*0201 tetramer+ Cell Frequencies
In the same 16 HLA A*0201+ CMV lgG+ individuals the baseline frequency of 
NLV-HLA A*0201-tetramer+ cells was 1.39% (+/-1.06%) of CD3+CD8+ cells. In 
one individual the NLV-HLA A*0201 tetramer frequency was enriched by culture 
with autologous monocyte-derived dendritic cells and whole CMV antigen using 
the protocol described by Peggs et al.[Peggs, Verfuerth, Pizzey, Ainsworth, 
Moss, and Mackinnon 2002] The frequency of NLV-HLA A*0201 tetramer+ cells 
was increased from 1.30% to 5.92% of CD3+CD8+ cells after culture and the 
number of cells expressing CD69 in response to NLV peptide was 
correspondingly increased from 0.9% to 3.81% of CD3+CD8+ cells. In all 
individuals tested the CD69 response in CD3+CD8+ cells was lower than the 
frequency of baseline NLV-HLA A*0201 tetramer+ CTLs (Figure 6.4). The mean
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frequency of CD69+ CTLs after NLV peptide stimulation was 65% +/- 23% of the 
frequency of NLV tetramer+ cells (p=0.0002 in a two-tailed paired Student’s t- 
test). The frequency of CD69+ CD3+CD8+ cells following peptide stimulation was 
well correlated with the baseline frequency of NLV-HLA A*0201 tetramer+ cells 
in these individuals. The effect of peptide stimulation on tetramer frequency 
could not be measured as the addition of exogenous stimulatory peptide 
prevented the subsequent binding of tetramers to CTLs (data not shown).
In the four HLA*0201+B*0702+ individuals NLV-HLA A*0201 tetramer+ cell 
frequencies were ranked 4th, 8th, 11th and 16th of 16 individuals assessed.
CD69 responses were closely correlated with baseline NLV-HLA A*0201 
tetramer frequency although in 15 of 16 individuals tested the baseline NLV- 
HLA A*0201 tetramer frequency was greater than the frequency of CD3+CD8+ 
CD69+ cells after peptide stimulation (Figures 6.3 and 6.4(A)).
6.4.4 CMV peptide-stimulated IFN^y ELI Spot-Reactive Cell Frequencies
The frequency of CMV-specific CD3+CD8+ cells in NLV peptide-stimulated IFN-y 
ELISpot assay (assessed in 10 of the 16 individuals) was 0.30%+/-0.12%.
The mean frequency of IFN-y ELISpot reactive CTLs after NLV peptide 
stimulation was 31% +/- 22% of the frequency of NLV tetramer+ cells and 
48%+/-13% of the frequency of CD69+ CTLs after NLV peptide stimulation 
(p=0.002 and p=0.02 respectively in a paired two-tailed Student’s t test)
In the 3 HLA*0201+B*0702+ individuals tested NLV- peptide-stimulated IFN-y 
ELISpot positive cell frequencies were ranked 5th, 7th, and 10th of the 10 
individuals assessed. CD3+CD8+ CD69 responses following NLV peptide 
stimulation were closely correlated to the frequency of CMV-specific CD3+CD8+ 
cells in the NLV peptide-stimulated IFN-y ELISpot assay although in 8 of 10 
individuals tested the CD69 response was greater than the ELISpot reactive cell 
frequency (Figures 6.3 and 6.4(B)).
6.4.5 CMV peptide-stimulated Intracellular IFN-y Generation
In four individuals intracellular IFN^y generation was determined after NLV 
peptide stimulation under the same conditions. Intracellular IFN-y generation
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was seen in 0.91%+/-0.69% of CD3+CD8+ cells. In all individuals the 
frequencies of NLV peptide-stimulated CD3+CD8+ IFN-^ y generating cells were 
55.9%+/-21% of the frequency of CD3+CD8+NLV-HLA A*0201 tetramer+cells 
(p=0.07 in a two-tailed paired Student’s t test), 86%+/- 26% of the frequency of 
NLV peptide-stimulated CD3+CD8+CD69+ cells (not significant) and 122% +/- 
78% of the frequency of CD3+CD8+ NLV-HLA A*0201 IFN-y ELISpot positive 
cells (not significant).
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6.4.6 TCR Vp Sub-family Distribution in CMV Peptide Responder Cells
The TCR Vp sub-family distribution of CD8+ cells was determined on 12 healthy 
subjects and normal ranges generated (as mean +/- 1.96 x (standard 
deviation)).The mean frequencies of individual TCR Vp sub-families determined 
by direct staining of PBMCs (as opposed to whole blood) and without additional 
CD3 antibody staining were closely correlated with the normal ranges supplied 
by the manufacturers. PBMC stained CD8+ TCR Vp sub-family frequencies 
were closely correlated to the manufacturer’s normal values (Pearson co­
efficient of correlation of 0.93, p<0.0001, and linear regression graph slope of 
1.18 +/-0.08 indicating that the PBMC method gave a generally slightly higher 
value for TCR Vp sub-family frequencies than the whole blood staining method). 
TCR Vp sub-family frequencies in CD4+ cells were also derived from the non- 
CD8+ cell fraction after direct staining of PBMCs. TCR Vp sub-family 
frequencies for CD4+ cells derived thus were also closely correlated to the 
manufacturer’s normal values for CD3+CD4+ cells (Pearson co-efficient of 
correlation of 0.97, p<0.001), with a linear regression slope of 0.63+/-0.03 
indicating that the PBMC non-CD8+ method gave a generally lower value for 
frequencies of TCR Vp sub-families than the whole blood CD3+CD4+ method. 
This was expected as the non-CD8+ cell fraction also contains B cells and CD8~ 
and CD8weak NK cells in addition to CD4+ cells. This finding emphasises the 
importance of establishing and using the normal ranges for the specific method 
and antibodies used.
TCR Vp sub-family distribution was assessed in 6 HLA A*0201+CMV lgG+ 
individuals in baseline (unmanipulated) cells and in CD8+CD69+ cells and 
CD8+CD69'cells following stimulation with NLV peptide.
Following NLV peptide stimulation the TCR Vp sub-family distribution in CD8+ 
CD69' non-responders closely resembled that of baseline unmanipulated CD8+ 
cells in all individuals. In contrast, the TCR Vp sub-family distribution in 
CD8+CD69+ responders demonstrated significant skewing with an increase in 
the frequency of some TCR Vp sub-families and a decrease in others within 
each individual. The mean percentage modular perturbation (either increase or 
decrease) from the baseline value for TCR Vp sub-family frequency in CD8+ 
cells was 69% +/- 27% for CD69+ responders and only 17% +/- 4% for CD69'
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cells (p=0.005 In an unpaired two-tailed Student’s t-test, with Welch’s 
correction).
The values for TCR Vp sub-family frequencies in non-CD8+CD69' cells closely 
resembled that of baseline unmanipulated non-CD8+ cells in all individuals. The 
mean modular perturbation from the baseline value for TCR Vp sub-family 
frequency in non-CD8+ cells was not significantly greater in CD69+ cells (26% 
+/- 6.4%) than for CD69' cells (15% +/- 3.2%) in an unpaired two-tailed Student 
t test, with Welch’s correction.
Although all 6 individuals tested demonstrated marked increases in some TCR 
Vp sub-family frequencies in CD8+CD69+cells above baseline values, overused 
TCR Vp sub-families (as defined above) after NLV peptide stimulation were 
identified in only 4 of the 6 individuals tested (Figure 6.5). The median number 
of overused TCR Vp sub-families in these individuals was 3. Only one individual 
tested had one selectively overused individual TCR Vp sub-family in non-CD8+ 
CD69+ cells whereas all other individuals had no individual selectively overused 
TCR Vp sub-families in non-CD8+ CD69+ cells.
In the 4 individuals who demonstrated individual overuse of TCR Vp sub­
families in CD8+ CD69+ cells after NLV peptide stimulation, one overused TCR 
Vp 13.6, (individual 2), one overused TCR Vp 5.2 (individual 4) one TCR Vps 
4.0, 7.1, 11.0 and 13.6 (Individual 5) and one TCR Vps 2.0, 11.0 and 23.0 
(individual 6). These data are shown in Figure 6.7, along with published data 
from three related studies for comparison.
TCR Vp sub-family distribution in CD8+ cells was also assessed in individual 2 
following NLV peptide stimulation of cells which had been subjected to 3 rounds 
of stimulation with whole CMV antigen over 21 days with autologous monocyte- 
derived dendritic cell enrichment. TCR Vp sub-family 13.6 was overused (in 
common with that seen after NLV peptide stimulation of fresh PBMCs in this 
individual) and also TCR Vp 18.0 (which was not overused in fresh PBMCs from 
this individual stimulated with NLV, Figure 6.7).
Of the two other individuals tested one did show some evidence of selective 
TCR Vp overuse with increases of >/= 100% above baseline in CD8+CD69+cells 
(in TCR Vp sub-families 4.0 and 18, and 7.2 respectively) following PBMC 
stimulation with NLV peptide but the absolute values did not increase to levels 
above the normal range.
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Figure 6.5 (See over for figure legend).
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Figure 6.5 (Previous page). Changes in TCR Vp sub-family distribution in 
CD8+ cells in 6 HLA A*0201+ CMV lgG+ individuals after stimulation with NLV 
peptide. Large increases in the frequency of some TCR Vp sub-families with 
decreases in others were seen in CD8+CD69+ cells in all individuals, whereas 
TCR Vp sub-family frequencies remained relatively unchanged in CD8+CD69' 
cells. TCR vp sub-families that increased after NLV peptide stimulation in 
CD8+CD69+ cells by >/=100% on baseline values and to a level above the 
normal range are marked *.
Figure 6.6 (Following page). Frequency of over-represented TCR Vp sub­
families in CD8+CD69+ cells following NLV peptide stimulation in 6 HLA A*0201+ 
CMV lgG+ individuals and comparisons with published data. (Note that no 
assessment of TCR Vp sub-families 6 or 15 was possible, as the IO Betamark 
kit does not contain antibodies to these sub-families.) Over-represented TCR 
Vp sub-families were defined as those that increased in frequency by >/= 100% 
after NLV peptide stimulation and to values above the normal range.
Peggs et al stimulated HLA A*0201+ CMV lgG+ individuals with whole CMV 
antigen utilising monocyte-derived dendritic cells as APCells. Cells were then 
sorted by flow cytometry based on HLA A*0201-NLV tetramer positivity. CDR3 
length was assessed by PCR using primers for common TCR Vp sub-families: 
the Vp sub-families containing significant expanded size class peaks are 
shown. Wills et al examined TCR Vp sub-family distribution (utilising flow 
cytometry with a panel of TCR Vp monoclonal antibodies) of NLV peptide 
responding CD8+ cells in 4 HLA A0201+ CMV lgG+ donors. Hamel utilised the 
same strategy as Peggs (other than using a recombinant adenovirus expressing 
pp65 for antigen presentation).
225
11 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 20 21 22 23 24
TCR V Beta Sub-family
□  CD8+CD69+ NLV peptide stimulated cells 
Peggs et al 2001
■ i  Wills et al 1996
□ □  Hamel et al 2003
Figure 6.6 (See above for figure legend)
A
200-
100-
□  CD8+CD69'
□  CD8+CD69+
U - T I
i f l0)c
I? -100-n
c  
o
<D O)
g 2001
T - M  (O  T t r -
lf>
B
O
100-
n n ■ctr J in ,  □ cnu -<nr 1. J - i .n J=LU TT
-100- ( NM^ r CMMr « N| 0 0 ( J )in in in s  s
N r N ( O t » S C O O n ( M «  
t-  t-  t-  cm
TCR V Beta Subfamily
Figure 6.7 Changes in TCR Vp sub-family distribution in CD8+ cells in an 
HLA A*0201+ CMV lgG+ individual after;
(A), stimulation with NLV peptide alone for 12 hours under standard 
conditions
(B). 3 rounds of stimulation with whole CMV antigen over 21 days (with 
autologous monocyte-derived dendritic cell enrichment).
TCR Vp sub-families that increased after stimulation in CD8+CD69+ cells by 
>/=100% on baseline values, and to a level above the normal range are
marked *.
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6.4.7 Comparison of TCR Vp Sub-family Distribution within Individuals 
after HLA-Matched Allostimulation and after CMV Peptide Stimulation
PBMCs from 4 HLA A*0201+ CMV lgG+ individuals (Individuals 3,4,5 and 6) 
were allostimulated with irradiated fully or partially HLA-matched PBMCs 
utilising both the OKT3 and the cytokine strategies for potentiating 
allostimulation. TCR Vp sub-family distribution in CD8+CD69+ and CD8+CD69‘ 
responder cells was measured after allostimulation for 72 hours. After 
allostimulation following OKT3 pre-treatment of stimulator cells the mean 
percentage modular petubation from the baseline value for TCR Vp sub-family 
frequency in CD8+ cells was greater for CD8+CD69+ responders than 
CD8+CD69' cells (82.9% +/- 46.6% vs. 27.4% +/- 8.1%) although this difference 
failed to reach statistical significance in an unpaired two-tailed Student’s t-test, 
(with Welch’s correction). Over-represented TCR Vp sub-families in CD8+ 
CD69+ cells after OKT3 pre-treated allostimulation were identified in all 4 of the 
individuals tested. The median number of over-represented TCR v p  sub­
families in these individuals was 2 (range 1-10).
Following allostimulation with cytokine pre-treated stimulators for 72 hours the 
mean percentage modular perturbation from the baseline value for TCR Vp sub­
family frequency in CD8+ cells was significantly greater in CD8+CD69+ 
responders (79.8% +/- 9.0%) than in CD8+CD69" cells (38.3% +/-17.0%) 
(p=0.02 in an unpaired two-tailed Student’s t-test). Over-represented TCR Vp 
sub-families in CD8+CD69+ cells after cytokine-modified MLR allostimulation 
were identified in all 4 individuals tested. The median number of over­
represented TCR Vp sub-families in these individuals was 2 (range 1-4). TCR 
Vp sub-family overuse in CD8+CD69+ cells following HLA-matched 
allostimulation using OKT3 or cytokine techniques is summarised in Table 6.3. 
Evidence of shared preferential usage of TCR v p  sub-families after 
allostimulation and after CMV-peptide stimulation was seen, with 3 of 4 pairs 
tested demonstrating over-representation of a common TCR v p  sub-family after 
OKT3 pre-treated allostimulation and NLV peptide stimulation, whereas 1 of 3 
pairs tested demonstrated over-representation of a common TCR Vp sub-family 
after cytokine pre-treated allostimulation and NLV peptide stimulation.
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Pair HLA
Matching
Allostimulation
technique
Over-represented TCR Vp 
sub-families in CD8+CD69+ 
cells
3
A B and DR 
fully matched
OKT3 1, 13.2,21.3
Cytokine 16
4
A, B and DR 
fully matched
OKT3 1,2,4, 5.2, 5.3, 7.1 
13.2, 13.6, 18, 22
Cytokine nd
5
A, B and DR 
matched
OKT3 4
Cytokine 4, 5.1, 13.6,22
6
Single A locus 
mismatch
OKT3 11
Cytokine 9,21.3
Table 6.3 Over-represented TCR Vp sub-families in HLA fully or partially 
matched CD8+CD69+ alloresponder cells. TCR vp sub-families also over­
represented in CD8+CD69+ cells following NLV peptide stimulation are marked 
in red. nd= not done
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6.5 Chapter Discussion
These results demonstrate that CD69 can be used to identify HLA A*0201 + 
CD8+ T cells activated specifically by the addition of the HLA A*0201 -restricted 
CMV peptide NLV. These responding CD8+ cells were likely have been 
activated via their TCRs by the presentation of NLV peptide in the context of 
HLA A*0201, although proof that this was the case would be provided by 
demonstration that activation of CD8+ cells could be blocked by the addition of 
anti-HLA Class I antibody. However the CD69+ responses were restricted to 
CD8+ cells and the frequency of CD8+CD69+ cells following NLV peptide 
stimulation was well correlated with the frequency of NLV-HLA A*0201 
tetramer+cells.
The frequency of NLV-stimulated CD8+CD69+ cells was significantly lower than 
the frequency of NLV-HLA A*0201 tetramer+ cells indicating that only a 
proportion of NLV-HLA A*0201 tetramer+ cells would be identified by CD69 
expression following single round of NLV peptide stimulation. However the 
frequency of NLV peptide-stimulated CD8+CD69+ cells was greater than the 
frequency of CD8+IFN-y ELI Spot-reactive cells, suggesting that following NLV 
peptide stimulation CD69 expression is likely to identify functional (antigen- 
responding) CTLs, including (but not limited to) IFN-y secreting cells. NLV 
peptide-stimulated CD69+ cells may include perforin-secreting cells.
One round of NLV peptide stimulation resulted in upregulation of CD69 on a 
relatively small percentage of CD8+ responder cells and repeated rounds of 
peptide stimulation would be needed to enable the selection of significant 
numbers of CMV-specific CTLs based on their expression of CD69. Moreover, 
the generation of CD4+ CMV-specific cells, necessary to provide Th1/2 activity 
needed to sustain antiviral activity in vivo, would require the use of whole CMV 
antigen and professional APCells.
Selective TCR Vp sub-family usage in CTLs in HLA A*0201+ individuals has 
been described after repeated CMV NLV peptide stimulation over 10-15 days 
with IL-2 supplementation, measured by flow cytometry utilising panels of 
antibodies directed against different TCR Vp sub-families. [Weekes et al. 
1999;Wills et al. 1996b] Selective expansions of TCR Vp sub-families have 
latterly been demonstrated by TCR Vp spectratyping by CDR3 gene fragment
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PCR in NLV-HLA A*0201 tetramer+ CTLs, after repeated administration of 
whole CMV antigen in dendritic cell enriched cultures or by recombinant 
adenovirus expressing human CMV pp65.[Hamel et al. 2003;Peggs, Verfuerth, 
et al 2003c]
There are no published data comparing the TCR Vp sub-family usage in CMV 
reactive CTLs and alloreactive CTLs within individuals.
Selective overuse of TCR Vp sub-families in NLV peptide-stimulated 
CD8+CD69+ cells was seen, although TCR Vp sub-family distribution was not as 
extremely skewed as previously reported after repeated/prolonged NLV peptide 
stimulation.[Weekes et al 1999] The latter observation is probably a result of the 
limitations of a single round of peptide stimulation; T cells with affinity for HLA 
A*0201-NLV peptide are activated but there is limited time available for a high- 
affinity activated T cell clone to proliferate and achieve relative dominance 
within the T cell pool. Additionally no exogenous cytokines or co-stimulation 
(e.g. IL-2, anti-CD28) were used to augment antigen presentation or T cell 
activation. Early T cell responses to NLV peptide identified by CD69 expression 
may not be as focussed as T cell responses after repeated rounds of antigenic 
stimulation; this has implications for cell sorting techniques based on CD69 
expression after CMV-peptide stimulation.
TCR Vp sub-family distribution in CD8+CD69+ cells after NLV peptide 
stimulation varied between individuals but TCR vp sub-families 11 and 13.6 
were over-represented in 2 of 6 individuals.
Weekes et al reported over-representation of TCR vp sub-family 13 in 2 of 3 
HLA A*0201+ individuals following repeated rounds of NLV peptide stimulation. 
Peggs found size class peaks expanded in Vp 13 by CDR3 PCR in NLV-HLA 
A*0201 tetramer* cells following repeated rounds of stimulation with whole CMV 
antigen, and also in TCR Vp sub-family 6 (the frequency of which was not 
determined by the panel of TCR vp sub-family epitope antibodies used here). 
Thus a single round of NLV peptide stimulation allows the identification of 
peptide-responding CD8+ cells by virtue of their upregulated expression of 
CD69, with evidence of non-random TCR Vp sub-family overuse consistent with 
that seen in the published literature after repeated rounds of antigenic 
stimulation.
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In all 4 HLA fully/partially HLA-matched pairs, after 72 hours of allostimulation, 
responder CD8+CD69+ cells demonstrated skewing of TCR Vp sub-family 
distribution (with 3 demonstrating individual over-represented TCR vp sub­
families as defined in Chapter 6.3). Different TCR Vp sub-families were over­
represented within individuals after allostimulation using either the OKT3 
technique or the cytokine technique.
In 3 pairs, responding CD8+ cells demonstrated over-represented TCR Vp sub­
families in common after NLV peptide stimulation and OKT3 allostimulation, 
supporting the possibility of cross-reactivity of allospecific and CMV-specific 
CTLs which warrants further investigation. CDR3 PCR-based spectratyping of 
alloresponders identified by CD69 is not possible by virtue of the presence of 
contaminating DNA from allogeneic stimulator cells (which express CD69 post 
irradiation and upon apoptosis).[Chen et al. 1997] Confirmatory work using 
CDR3 PCR-based spectratyping could be done if a method to sort 
alloresponding cells from stimulators was developed. Further work could include 
crossover proliferative assays and cytotoxicity assays for alloreactivity in CMV 
responders (and the assessment of CMV-specific responses in alloresponding 
cells) to investigate whether alloreactive cells exhibit enhanced CMV reactivity 
and CMV reactive cells exhibit enhanced alloreactivity.
Assessment of donor T cell TCR vp sub-family distribution by flow cytometry 
could be used to produce more individually tailored cell fractions with depletion 
of specific TCR Vp sub-families over-represented in donor cell fractions after 
allostimulation but not common to viral antigen-stimulated responses.
TCR vp sub-family distribution could also be used to differentiate donor T cells 
with specificity for tumour antigens from alloreactive T cells. [Jiang et al. 1997] 
In a recent murine model Vp families exhibiting reactivity to the leukaemia ceils 
were then enriched for and administered in an AHSCT model to assess in vivo 
GvL potential. In syngeneic transplants, enrichment for pools of selected Vp 
families of T cells conveyed a beneficial GvL response to recipients. 
Furthermore, in a haploidentical allogeneic model, enrichment of myeloid 
leukaemia-specific TCR Vp cells exhibited significant GvL responses with 
concomitant minimization of GvHD development. [Patterson and Korngold 
2001] However a problem with these strategies is likely to arise as a result of 
the degree of degeneracy of TCR-MHC/peptide antigen interaction, and the
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likely lack of sensitivity and specificity of any given TCR Vp sub-family for a 
given mHag or viral antigen. Thus selective depletion of an individual TCR Vp 
sub-family over-represented in T cells specific for such antigens is unlikely to 
remove all T cells specific for this antigen as others will belong to other TCR Vp 
sub-families.
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Chapter 7 Development of the CD69-based Selective Allodepletion
Strategy to a Clinical Scale
7.1 Introduction
The aim of development of the strategy of CD69-based selective allodepletion is 
to apply the technique at a clinical level in order to reduce GvHD whilst 
improving immune reconstitution (and potentially preserving the GvL effect of 
donor allogeneic cells). Moreover in order to produce an allodepleted product of 
clinical relevance, development of the CD69 allostimulation and subsequent 
allodepletion techniques at a much larger scale was required.
To date selective allodepletion has been performed at a clinical scale using only 
the CD25-based strategy. Andr6-Schmutz et al reported a phase 1/2 study of 
re-infusion of CD25-immunotoxin-mediated allodepleted T cells to HLA- 
mismatched paediatric recipients after AHSCT. To prepare selectively 
allodepleted T cells, 5x107 donor PBMCs were cultured in vitro in a one-way 
MLR with 5*107 irradiated (30 Gy) stimulating PBMCs. After 3 days of in vitro 
activation, the MLR culture was treated overnight at 37 C with 10"8 mol/L of 
anti-CD25 antibody-conjugated immunotoxin RFT5-SMPT-dgA in RPMI-1640 
containing 20 mmol/L ammonium chloride (pH 7*8), to deplete CD25+ 
alloreactive cells. After assessment of reduction of CD25* cells in after 
immunotoxin treatment (by flow cytometry) and confirmation of reduction of first 
party proliferative responses (less than 1 % residual anti-host alloreactivity was 
recorded in 12 of 16 procedures) allodepleted cells were infused to the patient 
in escalating doses (1,4, 6, and 8x105 T cells/kg ). [Andre-Schmutz e ta i 2002]. 
Soloman et al have published details of a clinical-scale strategy of selective 
allodepletion of donor T cells, also based on immunotoxin-mediated destruction 
of CD25+ alloreactive cells. [Solomon et al 2002] To prepare stimulator cells, 
healthy donors underwent leucopheresis (10-12 Litres of blood volume) and 
PBMCs were obtained by processing on the Fenwall CS300 Plus blood 
separator. Responder cells were generated from G-CSF primed healthy donors 
(10pg/kg/day for 5-6 days) who were then leucopheresed. Stimulator cells were 
cultured in X VIVO-15 with 5% autologous plasma and 100IU/ml recombinant 
IL-2 in 300, 1000 and/or 3000 ml Lifecell gas-permeable bags. Stimulator cells 
were suspended at 108/ml in culture medium and OKT3 (15pg/108 cells) for 20
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minutes. CD3+ cells were then isolated using sheep anti-mouse (SAM) 
magnetic beads and the MaxSep system. The stimulator cells were left in 
culture medium overnight to allow spontaneous detachment of the SAM 
magnetic beads. Stimulator CD3+ cells were then expanded in 3000ml Lifecell 
bags pre-coated with OKT3 (50jxg/t08 cells) at a concentration of 0.6 x 106 
cells/ml. Cells were expanded over 48-72 hours in this manner and then 
washed prior to cryopreservation. Responder T cells were obtained from the 
CD34’ fraction after CD34 selection on the Isolex 300i automated device. 
Irradiated stimulator cells (2500 cGy) at a concentration of 5 x 106/ml were 
added to live responder cells at a S;R ratio of 1:1 and the MLR cultured under 
standard conditions for 72 hours. The RFT5-SMPT-dgA anti-CD25 immunotoxin 
was added at 24 and at 48 hours with ammonium chloride. Efficiency of 
depletion was assessed by flow cytometry and by proliferation assays with first 
party stimulators before and after selective allodepletion.
Using this strategy, stimulator cell selection and expansion yielded >2 x101° 
CD3+ stimulator cells. After anti-CD25 immunotoxin mediated-selective 
depletion, recovery of cells was 70% and viability 85%, permitting a potential 
selectively allodepleted T cell dose of > 108CD3+ cells/kg recipient body weight. 
Proliferative responses to original stimulators after selective allodepletion were 
2.6% of those seen with unmanipulated responders, with preservation of third 
party responses. This strategy has now been used for the preparation of 
selectively allodepleted T cells from HLA-matched sibling donors and the 
preliminary results of a Phase 1 safety study have been reported in abstract 
form.[Solomon et al 2003]
Recently, new and stringent regulations governing both the conduct of clinical 
trials and the environment in which cellular products for clinical use are 
produced and stored have been introduced. The European Clinical Trials 
Directive (EuCTD, 2001 /20/EC ([Anon 2001]) was introduced in May 2004. The 
aims of this directive were to harmonise and simplify the administrative 
procedures and standards of protection for clinical trial participants. It has far- 
reaching consequences for the conduct of clinical trials, including those utilising 
the manufacture and ex vivo manipulation of cellular products. The EuCTD has 
been implemented in the UK through new national legislation drawn up for 
parliamentary approval by the Medicines and Healthcare Products Regulatory 
Authority (MHRA).
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The environment within which a cellular product designed for human use is 
manipulated (and stored) has come under increasing scrutiny and regulation in 
recent years. The Foundation for the Accreditation of Cellular Therapy (FACT) 
has implemented programs of voluntary inspection and accreditation for 
laboratories involved in haematopoietic cellular therapy. These programs were 
based on the standards of the clinical and laboratory professionals of the 
American Society of Blood and Marrow Transplantation (ASBMT) and the 
International Society for Cellular Therapy (ISCT). FACT has collaborated with 
European colleagues in the development of the Joint Accreditation Committee 
in Europe (JACIE).
National guidelines have been periodically issued in the UK to address the 
manufacture and storage of cellular products (other than red cells, platelets and 
plasma products manufactured by the blood transfusion service). In 1997 the 
Department of Health (DoH) issued Guidance Notes on the Processing, Storage 
and Issue of Bone Marrow and Blood Stem Cells’,[Department of Health 1997] 
which have been superseded by the Tissue Banking Code of Practice issued in 
2001 .[Department of Health 2001] The latter document covers all human 
tissues used for any therapeutic purpose (including clinical trials) including 
haematopoietic stem cells and donor leucocytes. This code of practice states 
that all products must be produced using good manufacturing practice (GMP) 
and under conditions of good laboratory practice (GLP) including 
microbiological screening of donors, bacterial testing of processed products, 
and storage of products in liquid nitrogen vapour. Furthermore GMP demands 
the use of validated procedures and processes with product definition, vigorous 
sterility testing, and records of reagents used. GLP requires the use of an 
accredited production laboratory utilising standard operating procedures 
(SOPs), Conformity Europ6ene (CE)-marked and validated equipment, “closed” 
systems where possible, quality assurance and meticulous record keeping. This 
Tissue Banking Code of Practice is to be reviewed no later than June 2005. 
Accreditation of laboratories covering all aspects of the laboratory environment, 
staff training, product manufacture, storage, release criteria and quality control 
is now awarded by the MHRA (formerly by the Medicines Control Agency, 
(MCA) up to 2003) ‘on behalf of the DoH’ in UK to tissue banks.
The development of the CD69-based allodepletion strategy to a clinical scale 
encompassed the production and testing of an antibody suitable for clinical ex
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vivo use. Different monoclonal antibodies to different epitopes of CD69 have 
been described,[Gerosa et al. 1991] and thus depletion efficiency using a given 
cell sorting technique might be different using different anti-human CD69 
antibodies. Several different techniques are available at a bench level for the 
immunomagnetic depletion of CD69* cells and some of these can be used in 
automated or semi-automated devices specifically designed and used for 
sorting allogeneic haematopoietic stem cell grafts prior to clinical use.
7.2 Aims of Experiments described in this Chapter
1. Identification of a CD69 antibody suitable for production (qualitatively and 
quantitatively) for use at a clinical scale;
2. Development of cell culture/allostimulation conditions at a clinical scale;
3. Testing of various technologies for CD69 expression-based depletion of 
alloreactive cells;
4. Development of depletion strategies quantitatively and qualitatively to a 
clinical scale.
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7.3 Materials and Methods
7.3.1 Anti-human CD69 Antibody TP1 55.3
The monoclonal murine lgG2b anti-human CD69 antibody TP1 55.3[Cebrian et 
al. 1988] was produced in a culture fermentation system from murine hybridoma 
cells (Prof Sanchez-Madrid, University of Madrid, Spain). P3-X63-AG.8653 x 
BALB/c murine hybridoma cells were cultured in complete medium (with 10% 
FCS from transmissible spongiform encephalopathy (TSE) -free sources). 
Supernatant was centrifuged to remove cells and debris, filtered (200pm) and 
stored at -70°C.
The CD69 antigen is a 60 kDa disulfide-linked dimeric structure containing two 
differentially glycosylated forms (33 and 27 kDa) of a single core protein, which 
are covalently associated. TP1 55.3 antibody immunoprecipitates the 60 kDa 
homodimer and both 27 kDa and 33 kDa subunits from activated peripheral 
blood lymphocytes.[Cebrian eta ! 1988]
7.3.2 Anti-human CD69 Antibody-CH11
The monoclonal murine lgG1 anti-human CD69 antibody CH11 (Novocastra 
Laboratories, Newcastle upon Tyne, UK) was produced using a prokaryotic 
recombinant protein corresponding to the C terminal of the human CD69 
molecule as an immunogen with the hybridoma partner mouse myeloma cell 
line (p3-NS1-Ag4-1) and was supplied directly from the manufacturers in 
solution at a concentration of 5pg/ml.
7.3.3 Bulk Allostimulation Strategies
Allostimulation using HLA-mismatched irradiated (30Gy) stimulator and live 
responder PBMCs was assessed by responder CD69 upregulation (Chapter 
2.2.1-2) at 72 hours and proliferation (thymidine uptake) at 120 hours (Chapter 
2.3.2) in various culture conditions as detailed in Table 7.1. The S:R ratio was 
constant at 1:1 and cells were cultured under standard conditions in complete 
medium with 10% human AB serum. For small-scale allostimulation
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experiments fresh PBMCs were obtained from healthy volunteers. For large- 
scale HLA-mismatched allostimulation experiments, single-donor buffy coats 
were supplied from North London Transfusion centre and PBMCs were 
extracted by density gradient centrifugation (Chapter 2.1.3).
Resuscitated cryopreserved PBMCs from HLA-matched unrelated volunteer 
donors and AHSCT recipients were used to assess HLA-matched cytokine- 
modified allostimulation at an intermediate scale. HLA-matched stimulators 
were pre-treated with 10OOiu/million cells of IFN-yand TNF-a prior to use in the 
modified MLR, and IL-4 added to HLA-matched MLR cultures as described in 
Chapter 2.3.3. (The HLA typing of matched pairs used in larger scale 
allostimulation experiments is detailed in Table 7.2).
HLA
Matching
Allostimulation
Condition
Final 
Volume 
Of MLR
Responder Cells
Final
concentration
Final
number
HLA-
Mismatched
96-well plate
200jA. 0.5 x I lf /m l 10*
24-well plate
2mls 0.5x1 Of1/ml 10®
160cm3 
Stericell bag 140mls 1.5 x 1(f/ml 210x10®
HLA-
Matched
96-well plate
200fjL 0.5x10%?/ 10®
24-well plate
2mls 0.5 x 1(f/ml 10®
160cm3 
Stericell bag 100m Is 0.5x10%?/ 50x10®
Table 7.1 HLA-mismatched and HLA-matched allostimulation conditions for 
scale-up experiments.
7.3.4 Generation of CD69* T cells with Mitogens
In order to produce large number of CD69+ T cells to evaluate cell-sorting 
systems, fresh human PBMCs were activated with the polyclonal mitogens 
Phaseolus vulgaris agglutinin (phytohaemagglutinin, PHA) or the combination of 
Pokeweed Mitogen (PMA) and Calcium lonophore (CAI, all Sigma-Aldrich).
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Phaseolus vulgaris agglutinin consists of two molecular species, an 
erythroagglutinin which has low mitogenic activity and high erythroagglutinin 
activity, and leucoagglutinin, which has high mitogenic and leucoagglutinating 
activity, but very low erythroagglutinating activity. PHA was supplied as a 
lyophilised powder and diluted in DMSO to a working concentration of 
100ug/ml. 2|xg of PHA was added to 1 ml of PBMCs (at a cell concentration of 
106/ml) and the cell suspension incubated under standard conditions for 4-12 
hours. PMA was supplied as a dry powder stored desiccated below -20°C. A 
stock dilution of PMA was prepared by dissolving PMA powder in DMSO to a 
concentration of 0.5mg/ml and immediately diluting 1:100 in HBSS. 20pL 
aliquots of stock dilution were stored at -20°C at a concentration of 5pg/ml. At 
the time of use aliquots were thawed and diluted 1:10 in complete medium to 
give a final working concentration of 500ng/ml. CAI was supplied as a dried 
powder stored desiccated below -20°C. A stock dilution was prepared by 
dissolution in DMSO to a concentration of 0.5mg/ml and stored at room 
temperature. A working concentration of 5jig/ml was prepared by diluting the 
stock 1:100 in complete medium. To activate fresh PBMCs with PMA and CAI, 
50pL of working concentration of PMA and 100pL of working concentration of 
CAI were added to each 0.5mls of PBMC suspension (at a cell concentration of 
1 x 106/ml) which were then incubated overnight under standard conditions. 
Following activation with mitogens, PBMC suspensions were centrifuged for 10 
minutes at 200g and resuspended (at 106 cells/ml) twice. The proportion of T 
cells activated by mitogens was assessed by flow cytometry after staining with 
5pL of CD3-FITC and CD69-PE /105cells, (both BD) (Chapter 2.2 1). Activated 
PBMCs were mixed with resting PBMCs to adjust the frequency of CD3+CD69+ 
cells to between 5-20% for subsequent cell sorting experiments.
7.3.5 Small Scale Ellglx Microparticle Depletion
Depletion of 2 x 106 PBMCs containing 5-10% mitogen-activated CD3+CD69+ 
cells with TP1 55.3 antibody and the Eligix microparticle system (Chapter 2.5.3) 
was undertaken in three separate experiments with varying quantity of antibody 
used per million cells.
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7.3.6 Small Scale Dynabead Depletion
The Dynabead immunomagnetic sorting system (Chapter 2.5.2) was tested with 
the TP1 55.3 antibody at a small scale. Depletion of 2 x 106 PBMCs containing 
5-10% mitogen-activated CD3+CD69+ cells was performed with varying 
amounts of TP1 55.3 antibody and different Dynabead:cell ratios.
7.3.7 Intermediate Scale Dynabead Depletion
The CH11 murine lgG1 anti-human CD69 was tested with the Dynabead 
system at an intermediate scale using 5 HLA-matched unrelated donor-recipient 
pairs. The cytokine-modified MLR (Chapter 2.3.3) was used to potentiate 
allostimulation. 50 x 106 live responders were incubated with 50 x 106 irradiated 
stimulator cells in Lifecell 160cm3 bags. Stimulators were pre-treated with IFN-y 
and TNF-a and IL-4 added to the MLR culture as per the cytokine-modified 
MLR protocol (Chapter 2.3.3).
After initial optimizing experiments, 12.5pL (62.5 ng) /million responder PBMCs 
of CH11 antibody was used. Dynabeads were used at a bead: cell ratio of 5:1. 
Details of donor/recipient characteristics are shown in Table 7.2 
CD69 expression on CD3+ responder cells was determined by flow cytometry 
after 72 hours after co-culture with stimulators in the cytokine-modified MLR and 
following immunomagnetic depletion of CD69+ cells. First and third party (HLA- 
mismatched) MLRs were set up with unmanipulated responder cells and 
allodepleted responder cells as described in Chapter 2.4.2.
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Pair Stimulator Responder
1 A*0101, 2402 
B*5101, 5201 
C*1202, 0202 
DRB1*1502,0701
HLA-matched at A, B, C and 
DR
2 A*0101, 02011 
B*5701, 4002 
C*0202, 0602 
DRB1*1101,1104
HLA-matched at A, B, C and 
DR
3 A*02011, 3301 
B*1402, 3501 
C*0401, 0801 
DRB1*
HLA-matched at A, B, C and 
DR
4 A*0201, 3101 
B*1301, 1801 
C*0601,0701 
DRB1*1301,0701
HLA-matched at A, B, C and 
DR
5 A*0201, 2402 
B*5101, 4402 
C*0401, 0501 
DRB1 *1601,0407
HLA-matched at A, B, and DR 
Single C locus mismatch
Table 7.2 HLA typing of HLA-matched pairs used to evaluate allodepletion 
with the CH11 anti-human CD69 antibody and the Dynal Immunomagnetic cell 
sorting system at an intermediate scale.
7.3.8 Clinical Scale Dynabead Depletion
After initial small scale experiments to determine the efficiency of the Dynabead 
immunomagnetic cell sorting system, 3 clinical scale allostimulation and 
selective allodepletion procedures were performed using the Isolex 300i (with 
v2.5 software).
210 x 106 fresh stimulator PBMCs were obtained from single-donor buffy coats 
(Chapter 7.3.3) and suspended in complete medium with human AB serum at 3 
x 106 cells/ml and irradiated. These were resuspended in a Lifecell 160cm3 bag 
to which 70 mis of fresh live HLA-mismatched responder cells in complete 
medium with human AB serum (at 3 x 106 cells/ml) (from a single donor buffy 
coat) was added, to give a final responder concentration of 1.5 x 106 cells/ml. 
First and third party primary MLRs were set up in parallel. The bulk cell
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suspension was incubated under standard conditions for 72 hours and CD69 
expression on responder CD3+ cells prior to and after depletion on the Isolex 
300i automated device was measured by flow cytometry (Chapter 2.2.1-2). 12 
mis (14.4pg) of TP1 55.3 was used (limited by the maximal volume allowable on 
the Isolex 300i) with a Dynabead:cell ratio of 5:1 for each procedure. A 
depletion procedure on the Isolex 300i involved following the automated path for 
positive selection up to a certain stage, and then recovery of the negative cell 
fraction was performed. Working buffer was made up as follows: 360mls of 
sodium citrate 4% solution (Baxter) and 120 mis of 25% Human Albumin 
Solution, (HAS, North London Blood Transfusion Centre) (or 150mls of 20% 
HAS) was added to a 3-litre bag of PBS (Baxter) under sterile conditions within 
a tissue culture hood. Total working buffer bag weight was greater than 3250g 
(and less than 7000g). 20mls of the working buffer was transferred into a sterile 
disposable 20ml syringe with a 21G needle and label ‘Buffer Blank’ (to be used 
as a substitute for releasing agent). 20mls of working buffer was reserved for 
Dynabead washing. 14.4 pg of TP1 55.3 CD69 antibody in a volume of 12 mis 
was drawn up into a syringe labelled ‘CD69 antibody’.
The contents of one vial of Dynabeads were then removed (10 mis volume) and 
transferred to a sterile 50ml tube (Nunc) within a tissue culture hood.
10mls of working buffer was added to the tube to bring the total volume to 
20mls and the tube was then exposed to the MPC-1 for 2 minutes. The 
supernatant was aspirated and discarded. The tube was then removed from the 
MPC-1 and the beads resuspended in 10 mis of working buffer and transferred 
to a sterile disposable 20ml syringe.
The Lifecell culture bag was then connected to the Isolex cell source bag 
(supplied with the Isolex disposable plastics kit) using a plasma transfer set 
(Baxter) and the cell suspension transferred from the Lifecell bag to the Cell 
Source bag. The plasma transfer set was sealed with 2 disposable plastic 
haemostats and a heat-sealer.
The Isolex 300i magnetic cell sorter was then powered up and the system 
initialisation step carried out. When the ‘Select a procedure’ screen appeared 
‘Positive Selection Only’ was selected. The Isolex 300i disposable set was then 
installed as per manufacturers instructions. The buffer, buffer blank (dummy 
release agent), and CD69 antibody were then added sequentially to bags on
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weight scale 6, 2, and 3 respectively. The Dynabeads were then added to the 
rocker arm chamber and the cell source bag connected to the C1 tube and 
attached to weight scale 1. Buffer was then transferred automatically via the 
disposable plastic tubing network to the release agent, antibody and cell source 
bags. After buffer transfer the platelet wash step was initialised. When the 
platelet wash was complete the contents of the CD69 antibody bag were 
pumped into the cell suspension. The antibody was then incubated with the 
cells for 15 minutes while the cell and antibody suspension recirculated through 
the spinning membrane to allow thorough mixing. When the antibody and cells 
finished incubation, the cells were then transferred to the rocker arm chamber 
for rosetting with the Dynabeads for 30minutes. At the end of this period, 
immediately prior to the magnetic separation step, the red STOP button was 
pressed to terminate the automated procedure. *Cell Recovery Mode’ was then 
entered, and option 4 (Transfer chamber to Wash Bag 2’) selected. After mixing 
for 2 minutes, magnetic separation of the cell suspension was activated and the 
cell suspension in the rocker arm chamber drained over the secondary magnet, 
into wash bag 2 on weight scale 5. After rinsing the drain path, cells were 
transferred from wash bag 2 to the end product bag on weight scale 4 and the 
red stop button pressed to end the depletion procedure. The end product bag 
containing the depleted cell suspension was heat sealed and removed.
The yield and viability of CD3*CD69~ cells was assessed by cell counting and 
trypan blue staining (Chapter 2 1.4) and the depletion efficiency of CD3+CD69+ 
cells by flow cytometry (Chapter 2.2.1-2). First and third party MLRs were set up 
using the depleted fraction as responders to assess the functional efficacy and 
specificity of allodepletion.
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CD69 Antibody Bag Mixing Bags
Weight Scale Arm 
Buffer
Operating Screen
Spinning Membrane 
(washing device)
The Isolex 300i Automated Cell Sorter Device
Dynabead Bag
Secondary
Magnet
Primary Magnet 
Rocker Arm
Figure 7.1 The Isolex 300i immunomagnetic automated cell-sorting device.
7.4 Results
7.4.1 Initial TP1 55.3 Production
Utilising a simple culture flask fermentation system the concentration of this 
antibody in filtered supernatant was measured by murine IgG ELISA (Chapter 
2.8) at 1200ng/ml. Unfortunately the hybridoma supernatant from TP1 55.3 
proved to be persistently positive (in culture-based assays) for mycoplasma 
pneumoniae despite eradication steps at the Therapeutic Antibody Centre, 
Oxford and also at the Centre for Applied Microbiology and Research, Porton 
Down. Although the mycoplasma pneumoniae infection could be eradicated 
from the TP1 55.3 hybridoma cells by exposure to clarithromycin, hybridoma 
cells retained no ability to secrete functional anti-human CD69 after this 
treatment.
7.4.2 Bulk Allostimulation Strategies
Upregulation of CD69 on HLA-mismatched CD3+ responder cells after 72 
hours) was not significantly different to that seen in 96 round-bottomed-well 
plates when MLR cultures were in 24 flat-bottomed-well plates or in Stericell 
160cm3 cell culture bags. However HLA-mismatched responder proliferation 
after 120 hours of allostimulation was significantly lower when allostimulation 
was in Lifecell 160cm3 cell culture bags compared to that seen after 
allostimulation in 96 round-bottomed-well plates, (Figure 7.2).
Similarly proliferation at 120 hours (expressed as the percentage RRI) of HLA- 
matched responders after cytokine-modified allostimulation was lower after 
larger scale allostimulation than that seen after allostimulation in 96 round- 
bottomed-well plates (but not significantly so, data not shown).
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Figure 7.2 HLA-mismatched allostimulation under various different conditions. CD69 expression on CD3+ responders (above that seen 
with autologous stimulators) after 72 hours of allostimulation is shown on the left and responder proliferation after 120 hours of 
allostimulation is shown on the right, after co-culture in 96 round-bottomed well plates, 24 well plates or 160cm3 LifeCell bags (as detailed 
in Table 7.2). The results of 5 HLA-mismatched pairs are shown. Error bars represent standard deviation. (*= p</=0.05 in a two-tailed, 
paired Student’s t-test).
7.4.3 Small Scale Ellgix Microparticle Depletion
The Eliglx system was found to have moderate (and variable) depletion 
efficiency of CD3+CD69+ cells (between 40 and 65%) when used at various 
particle/cell ratios. Values for depletion efficiency of CD3+CD69+ cells using 
Eligix microparticle sorting technology at varying concentrations of TP1 55.3 
antibody/ million responder PBMCs (at a particle:cell ratio of 25:1) are shown in 
Figure 7.3.
7.4.4 Small Scale Dynabead Depletion
In small-scale procedures the Dynabead system was found to have better 
CD3+CD69+ cell depletion efficiency than the Eligix system. Optimal 
CD3+CD69+ cell depletion efficiency was seen with 150ng TP1 55.3 
antibody/million responder cells when 5-10% of CD3+ responder cells were 
CD69+ (Figure 7.3). The depletion efficiency for CD3+CD69+ cells at varying 
bead:cell ratios with 150ng of TP1 55.3 antibody/million responder cells with the 
Dynabead system is shown in Figure 7.4. Maximal depletion efficiency (mean 
97% +/-5%) was seen under these conditions at a Dynabeadicell ratio of 5:1. 
Initially the yield of CD3+CD69‘ cells using this system was poor (mean 
CD3+CD69' yield 28% +/- 14%) The protocol was duly modified to include a 
second wash of the magnet-bound Dynabeads, which increased the yield 
significantly to a mean of 89% +/- 18% without reducing depletion efficiency 
(Figure 7.5).
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Figure 7.3 Depletion efficiency of mitogen-activated CD3+CD69+ cells using 
Eligix microparticle and Dynabead immunomagnetic systems with TP1 55.3 
antibody at varying concentrations (per million responder PBMCs). Particle:cell 
ratio was 25:1 for Eligix depletions and 5:1 for Dynabead depletions. 5-10 
separate depletion procedures were undertaken for each condition. Error 
bars represent standard deviation.
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Figure 7.4 Depletion efficiency (%) of mitogen-activated CD3+CD69+ cells 
using the Dynabead Immunomagnetic system with TP1 55.3 antibody 
(150ng/million responder PBSCs) at varying particle:cell ratios. 3-5 separate 
depletion procedures were undertaken for each condition. Error bars represent 
standard deviation.
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Figure 7.5 Yield of CD3+CD69‘ cells using the Dynabead immunomagnetic 
system utilising a single or double wash procedure of cells bound to the magnet 
(TP1 55.3 antibody at 150ng concentration/million responder PBSCs, 
particle:cell ratio of 5:1). Error bars represent standard deviation.
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7.4.5 Intermediate Scale Dynabead Depletion
Allostimulation and subsequent allodepletion was tested at an intermediate 
scale in 5 HLA-matched unrelated donor-recipient pairs using the cytokine- 
modified MLR for allostimulation. CD69 expression (above that seen with 
autologous stimulators) was 7.3% +/- 13.7% on CD3+ responder cells after 
cytokine-modified MLR co-culture with irradiated stimulator cells for 72 hours in 
Lifecell bags under the conditions detailed in Table .7.2. Mean depletion 
efficiency (of CD3+CD69+ cells) with the Dynabead immunomagnetic system 
using the handheld MPC-1 was 74%+/-48%. However in one pair (pair 1) CD69 
expression on CD3+ responder cells increased after Dynabead depletion of 
CD69+ cells and this was regarded as a technical failure of the depletion 
procedure. Of the remaining 4 pairs the depletion efficiency of CD3+CD69+ cells 
was 93%+/-14%.
4 of the 5 pairs tested had a first party proliferative response at 120 hours of co­
culture in the primary cytokine modified MLR greater than 5% of that seen with 
HLA-mismatched third party stimulators (RRI>5%).
When allostimulated and CD69-depleted cells were used as responders, 
proliferation to HLA-matched (first party) stimulators in the secondary cytokine- 
modified MLR was reduced in 3 of these 4 pairs, 2 to a RRI < 5% and one to a 
RRI of 5.8%. One pair tested exhibited increased first party proliferation with 
depleted responders, (with an increase in RRI from 12% to 22%) - this was the 
pair that exhibited increased CD69 expression on CD3+ responders after 
depletion as a result of technical failure of the depletion procedure (Figure 7.6). 
Responder proliferation to third party stimulators was preserved in all samples 
tested with a mean post-depletion value of 74% +/- 44% of that seen pre­
depletion.
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Figure 7.6 Proliferative responses to first party stimulation pre- and post- 
allodepletion with Dynabeads and CH11 antibody in 4 HLA-matched unrelated 
pairs utilizing the cytokine-modified MLR. The RRI of 5% is marked; A RRI in 
the cytokine-modified MLR below this level was associated with a high negative 
predictive value for acute GvHD in HLA-matched sibling AHSCT.[Bishara, 
Brautbar, Nagler, Slavin, Leshem, Cohen, and Kedar 1994]
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7.4.6 Clinical Scale Dynabead Depletion
PBMCs from HLA-mismatched single donor buffy coats (North London Blood 
Transfusion Centre) were co-cultured with irradiated PBMC stimulators in 
Lifecell bags under the conditions detailed in Table 7.2. After 72 hours of 
allostimulation the responder cells were depleted of CD69* cells using the TP1
55.3 antibody and the Dynabead system on the Isolex 300i automated cell 
selection device as described in 7.3.8.
Viability after automated depletion on the Isolex 300i was 84%+/-23% assessed 
by trypan blue staining. Depletion efficiency of CD3+CD69+ cells was 93% +/- 
10% (n=3) and yield of CD3+CD69' cells 75% +/- 28% (n=3), despite having to 
use a sub-optimal concentration of TP1 55.3 of approx 70ng/million responder 
PBMCs (Figure 7.6).
First party proliferative responses after allostimulation and depletion were 19% 
+/- 7% of those seen with unmanipulated responder cells, with preservation of 
third party responses (95 %+/- 40% of pre-depletion values), (Figure 7.7). 
Although no sterility testing was undertaken during these automated depletion 
procedures the Isolex 300i has been used in our laboratory to select 
CD4+CD25+ T regulatory cells under the same aseptic technique utilising the 
same disposable plastic tubing kits and end-product collection bags as those 
used to perform a CD69 depletion. Culture samples of the end product of 5 
such selection procedures sent for microbiological culture (Department of 
Microbiology, Royal Free Hospital, London UK) did not demonstrate any 
evidence of bacterial contamination of the end product thus validating the 
sterility of the system.
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Figure 7.7 Depletion efficiency (% CD3+CD69+) and yield of viable CD3+ 
CD69' cells using the TP1 55.3 antibody, the Dynabead system and the Isolex 
300i at a clinical scale (Error bars represent standard deviation, n=3)
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Figure 7.8 Responder cell proliferation after selective allodepletion (using the 
TP1 55.3 antibody, the Dynabead system and the Isolex 300i at a clinical 
scale), to first and third party HLA-mismatched stimulators, expressed as 
percentage of values seen with unmanipulated responder cells. (Error bars 
represent standard deviation, n=3)
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7.4.7 Purification of CH11 antibody
As the TP1 55.3 antibody repeatedly tested positive for mycoplasma 
pneumoniae we sourced and tested an alternative murine anti-human-CD69 
antibody, CH11. In scale-up experiments the CH11 antibody gave optimal 
depletion of CD69+ T cells at a concentration of 62.5ng/million PBMCs i.e 
approximately 40ng/million CD3+ T cells. Based on this observation, in order to 
deplete an average allogeneic peripheral blood stem cell (PBSC) graft for an 
adult (which contains 2-3x10® donor T cells/kg recipient body weight) 
approximately 1 mg of CH11 antibody would be required. 4000mls of 
unprocessed CH11 antibody (at 5ug/ml i.e a total unprocessed amount of 
20mg) was therefore sourced from Novocastra Laboratories, who produced the 
antibody in house from their own hybridoma (using recombinant antigen). 
Details of reagents used in the production of the CH11 antibody are listed in 
Table 7.3. The unprocessed CH11 antibody had not been tested for 
mycoplasma pneumoniae (although all reagents were screened). All culture 
media used at Novocastra Laboratories in production of the CH11 antibody was 
recorded and came from TSE-free sources (Table 7.3).
Reagent Supplier Batch Number
RPM1-1640 Sigma-Aldrich R8758
FCS Sigma-Aldrich F4135
Condimed Roche 1088947
Pen/Strep/Am pB Sigma-Aldrich G7513
Glutamine Sigma-Aldrich G7513
Table 7.3 Reagents used in the production of the CH11 antibody at 
Novocastra Laboratories.
On advice from Dr Elaine Godfrey at the MCA, the antibody was processed at 
the Bristol Institute for Transfusion Sciences (BITS). The processing of the 
CH11 antibody is outlined in Figure 7.8. The projected net yield was 47% (i.e 
9.4mg of processed CH11 antibody would be produced from 20mg of 
unprocessed Ch11 antibody). Unfortunately technical problems with the Protein 
G chromatography column led to retention of most of the CH11 antibody within 
the matrix of the column (which was not recoverable) and the final yield was 
less than 1mg of processed antibody.
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Figure 7.9 The purification process employed and the testing points to 
ensure quality control for the processing of CH11 anti-CD69 antibody suitable 
for use ex vivo in a clinical study of CD69-mediated allodepletion. PAGE- 
Polyacrylamide Agarose Gel Electrophoresis, IEF=lmmunoelectrofixation
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7.5 Chapter Discussion
Previous work has been published work describing depletion of CD69+ 
alloreactive cells. [Fehse et al 2000a;Fehse et al 2000b;Koh et al 1999;Koh et al 
2002]
In common with the work described in Chapters 3 and 4 of this thesis, all 
utilised the Miltenyi/MACS immunomagnetic depletion system. In order to test 
the safety of the strategy of CD69-mediated selective allodepletion in reducing 
GvHD in the setting of HLA-matched sibling AHSCT, the techniques of 
allostimulation and allodepletion needed to be scaled up and performed under 
sterile conditions.
Firstly we sought to address the issue of whether allostimulation could be 
achieved as effectively in cell culture bags (containing 50-200 x 106 stimulator 
and responder PBMCs) as in small-scale conditions. In HLA-mismatched pairs, 
although no significant difference was seen in responder cell CD69 expression 
after 72 hours in the MLR, responder proliferation at 120 hours was significantly 
lower when cells were co-cultured in a large-scale MLR in cell culture bags. 
This difference might be explained by the occurrence of less cell-cell contact in 
cell culture bags. (Indeed we consistently observed lower responder cell 
proliferation in flat-bottomed- well plates when compared to round-bottomed- 
well plates, presumably for this reason). This problem was addressed by 
increasing the responder (and stimulator) cell concentration in bulk MLRs 
performed in cell culture bags. However to preserve responder cell viability 
responder cell concentrations in large scale MLRs in cell culture bags were 
limited to 1.5 x 106/ml. Less effective reduction in first party proliferative 
responses following depletion of alloreactive cells was observed in both 
intermediate scale HLA-matched depletions (using the CH11 antibody) and 
large-scale HLA-mismatched depletions performed on the Isolex 300i (with the 
TP1 55.3 antibody) when compared to small-scale depletions using the 
MACs/Miltenyi system, despite comparable depletion efficiency of CD3+CD69+ 
cells. Less efficient allostimulation might be one explanation for this 
observation.
Two different immunomagnetic depletion systems were tested at a small-scale 
using the TP1 55.3 anti-CD69 antibody. The Eligix system was found to have 
variable depletion efficiency and only achieved depletion efficiency consistently
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greater than 50% at the highest antibody concentration tested (300ng/million 
PBMCs). Thus this system would require large amounts of antibody to deplete 
alloreactive T cells at a clinical scale, and was still relatively inefficient, and 
therefore was not selected for further experiments.
The Dynabead system was found to have consistent and high depletion 
efficiency, maximal at a concentration of TP1 55.3 antibody of 150ng/million 
PBMCs in small-scale experiments and was therefore selected for further 
investigation at a larger scale. Initially the yield of CD3*CD69~ cells post 
depletion was unacceptably low (at 25%) presumably because non-alloreactive 
cells were retained on the magnet along with CD3+CD69+ cells. A second wash 
step was added to remove more of these CD3+CD69’ cells, which successfully 
increased the yield of these cells to consistently more than 80%.
In intermediate scale HLA-matched depletions the Dynabead system was 
tested with the CH11 antibody. When data from the one depletion procedure 
that failed was excluded, depletion efficiency of CD3+CD69+ cells was 93%, 
equivalent to that seen in small-scale experiments using the Dynabead system 
and the TP1 55.3 antibody.
The Dynabead system also had the advantage of having an available, CE- 
marked automated device upon which to perform large-scale depletions under 
sterile closed conditions, the Isolex 300i. This device is an automated cell- 
sorting device that uses a semi-closed disposable sterile plastics system and 
has established use in positive selection of CD34* cells.[Abonour et al. 
1998;Cornetta et al. 1998] The device has also been shown to be very effective 
in depletion of T cells when CD34* cell selection is combined with a depletion 
procedure. [Martin-Henao etal. 2001]
Two stage procedures of CD34+ cell selection followed by depletion of 
malignant B cells or breast cancer cells in processing of PBSCs from patients 
with lymphoproliferative conditions have also been reported. The depletion step 
adds an additional 2 log reduction in the frequency of malignant cells.[Dreger et 
al. 2000;Mohr etal. 2001;Paulus etal. 1997]
Furthermore, when the two clinical scale devices currently available for CD34+ 
cell selection PBSC apheresis products, (the CliniMACS and the Isolex 300i), 
were compared directly (by pooling and splitting two PBSC harvests collected 
on sequential days from 10 patients and processing half of each pooled harvest 
on each device), the median recovery of colony-forming units was significantly
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greater from the Isolex 300i product as was expansion of cells in either erythroid 
or granulocytic lineage-specific). This was due to a higher proportion of 
apoptotic cells in the CliniMACS product. Hence the Isolex 300i product 
contained fewer apoptotic cells and consequently had greater functional 
capacity in culture and therefore was deemed the most suitable device upon 
which to perform the clinical-scale depletion procedure.[Watts et al. 2002] 
Depletion efficiency of CD3+CD69+ cells using Dynabeads and the TP1 55.3 
antibody at a large-scale (200 x 106 responder cells) on the Isolex 300i device 
compared favourably with published data.
Dynabeads have been used by Luqman et al at a bench level and on the Isolex 
device to deplete CD69 alloreactive cells following HLA-mismatched 
allostimulation. They reported a depletion efficiency of CD69+ cells of 72%+/-8% 
and a yield of CD3+CD69' of 77.3% +/- 7% (n=3) although no data on reduction 
in functional alloreactivity was presented. [Ho et al. 2003]
The depletion efficiency of CD3+CD69+ HLA-mismatched responders on the 
Isolex 300i was higher than that seen with Dynabeads at a smaller scale for the 
cone of TP1 55.3 used (60ng/million cells) (93% vs 70% probably because of 
the increased efficiency of the depletion process on the automated device, 
which has a secondary magnet. Sufficient numbers of HLA-matched stimulator 
and responder cells were not available for assessment of large-scale 
allostimulation and depletion on the Isolex 300i device, although it is likely that 
in parallel with HLA-mismatched pairs, depletion efficiency using Dynabeads on 
the automated device would be equivalent to, or better than that seen at a 
small-scale.
First party proliferative responses after depletion of HLA-mismatched 
responders at a large-scale on the Isolex 300i were reduced to 19% of those 
seen with unmanipulated cells despite a depletion efficiency of >90%. The 
higher residual first party proliferative responses seen after depletion on the 
Isolex 300i might have resulted from less efficient allostimulation in cell culture 
bags (vide supra) or from sub-optimal depletion efficiency, perhaps as a result 
of the limitation of the amount of TP1 55.3 antibody set by the relatively low 
concentration of this antibody following its in house production in a cell culture 
flask fermentation system, and the constraints set by the maximal depleting 
antibody volume permitted on the Isolex 300i device.
259
210x106 responder PBMCs were depleted on the Isolex 300i, equivalent to 
approximately 1.5x108 CD3+ cells. This T cell dose is considerably less than 
that contained in an average allogeneic PBSC graft for a 70kg adult 
(approximately 101° CD3+ T cells) although greater than the T cell dose needed 
to cause GvHD after AHSCT (7 x 107 cells for a 70 kg matched sibling recipient, 
7 x 106 cells for a 70 kg matched unrelated recipient and as little as 7 x 105 cells 
for a 70 kg haploidentical recipient).
For the purposes of the clinical pilot study the primary aim would be to 
demonstrate safety of infusion of the selectively allodepleted T cell fraction to 
HLA-matched sibling PBSC recipients. Escalating doses of selectively 
allodepleted T cells will be re-infused. Only at doses of 106 selectively depleted 
T cells/kg will reach the threshold where GvHD might be expected in this setting 
with a similar number of non-selected T cells re-infused. The scale up 
experiments performed on the Isolex 300i have thus shown that the device can 
adequately allodeplete such numbers of donor T cells (in the HLA-mismatched 
setting).
Obtaining an antibody safe for clinical (albeit ex-vivo) use has been 
exceptionally difficult. Despite several different strategies we have been unable 
to eradicate the mycoplasma pneumoniae infection from the hybridoma cells 
that produce the TP1 55.3 antibody without adversely affecting the secretion 
activity of the cells. The vast majority of the supply of an alternative anti-CD69 
antibody (CH11) was lost during purification procedure.
After the failure of the processing procedure of CH11 antibody attempts were 
made to produce larger quantities of TP1 55.3 antibody and to eradicate the 
mycoplasma pneumoniae. Small-scale experiments demonstrated optimal 
depletion of CD69+ T cells at a concentration of TP1 55.3 of 150ng/million 
PBMCs, although good depletion was still seen at concentrations of 60- 
70ng/million PBMCs at a larger scale using the Isolex 300i. Based on this 
observation, in order to deplete an entire average PBSC graft for an adult 
approximately 1-2mg of TP1 55.3 would be needed. Clearly the antibody would 
need to be produced in larger quantities and processed to ensure both sterility 
and increased concentration (by 2 logs) in order to be suitable for use at a full 
clinical scale using the Isolex 300i (which has a maximal volume of depleting 
antibody of 12 mis).
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A fermentation system to produce hybridoma supernatant containing TP1 55.33 
antibody at a greater concentration than that produced after cell culture in 
80cm3 cell culture flasks (1200ng/ml) has been designed, using cylindrical cell 
culture flasks and a rotating platform (Jencons, Forest Row, UK).
In order to further concentrate the antibody and to purify it to render it free of 
infection with mycoplasma pneumoniae a process has been designed utilising 
antibody elution on a Prosep-A chromatography column (Prosep, Elland, UK) 
followed by pathogen removal on the Intercept Q anion exchanger (Millipore). 
The latter device efficiently and economically removes picogram to nanogram 
concentrations of negatively-charged trace impurities resulting in a 5 log 
reduction in virus and a 3-4 log reduction in pathogen DNA and endotoxin. This 
procedure has a predicted yield of 85% of TP1 55.3 antibody and will produce a 
final concentration of antibody of approximately 150 pg/ml. Thus the 1-2 mg of 
antibody needed to deplete an entire adult PBSC on the Isolex 300i would be 
contained in a volume of approximately 10mls, within the depleting antibody 
volume limit stipulated.
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Chapter 8 General Discussion
8.1 Allostimulation Prior to Selective Allodepletion
Although non-selective T cell depletion in AHSCT is the most effective method 
for prevention of clinically significant GvHD, it is associated with increased rate 
of disease relapse as a result of the removal of T cells with specific anti- 
leukaemic activity. Therefore the development of techniques to selectively 
remove, destroy or anergise the T cell component that mediates GvHD from 
allogeneic haematopoietic grafts have assumed a high priority in recent years. 
Gribbin et al induced alloantigen-specific anergy in T cells by complete 
blockade of B7-mediated co-stimulation. In the MLR this resulted in reduced 
proliferation and lower HTLp frequencies against the original stimulator cells but 
not against third-party stimulator cells.[Gribben et al. 1996] In addition, Taub et 
al induced specific T-cell tolerance in human T cells by providing them with an 
alloantigen-specific TCR signal in the presence of wortmannin.[Taub et al. 
1997]
However, an important drawback of anergy induction is that reintroduction of IL- 
2 reverses anergy and production of IL-2 plays a pivotal role in human acute 
GVHD.[Roy et al. 1995]
The work presented in this thesis examines the identification of alloreactive T 
cells and their subsequent removal from the donor T cell pool based on their 
expression of the activation marker CD69 after co-culture with irradiated 
recipient cells.
In the HLA-matched AHSCT setting only mHag disparity exists between donor 
and recipient and these antigens cannot be routinely typed for at this juncture. 
Moreover if donor/recipient pairs were to be typed for mhags and donors 
selected on the basis of minimal mHag disparity then this would result in
1. A vastly reduced acceptable donor pool (if the donor was required to be 
matched at HLA Class I and II and multiple mHag loci in addition).
2. The potential loss of donor T cell GvL activity mediated by donor T cells 
with specificity for mHags preferentially expressed on recipient leukaemic
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cells. In this situation some degree of mHag disparity between donor and 
recipient would be desirable.
MinorHags have been shown to have tissue-specific expression but 
haematopoietic lineage-expression has not as of yet been described.
In order to extend the applicability of the allostimulation and allodepletion 
protocol to most HLA-matched (sibling and unrelated donor) pairs work 
presented here examines a technique of activating recipient T cells and their 
subsequent use as APCells in the allostimulation step. It was envisaged that 
this strategy would be advantageous when applied in the setting of myeloid 
malignancies when recipient myeloid APCells and leukaemic cells might 
express shared antigens that might be presented to alloreactive donor T cells. 
Removal of such cells might lead to a loss of T cells with leukaemia-specific 
activity with a concomitant reduction in the donor T cell-mediated GvL effect 
(Figure 8.1).
Conversely an antigen-presenting system utilising myeloid-derived APCs (such 
as monocyte-derived dendritic cells) might be advantageous when used to 
present host alloantigens to the donor T cell pool prior to selective allodepletion 
in the setting of recipient lymphoid leukaemias, when the use of lymphoid APCs 
might present antigens to the donor T cell pool that are over-expressed on 
leukaemic cells.
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Donor alloreactive T cells specific for recipient mHags
Allogeneic Recipient 
Lymphoid Antigen 
Presenting Cell
Non-myeloid restricted Myeloid-restricted
mHag mHag
Allogeneic Myeloid 
Recipient Antigen 
Presenting Cell
Allogeneic 
Recipient Leukaemic 
Blast Cell
Figure 8.1 The choice of host APCells and the potential for shared expression of lineage-specific mHags on myeloid leukaemic
blasts.
8.2 The Retention of Anti-leukaemic Activity after Selective
Allodepletion
Although the work presented in this thesis extends previously published work (in 
both in vitro human donor-recipient pairs and a murine model), particularly in 
HLA-matched setting, the issue of retention of anti-leukaemic activity has not 
been specifically addressed. Retention of the GvL effect would be of paramount 
importance to any strategy of selective depletion of host-specific T cells within 
the donor T cell pool. Previously published work describing the CD25-mediated 
strategy of selective allodepletion has examined retention of anti-leukaemic 
blast activity within the donor T cell pool.
The studies of Montagna et al and Mavroudis et al demonstrated that CTLp and 
HTLp frequencies against recipient leukaemic blast cells were maintained after 
CD25-mediated allodepletion.[Mavroudis et al 1996;Montagna et al 1999] 
However the indirect nature of CTLp and HTLp assays, which involve in vitro 
restimulation and wide confidence intervals, could potentially obscure significant 
changes. They are also dependent on the availability of viable recipient 
leukaemic blasts (in addition to both recipient and donor PBMCs), which were 
not available for the vast majority of donor-recipient pairs tested herein. An 
alternative approach would be to indirectly study the frequency of T cells within 
the donor T cell pool with specificity for candidate tumour antigens such as the 
PR1 epitope of Proteinase 3. It has been shown that cytotoxic T lymphocytes 
specific for the PR1 peptide preferentially lyse primary leukaemic blasts from 
patients with AML,[Molldrem et al. 1996a] preferentially inhibit leukaemic CFU- 
GM colony formation,[Molldrem et al. 1997] and have been correlated with 
clinical responses to IFN-cr and allogeneic HSCT in patients with CML.[Molldrem 
et al. 2000] Frequencies of PR1-specific CTLs have been quantified by tetramer 
assays and are preserved after CD25-mediated allodepletion of HLA- 
mismatched responders after stimulation with LCLs.[Amrolia et al 2003a] This 
approach might be useful for proof of principle that anti-leukaemic activity in the 
donor T cell pool is not removed after allodepletion based on CD69 expression 
but it must be stressed that;
1. HLA Class I tetramer-based assays merely enumerate T cells with high- 
affinity TCR specificity of the antigen concerned (and give no information
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about the functionality of such T cells, or of the presence of CD4+ T cell 
helper activity).
2. Increased expression of PR 1/proteinase 3 on leukaemic blasts is by no 
means a universal finding in myeloid leukaemias, and when host blast 
cells are not available (for confirmation of expression of Proteinase 3) 
then the demonstration of retention of CTLs specific for at least one other 
myeloid-leukaemia-associated antigen would be desirable. Indeed a pool 
of tetramers for myeloid-leukaemia specific or-selective antigens could 
be employed to assess donor T cell residual anti-leukaemic activity, 
perhaps selected based on individual recipient blast cell phenotype.
Suitable candidate antigens over-expressed on acute myeloid leukaemia blasts 
include the Wilm’s Tumour Antigen (WT-1) and the myeloperoxidase-related 
antigen MY4. [Scheibenbogen et al. 2002] [Braunschweig et al. 2000;Molldrem 
etal. 2002]
It is possible that tetramer assays might also be useful in confirming the efficacy 
and specificity of the selective allodepletion protocol. In HLA-matched donor 
recipient pairs alloreactive donor T cells will have specificity for mHags and the 
reduction in frequency of mHag specific T cells within the donor pool could be 
directly demonstrated by use of mHag-peptide tetramers.
However some mHags are restricted to haematopoietic tissues (e.g. HA-1) and 
retention of T cells with specificity against such mHags after selective 
allodepletion might be desirable as such T cells could exert a GvL effect via 
their host haematopoietic cell-restricted specificity. In order to ensure that such 
T cells are not lost after selective allodepletion, allostimulation would need to be 
via non-haematopoietic host cells. Such a protocol has been published 
describing the use of host keratinocytes as APCs and the subsequent depletion 
of donor alloreactive T cells by immunomagnetic sorting based on various T cell 
activation markers. In five HLA-identical patient-donor combinations the effect of 
depletion of keratinocyte mHag-activated donor T cells was a 10-fold reduction 
in recipient keratinocyte-HTLp frequency with preservation of recipient 
leukaemic blast HTLp frequencies.[van Dijk et al 1999] However keratinocytes 
induce anergy in donor T cells (due to the lack of expression of co-stimulatory 
molecules) and this lack of stimulatory capacity must be corrected by addition of
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an anti-CD28 antibody or by transfection of host keratinocytes with B7-1 or B7- 
2.[van Dijk et al. 1996] Additionally the construction of a host keratinocyte cell 
layer capable of presenting alloantigens on sufficient scale for the clinical 
application of such a strategy would be a technically difficult proposition.
An alternative approach to demonstrating the retention of donor T cells able to 
exert a GvL effect would be the use of a murine model. Such a model would 
need to demonstrate simultaneously the reduction in GvHD associated with the 
reinfusion of selectively allodepleted T cells and the preservation of an in vivo 
anti-leukaemic effect. Lethally irradiated BALB/c mice might be inoculated with 
BCL1 cells (a primary leukaemia/lymphoma cell line) and;
1. C57BL/6 T-cell-depleted bone marrow cells. These mice should develop 
fatal leukaemia.
2. Unmanipulated 5 x 106 untreated C57BL/6 T cells. All mice should die of 
GvHD.
3. Similar numbers of CD69-mediated allodepleted C57BL/6 T cells- 
recipients should survive more than 100 days without detectable BCL1 
tumour cells and free of GVHD.
8.3 The Retention of Anti-viral Activity after Selective Allodepletion
The work presented in Chapter 4 of this thesis demonstrates that the process of 
allostimulation and subsequent allodepletion (based on the expression of CD69 
on alloreactive responder T cells) preserves the majority of functional CMV- 
specific cells within the donor T cell pool. These are the first data to 
demonstrate directly the preservation of functional CMV-and EBV- cell 
frequencies after selective allodepletion of HLA-matched responders and are 
also the first data to demonstrate this in HLA serotypes other than HLA A*0201. 
It is of great interest that selective depletion leads to a modest decrease in the 
frequency of CMV-specific cells using either technique for allostimulation of 
HLA-matched responders. This would not be of relevance to the clinical 
application of the technique of CD69-mediated allodepletion as the majority of 
functional CMV cells are retained. Peggs et al used adoptive transfer of very
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small numbers of donor-derived CMV cells after AHSCT which led to massive in 
vivo expansion of CD8+ CMV-specific cells (as detected by HLA A*0201-CMV 
peptide tetramers). The authors estimated that the infused CMV tetramer+ 
cytotoxic T-cell doses were about 350-400 T cells/kg recipient body weight and 
that these were subsequently expanded by 3-5 logs in wVo.[Peggs et al 2003c] 
Even if a CMV IgG + HLA A*0201+ donor with a baseline frequency of 
CD3+CD8+ CMV-Tetramer+ cells of 1% lost 30% of these cells during the 
process of selective allodepletion (based on CD69 expression) in the HLA- 
matched setting, the selectively allodepleted T cell pool would still contain a 
frequency of CD3+CD8+ CMV tetramer+ cells of 0.7%. This would equate to a 
CD3+CD8+ CMV tetramer+ cell dose of approximately 2000 cells/kg recipient 
body weight if as little as 106/kg recipient body weight selectively allodepleted T 
cells were infused, well above the threshold level of CMV-specific T cells shown 
to expand in vivo after adoptive transfer, and confer clinical benefit to the 
recipient in terms of clearance of CMV viraemia. Additional work on the 
retention of virus-specific cells after selective allodepletion crucially needs to 
identify the presence of adequate numbers of pathogen-specific CD4+ cells in 
allodepleted T cell pool. It remains difficult to quantify the frequency of such 
cells as HLA Class II tetramers remain technically challenging to construct and 
ELISpot assays would need to be augmented by an additional antigen- 
presenting cell system in order for HLA Class ll-restricted pathogen antigens to 
be effectively presented to pathogen-specific CD4+ T cells. One approach for 
the quantification of CMV-specific CD4+ T cell responses would be to assess 
CMV whole antigen-stimulated intracellular IFN-y generation by flow cytometry. 
This strategy requires additional T cell stimulation with anti-CD28 antibody and 
has the advantage of not being restricted to a given HLA Class II type (as many 
different CMV antigens could be processed from the whole CMV antigen 
source). The pivotal role of CD4+ help in maintaining a functional CD8+ CMV- 
specific response post AHSCT has recently been identified by Gratama et al 
and the retention of CMV-specific CD4+ cells after the process of selective 
allodepletion has yet to be demonstrated. [Cornelissen et al. 2003]
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8.4 The Retention of T regulatory cells after Selective Allodepletion
The kinetics of expression of two activation antigens (CD69 and CD25) on 
responder cells after alloantigen expression have been closely examined after 
both HLA-mismatched and HLA-matched allostimulation. These activation 
antigens were known to have different kinetics of expression on alloresponding 
T cells, with CD69 expression occurring earlier than CD25 expression.[Craston 
et al 1997] The co-expression of both antigens on alloresponding T cells has 
not previously been described in the literature. The results presented in Chapter 
5 of this thesis demonstrate that three responder cell subsets can be identified 
by their expression of one or the other or both of these activation markers 
although the possibility that individual cells move between these cell subsets 
over time during the alloresponse cannot be discounted. Thus the strategy of 
selective allodepletion based on the expression of both of these activation 
antigens at a single time point, should improve the efficacy of depletion of 
alloreactive cells and the single report in the literature of this strategy supports 
this hypothesis.[Fehse et al 2000a] Whether sequential depletions of CD69+ 
alloresponders followed by CD25+ alloresponders improves the efficacy of 
selective depletion above that seen with a dual depletion process based on the 
expression of both antigens at a single time point remains to be determined. 
The strategy of selective allodepletion based on the expression of CD69 alone 
on alloresponders has the advantage of preservation of both frequency and 
function of CD4+CD25+ T regulatory cells within the donor T cell pool, although 
the significance of this experimental observation remains to be determined as 
the role of such cells with in the donor T cell pool in human AHSCT remains a 
subject of great debate.
8.5 The Phenotype of Alloreactive and Non-alloreactive T cells
An experimental technique for the determination of TCR V(3 sub-family 
distribution on alloreactive and non-alloreactive responder cells following 
allostimulation in the MLR was described in Chapter 5. This technique, by which 
CD69+ and CD69' responder cells can be identified and TCR vp sub-family 
distribution measured by flow cytometry can reliably differentiate between
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stimulator cells and responder cells. This is not the case for methods previously 
used to measure TCR Vp sub-family spectratype of alloresponder cells in the 
MLR by DNA PCR for CDR3 length. As expected some skewing of TCR Vp 
sub-family distribution was seen in both HLA-mismatched and HLA-matched 
alloresponders with increases in frequency of several individual TCR vp sub­
families in each individual tested suggesting responses to several alloantigens 
in both settings. Moreover the non-alloreactive donor T cell pool maintained a 
TCR Vp sub-family distribution very close to that of baseline donor T cells for 
both CD4+ and CD8+ cells, which would support the hypothesis that the clinical 
reinfusion of selectively allodepleted T cells contain a broad spectrum of T cell 
immune activity. A very recent publication where TCR Vp spectratyping of HLA- 
mismatched alloresponder cells (identified and sorted by flow cytometry on the 
basis of the dual expression of CD4HI and CD38+) was measured by PCR for 
CDR3 has confirmed this observation.[Martins et al. 2004]
The memory/effector phenotype analysis of alloresponder T cells (based on the 
expression of CD45RA isoform and the chemokine receptor CCR7) has 
demonstrated that after HLA-mismatched allostimulation, CD4+CD69+ 
alloresponder T cells contain a mixture of TCm, TEm and naive T cells, with a 
modest but statistically significant increase in the proportion of Tem cells 
compared to that seen in baseline responder T cells. The significance of this 
observation remains to be determined and suggests that a proportion of human 
T cells, identifiable as alloresponders by upregulation of expression of CD69, 
have either previously encountered alloantigen or have shared TCR affinity with 
alloantigen and previously encountered (pathogen-related) antigen.
No data have been published specifically describing TEm. TcMand naTve subsets 
based on this classification, although there is an increasing body of evidence 
showing CD62L' cells (which contain TEM cells) are unable to act as effector 
cells mediating GvHD in murine models, and CD62L" human cells have been 
shown to be hyporesponsive (in terms of proliferative responses) to alloantigen 
in in vitro experiments.[Anderson et al. 2003;Chen et al. 2004b;Foster et al. 
2004b;Xystrakis et al. 2004] It may also therefore be the case that CD4+CD69+ 
human alloresponder TEM cells, although present in alloreactive cell fractions 
are not able to mediate GvHD. It would be fruitful to correlate the memory and
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effector T cell subsets (as defined by Lanzavecchia and Sallusto) in CD69+ 
alloreactive cells with their expression of CD62L to further elaborate this.
8.6 The use of CD69 to identify CMV-reactive T cells
CD69 as an activation antigen upregulated with relatively rapid kinetics on the 
surface of T lymphocytes could be used to identify cells responding to antigenic 
stimuli other than alloantigens and this possibility was examined with stimulation 
of donor T cells from HLA A*0201+ CMV lgG+ individuals by the CMV 
integument protein pp65-derived NLV nonamer. CMV specific CD8+ cells can 
be identified by their expression of CD69 following relatively short periods of 
stimulation without additional cytokine or antibody stimulation. Such responder 
cells demonstrate some evidence for skewing of TCR Vp sub-family distribution 
and the data presented in Chapter 6 are consistent with the limited amount of 
published data. Data have been published describing the selection of CMV- 
specific HLA A*0201-NLV Tetramer + cells by flow cytometry, however this 
strategy is restricted to HLA A0201+ individuals and the CMV-specific cell 
fraction would contain only CD8+ cells, with no CD4+ CMV-specific cells that are 
crucial for maintaining donor-derived CMV specific responses post- 
AHSCT.[Braunschweig et al 2000;Cornelissen et al 2003;Keenan et al 2001]
It is feasible to imagine the development of a system whereby CD69 expression 
on T cells is used to identify and to positively select donor T cells with CMV- 
specificity and this system could be applied to donors with a variety of HLA 
Class I serotypes. A wide selection of immunogenic CMV-derived peptides with 
known HLA Class I restriction have been identified and are commercially 
available and indeed several were used and shown to reliably induce IFN-y 
responses in ELISpot assays in the work described herein. However for optimal 
impact in clinical use such a system would need to utilise a more developed 
antigen-presenting system, perhaps with the use of whole CMV antigen and 
enrichment of donor monocyte-derived dendritic cells able to present HLA Class 
ll-restricted CMV antigens to CD4+ T helper cells.
Any strategy to select CMV-specific T cells by antigenic/peptide stimulation of T 
cells and their subsequent selection based on expression of CD69 might be 
disadvantaged by the existence of donor T cells with TCRs with shared affinity
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for both CMV antigens and alloantigens. Such cells, if used for adoptive 
immunotherapy, might expand in vivo and mediate GvHD. Data presented in 
Chapter 6 demonstrates that some individuals share preferential TCR Vp sub­
family distribution in both CMV NLV peptide-stimulated CD69+ T cells and HLA- 
matched allostimulated CD69+ responder T cells supporting the existence of 
such shared-affinity T cells. Further experiments to confirm this hypothesis 
could include TCR Vp spectratype analysis (by CDR3 PCR) and subsequent 
sequencing to identify accurately T cell clones responding to CMV peptides and 
to allostimulation. CMV-responders could be sorted by positive selection of 
CD69+ cells after NLV stimulation whereas PKH-26 labelled responder T cells 
after allostimulation could be sorted by flow cytometry based on expression of 
CD69 and PKH-26 dye to accurately distinguish them from stimulator cells in 
the MLR. Functional experiments could be performed to assess the 
alloproliferative capacity (as responders in the MLR) of T cells within the CMV- 
reactive pool after NLV stimulation and compared to that of unmanipulated cells 
and CMV-peptide non-responders.
In order to minimise the potential for GvHD of CMV-peptide/antigen-stimulated 
allogeneic T cells a sequential manipulation programme could be employed with 
allostimulation and subsequent depletion of alloreactive responder cells based 
on their expression of CD69. The non-alloreactive donor T cell pool could then 
be stimulated with CMV antigen/peptide and CMV-specific non-alloreactive 
responder cells positively selected based on their expression of CD69. Using 
this sequential strategy a pool of viral peptides from different pathogens 
important in AHSCT (e.g. EBV, RSV, adenovirus) could be used simultaneously 
to stimulate the donor T cell pool after allostimulation and allodepletion to 
generate a cocktail of non-alloreactive virus-specific donor T cells for adoptive 
immunotherapy post AHSCT to improve immune reconstitution without GvHD.
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8.7 Testing the CD69-mediated Selective Allodepletion Strategy in a 
clinical pilot study of AHSCT for AML
Many techniques have been investigated to identify and selectively remove 
alloreactive T cells from the donor T cell pool to reduce GvHD and improve 
immune reconstitution. Many of these involve cell sorting by flow cytometry, a 
technique difficult to develop to a clinical scale whilst maintaining cell viability 
and sterility. The identification of alloreactive T cells within the donor T cell pool 
by their expression of CD69 has several distinct advantages over many such 
methods. These include more rapid expression after allostimulation than other 
activation antigens and the absence of any T cell subsets with constitutional 
expression of CD69 that would be removed as bystanders during allodepletion 
based on CD69 expression. Antibody-mediated cell selection procedures are 
potentially more specific than the use of immunotoxins, which can exert a non­
specific toxic effect mediated by their ricin moiety. Moreover CD69-mediated 
allodepletion led to virtual abrogation of GvHD in a totally MHC mismatched 
murine model and was associated with a significant survival advantage of 
recipients of non-allodepleted T cells. The major disadvantage of the CD69- 
based strategy is the lack of an available clinical-grade anti-CD69 antibody. The 
scale-up experiments presented in Chapter 7 demonstrate the efficacy of two 
potential anti-CD69 antibodies and highlight some of the problems encountered 
in the process of purification and production of such antibodies.
We have designed a clinical pilot study to test the safety of the CD69 
allodepletion strategy in adult AHSCT recipients. Adult patients with acute 
myeloid leukaemia will be entered into the study. They will receive allogeneic 
PBSC grafts from HLA-matched sibling donors after chemotherapy, immune 
suppression and fractionated total body irradiation. Recipients will be 
conditioned with Fludarabine (30mg/m2) on days -9  to -7  by intravenous 
infusion and with cyclophosphamide 60 mg/m2 on days -6  and -5  by intravenous 
infusion. Total body irradiation will be given in 8 fractions over 4 days on days -4  
to-1 to a total dose of 1440cGy. The reinfusion of HLA-matched sibling donor 
PBSC will be split into two fractions, given at different times. The donor PBSC will 
be undergo positive selection for CD34+ cells under sterile conditions using the 
Isolex 300i. The CD34+ fraction will be reinfused at day 0 to ensure rapid 
neutrophil and platelet engraftment.
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The CD34" T cell fraction will then be cultured in cell culture bags with cytokine 
pre-stimulated irradiated recipient mononuclear cells to stimulate alloreactive T 
cells within the donor T cell pool. The CD69+ alloreactive donor T cells will then be 
depleted with anti-CD69 antibody on the Isolex 300i and the CD69" non- 
alloreactive donor T cell pool will be cryopreserved. The allodepleted fraction will 
be tested for efficacy and specificity of allodepletion in a secondary cytokine- 
modified MLR with first and third party stimulators, and for microbiological infection 
Fractions found to have residual alloreactivity or to be bacterially contaminated will 
be discarded. Allodepleted T cells with a post-depletion RRI of 5% or less (as 
defined by Bishara et al,[Bishara et al 1994]) will be reinfused to patients at Day 
+12 to aid immune reconstitution, initially at a dose of 105 T cells/kg recipient body 
weight. If no severe GvHD is seen in the first cohort of patients, the next 5 will 
receive a dose of CD69' allodepleted T cells of 3x105/kg recipient body weight and 
if no severe GvHD is seen in the second cohort a further 5 patients will receive a 
dose of CD69’ allodepleted T cells of 106/kg recipient body weight. A control group 
of patients will receive an identical CD34-selected transplant with no allodepleted 
T cell reinfusion. Detailed SOPs for the validation and execution of all steps 
involved in the process of production, testing and release of selectively 
allodepleted T cells have been produced and are currently being tested pending 
the production of sufficient quantities of clinical-grade anti-CD69 antibody.
Only when tested in such a clinical setting will the safety of the strategy of re­
infusing CD69-mediated selectively allodepleted donor T cells be ascertained 
and the efficacy of this strategy confirmed in reducing and/or preventing 
clinically significant GvHD. The donor T cell alloresponse in vivo is far more 
complex than any in vitro model that has been developed to quantify the 
alloresponse (such as proliferation assays or cytokine release assays) and thus 
the ultimate realisation of the technique will be its use in vivo.
The speed and breadth of immune reconstitution after the infusion of selectively 
allodepleted T cells using this strategy will be monitored quantitatively and 
qualitatively over time with flow cytometric enumeration of lymphocyte subsets 
(CD3+CD4+, CD3+CD8+, CD3'CD56+, CD4+CD25+ etc) and TCR Vp CDR3 
spectratyping and TCR Vp sub-family frequency distribution in CD4+ and CD8+ 
subsets by the flow cytometric technique validated in Chapter 5. Naive and
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memory T cell subsets will also be enumerated based on their expression of 
CD45RA and CCR7 over time post AHSCT.
The ability of selectively allodepleted donor T cells to provide donor-derived 
immunity against specific pathogens will be monitored over time by the 
measurement of frequencies of viral-specific T cells within recipient blood by 
CMV-HLA Class I tetramer and CMV and EBV ELISpot assays.
8.8 Other Strategies for Potentiating the GvL Effect
In addition to reducing GvHD whilst augmenting immune reconstitution, the 
other potential advantage of the strategy of reinfusion of selectively allodepleted 
donor T cells is preservation of the GvL effect, which is known to be lost after 
profound non-selective T cell depletion. Other strategies for potentiating the 
GvL effect without causing GvHD have been explored in recent years.
One such strategy is the amplification of GvL-reacting lymphocytes in vitro.
The precursor frequency of allogeneic leukaemic blast-reactive T cells is very 
low, (typically in the order of 1/1,000,000 in the unprimed donor).[Jiang et al. 
1991]
Attempts to expand T cell clones with leukaemic blast -specificity would 
therefore require very efficient in vitro T cell selection and expansion 
techniques. Current techniques to raise donor-specific anti-leukaemic blast cell 
T cell lines for clinical use are inconsistent - not all donor-recipient pairs 
generate specific cytotoxic anti-leukaemia clones, and T cell expansion in vitro 
is unreliable.[Falkenburg et al. 1993] This may be due in part to the failure of the 
leukaemic blast cell stimulators to present an immunodominant antigen to the 
responder. The current inability to identify tissue-restricted antigens on 
leukaemic blasts is a great limitation to generating anti-leukaemic T cell clones. 
In this regard the generation of anti-leukaemic cytotoxic T cells responding to 
peptides derived from the myeloid-restricted granule protein proteinase-3 may 
serve as a model for generating strong T cell responses to identified 
antigens.[Molldrem et al. 1996b] We are in the process of developing an in vitro 
strategy of selective allodepletion (based on CD69 expression on alloresponder 
cells) followed donor T cell stimulation by anti-CD28/IL12-stimulated AML blast 
cells to raise non-alloreactive AML-specific T cells for subsequent in vitro 
expansion, with potential for clinical use in relapsed AML patients.
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An alternative approach to potentiate donor anti-tumour T cell activity is the use 
of vaccines based on tumour antigens, which could be administered to the 
donor, or the recipient, after transplantation to boost specific immunity. Some 
progress has been made in the immunotherapy of multiple myeloma by 
vaccinating the donor with myeloma protein to generate idiotype-specific T 
cells.[Kwak et al. 1996;Kwak et al. 2004] However, it has yet to be 
demonstrated that donor vaccination improves the already demonstrable graft- 
versus-myeloma effect after allogeneic BMT.[Alyea et al. 2001]
Other possible immunogenic leukaemic blast cell antigens suitable for use as 
vaccines are peptides derived from leukaemia-specific fusion proteins (such as 
the bcr-abl products p210 or p190 in CML or ALL, and the t(15;17) fusion 
protein in acute promyelocytic leukaemia. Preliminary results from a Phase 2 
clinical trial have demonstrated safety of administration of a tumour-specific, 
bcr-abl-derived fusion peptide vaccine to patients with CML, and also that such 
a vaccine elicits a bcr-abl peptide-specific T-cell immune response, although the 
results are too early to show any clinical benefit of such a strategy.[Cathcart et 
al. 2004] However attempts to generate donor-derived T cells specific to the 
t(15;17) fusion protein for the adoptive treatment of acute promyelocytic 
leukaemia has proved less successful.[Dermime etal. 1996]
As more is learned about the defects in surface expression of critical molecules 
on malignant cells, it may become easier to design ways to correct defects in 
antigen-presentation and co-stimulation associated with leukaemic blasts and 
render them more susceptible to immune attack. IFN-y and GM-CSF upregulate 
MHC molecule expression and render defective leukaemic blast cells 
susceptible to cytolysis by allogeneic CTLs.[Dermime et al. 1997]
The importance of co-stimulation by the leukaemia cell in generating a strong 
immune response has opened up the possibility of using leukaemia cell 
vaccines transfected with the B7 co-stimulatory molecules.[Schultze et al. 1996] 
In animal models this can render nonimmunogenic tumours strongly 
immunogenic. Other promising strategies include transfection of AML blasts with 
co-stimulatory molecules and the IL-12 gene to improve antigen-presentation to 
autologous or donor T cells.[Dunussi-Joannopoulos et al. 1999]
Recently the role ability of allogeneic donor NK cells in providing a sustained 
anti-leukaemic effect has been identified. One of the functions of HLA Class I 
alleles is interaction with NK cells. Receptors termed killer immunoglobulin-like
276
receptors (KIRs) on NK cells recognize HLA Class I molecules. KIR2DL1 
(CD158a) recognises HLA C alleles belonging to the C2 group and KIR2DL2 
and KIR2DL3 (CD158b) recognises HLA C alleles belonging to the C1 group. 
KIR3DL1 recognises HLA Bw4 alleles. Interaction between donor KIR and 
recipient HLA Class I allele inhibits reactivity of the NK cell. Failure to recognize 
the appropriate KIR ligand on a mismatched cell can trigger NK cell elimination 
of that target cell. Recent analysis of haploidentical haematopoietic 
transplantation for acute myeloid leukaemia has shown a reduction of graft 
failure, GvHD and relapse in those with KIR ligand incompatibility in the graft- 
versus-host direction.[Ruggeri et al. 1999a] Furthermore murine models have 
demonstrated the ability of KIR mismatched allogeneic NK cells to exert an anti- 
leukaemic effect without causing GvHD.[Ruggeri et al. 2002] The anti-leukaemic 
effect of allogeneic KIR mismatched donor NK cells is limited to myeloid 
leukaemic blasts that express LFA-1, necessary for NK-mediated cytotoxicity. 
The effect of KIR mismatch is most prominent in the haploidentical setting 
where the graft has been profoundly depleted of T cells. The role of donor KIR 
mismatch is less well established in mismatched unrelated donor AHST. Davies 
et al reported a series of 175 such AHSCTs and found no effect of KIR 
mismatch (assessed by HLA-Bw4 and HLA-C alleles as described by Ruggeri 
et al,[Ruggeri et al. 1999b]) on relapse or survival, although only a small 
proportion of recipients had AML.[Davies et al. 2002] However Giebel et al have 
reported 130 unrelated donor AHSCTs with pre-transplantation antithymocyte 
globulin (ATG) as part of recipient conditioning. Recipients with KIR ligand- 
incompatible donors had a higher probability of overall survival and disease-free 
survival and lower relapse rates compared with those without KIR ligand 
incompatibility. All patients with myeloid malignancies receiving transplants from 
KIR ligand-disparate donors were alive and disease-free with a median follow 
up of 4.5 years.[Giebel et al. 2003] These data support the association of NK 
cell alloreactivity with better outcome after unrelated donor AHSCT when ATG is 
used as part of GvHD prophylaxis. The relative importance of KIR mismatching 
in AHSCT may therefore depend on the level of T cells within the graft. 
Additionally it is becoming increasingly apparent that donor NK cells express 
activatory receptors (for which the ligands remain unidentified) as well as 
inhibitory receptors. In HLA A, B and DR-matched sibling AHSCT performed for 
myeloid disease, overall survival was worse in patients homozygous for group 2
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HLA-C than in patients who carried a group 1 HLA-C (C1) allele. This effect was 
seen only when the donor additionally carried the activating KIR gene 
KIR2DS2.[Cook et al. 2004]
Moreover it has been shown that KIR expression within individuals is 
heterogeneous and independent of anticipated HLA class I ligands.[Becker et 
al. 2003] Thus it seems that the role of donor allogeneic NK cells may be an 
important one in exerting a GvL effect after AHSCT but this may not simply rely 
on the predictable KIR mismatch associated with HLA C group disparity 
between donor and recipient. Additionally, the beneficial effect of donor NK cell 
alloreactivity is masked by the effects of residual alloreactive donor T cells 
(even after non-selective T cell depletion). [Bishara etal. 2004;Lowe etal. 2003] 
In the HLA-mismatched setting, selective depletion of alloreactive T cells using 
the CD69-mediated strategy might provide the beneficial effects of donor T cells 
(GvL, immune reconstitution) without GvHD thus permitting the beneficial 
effects of KIR mismatched donor NK cells to impact on recipient survival.
8-9 Final concluding remarks
The strategy of selective allodepletion of HLA-matched donor T cells based on 
removal of alloreactive cells expressing the activation antigen CD69 has been 
examined in vitro.
Donor-derived T cells are now recognised as major determinants of outcome 
post AHSCT by providing a GvL effect and host immune reconstitution. The 
work presented in this thesis described modification of the host antigen 
presenting system that enables the strategy to be applied in both HLA-matched 
unrelated donor-recipient pairs and HLA-matched sibling donor-recipient pairs. 
The strategy retains the majority of functional anti-CMV and anti-EBV T cells 
within the donor T cell pool. The alloreactive and non-alloreactive T cell subset 
phenotype and TCR vp sub-family distribution has been described. CD69 may 
be used to identify donor T cells specific for CMV and thus the system could be 
used in sequential allostimulation and viral antigen stimulation to provide non- 
alloreactive pathogen-specific donor T cells for safe adoptive T cell therapy to 
enhance recipient immune reconstitution post AHSCT.
Ultimately, the true test of safety and efficacy of the CD69 selective 
allodepletion strategy is in the setting of a clinical pilot study and the
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development and testing of cell selection systems suitable for the production of 
selectively allodepleted donor T cells for such clinical use have been described.
279
Bibliography
Abonour R, Scott KM, Kunkel LA e t  a l .  Autologous transplantation of mobilized peripheral blood 
CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone 
Marrow Transplant. 1998; 22: 957-963.
al Daccak R, Loiseau P, Rabian C e t  a l .  HLA-DR, DQ, and/or DP genotypic mismatches 
between recipient-donor pairs in unrelated bone marrow transplantation and transplant clinical 
outcome. Transplantation 1990; 50: 960-964.
Allison JP. CD28-B7 interactions in T-cell activation. Curr.Opin.Immunol. 1994; 6: 414-419.
Almid C, Carto-Stella C, Wagner JE, Rizzoli V. Umbilical cord blood as a source of 
hematopoietic stem cells: from research to clinical application. Haematologica 1995; 80: 473- 
479.
Alwan WH, Record FM, Openshaw PJ. CD4+ T cells clear virus but augment disease in mice 
infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. 
Clin.Exp.Immunol. 1992; 88: 527-536.
Alyea E, Weller E, Schlossman R e t  a l .  T-cell-depleted allogeneic bone marrow transplantation 
followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft- 
versus-myeloma effect. Blood 2001; 98: 934-939.
Alyea EP, Soiffer RJ, Canning C e t  a l . Toxicity and efficacy of defined doses of CD4(+) donor 
lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 
3671-3680.
Amrolia PJ, Muccioli-Casadei G, Huls H  e t a l . Adoptive Immunotherapy with Allo-Depleted 
Donor T Cells To Improve Immunity After Haplo-ldentical Stem Cell Transplantation. Blood 
2003b; 11:153a-153a.
Amrolia PJ, Muccioli-Casadei G, Yvon E e t a l . Selective depletion of donor alloreactive T cells 
without loss of antiviral or antileukemic responses. Blood 2003a; 102: 2292-2299.
Ancin I, Ferra C, Gallardo D e t  a l .  Do corticosteroids add any benefit to standard GVHD 
prophylaxis in allogeneic BMT? Bone Marrow Transplant. 2001; 28: 39-45.
Anderson BE, McNiff J, Yan J e t  a l .  Memory CD4+ T cells do not induce graft-versus-host 
disease. J.CIin.Invest 2003; 112: 101-108.
Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S e t  a l .  Immune reconstitution without graft- 
versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 
2002; 360: 130-137.
Anon. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on 
the approximation of the laws, regulations and administrative provisions of the Member States 
relating to the implementation of good clinical practice in the conduct of good clinical trials on 
medicinal products for human usehuman use. Official J Eur Communities : 2001; L121: 34-44. 
Abstract
Antin JH, Lee SJ, Neuberg D e t  a l .  A phase I/ll double-blind, placebo-controlled study of 
recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem 
cell transplantation. Bone Marrow Transplant. 2002; 29: 373-377.
Appay V, Dunbar PR, Callan M e t  a l .  Memory CD8+ T cells vary in differentiation phenotype in 
different persistent virus infections. Nat. Med. 2002; 8: 379-385.
Appleton AL, Sviland L, Peiris JS e t  a l .  Role of target organ infection with cytomegalovirus in the 
pathogenesis of graft-versus-host disease. Bone Marrow Transplant. 1995; 15: 557-561.
280
Arnold PY, Davidian DK, Mannie MD. Antigen presentation by T cells: T cell receptor ligation 
promotes antigen acquisition from professional antigen-presenting cells. Eur.J.Immunol. 1997; 
27: 3198-3205.
Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor 
mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.
Ash RC, Casper JT, Chitambar CR e t  a l .  Successful allogeneic transplantation of T-cell- 
depleted bone marrow from closely HLA-matched unrelated donors. N.Engl.J.Med. 1990; 322: 
485-494.
Ashwell JD, Chen C, Schwartz RH. High frequency and nonrandom distribution of alloreactivity 
in T cell clones selected for recognition of foreign antigen in association with self class II 
molecules. J.lmmunol. 1986b; 136: 389-395.
Ashwell JD, Chen C, Schwartz RH. High frequency and nonrandom distribution of alloreactivity 
in T cell clones selected for recognition of foreign antigen in association with self class II 
molecules. J.lmmunol. 1986a; 136: 389-395.
Atkinson K, Farrelly H, Cooley M, O'Flaherty E, Downs K, Biggs J. Human marrow T cell dose 
correlates with severity of subsequent acute graft-versus-host disease. Bone Marrow 
Transplant. 1987; 2: 51-57.
Aubert G, Hassan-Walker AF, Madrigal JA e t  a l . Cytomegalovirus-specific cellular immune 
responses and viremia in recipients of allogeneic stem cell transplants. J.lnfect.Dis. 2001; 184: 
955-963.
Aversa F, Tabilio A, Velardi A e t  a l .  Treatment of high-risk acute leukemia with T-cell-depleted 
stem cells from related donors with one fully mismatched HLA haplotype. N.Engl.J.Med. 1998; 
339: 1186-1193.
Aversa F, Tabilio A, Velardi A, Martelli MF. Allogeneic transplantation across the HLA barriers. 
Rev.Clin.Exp.Hematol. 2001; 5: 147-161.
Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell 
transplants (RI-HSCT). Bone Marrow Transplant. 2002; 29: 191-195.
Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute 
GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J.Exp.Med. 1996; 
183: 2645-2656.
Becker S, Tonn T, Fussel T e t  a l .  Assessment of killer cell immunoglobulinlike receptor 
expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR 
expression independent of anticipated HLA class I ligands. Hum.Immunol. 2003; 64: 183-193.
Berger MA, Korngold R. Immunodominant CD4+ T cell receptor Vbeta repertoires involved in 
graft-versus-host disease responses to minor histocompatibility antigens. J.lmmunol. 1997; 159: 
77-85.
Bernaudin F, Souillet G, Vannier JP e t  a l .  [Treatment of severe forms of sickle cell anemia with 
bone marrow allograft: French experience (15 cases). SFGM]. Nouv.Rev.Fr.Hematol. 1993; 35: 
319-323.
Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966; 62: 21-78.
Bishara A, Brautbar C, Cohen I, Nagler A. Positivity in a modified mixed leukocyte reaction test 
correlates with molecular HLA-C disparity in prediction of unrelated bone marrow 
transplantation outcome. Hum.Immunol. 1999; 60: 833-839.
281
Bishara A, Brautbar C, Nagler A e t  a l . Prediction by a modified mixed leukocyte reaction assay 
of graft-versus-host disease and graft rejection after allogeneic bone marrow transplantation. 
Transplantation 1994; 57: 1474-1479.
Bishara A, De Santis D, Witt CC e t  a l .  The beneficial role of inhibitory KIR genes of HLA class I 
NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual 
donor-alloreactive T cells causing GVHD. Tissue Antigens 2004; 63: 204-211.
Blaise D, Olive D, Him M e t  a l .  Prevention of acute GVHD by in vivo use of anti-interleukin-2 
receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow 
Transplant. 1991; 8: 105-111.
Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free 
survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. 
Lancet 1995; 345: 1144-1146.
Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 
interaction with CTLA4-lg reduces lethal murine graft-versus-host disease across the major 
histocompatibility complex barrier in mice. Blood 1994; 83: 3815-3825.
Blazar BR, Taylor PA, Panoskaltsis-Mortari A e t  a l .  Blockade of CD40 ligand-CD40 interaction 
impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and 
function after bone marrow transplantation. J.lmmunol. 1997; 158: 29-39.
Boise LH, Minn AJ, Noel PJ e t  a l .  CD28 costimulation can promote T cell survival by enhancing 
the expression of Bcl-XL. Immunity. 1995; 3: 87-98.
Bomberger C, Singh-Jairam M, Rodey G e t  a l .  Lymphoid reconstitution after autologous PBSC 
transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 1998; 91: 2588- 
2600.
Borrego F, Robertson MJ, Ritz J, Pena J, Solana R. CD69 is a stimulatory receptor for natural 
killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999; 97: 
159-165.
Braunschweig I, Wang C, Molldrem J. Cytotoxic T lymphocytes (CTL) specific for 
myeloperoxidase-derived HLA-A2-restricted peptides specifically lyse AML and CML cells.
Blood 2000; 96: 3291-3296.
Browning M.B, Woodliff J.E, Konkol M.C, Pati N.T., Truitt R.L., and Johnson B.D. CD150 as a 
potential marker for alloactivated CD4+CD25+ regulatory T cells. Biol.Blood Marrow Transplant. 
9(2). 1-1-2003. Abstract
Bryant PW, Lennon-Dumenil AM, Fiebiger E, Lagaudriere-Gesbert C, Ploegh HL. Proteolysis 
and antigen presentation by MHC class II molecules. Adv.lmmunol. 2002; 80: 71-114.
Buggins AG, Mufti GJ, Salisbury J e t  a l . Peripheral blood but not tissue dendritic cells express 
CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715-1720.
Campbell JJ, Bowman EP, Murphy K et a l .  6-C-kine (SLC), a lymphocyte adhesion-triggering 
chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7. 
J.Cell Biol. 1998; 141: 1053-1059.
Campbell JJ, Murphy KE, Kunkel EJ e t  a l .  CCR7 expression and memory T cell diversity in 
humans. J.lmmunol. 2001; 166: 877-884.
Cantor AB, Orkin SH. Hematopoietic development: a balancing act. Curr.Opin.Genet.Dev. 2001; 
11: 513-519.
Carpenter PA, Pavlovic S, Tso JY e t  a l .  Non-Fc receptor-binding humanized anti-CD3 
antibodies induce apoptosis of activated human T cells. J.lmmunol. 2000; 165: 6205-6213.
282
Carpino N, Turner S, Mekala D et a l .  Regulation of ZAP-70 activation and TCR signaling by two 
related proteins, Sts-1 and Sts-2. Immunity. 2004; 20: 37-46.
Caruso A, Licenziati S, Corulli M e t  a l .  Flow cytometric analysis of activation markers on 
stimulated T cells and their correlation with cell proliferation. Cytometry 1997; 27: 71-76.
Cathead K, Pinilla-lbarz J, Korontsvit T e t  a l .  A multivalent bcr-abl fusion peptide vaccination 
trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-1042.
Cavazzana-Calvo M, Fromont C, Le Deist F e t  a l .  Specific elimination of alloreactive T cells by 
an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 1990; 50:1-7.
Cavazzana-Calvo M, Stephan JL, Sarnacki S e t  a l . Attenuation of graft-versus-host disease and 
graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype 
disparate mouse combination. Blood 1994; 83: 288-298.
Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma 
and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched 
sibling bone marrow transplantation. Blood 2001; 98: 1594-1600.
Cebrian M, Yague E, Rincon M, Lopez-Botet M, de Landazuri MO, Sanchez-Madrid F.
Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on 
activated human lymphocytes. J.Exp.Med. 1988; 168:1621-1637.
Chakrabarti S, Mackinnon S, Chopra R e t  a l .  High incidence of cytomegalovirus infection after 
nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune 
reconstitution. Blood 2002; 99: 4357-4363.
Chakraverty R, Robinson S, Peggs K e t  a l .  Excessive T cell depletion of peripheral blood stem 
cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone 
Marrow Transplant. 2001; 28: 827-834.
Chao NJ, Schlegel PG. Prevention and treatment of graft-versus-host disease. 
Ann.N.Y.Acad.Sci. 1995; 770: 130-140.
Chao NJ, Schmidt GM, Niland JC et a l .  Cyclosporine, methotrexate, and prednisone compared 
with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 
N.Engl.J.Med. 1993; 329: 1225-1230.
Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft- 
versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell 
purging process. Blood 2002; 99: 3083-3088.
Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic C. Blood 2004a; 103: 
1534-1541.
Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L- memory T 
cells without graft-versus-host disease. Blood 2004b; 103: 1534-1541.
Chen JC, Davis BH, Leon MA, Leong LC. Gamma radiation induces CD69 expression on 
lymphocytes. Cytometry 1997; 30: 304-312.
Chmielowski B, Muranski P, Ignatowicz L. In the normal repertoire of CD4+ T cells, a single 
class II MHC/peptide complex positively selects TCRs with various antigen specificities. 
J.lmmunol. 1999; 162: 95-105.
Clark FJ, Gregg R, Piper K e t  a l .  Chronic graft-versus-host disease is associated with increased 
numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004; 103: 2410-2416.
283
Clark RE, Dodi IA, Hill SC e t  a l .  Direct evidence that leukemic cells present HLA-associated 
immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887- 
2893.
Cleaver SA. The Anthony Nolan Research Centre. Bone Marrow Transplant. 1993; 11 Suppl 1: 
38-40.
Cook MA, Milligan DW, Fegan CD e t  a l .  The impact of donor KIR and patient HLA-C genotypes 
on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid 
leukemia. Blood 2004; 103: 1521-1526.
Cooke KR, Gerbitz A, Crawford JM e t  a l . LPS antagonism reduces graft-versus-host disease 
and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
J.Clin.Invest 2001; 107: 1581-1589.
Comelissen, J. J, Brooimans, R., Niesters, H. A., Southwick, P. A., Sullivan, L. A., van 
Doomum, G„ Lowenburg, B., and Gratama, J. W. Effective Recovery of CD4+ CMV-specific 
Helper T cells in the Presence of CMV-specific CD8+ T-Cells is Pivotal for the prevention of 
Recurrent CMV-Reactivation Following Allogeneic Stem Cell Transplantation. Blood 102. 2003. 
Abstract
Cometta K, Gharpure V, Mills B e t  a l .  Rapid engraftment after allogeneic transplantation using 
CD34-enriched marrow cells. Bone Marrow Transplant. 1998; 21: 65-71.
Counce S, Smith P. Strong and weak histocompatibility gene differences in mice and their role 
in the rejection of homografts of tumours and skin. Annals of Surgery 1956; 144: 198-204.
Craston R, Koh M, Me DA, Ray N, Prentice HG, Lowdell MW. Temporal dynamics of CD69 
expression on lymphoid cells. J.lmmunol.Methods 1997; 209: 37-45.
Cray C, Levy RB. Virus-associated immune responses in mice undergoing GVHR exacerbated 
by concurrent MCMV infection. Transplantation 1990; 50:1027-1032.
Cray C, Levy RB. CD8+ and CD4+ T cells contribute to the exacerbation of class I MHC 
disparate graft-vs-host reaction by concurrent murine cytomegalovirus infection.
Clin.Immunol.Immunopathol. 1993; 67: 84-90.
Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of interleukin- 
1 alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic 
bone marrow transplantation. Br.J.Haematol. 2003; 122: 778-787.
Cwynarski K, Ainsworth J, Cobbold M e t  a l .  Direct visualization of cytomegalovirus-specific T- 
cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97:1232-1240.
Daniel C, Horvath S, Allen PM. A basis for alloreactivity: MHC helical residues broaden peptide 
recognition by the TCR. Immunity. 1998; 8: 543-552.
Datta AR, Barrett AJ, Jiang YZ e t  a l .  Distinct T cell populations distinguish chronic myeloid 
leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from 
GVL reactions. Bone Marrow Transplant. 1994; 14: 517-524.
Dausett J, Rapaport FT. Tissue alloantigens and transplantaio. In: H Balner, FJ Cleton, editors. 
Histocompatibility testing. Copenhagen: Munksgaar, 1965: 63-78.
Davies, J. K, Koh, M. B, Lowdell, M. W., and Prentice, H. G. Potentiating the MLR. Biol.Blood 
Marrow Transplant. 2003. Abstract
284
Davies SM, Kollman C, Anasetti C e t  a l .  Engraftment and survival after unrelated-donor bone 
marrow transplantation: a report from the national marrow donor program. Blood 2000; 96: 
4096-4102.
Davies SM, Ruggieri L, DeFor T e t  a l .  Evaluation of KIR ligand incompatibility in mismatched 
unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002;
100: 3825-3827.
Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988;
334: 395-402.
de Bueger M, Bakker A, Van Rood JJ, Van der WF, Goulmy E. Tissue distribution of human 
minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates 
heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J.lmmunol. 
1992; 149: 1788-1794.
De Koning J, Van Bekkum DW, Dicke KA, Dooren LJ, Radi J, Van Rood JJ. Transplantation of 
bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. 
Lancet 1969; 1: 1223-1227.
De Palma R, Gorski J. Restricted and conserved T-cell repertoires involved in allorecognition of 
dass II major histocompatibility complex. Proc.Natl.Acad.Sd.U.S.A 1995; 92: 8836-8840.
DeGast GC, Mickelson EM, Beatty PG e t  a l .  Mixed leukocyte culture reactivity and graft-versus- 
host disease in HLA-identical marrow transplantation for leukemia. Bone Marrow Transplant. 
1992; 9: 87-90.
Denny MF, Patai B, Straus DB. Differential T-cell antigen receptor signaling mediated by the Src 
family kinases Lck and Fyn. Mol.Cell Biol. 2000; 20: 1426-1435.
Department of Health. Guidance notes on the processing, storage and issue of bone marrow 
and blood stem cells. 1997. Report
Department of Health. A code of practice for tissue banks providing tissues of human origin for 
therapeutic purposes. 2001. Report
Dermime S, Bertazzoli C, Marchesi E e t  a l .  Lack of T-cell-mediated recognition of the fusion 
region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia 
patients. Clin.Cancer Res. 1996; 2: 593-600.
Dermime S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a 
graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following 
allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997; 19: 989-999.
Dickinson AM, Cavet J, Cullup H, Wang XN, Sviland L, Middleton PG. GvHD risk assessment in 
hematopoietic stem cell transplantation: role of cytokine gene polymorphisms and an in vitro 
human skin explant model. Hum.Immunol. 2001; 62: 1266-1276.
Dickinson AM, Sviland L, Wang XN e t  a l .  Predicting graft-versus-host disease in HLA-identical 
bone marrow transplant: a comparison of T-cell frequency analysis and a human skin explant 
model. Transplantation 1998; 66: 857-863.
Djilali-Saiah I, Ouellette P, Caillat-Zucman S, Debray D, Kohn Jl, Alvarez F. CTLA-4/CD 28 
region polymorphisms in children from families with autoimmune hepatitis. Hum.Immunol. 2001; 
62: 1356-1362.
Dreger P, Viehmann K, von Neuhoff N e t  a l . A prospective study of positive/negative ex vivo B- 
cell depletion in patients with chronic lymphocytic leukemia. Exp.Hematol. 2000; 28: 1187-1196.
285
Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T cell- 
depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996; 17:1093- 
1099.
Duarte RF, Chen FE, Lowdell MW e t  a l .  Functional impairment of human T-lymphocytes 
following PHA-induced expansion and retroviral transduction: implications for gene therapy. 
Gene Ther. 2002; 9: 1369-1368.
Dumont-Girard F, Roux E, van Lier RA et a l . Reconstitution of the T-cell compartment after 
bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 1998; 92: 
4464-4471.
Dunn HS, Haney DJ, Ghanekar SA, Stepick-Biek P, Lewis DB, Maecker HT. Dynamics of CD4 
and CD8 T cell responses to cytomegalovirus in healthy human donors. J.Infect.Dis. 2002; 186: 
15-22.
Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP. 
Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent 
therapeutic and long-lasting protective immunity. Blood 1999; 94: 4263-4273.
DuPont B, Hansen JA. Human mixed-lymphocyte culture reaction: genetics, specificity, and 
biological implications. Adv. Immunol. 1976; 23: 107-202.
Durie FH, Aruffo A, Ledbetter J e t  a l .  Antibody to the ligand of CD40, gp39, blocks the 
occurrence of the acute and chronic forms of graft-vs-host disease. J.CIin.Invest 1994; 94: 
1333-1338.
Edinger M, Hoffmann P, Ermann J e t  a l .  CD4+CD25+ regulatory T cells preserve graft-versus- 
tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Nat. Med. 2003; 9: 1144-1160.
Einsele H, Ehninger G, Hebart H e t  a l .  Incidence of local CMV infection and acute intestinal 
GVHD in marrow transplant recipients with severe diarrhoea. Bone Marrow Transplant. 1994;
14: 955-963.
Einsele H, Rauser G, Grigoleit U e t  a l .  Induction of CMV-specific T-cell lines using Ag- 
presenting cells pulsed with CMV protein or peptide. Cytotherapy. 2002; 4: 49-54.
El Kassar N, Legouvello S, Joseph CM e t  a l .  High resolution HLA class I and II typing and CTLp 
frequency in unrelated donor transplantation: a single-institution retrospective study of 69 BMTs. 
Bone Marrow Transplant. 2001; 27: 35-43.
Falkenburg JH, Faber LM, van den EM e t  a l .  Generation of donor-derived antileukemic cytotoxic 
T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone 
marrow transplantation. J.lmmunother. 1993; 14: 305-309.
Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of alloreactive donor 
T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69).
Br.J.Haematol. 2000a; 109: 644-651.
Fehse, B., Goldmann, M., Frerk, O., Bulduk, M., and Zander, A. R. Depletion of alloreactive 
donor T cells using immunomagnetic cell selection. Bone Marrow Transplant. 25 Suppl 2, S39- 
S42. 2000. Abstract
Feng C, Woodside KJ, Vance BA e t  a l .  A potential role for CD69 in thymocyte emigration. 
Int.lmmunol. 2002; 14: 535-544.
Ferrara J, Mauch P, Murphy G, Burakoff SJ. Bone marrow transplantation: the genetic and 
cellular basis of resistance to engraftment and acute graft-versus-host disease.
Surv.Immunol.Res. 1985; 4: 253-263.
286
Field EH, Gao Q. CD4 regulatory cells in immune tolerance. J.Lab Clin.Med. 1998; 132: 91-96.
Filipovich AH, McGlave PB, Ramsay NK, Goldstein G, Warkentin PI, Kesey JH. Pretreatment of 
donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host 
disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1982; 1:1266-1269.
Ford CE, Hamerton JL, Barnes DWH, Loutit JF. Cytological identification of radiation chiaeras. 
Nature 1956; 177: 239-247.
Forster R, Schubel A, Breitfeld D e t  a l .  CCR7 coordinates the primary immune response by 
establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 23-33.
Foster AE, Marangolo M, Sartor MM e t  a l .  Human CD62L- Memory T Cells are Less 
Responsive to Alloantigen Stimulation Than CD62L+ Naive T Cells: Potential for Adoptive 
Immunotherapy. Blood 2004. July 1 E-Pub ahead of print
Franzke A, P i a o  W, Lauber J e t  a l .  G-CSF as immune regulator in T cells expressing the G-CSF 
receptor: implications for transplantation and autoimmune diseases. Blood 2003; 102: 734-739.
Friedman TM, Gilbert M, Briggs C, Komgold R. Repertoire analysis of CD8+ T cell responses to 
minor histocompatibility antigens involved in graft-versus-host disease. J.lmmunol. 1998; 161: 
41-48.
Friedman TM, Statton D, Jones SC, Berger MA, Murphy GF, Komgold R. Vbeta spectratype 
analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens 
involved in graft-versus-host disease: correlations with epithelial tissue infiltrate. Biol.Blood 
Marrow Transplant. 2001; 7: 2-13.
Gallardo D, Arostegui Jl, Balas A e t  a l .  Disparity for the minor histocompatibility antigen HA-1 is 
associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not 
affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human 
leucocyte antigen-identical sibling donor transplantation. Br.J.Haematol. 2001; 114: 931-936.
Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary 
immune responses to human CMV: a critical role for IFN-gamma -producing CD4+ T cells in 
protection against CMV disease. Blood 2003; 101: 2686-2692.
Gandhi MK, Wills MR, Okecha G e t  a l .  Late diversification in the clonal composition of human 
cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell 
transplantation. Blood 2003; 102: 3427-3438.
Gao Q, Rouse TM, Kazmerzak K, Field EH. CD4+CD25+ cells regulate CD8 cell anergy in 
neonatal tolerant mice. Transplantation 1999; 68: 1891-1897.
Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ 
memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003; 101: 4260- 
4266.
Gerosa F, Tommasi M, Scardoni M e t  a l . Structural analysis of the CD69 early activation 
antigen by two monoclonal antibodies directed to different epitopes. Mol. Immunol. 1991; 28: 
159-168.
Giebel S, Locatelli F, Lamparelli T e t  a l . Survival advantage with KIR ligand incompatibility in 
hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
Gilbert KM, Boger S, Fifer EK. Butyric acid derivative induces allospecific T cell anergy and 
prevents graft-versus-host disease. Immunopharmacol.lmmunotoxicol. 2003; 25: 13-27.
Gillespie GM, Wills MR, Appay V e t  a l .  Functional heterogeneity and high frequencies of 
cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J.Virol. 2000;
74: 8140-8150.
287
Gluckman E, Devergie A, Thierry D e t  a l . Clinical applications of stem cell transfusion from cord 
blood and rationale for cord blood banking. Bone Marrow Transplant. 1992; 9 Suppl 1:114-117.
Godfrey WR. Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive cells based on 
CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004; 103: 
1158-1165.
Godthelp BC, van Tol MJ, Vossen JM, van Den Elsen PJ. T-Cell immune reconstitution in 
pediatric leukemia patients after allogeneic bone marrow transplantation with T-cell-depleted or 
unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires. Blood 1999; 
94: 4358-4369.
Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999;
402: 255-262.
Gorochov G, Neumann AU, Kereveur A e t  a l .  Perturbation of CD4+ and CD8+ T-cell repertoires 
during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy.
Nat. Med. 1998; 4: 215-221.
Gorski J, Yassai M, Zhu X e t  a l .  Circulating T cell repertoire complexity in normal individuals and 
bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. 
J.lmmunol. 1994; 152: 5109-5119.
Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation 
and adoptive immunotherapy. Immunol.Rev. 1997; 157: 125-140.
Goulmy E, Termijtelen A, Bradley BA, Van Rood JJ. Alloimmunity to human H-Y. Lancet 1976;
2: 1206.
Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent 
mechanisms are both important for the development of graft-versus-host disease after murine 
bone marrow transplantation. J.CIin.Invest 1997; 100: 904-911.
Gribben JG, Guinan EC, Boussiotis VA e t  a l .  Complete blockade of B7 family-mediated 
costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate 
graft-versus-host disease and extend the donor pool. Blood 1996; 87: 4887-4893.
Grab JP, Grundy JE, Prentice HG e t  a l .  Immune donors can protect marrow-transplant 
recipients from severe cytomegalovirus infections. Lancet 1987; 1: 774-776.
Guinan EC, Boussiotis VA, Neuberg D e t  a l .  Transplantation of anergic histoincompatible bone 
marrow allografts. N.Engl.J.Med. 1999; 340: 1704-1714.
Hall BL, Finn OJ. T cell receptor V beta gene usage in allograft-derived cell lines analyzed by a 
polymerase chain reaction technique. Transplantation 1992; 53:1088-1099.
Hamann D, Baars PA, Rep MH e t  a l .  Phenotypic and functional separation of memory and 
effector human CD8+ T cells. J.Exp.Med. 1997; 186: 1407-1418.
Hamel Y, Rohrlich P, Baron V e t  a l .  Characterization of antigen-specific repertoire diversity 
following in vitro restimulation by a recombinant adenovirus expressing human cytomegalovirus 
pp65. Eur.J.Immunol. 2003; 33: 760-768.
Harris DT, Sakiestewa D, Lyons C, Kreitman RJ, Pastan I. Prevention of graft-versus-host 
disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that 
target the interleukin 2 (IL-2) receptor. Bone Marrow Transplant. 1999; 23:137-144.
Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can 
be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. 
Blood 2002; 99: 3041-3049.
288
Hatton K, Hirano T, Miyajima H ©/ a l .  Differential effects of anti-Fas ligand and anti-tumor 
necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998; 
91:4051-4055.
Heemskerk MH, de Paus RA, Lurvink EG e t  a l .  Dual HLA class I and class II restricted 
recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. 
Proc.Natl.Acad.Sci.U.S.A 2001; 98: 6806-6811.
Helene M, Lake-Bullock V, Bryson JS, Jennings CD, Kaplan AM. Inhibition of graft-versus-host 
disease. Use of a T cell-controlled suicide gene. J.lmmunol. 1997; 158: 5079-5082.
Hennecke J, Wiley DC. Structure of a complex of the human alpha/beta T cell receptor (TCR) 
HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, 
HLA-DR4 (DRA*0101 and DRB 1*0401): insight into TCR cross-restriction and alloreactivity.
J.Exp.Med. 2002; 195: 571-581.
Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. 
N.Engl.J.Med. 1994; 331: 679-680.
Hewitt CR, Feldmann M. Human T cell clones present antigen. J.lmmunol. 1989; 143: 762-769.
Hill GR, Cooke KR, Teshima T e t a l .  Interleukin-11 promotes T cell polarization and prevents 
acute graft-versus-host disease after allogeneic bone marrow transplantation. J.CIin.Invest 
1998; 102:115-123.
Hirschhorn R. Treatment of genetic diseases by allotransplantation. Birth Defects Orig.Artic.Ser. 
1980; 16: 429-444.
Ho, C, Van Epps, D. W, Loudovaris, M, Bender, J, and Luqman, M. Elimination of alloreactive T 
cells from haematopoietic grafts using the Isolex(R) immunomagnetic cell selection system. 
Bone Marrow Transplantation 25.S155. 2003. Abstract
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) 
regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow 
transplantation. J.Exp. Med. 2002; 196: 389-399.
Holler E, Kolb HJ, Mittermuller J e t  a l .  Modulation of acute graft-versus-host-disease after 
allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in 
the course of pretransplant conditioning: role of conditioning regimens and prophylactic 
application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 
86: 890-899.
Hollsberg P. Contribution of HLA class I allele expression to CD8+ T-cell responses against 
Epstein-Barr virus. Scand.J.lmmunol. 2002; 55: 189-195.
Horowitz MM, Gale RP, Sondel PM e t  a l .  Graft-versus-leukemia reactions after bone marrow 
transplantation. Blood 1990; 75: 555-562.
Hromadnikova I, Sedlacek P, Stary J e t  a l .  An in vitro skin explant assay as a predictive assay 
for graft-versus-host disease in a cohort of pediatric transplants. Pediatr.Transplant. 2001; 5: 
258-265.
Hromas R, Cometta K, Srour E, Blanke C, Broun ER. Donor leukocyte infusion as therapy of 
life-threatening adenoviral infections after T-cell-depleted bone m a r r o w  transplantation. Blood 
1994; 84: 1689-1690.
Huang D, Giscombe R, Zhou Y, Pirskanen R, Lefvert AK. Dinucleotide repeat expansion in the 
CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis. 
J.Neuroimmunol. 2000; 105: 69-77.
289
Ignatowicz L, Kappler J, Marrack P. The repertoire of T cells shaped by a single MHC/peptide 
ligand. Cell 1996; 84: 521-529.
Ihara K, Ahmed S, Nakao F e t  a l . Association studies of CTLA-4, CD28, and ICOS gene 
polymorphisms with type 1 diabetes in the Japanese population. Immunogenetics 2001; 53: 
447-454.
Jacobsen N, Andersen HK, Skinhoj P e t  a l .  Correlation between donor cytomegalovirus 
immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation. 
Scand.J.Haematol. 1986; 36: 499-506.
Jacobsen N, Badsberg JH, Lonnqvist B e t  a l .  Graft-versus-leukaemia activity associated with 
CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft- 
versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow 
Transplantation Group. Bone Marrow Transplant. 1990; 5: 413-418.
Jacobsen N, Lonnqvist B, Ringden O e t  a l . Graft-versus-leukaemia activity associated with 
cytomegalovirus seropositive bone marrow donors but separated from graft-versus-host disease 
in allograft recipients with AML. Eur.J.Haematol. 1987; 38: 350-355.
Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host 
disease. Curr.Pharm.Des 2004; 10: 1195-1205.
Jacobson LO, Simmons EL, Marks EK, Eldredge JH. Recovery from Radiation Injury. Science 
1951; 113:510-511.
Janeway CA, Travers PJ, Walport M., Capra JD. Immunobiology. 4th Edition, 1999. 407-408
Jarvinen LZ, Blazar BR, Adeyi OA, Strom TB, Noelle RJ. CD154 on the surface of CD4+CD25+ 
regulatory T cells contributes to skin transplant tolerance. Transplantation 2003; 76:1375-1379.
Jiang YZ, Kanfer EJ, Macdonald D, Cullis JO, Goldman JM, Barrett AJ. Graft-versus-leukaemia 
following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes 
reacting to host leukaemia cells. Bone Marrow Transplant. 1991; 8: 253-258.
Jiang YZ, Mavroudis DA, Dermime S, Molldrem J, Hensel NF, Barrett AJ. Preferential usage of 
T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: 
implications for separating graft-versus-leukemia effect from graft-versus-host disease. Bone 
Marrow Transplant. 1997; 19: 899-903.
Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress 
alloreactivity after BMT. Biol.Blood Marrow Transplant. 2002; 8: 525-535.
Jones M, Cray C, Levy RB. Concurrent MCMV infection augments donor antihost-specific 
activity and alters clinical outcome following experimental allogenic bone marrow 
transplantation. Transplantation 1996; 61: 856-861.
Jones SC, Friedman TM, Murphy GF, Komgold R. Specific donor Vbeta-associated CD4 T-cell 
responses correlate with severe acute graft-versus-host disease directed to multiple minor 
histocompatibility antigens. Biol.Blood Marrow Transplant. 2004; 10: 91-105.
Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft- 
versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia 
response. Biol.Blood Marrow Transplant. 2003; 9: 243-256.
Judd BA, Koretzky GA. Antigen specific T lymphocyte activation. Rev.lmmunogenet. 2000; 2: 
164-174.
June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell 
activation. Immunol.Today 1990; 11: 211-216.
290
Karulin AY, Hesse MD, Tary-Lehmann M, Lehmann PV. Single-cytokine-producing CD4 
memory cells predominate in type 1 and type 2 immunity. J.lmmunol. 2000; 164: 1862-1872.
Keenan RD, Ainsworth J, Khan N e t  a l .  Purification of cytomegalovirus-specific CD8 T cells from 
peripheral blood using HLA-peptide tetramers. Br.J.Haematol. 2001; 115: 428-434.
Keever CA, Small TN, Flomenberg N e t  a l .  Immune reconstitution following bone marrow 
transplantation: comparison of recipients of T-cell depleted marrow with recipients of 
conventional marrow grafts. Blood 1989; 73: 1340-1350.
Kern F, Surel IP, Faulhaber N e t  a l .  Target structures of the CD8(+)-T-cell response to human 
cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J.Virol. 1999; 73: 
8179-8184.
Kingsley Cl, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft 
rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J.lmmunol. 2002; 
168: 1080-1086.
Kishi Y, Kami M, Oki Y e t  a l .  Donor lymphocyte infusion for treatment of life-threatening 
respiratory syncytial virus infection following bone marrow transplantation. Bone Marrow 
Transplant. 2000; 26: 573-576.
Klangsinsirikul P, Carter Gl, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion 
of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay 
donor DC reconstitution. Blood 2002; 99: 2586-2591.
Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA e t  a l .  Direct cloning of leukemia-reactive 
T cells from patients treated with donor lymphocyte infusion shows a relative dominance of 
hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. 
Leukemia 2004; 18: 798-808.
Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. Alloantigen-specific T-cell 
depletion in a major histocompatibility complex fully mismatched murine model provides 
effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment.
Br.J.Haematol. 2002; 118: 108-116.
Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic 
stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999; 23: 
1071-1079.
Kolb HJ, Schattenberg A, Goldman JM e t  a l .  Graft-versus-leukemia effect of donor lymphocyte 
transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation 
Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
Kollman C, Howe CW, Anasetti C e t  a l .  Donor characteristics as risk factors in recipients after 
transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 
2043-2051.
Kranz DM. Incompatible differences: view of an allogeneic pMHC-TCR complex. Nat.lmmunol. 
2000; 1: 277-278.
Kubo K, Yamanaka K, Kiyoi H e t  a l . Different T-cell receptor repertoires between lesions and 
peripheral blood in acute graft-versus-host disease after allogeneic bone marrow 
transplantation. Blood 1996; 87: 3019-3026.
Kwak LW, Neelapu SS, Bishop MR. Adoptive immunotherapy with antigen-specific T cells in 
myeloma: a model of tumor-specific donor lymphocyte infusion. Semin.Oncol. 2004; 31: 37-46.
Kwak LW, Pennington R, Longo DL. Active immunization of murine allogeneic bone marrow 
transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific 
antitumor effect of marrow grafts. Blood 1996; 87: 3053-3060.
291
Lacey SF, Villacres MC, La Rosa C e t  a l .  Relative dominance of HLA-B*07 restricted CD8+ T- 
lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 
and HLA-B*07 alleles. Hum. Immunol. 2003; 64: 440-452.
Lampert IA, Moore RH, Huby R, Cohen J. Observations on the role of endotoxin in graft-versus- 
host disease. Prog.Clin.Biol.Res. 1988; 272: 351-359.
Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and 
memory cells. Science 2000; 290: 92-97.
Larsson K, Aschan J, Remberger M, Ringden O, Winiarski J, Ljungman P. Reduced risk for 
extensive chronic graft-versus-host disease in patients receiving transplants with human 
leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive 
therapy against cytomegalovirus. Transplantation 2004; 77: 526-531.
Laughlin MJ. Umbilical cord blood for allogeneic transplantation in children and adults. Bone 
Marrow Transplant. 2001; 27: 1-6.
Lauzurica P, Sancho D, Torres M e t  a l . Phenotypic and functional characteristics of 
hematopoietic cell lineages in CD69-deficient mice. Blood 2000; 95: 2312-2320.
Leake CD LBW. The erythropoietic action of red bone marrow and spleen extracts. Journal of 
Pharmacology and Experimental Therapy . 1929; 75-77.
Lechler Rl, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney 
allografts by the addition o f  donor strain dendritic cells. J.Exp. Med. 1982; 155: 31-41.
Lechner F, Cuero AL, Kantzanou M, Klenerman P. Studies of human antiviral CD8+ 
lymphocytes using class I peptide tetramers. Rev.Med.Virol. 2001; 11: 11-22.
Leeuwenberg JF, Van Damme J, Meager T, Jeunhomme TM, Buurman WA. Effects of tumor 
necrosis factor on the interferon-gamma-induced major histocompatibility complex class II 
antigen expression by human endothelial cells. Eur. J.lmmunol. 1988; 18: 1469-1472.
Lehner PJ, Wang EC, Moss PA e t  a l .  Human HLA-A0201-restricted cytotoxic T lymphocyte 
recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. 
J.Exp.Med. 1995; 181: 79-91.
Leiva LE, Regueira O, Sorensen RU. Peripheral blood mononuclear cell sonicates as an 
alternative to irradiated allogeneic cells to stimulate a mixed lymphocyte reaction and to 
enumerate CD69+ alloreactive T cells. Hum.Immunol. 1997; 56: 49-56.
Li YY, Smith KD, Shi Y, Lutz CT. Alloreactive anti-HLA-B7 cytolytic T cell clones use restricted T 
cell receptor genes. Transplantation 1996; 62: 954-961.
Lim A, Trautmann L, Peyrat MA e t  a l .  Frequent contribution of T cell clonotypes with public TCR 
features to the chronic response against a dominant EBV-derived epitope: application to direct 
detection of their molecular imprint on the human peripheral T cell repertoire. J.lmmunol. 2000; 
165: 2001-2011.
Lindahl KF, Wilson DB. Histocompatibility antigen-activated cytotoxic T lymphocytes. I.
Estimates of the absolute frequency of killer cells generated in vitro. J.Exp.Med. 1977a; 145: 
500-507.
Lindahl KF, Wilson DB. Histocompatibility antigen-activated cytotoxic T lymphocytes. II. 
Estimates of the frequency and specificity of precursors. J.Exp.Med. 1977b; 145: 508-522.
Little AM, Madrigal JA. Molecular matching in allogeneic bone marrow transplantation. 
Eur.J.Immunogenet. 1999; 26: 35-41.
292
Liu Z, Sun YK, Xi YP e t  a l .  Contribution of direct and indirect recognition pathways to T cell 
alloreactivity. J.Exp.Med. 1993; 177: 1643-1650.
Ljungman P. Immune reconstitution and viral infections after stem cell transplantation. Bone 
Marrow Transplant. 1998; 21 Suppl 2: S72-S74.
Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV 
serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell 
transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255-4260.
Lobashevsky A, Kotb M, Gaber AO. Selective T cell receptor Vbeta gene usage by alloreactive 
T cells responding to defined HLA-DR alleles. Transplantation 1996; 62: 1332-1340.
Longmate J, York J, La Rosa C e t  a l .  Population coverage by HLA class-l restricted cytotoxic T- 
lymphocyte epitopes. Immunogenetics 2001; 52:165-173.
Lonnqvist B, Ringden O, Ljungman P, Wahren B, Gahrton G. Reduced risk of recurrent 
leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br.J. Haematol. 
1986; 63: 671-679.
Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection 
associated with and preceding chronic graft-versus-host disease. Transplantation 1984; 38: 
465-468.
Lorenz E, Congdon CC, Uphoff D. Modification of acute irradiation injury in mice and guinea 
pigs by bone marrow injections. Radiology 1951; 58: 863-877.
Lowdell MW, Craston R, Samuel D e t  a l . Evidence that continued remission in patients treated 
for acute leukaemia is dependent upon autologous natural killer cells. Br.J.Haematol. 2002;
117: 821-827.
Lowe EJ, Turner V, Handgretinger R e t a l .  T-cell alloreactivity dominates natural killer cell 
alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow 
transplantation. Br.J.Haematol. 2003; 123: 323-326.
Lucarelli G, Polchi P, Izzi T e t  a l .  Allogeneic marrow transplantation for thalassemia. 
Exp.Hematol. 1984; 12: 676-681.
Maccario, R, Cometa, A, Moretta, A, Comoli, D, Montagna, D, Avanzini, MA, Labirio, M, 
Giorgiani, G, Zecca, M, and Locatelli, F. Depletion of MLC-activated CD69+ cells combined with 
CTLA4-lg treatment as a strategy to control T-Cell mediated alloreactivity. Bone Marrow 
Transplant. 2003. Abstract
Mackinnon S, Goldman JM. Bone marrow transplantation for patients with chronic myeloid 
leukaemia. Br.J. Hosp. Med. 1988; 39: 226-230.
Mackinnon S, Papadopoulos EB, Carabasi MH e t  a l .  Adoptive immunotherapy evaluating 
escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow 
transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. 
Blood 1995; 86: 1261-1268.
Madrigal JA, Scott I, Arguello R, Szydlo R, Little AM, Goldman JM. Factors influencing the 
outcome of bone marrow transplants using unrelated donors. Immunol.Rev. 1997; 157: 153- 
166.
Mannie MD, Nardella JP, White GA, Arnold PY, Davidian DK. Class II MHC/peptide complexes 
on T cell antigen-presenting cells: agonistic antigen recognition inhibits subsequent antigen 
presentation. Cell Immunol. 1998; 186: 111-120.
Mannie MD, Walker MR. Feedback activation of T-cell antigen-presenting cells during 
interactions with T-cell responders. J.Leukoc.Biol. 2001; 70: 252-260.
293
Margolis DA, Casper JT, Segura AD e t  a l .  Infiltrating T cells during liver graft-versus-host 
disease show a restricted T-cell repertoire. Biol.Blood Marrow Transplant. 2000; 6: 408-415.
Marijt WA, Heemskerk MH, Kloosterboer FM e t  a l . Hematopoiesis-restricted minor 
histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of 
relapsed leukemia. Proc.Natl.Acad.Sci.U.S.A 2003; 100: 2742-2747.
Martin-Henao GA, Picon M, Amill B e t  a l . Combined positive and negative cell selection from 
allogeneic peripheral blood progenitor cells (PBPC) by use of immunomagnetic methods. Bone 
Marrow Transplant. 2001; 27: 683-687.
Martins SL, St John LS, Champlin RE e t  a l . Functional assessment and specific depletion of 
alloreactive human T cells using flow cytometry. Blood 2004. July 29. E-Pub ahead of print
Marzto R, Mauel J, Betz-Corradin S. CD69 and regulation of the immune function. 
Immunopharmacol.lmmunotoxicol. 1999; 21: 565-582.
Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. 
Immunol.Today 1998; 19: 395-404.
Massumoto C, Benyunes MC, Sale G e t  a l .  Close simulation of acute graft-versus-host disease 
by interleukin-2 administered after autologous bone marrow transplantation for hematologic 
malignancy. Bone Marrow Transplant. 1996; 17: 351-356.
Matesic D, Lehmann PV, Heeger PS. High-resolution characterization of cytokine-producing 
alloreactivity in naive and allograft-primed mice. Transplantation 1998; 65: 906-914.
Mathe G, Jammet H, Pendic B. Transfusions and grafts of homologous bone marrow in humans 
accidentally irradiated to high doses. Revue Frances Etudes Clinical Biology 1959; 4: 226-229.
Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994; 12: 991- 
1045.
Mavroudis DA, Dermime S, Molldrem J et a l .  Specific depletion of alloreactive T cells in HLA- 
identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia 
reactions. Br.J.Haematol. 1998; 101: 565-570.
Mavroudis DA, Jiang YZ, Hensel N e t  a l . Specific depletion of alloreactivity against haplotype 
mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus- 
host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow 
Transplant. 1996; 17: 793-799.
Maximow A. Der Lymphozyt als gemeinsame Stammzelle der verschiedenen Blutelemente in 
der embryonalen Entwicklung und im postfetalen Leben der Sflugetiere. Folia Heamatol 
(Leipzig) 1990; 8: 125-141.
McKenzie RC, Sauder DN. The role of keratinocyte cytokines in inflammation and immunity.
J.Invest Dermatol. 1990; 95: 105S-107S.
Meijer RT, Yong SL, Ten Berge IJ, van Lier RA, Schellekens PT. Non FcR-binding murine 
antihuman CD3 monoclonal antibody is capable of productive TCR signalling and induces 
proliferation in the presence of costimulation. Clin.Exp.Immunol. 2001; 123: 511-519.
Mescher MF. Molecular interactions in the activation of effector and precursor cytotoxic T 
lymphocytes. Immunol.Rev. 1995; 146: 177-210.
Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human 
marrow transplantation. J.Infect.Dis. 1986; 153: 478-488.
294
Mickelson EM, Bartsch GE, Hansen JA, DuPont B. The MLC assay as a test for HLA-D region 
compatibility between patients and unrelated donors: results of a national marrow donor 
program involving multiple centers. Tissue Antigens 1993; 42: 466-472.
Mickelson EM, Longton G, Anasetti C e t  a l .  Evaluation of the mixed lymphocyte culture (MLC) 
assay as a method for selecting unrelated donors for marrow transplantation. Tissue Antigens 
1996; 47: 27-36.
Middleton PG, Norden J, Cullup H e t  a l .  Oestrogen receptor alpha gene polymorphism 
associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched 
sib-allo BMT. Bone Marrow Transplant. 2003; 32: 41-47.
Miller W, Flynn P, McCullough J e t  a l .  Cytomegalovirus infection after bone marrow 
transplantation: an association with acute graft-v-host disease. Blood 1986; 67:1162-1167.
Mohr M, Dalmis F, Hilgenfeld E e t a l .  Simultaneous immunomagnetic CD34+ cell selection and 
B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non- 
Hodgkin's lymphoma. Clin.Cancer Res. 2001; 7: 51-57.
Molldrem J, Dermime S, Parker K e t  a l . Targeted T-cell therapy for human leukemia: cytotoxic T 
lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid 
leukemia cells. Blood 1996; 88: 2450-2457.
Molldrem JJ, Clave E, Jiang YZ e t  a l . Cytotoxic T lymphocytes specific for a nonpolymorphic 
proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 
1997; 90: 2529-2534.
Molldrem JJ, Komanduri K, Wieder E. Overexpressed differentiation antigens as targets of graft- 
versus-leukemia reactions. Curr.Opin.Hematol. 2002; 9: 503-508.
Molldrem JJ, Lee PP, Wang C e t  a l .  Evidence that specific T lymphocytes may participate in the 
elimination of chronic myelogenous leukemia. Nat. Med. 2000; 6: 1018-1023.
Montagna D, Yvon E, Calcaterra V e t  a l . Depletion of alloreactive T cells by a specific anti­
interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral 
activity. Blood 1999; 93: 3550-3557.
Morimoto C, Letvin NL, Distaso JA, Aldrich WR, Schlossman SF. The isolation and 
characterization of the human suppressor inducer T cell subset. J.lmmunol. 1985; 134: 1508- 
1515.
Moron G, Dadaglio G, Leclerc C. New tools for antigen delivery to the MHC class I pathway. 
Trends Immunol. 2004; 25: 92-97.
Morris EC, Rebello P, Thomson KJ e t  a l . Pharmacokinetics of alemtuzumab (CAMPATH-1H) 
used for in vivo and in vitro T-cell depletion in allogeneic transplants: relevance for early 
adoptive immunotherapy and infectious complications. Blood 2003; 9: 257-265
Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I- 
minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility 
antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat.Med. 
1999a; 5: 839-842.
Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy 
of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic 
system-restricted minor histocompatibility antigens. Blood 1999b; 93: 2336-2341.
Nachbaur D, Bonatti H, Oberaigner W e t  a l . Survival after bone marrow transplantation from 
cytomegalovirus seropositive sibling donors. Lancet 2001; 358: 1157-1159.
295
Nakayama T, Kasprowicz DJ, Yamashita M e t  a l . The generation of mature, single-positive 
thymocytes in vivo is dysregulated by CD69 blockade or overexpression. J.lmmunol. 2002; 168: 
87-94.
Neisig A, Vangsted A, Zeuthen J, Geisler C. Assembly of the T-cell antigen receptor. 
Participation of the CD3 omega chain. J.lmmunol. 1993; 151: 870-879.
Ng WF, Duggan PJ, Ponchel F e t  a l .  Human CD4(+)CD25(+) cells: a naturally occurring 
population of regulatory T cells. Blood 2001; 98: 2736-2744.
Nguyen Q, Champlin R, Giralt S e t  a l .  Late cytomegalovirus pneumonia in adult allogeneic 
blood and marrow transplant recipients. Clin.Infect.Dis. 1999; 28: 618-623.
Nikaein A, Poole T, Fishbeck R e t  a l .  Characterization of skin-infiltrating cells during acute graft- 
versus-host disease following bone marrow transplantation using unrelated marrow donors. 
Hum.Immunol. 1994; 40: 68-76.
Nikaein A, Stelzer G, Duquesnoy RJ, Wallace JH. Monoclonal antibody analysis of responder 
and stimulator cells in the human autologous mixed lymphocyte reaction. Immunobiology 1984; 
166: 190-202.
Nimer SD, Giorgi J, Gajewski JL e t  a l .  Selective depletion of CD8+ cells for prevention of graft- 
versus-host disease after bone marrow transplantation. A randomized controlled trial. 
Transplantation 1994; 57: 82-87.
Nonn, M, Tubbe, I, Huber, C., and Hartwig, U. F. Selective depletion of human graft-versus-host 
disease-reactive t-cells by anti-CD95 mediated activation-induced cell death or via the T-cell 
activation antigen CD69 for preventing graft-versus-host disease in allogeneic bone marrow 
transplantation. Bone Marrow Transplantation. 2003. Abstract
Nonn, M, Tubbe, I, Huber, C., and Hartwig, U. F. Selective depletion of human GvHD reactive T 
cells by anti CD95 mediated activation induced cell death or via the T cell activation antigen 
CD69 for preventing GvHD in allogeneic bone marrow transplantation. Bone Marrow 
Transplant. 2003. Abstract
Norton J, Sloane JP. ICAM-1 expression on epidermal keratinocytes in cutaneous graft-versus- 
host disease. Transplantation 1991; 51: 1203-1206.
Nossal GJ. Negative selection of lymphocytes. Cell 1994; 76: 229-239.
O'Brien RM, Kemeny DM. Distribution of alloreactivity amongst the CD45 isoforms of circulating 
CD4 and CD8 T lymphocytes. Scand.J.lmmunol. 1998; 48: 679-683.
Odum N, Platz P, Jakobsen BK e t  a l .  HLA-DP and bone marrow transplantation: DP- 
incompatibility and severe acute graft versus host disease. Tissue Antigens 1987; 30: 213-216.
Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor 
administered before conditioning ameliorates graft-versus-host disease after allogeneic bone 
marrow transplantation in mice. Blood 1998; 92: 3960-3967.
Papiemik M. Natural CD4+ CD25+ regulatory T cells. Their role in the control of superantigen 
responses. Immunol. Rev. 2001; 182: 180-189.
Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional 
analysis of T lymphocyte clones. J.lmmunol. 1986; 136: 3543-3548.
Patterson AE, Komgold R. Infusion of select leukemia-reactive TCR Vbeta+ T cells provides 
graft-versus-leukemia responses with minimization of graft-versus-host disease following murine 
hematopoietic stem cell transplantation. Biol.Blood Marrow Transplant. 2001; 7: 187-196.
296
Paulus U, Schmitz N, Viehmann K, von Neuhoff N, Dreger P. Combined positive/negative 
selection for highly effective purging of PBPC grafts: towards clinical application in patients with 
B-CLL. Bone Marrow Transplant. 1997; 20: 415-420.
Payne KJ, Crooks GM. Human hematopoietic lineage commitment. Immunol. Rev. 2002; 187: 
48-64.
Peggs K, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S. Characterization of human 
cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro 
restimulation by antigen-pulsed dendritic cells. Blood 2002; 99: 213-223.
Peggs KS, Mackinnon S, Williams CD e t  a l .  Reduced-intensity transplantation with in vivo T-cell 
depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive 
myeloma: limited efficacy of graft-versus-tumor activity. Biol.Blood Marrow Transplant. 2003; 9: 
257-265.
Peggs KS, Verfuerth S, D'Sa S, Yong K, Mackinnon S. Assessing diversity: immune 
reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation. 
Br.J.Haematol. 2003; 120: 154-165.
Peggs KS, Verfuerth S, Pizzey A e t  a l . Adoptive cellular therapy for early cytomegalovirus 
infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 
362: 1375-1377.
Petersdorf EW, Gooley TA, Anasetti C e t  a l .  Optimizing outcome after unrelated marrow 
transplantation by comprehensive matching of HLA class I and II alleles in the donor and 
recipient. Blood 1998; 92: 3515-3520.
Pichler WJ, Wyss-Coray T. T cells as antigen-presenting cells. Immunol.Today 1994; 15: 312- 
315.
Pierdominici M, Mazzetta F, Caprini E e t a l .  Biased T-cell receptor repertoires in patients with 
chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). 
Clin.Exp.Immunol. 2003; 132: 323-331.
Pillow RP, Epstein RB, Buckner CD, Giblett ER, Thomas ED. Treatment of bone-marrow failure 
by isogeneic marrow infusion. N.Engl.J.Med. 1966; 275: 94-97.
Prentice HG, Blacklock HA, Janossy G e t  a l .  Use of anti-T-cell monoclonal antibody OKT3 to 
prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute 
leukaemia. Lancet 1982; 1: 700-703.
Prentice HG, Blacklock HA, Janossy G e t  a l . Depletion of T lymphocytes in donor marrow 
prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow 
transplant recipients. Lancet 1984; 1: 472-476.
Prentice HG, Gluckman E, Powles RL e t  a l . Impact of long-term acyclovir on cytomegalovirus 
infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV 
Prophylaxis Study Group. Lancet 1994; 343: 749-753.
Prince HE, Lape-Nixon M. CD69 expression reliably predicts the anti-CD3-induced proliferative 
response of lymphocytes from human immunodeficiency virus type 1-infected patients.
Clin.Diagn.Lab Immunol. 1997; 4: 217-222.
Ratanatharathm V, Ferrara J, Raymond H, Braun T, and Ayash L. A Phase I/ll study of 
recombinant human keratinoctye growth factor in patients with high risk haematologic 
malignancies undergoing mismatched related or unrelated donor transplant. Biology of Blood 
and Marrow Transplantation 2003; 9(2): 67-67. Abstract
Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by 
distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of
297
antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003; 101: 
1422-1429.
Rauser G, Einsele H, Sinzger C e t  a l .  Rapid generation of combined CMV-specific CD4+and 
CD8+ T-cell lines for adoptive transfer into allogeneic stem cell transplant recipients. Blood 
2003; 103: 3565-3572.
Reisner Y, Kapoor N, Kirkpatrick D e t  a l .  Transplantation for acute leukaemia with HLA-A and B 
nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood 
cells. Lancet 1981; 2: 327-331.
Rezvani K, Grube M, Brenchley JM e t a l .  Functional leukemia-associated antigen-specific 
memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous 
leukemia before and after stem cell transplantation. Blood 2003; 102: 2892-2900.
Riddell SR, Elliott M, Lewinsohn DA e t  a l .  T-cell mediated rejection of gene-modified HIV- 
spedfic cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 1996; 2: 216-223.
Ringden O, Paulin T, Lonnqvist B, Nilsson B. An analysis of factors predisposing to chronic 
graft-versus-host disease. Exp.Hematol. 1985; 13: 1062-1067.
Roy J, Blazar BR, Ochs L, Weisdorf DJ. The tissue expression of cytokines in human acute 
cutaneous graft-versus-host disease. Transplantation 1995; 60: 343-348.
Ruggeri L, Capanni M, Casucci M e t  a l .  Role of natural killer cell alloreactivity in HLA- 
mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
Ruggeri L, Capanni M, Urbani E e t  a l .  Effectiveness of donor natural killer cell alloreactivity in 
mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
Rutella S, Rumi C, Lucia MB e t  a l .  Induction of CD69 antigen on normal CD4+ and CD8+ 
lymphocyte subsets and its relationship with the phenotype of responding T-cells. Cytometry 
1999; 38:95-101.
Ryser JE, MacDonald HR. Limiting dilution analysis of alloantigen-reactive T lymphocytes. I. 
Comparison of precursor frequencies for proliferative and cytolytic responses. J.Immunol. 1979; 
122: 1691-1696.
Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: 
function, generation, and maintenance. Annu.Rev.Immunol. 2004; 22: 745-763.
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes 
with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
Santis AG, Lopez-Cabrera M, Hamann J, Strauss M, Sanchez-Madrid F. Structure of the gene 
coding for the human early lymphocyte activation antigen CD69: a C-type lectin receptor 
evolutionarily related with the gene families of natural killer cell-specific receptors.
Eur.J. Immunol. 1994; 24: 1692-1697.
Saoudi A, Seddon B, Fowell D, Mason D. The thymus contains a high frequency of cells that 
prevent autoimmune diabetes on transfer into prediabetic recipients. J.Exp.Med. 1996; 184: 
2393-2398.
Sasazuki T, Juji T, Morishima Y e t  a l .  Effect of matching of class I HLA alleles on clinical 
outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan 
Marrow Donor Program. N.Engl.J.Med. 1998; 339: 1177-1185.
Scheibenbogen C, Letsch A, Thiel E e t  a l .  CD8 T-cell responses to Wilms tumor gene product 
WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-2137.
298
Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response.
Blood Rev. 1996; 10:111-127.
Schumm, M, Scheule, K, Schumm, S, Seitz, S, Lang, P, Kuci, S, and Niethammer, D. 
Immunomagnetic depletion of allo-reactive T-cells with monoclonal antibodies against 
CD69,CD25 and HLA DR. Bone Marrow Transplant. 2003. Abstract
Shaw BE, Madrigal JA, Potter M. Improving the outcome of unrelated donor stem cell 
transplantation by molecular matching. Blood Rev. 2001; 15: 167-174.
Shimizu K, Fujii S, Fujimoto K, Kawa K, Yamada A, Kawano F. Tacrolimus (FK506) treatment of 
CD34+ hematopoietic progenitor cells promote the development of dendritic cells that drive 
CD4+ T cells toward Th2 responses. J.Leukoc.Biol. 2000; 68: 633-640.
Sidhu S, Deacock S, Bal V, Batchelor JR, Lombardi G, Lechler Rl. Human T cells cannot act as 
autonomous antigen-presenting cells, but induce tolerance in antigen-specific and alloreactive 
responder cells. J.Exp.Med. 1992; 176: 875-880.
Siefken R, Kurrle R, Schwinzer R. CD28-mediated activation of resting human T cells without 
costimulation of the CD3/TCR complex. Cell Immunol. 1997; 176: 59-65.
Sili U, Huls MH, Davis AR e t  a l .  Large-scale expansion of dendritic cell-primed polyclonal 
human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive 
immunotherapy. J.lmmunother. 2003; 26: 241-256.
Simms PE, Ellis TM. Utility of flow cytometric detection of CD69 expression as a rapid method 
for determining. Clin.Diagn.Lab Immunol. 1996; 3: 301-304.
Smith KA. Interleukin 2. Annu.Rev.Immunol. 1984; 2: 319-333.
Soiffer RJ, Fairdough D, Robertson M e t  a l .  CD6-depleted allogeneic bone marrow 
transplantation for acute leukemia in first complete remission. Blood 1997; 89: 3039-3047.
Solomon S, Tran T, Carter CS e t  a l .  Rapid Engraftment and Conserved Graft-Versus- 
Leukaemia Effect without Transplant-Related Mortality in Elderly Recipients of Allografts 
Selectively Depleted of Host-Reactive Lymphocytes. Blood 2003; 102: 238a-238a.
Solomon SR, Tran T, Carter CS e t  a l .  Optimized clinical-scale culture conditions for ex vivo 
selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in 
allogeneic PBSC transplantation. Cytotherapy. 2002; 4: 395-406.
Squrfflet JP, Legendre C. The economic value of valacyclovir prophylaxis in transplantation.
J.Infect.Dis. 2002; 186 Suppl 1: S116-S122.
Stanzani M, Martins SL, Saliba RM e t  a l . CD25 expression on donor CD4+ or CD8+ T cells is 
associated with an increased risk for graft-versus-host disease after HLA-identical stem cell 
transplantation in humans. Blood 2004; 103: 1140-1146.
Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and 
early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell 
response. J.Exp.Med. 1997; 185: 1605-1617.
Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency 
of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 2001; 166: 973-981.
Sun K, Welniak LA, Panoskaltsis-Mortari A e t  a l . Inhibition of acute graft-versus-host disease 
with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. 
Proc.Natl.Acad.Sci.U.S.A 2004; 101: 8120-8125.
Sviland L, Dickinson AM. A human skin explant model for predicting graft-versus-host disease 
following bone marrow transplantation. J.CIin.Pathol. 1999; 52: 910-913.
299
Sykulev Y, Brunmark A, Tsomides TJ e t  a l .  High-affinity reactions between antigen-specific T- 
cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility 
complex class I proteins. Proc.Natl.Acad.Sci.U.S.A 1994; 91: 11487-11491.
Taams LS, van Eden W, Wauben MH. Antigen presentation by T cells versus professional 
antigen-presenting cells (APC): differential consequences for T cell activation and subsequent T 
cell-APC interactions. Eur.J.Immunol. 1999; 29: 1543-1550.
Tallquist MD, Yun TJ, Pease LR. A single T cell receptor recognizes structurally distinct 
MHC/peptide complexes with high specificity. J.Exp.Med. 1996; 184: 1017-1026.
Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: 
interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. 
Transpl. Infect.Dis. 2001; 3: 60-69.
Taub DD, Murphy WJ, Asai O e t  a l .  Induction of alloantigen-specific T cell tolerance through the 
treatment of human T lymphocytes with wortmannin. J.lmmunol. 1997; 158: 2745-2755.
Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated a n d  e x p a n d e d  CD4(+)CD25(+) 
immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor a multipurpose cell-surface 
trigger for hematopoietic cells. Immunol.Today 1994; 15: 479-483.
Thomas ED, Buckner CD, Rudolph RH e t  a l .  Allogeneic marrow grafting for hematologic 
malignancy using HL-A matched donor-recipient sibling pairs. Blood 1971; 38: 267-287.
Thomis DC, Marktel S, Bonini C e t  a l .  A Fas-based suicide switch in human T cells for the 
treatment of graft-versus-host disease. Blood 2001; 97: 1249-1257.
Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone 
marrow cells. Radiation Research 1961; 14: 213-213.
Trenado A, Fisson S, Braunberger E, Klatzmann D, Salomon BL, Cohen JL. Ex vivo selection of 
recipient-type alloantigen-specific CD4(+)CD25(+) immunoregulatory T cells for the control of 
graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation. 
Transplantation 2004; 77: S32-S34.
Tsang JY, Chai JG, Lechler R. Antigen presentation by mouse CD4+ T cells involving acquired 
MHC class Ihpeptide complexes: another mechanism to limit clonal expansion? Blood 2003;
101: 2704-2710.
Tseng LH, Lin MT, Hansen JA e t  a l . Correlation between disparity for the minor 
histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after 
allogeneic marrow transplantation. Blood 1999; 94: 2911-2914.
Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. Blockade of CD134 (0X40)- 
CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of 
allogeneic bone marrow transplantation. Blood 2000; 95: 2434-2439.
Van Bekkum DW, de Vries MJ, van der WD. Lesions characteristic of secondary disease in 
germfree heterologous radiation chimeras. J.Natl.Cancer Inst. 1967; 38: 223-231.
van Dijk AM, Kessler FL, Stadhouders-Keet SA, Verdonck LF, de Gast GC, Otten HG. Selective 
depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of 
acute graft-versus-host disease. Br.J.Haematol. 1999; 107:169-175.
van Dijk AM, Otten HG, Vercauteren SM e t  a l . Human B7-1 is more efficient than B7-2 in 
providing co-stimulation for alloantigen-specific T cells. Eur.J.Immunol. 1996; 26: 2275-2278.
300
van Lier RA, Brouwer M, Rebel VI, van Noesel CJ, Aarden LA. Immobilized anti-CD3 
monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation 
and helper activity in human T lymphocytes. Immunology 1989; 68: 45-50.
van Maurik A, Herber M, Wood KJ, Jones ND. Cutting edge: CD4+CD25+ alloantigen-specific 
immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for 
anti-CD154 immunotherapy. J.Immunol. 2002; 169: 5401-5404.
van Oers MH, de Goede RE, Zeijlemaker WP. Antibody-dependent lymphocytotoxicity: an 
analysis of effector cell-target cell interactions. J.Immunol. 1978; 121: 499-504.
Varela-Calvino R, Sgarbi G, Wedderbum LR, Dayan CM, Tremble J, Peakman M. T cell 
activation by coxsackievirus B4 antigens in type 1 diabetes mellitus: evidence for selective TCR 
Vbeta usage without superantigenic activity. J.lmmunol. 2001; 167: 3513-3520.
Velardi, A. Non-alloreactive CMV specific donor cell clones for immunotherapy post transplant. 
Blood. 2003. Abstract
Via CS, Finkelman FD. Critical role of interieukin-2 in the development of acute graft-versus- 
host disease. Int. Immunol. 1993; 5: 565-572.
Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute 
graft-versus-host disease. J.lmmunol. 1996; 157: 5387-5393.
Vogelsang GB, Hess AD, Berkman AW e t  a t . An in vitro predictive test for graft versus host 
disease in patients with genotypic HLA-identical bone marrow transplants. N.Engl. J. Med. 1985; 
313: 645-650.
Walls T, Shankar AG, Shingadia D. Adenovirus: an increasingly important pathogen in 
paediatric bone marrow transplant patients. Lancet Infect. Dis. 2003; 3: 79-86.
Walter EA, Greenberg PD, Gilbert MJ e t  a l .  Reconstitution of cellular immunity against 
cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the 
donor. N.Engl.J.Med. 1995; 333: 1038-1044.
Wang XN, Proctor SJ, Dickinson AM. Frequency analysis of recipient-reactive helper and 
cytotoxic T lymphocyte precursors using a combined single limiting dilution assay.
Transpl. Immunol. 1996; 4: 247-251.
Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor 
histocompatibility antigens with a restricted tissue distribution. Blood 1998; 91: 2197-2207.
Watts MJ, Somervaille TC, Ings SJ e t  a l .  Variable product purity and functional capacity after 
CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale 
devices. Br.J.Haematol. 2002; 118: 117-123.
Weekes MP, Wills MR, Mynard K, Carmichael AJ, Sissons JG. The memory cytotoxic T- 
lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide- 
specific CTL clones that have undergone extensive expansion in vivo. J.Virol. 1999; 73: 2099- 
2108.
Whiteway A, Corbett T, Anderson R, Macdonald I, Prentice HG. Expression of co-stimulatory 
molecules on acute myeloid leukaemia blasts may effect duration of first remission.
Br.J.Haematol. 2003; 120: 442-451.
Wills MR, Carmichael AJ, Mynard K e t a l .  The human cytotoxic T-lymphocyte (CTL) response to 
cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell 
receptor usage of pp65-specific CTL. J.Virol. 1996; 70: 7569-7579.
Wucherpfennig KW. T cell receptor crossreactivity as a general property of T cell recognition. 
Mol.Immunol. 2004; 40: 1009-1017.
301
Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, 
busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine 
release and development of acute and chronic graft-versus-host disease in H-2-incompatible 
transplanted SCID mice. Blood 1994; 83: 2360-2367.
Xystrakis E, Bernard I, Dejean AS, Alsaati T, Druet P, Saoudi A. Alloreactive CD4 T 
lymphocytes responsible for acute and chronic graft-versus-host disease are contained within 
the CD45RChigh but not the CD45RCIow subset. Eur.J.Immunol. 2004; 34: 408-417.
Yabe H, Yabe M, Mitsuda R e t  a l .  [Clinical study of gut decontamination in bone marrow 
transplantation]. Kansenshogaku Zasshi 1988; 62: 527-533.
Yamamura M, Newton RC, James DC, Humble JG, Butler LJ, Hobbs JR. Uncomplicated HL-A 
matched sibling bone marrow graft for combined immune deficiency. Br.Med.J. 1972; 2: 265- 
269.
Yamashita K, Choi U, Woltz PC e t  a l .  Severe chronic graft-versus-host disease is characterized 
by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood 
2004; 103: 3986-3988.
Young NT, Roelen DL, Dallman MJ, Morris PJ, Welsh Kl. HLA-DRB1 amino acid disparity is the 
major stimulus of interleukin-2 production by alloreactive helper T-lymphocytes.
Immunogenetics 1998; 47: 310-317.
Zajac AJ, Blattman JN, Murali-Krishna K e t  a l . Viral immune evasion due to persistence of 
activated T cells without effector function. J.Exp.Med. 1998; 188: 2205-2213.
Zhang Z, Yang L, Young KJ, Zhang L. Suppression of alloimmune responses in vitro and in vivo 
by CD3(+)CD8(-)CD4(-)alphabeta(+) regulatory T cells. Transplant.Proc. 2001; 33: 84-85.
Ziegler SF, Ramsdell F, Hjerrild KA e t  a l . Molecular characterization of the early activation 
antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation 
antigens. Eur.J.Immunol. 1993; 23: 1643-1648.
Zuniga-Pflucker JC. T-cell development made simple. Nat.Rev.Immunol. 2004; 4: 67-72.
302
